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This thesis compiles a series of individual manuscripts and related analyses which 
encompass the topics of definition of acute bronchiolitis, evidence on the safety 
and efficacy of common interventions, and selection of outcomes and measurement 
instruments. It is preceded by a general overview on the nature and impact of this 
common condition in infants. At the time of writing (March 2015) two of the four 
individual manuscripts (presented in Chapter 2) have been published in peer 
reviewed journals, while the remaining two (Chapters 3 and 4) have been accepted 
for revision. My contribution to all projects that led to these manuscripts included 
developing the research ideas and research questions, designing the studies, writing 
the protocol and analysis plan, performing the data extraction, conducting all 
statistical analyses, writing and submitting all manuscripts; and responding to 
reviewers’ comments. The work in this thesis was conducted between 2009 and 
2014, under the supervision of Professors Martin Offringa, Cristina Sampaio, and 
José Costa Trindade. 
!
As I reflect on this journey, I can’t help to think that there is a gap between what 
these pages hold, and the twists and turns of the path that led me here. The 
thorough and comprehensive standardized language of reporting scientific 
manuscripts which I absolutely support as an integral part of rigorous and 
responsible research conduct, can ironically feel dry and meagre to express the 
many uncertainties and hurdles that went together with each project. Little will be 
stated here of the immense privilege but also tense challenge of working 
collaboratively, of the countless days spent dwelling in labyrinthine datasets, and of 
the almost acrobat-like need to balance science, clinics and personal life. Even if it 
was described, it would likely sound excessive in face of what is, pragmatically, 
only a small and temporary increment in broader scientific knowledge in this field. 
Ultimately, however, as Georges Perec alluded to in a dramatically different 
context, you would likely learn more of what was experienced from the blank 
spaces between the lines than in the words written here.  
!
My starting point was determined by previous experiences and circumstance, even 
as decisive moments along the journey looked strikingly stochastic. Throughout the 
medical course I was given the opportunity to taste the flavors of basic research in 
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such diverse fields as biochemistry, embryology and, later, cognitive neuroscience. 
From Professors Domingos Henrique, Leonor Parreira and Alexandre Castro-Caldas, 
with whom I had the privilege to work, I learned the need to balance creativeness 
and rigor when turning ideas into testable scientific hypotheses, the meticulousness 
and patience of experimental work, and most importantly, the drive to never stop 
questioning what seems well established. These lessons seemed to fade as I grew 
more interested in clinical science, and only late did I realize how much common 
ground there was between them, and how invaluable they were as I moved from 
bench to bedside, from the molecule to the individual and the population.  
!
The genuine pleasure of practicing pediatrics was soon to come, as was a growing 
interest in how scientific evidence was produced and appraised. Rather than the 
often clichéd discussion on the virtues and sins of the so-called “evidence-based 
medicine”, the focus was on the foundations, limits and applicability of evidence 
and quantitative medicine, and how it intertwined with experience and the patient 
perspective. An exploratory project on the placebo effect in childhood migraine 
with Professors Cristina Sampaio and Joaquim Ferreira introduced me to the 
principles of clinical pharmacology. Training at the Erasmus Program in Rotterdam 
provided a background on population epidemiology and the fascinating world of 
causal inference. The spark of methodology finally led me to a fellowship with 
Professors Martin Offringa and Hanneke van der Lee in Amsterdam, which was 
pivotal in opening doors to the realm of clinical epidemiology. The gaps in child 
health evidence were taking centre stage in this field, and initiatives were being 
established to improve the design, conduct and reporting of clinical trial research in 
children. As I embarked on this moving train, small yet decisive actions were being 
taken in Portugal to provide clinical research opportunities for residents, and a 
doctoral thesis became a natural next step. 
!
From inception, I gravitated towards the topic of wheezing disorders, particularly 
acute bronchiolitis, with the crucial mentorship from Professors Teresa Bandeira 
and José Costa Trindade. In hindsight, this choice wasn’t just driven by clinical 
interest in respiratory disease. There is more than meets the eye to the apparently 
monotonous seasonal bronchiolitis, as this condition reflects some of the challenges 
of practicing and researching in child health. First, it is a paradigm of an acute 
pediatric condition that is usually benign but encompasses a wide range of 
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severities and leads to uncertainties about long-term prognosis in the young 
developing child. Second, it evokes the contrast between the art of clinical 
assessment by experienced clinicians, and the quantification of measurable 
parameters such as physiological variables and clinical scales. Third, while known 
to every child health practitioner, acute bronchiolitis stands at a crossroads of 
different subspecialties and settings. Both inevitably entail different perspectives on 
its definition, on which interventions are useful, and on which outcomes are 
clinically relevant. Finally, it is also a showcase for the collision between strong 
opinion-based practice and limited high-quality evidence, with scarce innovation 
despite its impact for families and health care systems.  
!
A defining moment in the journey to this doctoral thesis was to come in mid-2008, 
as I joined the first edition of the Gulbenkian Program for Advanced Medical 
Education, directed by Professor Leonor Parreira and later Professors António 
Coutinho and Jorge Soares. This pioneering initiative in the portuguese panorama of 
medical research included a 6-month full time curriculum of intensive education in 
a vast array of cutting-edge fields of biomedicine, with a highly qualified 
international faculty. At times both informative and provocative, the program was 
invaluable in how it incited students to think outside the box of everyday clinical 
reasoning, to raise their standards of research to a higher level, and to expand 
horizons in an era of interdisciplinary -omics and systems biology. Faced with the 
promises and caveats of personalized medicine, it became apparent to me how 
important it is to have a dialogue between the mechanistic approaches of 
innovative translational science and the methodological rigor of clinical 
epidemiology, in order to ensure clinical relevance and minimize waste in clinical 
research endeavors. 
!
As I resumed my clinical training while pursuing the thesis projects, I faced the 
challenges of maintaining course and motivation despite the many obstacles of this 
part-time schedule. I was privileged to have full support from my doctoral program, 
from the Directors of the Department of Pediatrics at Lisbon’s Academic Medical 
Centre (Professors João Gomes-Pedro, Paulo Ramalho and Maria do Céu Machado), 
from the Laboratory of Clinical Pharmacology and Therapeutics at the University of 
Lisbon and Instituto de Medicina Molecular (Professors Cristina Sampaio and 
Joaquim Ferreira), from all my clinical colleagues and obviously from all three 
supervisors. Further, a strong ongoing collaboration was established with Professors 
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Lisa Hartling, Terry Klassen and Amy Plint in Canada, which was paramount to all 
thesis projects. Opportunities to participate in various research initiatives soon 
appeared, from the Standards for Research in Child Health (StaR Child Health) to 
the Cochrane Collaboration Child Health Field, and later also the Core Outcome 
Measures in Effectiveness Trials (COMET). These activities were time-intensive but 
rarely distracting, and contributed decisively to the methodological approaches of 
this thesis’ projects. Further, it has been invaluable to participate in the design, 
conduct and reporting of high-level international collaborative research projects, 
and, most importantly, these experiences provide perspectives for future postdoc 
activities.  
!
As discussed throughout this thesis, there are few certainties when predicting the 
developmental trajectories of wheezy children and infants after acute bronchiolitis. 
While tempting, a one-size-fits-all-approach to manage these children has 
repeatedly failed, and some have called it one of the last true art forms in medicine. 
It is hard to avoid the analogy with the paths of clinicians from medical doctoral 
programs such as the ones I participated in. The outcome of our own trajectories are 
likely determined by our background, the nature of our projects, our local settings 
and ultimately, our drive and personality. The part-time model has enormous 
challenges in the absence of a research-friendly environment and structure, one that 
is both fair and rigorous in how it values research work and output as well as 
clinical skills and productivity, be it during residency or after obtaining certification. 
The risks of failing at either clinics or research, or worst, to come short at both, 
cannot be ignored. Protracted projects are also another consequence, one that I 
endured as this thesis seemed at times to drag as “obras de Santa Engrácia”, 
endlessly at works. But lessons learned from what I have experienced from 
successful approaches in Canada, Netherlands or the United Kingdom, highlight 
how this effort of placing research as a core integrated value of the health care 
system is paramount. As I finish writing this thesis, the decisive circumstances 
which Portugal is currently facing, call for determination and vision in defining a 
bearing for clinical research. New opportunities are presenting to clinician 
researchers, but there is a long road ahead to leverage our assets and produce 
creative, competitive and meaningful patient-centered research, based on research 
infrastructures that are fit for purpose. The experience gained during this journey 




This thesis was written as an intersection between clinics and methodology, as well 
as pediatric practice and science. It reflects the guidance and work of a number of 
mentors and collaborators to whom I thank in the acknowledgments section. These 
manuscripts present merely fleeting evidence en route to a next, better, proof; rather 






AOM: Acute otitis media 
APMGF: Portuguese association of general practitioners 
AR: Adrenoceptor 
ARDS: Acute respiratory distress syndrome 
ASM: Airway smooth muscle 
AUC: Area under the curve 
BoV: Bocavirus 
BPD: Bronchopulmonary dysplasia 
CHD: Congenital heart disease 
CI: Confidence interval 
CLD: Chronic lung disease  
COMET: Core outcome measures in effectiveness trials (initiative) 
COPD: Chronic obstructive pulmonary disease 
COS: Core outcome sets 
COSMIN: Consensus-based standards for the selection of health measurement 
instruments (initiative) 
ED: Emergency department 
ES: Effect size 
FRC: Functional residual capacity 
GP: General practitioner 
GR: Glucocorticoid receptor 
GRADE: Grading of recommendations assessment, development and evaluation 
(initiative) 
GRE: Glucocorticoid-response elements 
hMPV: Human metapneumovirus  
ICC: Intraclass correlation coefficient 
ICD: International classification of diseases 
ICU: Intensive care unit 
IQR: Interquartile range 
ITT: Intention-to-treat 
LoA: Limits of agreement 
LOS: Length of stay 
LRTI: Lower respiratory tract infection 
M: Muscarinic (receptor) 
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ABSTRACT (SHORT) 
Acute viral bronchiolitis is the most common acute infection of the lower 
respiratory tract during the first year of life. It is a major cause of clinical morbidity 
and financial health burden, and encompasses a spectrum of disease severity. This 
thesis addresses the uncertainties of current evidence on two widely used 
treatments for bronchiolitis, i.e. bronchodilators and corticosteroids, and how this 
evidence is limited by shortcomings in key areas of clinical trial design, namely 
disease definition and outcome selection and measurement. The thesis specific aims 
were: 1. to assess the comparative efficacy and safety of bronchodilators and 
corticosteroids, used alone or in combination; 2. to identify outcomes reported in 
previous clinical trials in bronchiolitis, and a. to assess which outcomes are 
considered most important to different physicians, and b. to study the measurement 
properties of two commonly used respiratory distress scales (Respiratory Distress 
Assessment Instrument - RDAI, and the Respiratory Assessment Change Score - 
RACS); and 3. to study how physicians define bronchiolitis. Chapter 1 presents an 
overview of relevant epidemiological, clinical and pathophysiological findings in 
bronchiolitis, preceded by a historical perspective. Chapter 2 describes the results 
of a comprehensive comparative effectiveness systematic review of bronchodilators 
and corticosteroids, including 48 trials (4897 patients and 13 comparisons), with 
network meta-analysis. Chapter 3.1 presents an exploratory study to identify 
outcome domains and measurement instruments reported in 90 clinical trials of 
bronchiolitis included in 11 Cochrane systematic reviews. In Chapter 3.2, we 
report on a measurement study which evaluates the validity, reliability and 
responsiveness of RDAI and RACS, including data from up to 1765 infants with 
bronchiolitis enrolled in pediatric emergency departments. Finally, in Chapter 4 we 
present results from a nationwide electronic survey of pediatricians and general 
practitioners, where we assessed physician perspectives on both definition of 
bronchiolitis, and relevant outcomes and outcome domains for future bronchiolitis 
trials. 
!
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RESUMO (CURTO)  
A bronquiolite aguda é a mais frequente infecção das vias aéreas inferiores durante 
o primeiro ano de vida, e tem um impacto clínico e económico substancial. Esta
tese avalia a evidência actual sobre o uso de broncodilatadores e corticoesteróides, 
e de que forma essa evidência está limitada por dois aspectos metodológicos chave 
para o desenho de ensaios clínicos nesta área: a definição de bronquiolite, e a 
escolha e medição de “outcomes”. Os objectivos específicos incluem: 1. avaliar a 
eficácia e segurança comparativas de broncodilatadores e corticoesteróides, usados 
isoladamente ou em combinação; 2. identificar os “outcomes” reportados em 
ensaios clínicos de bronquiolite, e a. avaliar que “outcomes” são considerados mais 
relevantes por médicos, e b. estudar as propriedades de medida de duas escalas de 
dificuldade respiratória frequentemente usadas (Respiratory Distress Assessment 
Instrument - RDAI, e Respiratory Assessment Change Score - RACS); e 3. avaliar 
perspectivas médicas sobre a definição de bronquiolite. No Capítulo 1 revemos 
aspectos epidemiológicos, fisiopatológicos e clínicos da bronquiolite, enquadrados 
numa perspectiva histórica. No Capítulo 2 descrevemos os resultados de uma 
revisão sistemática comparativa sobre a eficácia e segurança de broncodilatadores 
e corticoesteróides, incluindo 48 ensaios (4897 doentes e 13 comparações), com 
meta-análise em rede. O Capítulo 3.1 apresenta um estudo exploratório que 
identifica domínios de “outcomes” e instrumentos de medida reportados em 90 
ensaios clínicos de bronquiolite incluídos em 11 revisões sistemáticas Cochrane. 
No Capítulo 3.2 descrevemos um estudo de medição em que se avaliam a 
validade, fiabilidade e responsividade das escalas RDAI e RACS, incluindo dados 
de até 1765 crianças no contexto de bronquiolite na urgência pediátrica. Por fim, 
no Capítulo 4 apresentamos os resultados de um inquérito electrónico nacional a 
médicos pediatras e de medicina geral e familiar, avaliando as perspectivas médicas 
sobre definição de bronquiolite, e sobre quais os “outcomes” considerados 
relevantes para futuros ensaios clínicos nesta área.  
!
Palavras-chave: bronquiolite, sibilância, outcomes, medição, meta-análise 
 31
SUMMARIES & LIST OF PUBLICATIONS
CHAPTER 2!
 32
SUMMARIES & LIST OF PUBLICATIONS
CHAPTER 2
ABSTRACT (LONG) 
Acute viral bronchiolitis is the most common acute infection of the lower 
respiratory tract during the first year of life. It is a major cause of clinical morbidity 
and financial health burden, and encompasses a spectrum of disease severity. 
Seasonal variation in incidence is attributed to the dynamics of viral transmission of 
its most frequent agent, respiratory syncytial virus. Despite its global impact, our 
understanding of the immunopathogenesis of this condition remains incomplete. 
Bronchiolitis is likely the result of a complex interplay between viral agent 
cytotoxicity,  dysregulated host immune response, and environmental factors. The 
majority of children who develop bronchiolitis are healthy term infants without any 
known predisposing factors, and most have a mild course. Prognostic factors 
include demographic, environmental, and family history determinants, as well as 
comorbidities. A growing body of epidemiological and translational evidence 
supports an association between bronchiolitis and recurrent wheeze and asthma, 
likely with complex and bidirectional causal links between these conditions. 
!
This thesis addresses the uncertainties of current evidence on two widely used 
treatments for bronchiolitis, i.e. bronchodilators and corticosteroids, and how this 
evidence is limited by shortcomings in key areas of clinical trial design, namely 
disease definition and outcome selection and measurement. The specific aims were: 
1. to assess the comparative efficacy and safety of bronchodilators and
corticosteroids, used alone or in combination; 2. to identify outcomes reported in 
previous clinical trials in bronchiolitis, and a. to assess which outcomes are 
considered most important to different physicians, and b. to study the measurement 
properties of two of the most commonly used respiratory distress instruments (the 
Respiratory Distress Assessment Instrument - RDAI, and the Respiratory Assessment 
Change Score - RACS); and 3. to study how physicians define bronchiolitis. 
!
Chapter 1 presents an overview of relevant epidemiological, clinical and 
pathophysiological findings in bronchiolitis, preceded by an historical perspective. 
It provides a rationale for the main topics addressed in the thesis, and how these 
can be addressed by recent methodological developments in trial design and 
synthesis research, including network meta-analysis, core outcome set 
development, and phenotype-based approaches to the classification of wheezing 
disorders. 
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Therapeutic management of bronchiolitis is an ever-controversial topic in 
pediatrics. There is substantial variation in treatment throughout the world, with 
most interventions failing to show consistent and relevant treatment effects. 
Conflicting evidence has emerged regarding the use of two commonly used 
treatments, bronchodilators and corticosteroids, alone or in combination, as results 
from the two largest randomised clinical trials in this field were recently published. 
Chapter 2 describes the results of a comprehensive comparative effectiveness 
systematic review of these two treatments, with 48 trials including 4897 patients 
and 13 comparisons. Evidence from both direct and indirect comparisons was 
considered, and network meta-analysis performed; a separate Cochrane review 
focused on corticosteroids is reported. Results do not support a clinically relevant 
stand-alone effect of systemic or inhaled corticosteroids, β2-adrenergic agonist or 
anticholinergics on most measured outcomes. Nebulized adrenaline (epinephrine) 
was beneficial for short term outcomes among outpatients, reducing hospital 
admissions on day 1 (risk ratio  (RR) 0.67, 95% confidence interval (CI) 0.50 to 
0.89; number needed to treat (NNT) 15), but not on day 7. Exploratory evidence 
from a single large trial suggested a longer term synergistic effect of combined 
treatment with systemic high-dose dexamethasone in outpatients (admissions on 
day 7 - RR 0.65, 95% CI 0.44 to 0.95; NNT 11). These latter results should be 
interpreted cautiously due to methodological caveats. While no relevant differences 
were found in short-term adverse effects for these interventions, harms of combined 
therapy need to be clarified further. None of the tested interventions were found to 
be beneficial in hospitalized patients. Overall, both direct and indirect comparisons 
supported these findings, and network meta-analysis allowed us to rank 
interventions in outpatients: for admissions on day 1, the probabilities of being the 
best treatment for adrenaline alone or combined with corticosteroids were 45% and 
39%, respectively. Our findings provide greater clarity for clinical decision-making 
regarding the relative benefits and harms of corticosteroids and bronchodilators in 
bronchiolitis. They also have implications for the design and conduct of future 
clinical trials and systematic reviews in this field. 
!
One of the key limitations of this comparative effectiveness review was the 
heterogeneity in the selection of outcomes and outcome measurements in included 
bronchiolitis trials. Chapter 3.1 presents an exploratory study to identify outcome 
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domains and measurement instruments reported in 90 clinical trials of bronchiolitis 
included in 11 Cochrane systematic reviews. We classified outcome domains 
according to two recent conceptual frameworks (by Sinha et al, and by the 
OMERACT initiative). We found that reported outcome measurements were mostly 
restricted to short-term clinician-based assessments of clinical severity/respiratory 
distress (97%) and healthcare use domains (59%), while few measured caregiver-
reported symptoms (14%) and quality of life (1%), or long-term outcomes (6%). The 
same was found for outcomes used to power these trials. Further, 23 different 
measurement instruments were identified, a majority of which were respiratory 
distress scales, while a few also encompassed other dimensions of disease severity 
(e.g. feeding, global status). The most frequently used scales were RDAI and RACS. 
Timings of measurement, metrics and methods of analysis differed widely. This 
preliminary work highlights the gaps in measured outcome domains and 
discrepancies in measurement instruments in bronchiolitis trials. 
!
Limitations in outcome selection could be addressed with the development and 
application of agreed standardized sets of outcomes (‘core outcome sets’ - COS), to 
be measured and reported, as a minimum, in all relevant clinical trials for a specific 
condition. Initiatives such as OMERACT and COMET have contributed to support 
the development and implementation of COS. Results presented in Chapter 4 
provide a first contribution to assess physician perspectives on “what to measure” in 
COS, i.e. relevant outcomes and outcome domains in bronchiolitis trials. We report 
on a large-scale nationwide online survey (ABBA study) including 514 pediatricians 
and 165 general practitioners (GPs). The top ranked and rated outcomes by both 
pediatricians and GPs were hospital admission and respiratory distress. Most 
outcomes that pediatricians scored above a commonly used threshold for 
consensus (i.e. 80%) were focused on core areas and domains of health resource 
use (hospital admission and length of stay), and pathophysiological manifestations, 
including clinical severity (respiratory distress and need for oxygen therapy), 
pulmonary function, and disease-related long-term manifestations (recurrent 
wheezing and asthma). Outcomes relating to life impact, such as quality of life or 
sleep, were more valued by GPs. Future steps in the development of a COS for 
bronchiolitis should consider effective methods for engaging, informing and 
obtaining consensus among key stakeholder groups, particularly parents. 
!
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When selecting instruments to measure outcomes from a COS (i.e. “how to 
measure”), it is imperative that their measurement properties are adequate and 
applicable for a purpose of evaluation. It is known that many respiratory scales 
were developed ad hoc, and their measurement properties have not been studied 
adequately. In Chapter 3.2, we provide data on the validity, reliability and 
responsiveness of RDAI and RACS. We included data from up to 1765 infants with 
bronchiolitis enrolled in two studies conducted in pediatric emergency departments 
(ED). We assessed RDAI construct validity by testing hypotheses of associations with 
physiological measures (respiratory rate, SatO2) and with constructs related to 
hospitalization, using correlation coefficients and multivariable analysis. RDAI/
RACS responsiveness was evaluated using anchors of change based on these 
constructs; measures of responsiveness included the area under the curve (AUC). 
RDAI test-retest agreement and inter-rater reliability were evaluated using limits of 
agreement (LoA) and Intraclass Correlation Coefficients (ICC). We found that 
baseline RDAI scores were weakly correlated with respiratory rate (r=0.38, 
p<0.001), and scores increased in lower SatO2 categories (p<0.001). Higher RDAI 
scores were associated with hospitalization (odds ratio 1.36, 95% CI 1.26 to 1.47); 
scores differed between participants that were discharged, admitted or stayed in ED 
(p<0.001). Our hypotheses were met, but the magnitude of associations was below 
our predefined thresholds. RDAI test-retest LoA were -3.80 – 3.64 (20% of the 
range), while inter-rater reliability was good (ICC=0.93). Formulated hypotheses for 
responsiveness were confirmed, with moderate responsiveness (AUC: RDAI 0.64 – 
0.70; RACS 0.72). We concluded that RDAI has poor to moderate construct validity, 
with good discriminative properties but considerable test-retest measurement error. 
RDAI and RACS are responsive measures of respiratory distress in bronchiolitis, but 
do not encompass all determinants of disease severity. These results suggest that 
both scales have limitations in their use as evaluative trial outcome measures. 
!
While bronchiolitis is a relatively straightforward clinical diagnosis for most child 
health practitioners, no standardised set of diagnostic criteria exists. The label 
‘bronchiolitis’ may overlap with acute wheezing and asthma, which hampers the 
interpretation of current evidence. In Chapter 4, we present results from the ABBA 
study focusing on perspectives of paediatricians and GPs on definition of 
bronchiolitis. We used principal component analysis (PCA) to explore dimensions 
underlying disease definition. Most paediatricians (76.5%) agreed with a definition 
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based on coryza, wheezing and/or crackles/rales, compared to 38.1% GPs (χ2, 
p<0.001). Less than 5% physicians agreed with a definition commonly used in 
clinical trials (<12 months, first episode of wheeze). We retained three dimensions 
on PCA: one based on coryza, rales/crepitations and no sudden onset; another on 
number of episodes and age; and a third on wheeze. Dimensions varied by 
physician specialization and training (p<0.01). Thus, physician definitions of 
bronchiolitis have considerable variability and often mismatch those of clinical 
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RESUMO (LONGO) 
A bronquiolite aguda é a infecção das vias aéreas inferiores mais frequente durante 
o primeiro ano de vida. Tem um impacto clínico e económico substancial, e
engloba um largo espectro de gravidade clínica. Apesar do seu impacto global, a 
imunopatogénese da doença permanece pouco esclarecida, resultando de uma 
combinação complexa de citotoxicidade viral, resposta imunitária desregulada, e 
factores ambientais. Entre os factores prognósticos contam-se determinantes 
demográficos, ambientais e familiares, e co-morbilidades. Existe crescente 
evidência de uma associação causal complexa e bidirecional entre bronquiolite, 
sibilância recorrente e asma.  
!
Esta tese avalia a evidência terapêutica actual em bronquiolite, e de que forma essa 
evidência está limitada por dois aspectos metodológicos chave para o desenho de 
ensaios clínicos nesta área: a definição de bronquiolite, e a escolha e medição de 
“outcomes”. Os objectivos específicos incluem: 1. avaliar a eficácia e segurança 
comparativas de broncodilatadores e corticoesteróides, usados isoladamente ou em 
combinação; 2. identificar os “outcomes” reportados em ensaios clínicos, avaliar 
que “outcomes” são considerados mais relevantes por médicos, e estudar as 
propriedades de medida de duas escalas frequentemente usadas (Respiratory 
Distress Assessment Instrument - RDAI, e Respiratory Assessment Change Score - 
RACS); e 3. avaliar perspectivas médicas sobre a definição de bronquiolite.  
!
No Capítulo 1 revemos aspectos epidemiológicos, fisiopatológicos e clínicos da 
bronquiolite, enquadrados numa perspectiva histórica. Apresentamos os 
fundamentos que suportam esta tese, e descrevemos desenvolvimentos 
metodológicos no desenho de ensaios clínicos e de revisões sistemáticas e meta-
análises, incluindo a meta-análise em rede, os core outcome sets (COS) (i.e. 
conjuntos de “outcomes” essenciais), e a identificação de fenótipos em doenças 
respiratórias com sibilância.  
!
A abordagem terapêutica da bronquiolite é um tema historicamente controverso. 
Há variabilidade nas práticas a nível global, e a evidência é contraditória quanto ao 
uso de broncodilatadores e corticoesteróides. No Capítulo 2 descrevemos os 
resultados de uma revisão sistemática comparativa sobre a eficácia e segurança 
destes dois fármacos, incluindo 48 ensaios (4897 doentes e 13 comparações). 
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Utilizámos evidência de comparações directas e indirectas, e efectuámos meta-
análise em rede; uma revisão Cochrane sobre corticoesteróides é descrita 
separadamente. O uso isolado de corticoesteróides inalados ou sistémicos, 
agonistas β2-adrenérgicos, e anticolinérgicos, não se associou a um efeito 
terapêutico clinicamente relevante para a maioria dos “outcomes”. O uso de 
adrenalina (epinefrina) nebulizada foi benéfico para “outcomes” a curto prazo em 
urgência hospitalar, com redução dos internamentos ao 1º dia (risco relativo (RR) 
0.67, intervalo de confiança 95% (IC95%) 0.50 a 0.89; número necessário tratar 
(NNT) 15), mas não ao 7º dia. Evidência exploratória de um ensaio clínico sugere 
um efeito sinérgico prolongado ao combinar adrenalina com dexametasona 
sistémica em dose alta (internamentos ao 7º dia - RR 0.65, IC95% 0.44 a 0.95; 
NNT 11). Porém, estes resultados devem ser interpretados com precaução, face a 
questões metodológicas. Não houve diferenças relevantes nos efeitos adversos a 
curto prazo, mas a segurança desta terapêutica combinada deve ser clarificada. 
Nenhuma das intervenções mostrou benefício em crianças internadas. Os 
resultados de comparações directas e indirectas foram consistentes, e a meta-
análise em rede classificou as intervenções pela probabilidade de ser o melhor 
tratamento (45% para a adrenalina isolada e 39% para a terapêutica combinada 
para internamentos ao 1º dia). Estes resultados clarificam os benefícios e riscos 
comparativos do uso de corticoesteróides e broncodilatadores, e permitem emitir 
recomendações para futuros ensaios clínicos e revisões sistemáticas nesta área.  
!
Uma das limitações identificadas por esta revisão sistemática foi a heterogeneidade 
na selecção de “outcomes” e instrumentos de medida. O Capítulo 3.1 apresenta 
um estudo exploratório que identifica domínios de “outcomes” e instrumentos de 
medida reportados em 90 ensaios clínicos de bronquiolite incluídos em 11 revisões 
sistemáticas Cochrane. Analisámos os domínios de “outcomes” de acordo com 
duas classificações conceptuais recentes (por Sinha et al, e pela iniciativa 
OMERACT). Constatámos que a maioria dos “outcomes” reportados estava restrita a 
avaliações clínicas da gravidade e dificuldade respiratória efectuadas por 
profissionais de saúde e medidas a curto prazo (97%), ou a domínios de uso de 
cuidados de saúde (59%). Pelo contrário, poucos “outcomes” avaliavam as 
perspectivas dos cuidadores sobre os sintomas (14%) ou qualidade vida (1%), assim 
como “outcomes” a longo prazo (6%). Por outro lado, identificámos 23 
instrumentos de medida diferentes, a maioria dos quais escalas de dificuldade 
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respiratória. Um pequeno numero de escalas incluía igualmente outras dimensões 
da gravidade da doença (e.g. estado geral, nutrição). As escalas mais 
frequentemente utilizadas foram a RDAI e a RACS. Constatou-se igualmente 
variabilidade no tempo de medição, na métrica usada e nos métodos de análise. 
Este estudo realça as lacunas na selecção de “outcomes” e as discrepâncias nos 
instrumentos de medida usados em ensaios clínicos de bronquiolite. 
!
Estas limitações poderiam ser ultrapassadas através do desenvolvimento e aplicação 
de COS em todos os ensaios clínicos, tal como proposto pelas iniciativas 
OMERACT e COMET. No Capítulo 4 descrevemos um primeiro contributo para 
avaliar as perspectivas de médicos sobre “o que medir” nestes COS, i.e. 
“outcomes” e domínios de “outcomes” relevantes. Trata-se de um inquérito 
electrónico nacional (estudo ABBA) que incluiu 514 pediatras e 165 médicos de 
medicina geral e familiar (MGFs). Os “outcomes” mais pontuados e melhor 
classificados por ambos os grupos foram o internamento hospitalar e a dificuldade 
respiratória. A maioria dos “outcomes” que os pediatras pontuaram acima de um 
limiar usado para consenso (80%) focavam domínios de uso de recursos de saúde 
(internamento hospitalar e duração de internamento), e manifestações 
fisiopatológicas, incluindo gravidade clínica (dificuldade respiratória e necessidade 
de oxigenioterapia), função pulmonar, e manifestações a longo prazo (sibilância 
recorrente e asma). Os MGFs valorizaram mais “outcomes” relacionados com 
impacto na via diária, como qualidade de vida ou sono. Um futuro COS em 
bronquiolite deve também envolver, informar e obter consenso com outros grupos 
de interesse, em particular pais e cuidadores.  
!
A escolha de instrumentos para medir “outcomes” num COS (i.e. “como medir”) 
implica que as suas propriedades de medição sejam adequadas, mas estas não 
estão adequadamente estudadas para muitas escalas respiratórias. No Capítulo 3.2 
descrevemos um estudo de medição em que se avaliam a validade, fiabilidade e 
responsividade das escalas RDAI e RACS. Incluímos dados de até 1765 crianças 
com bronquiolite, recrutadas em dois estudos que decorreram no contexto de 
urgência pediátrica. Avaliámos a validade de constructo da RDAI pela formulação 
de hipóteses sobre a associação das pontuações da escala com medidas fisiológicas 
(frequência respiratória, SatO2) e com constructos relacionados com o 
internamento, usando coeficientes de correlação e análise multivariada. A 
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responsividade da RDAI e da RACS foi avaliada recorrendo a referenciais de 
mudança baseados nos constructos referidos; entre as medidas de responsividade 
incluíram-se a area sob a curva (AUC). A concordância teste-reteste da RDAI e a 
fiabilidade inter-observador foi estudada usando os limites da concordância (LoA) e 
os coeficientes de correlação intra-classe (ICC). Constatámos que as pontuações 
RDAI estavam fracamente correlacionadas com a frequência respiratória (r=0.38, 
p<0.001), e que as pontuações aumentavam para categorias de SatO2 inferiores 
(p<0.001). Pontuações de RDAI superiores associaram-se a maior risco de 
internamento hospitalar (odds ratio 1.36, IC95% 1.26 a 1.47); houve diferenças 
significativas entre participantes que foram internados, que se mantiveram na 
urgência ou que tiveram alta (p<0.001). Embora as hipóteses formuladas se tenham 
confirmado, a magnitude das associações não atingiu os limiares que pré-
definimos. Os LoA para a concordância teste-reteste da RDAI foram -3.80 – 3.64 
(20% da amplitude da escala), e a fiabilidade inter-observador foi boa (ICC=0.93). 
Confirmámos as hipóteses formuladas para avaliar a responsividade, que foi 
moderada (AUC: RDAI 0.64 – 0.70; RACS 0.72). Concluímos que a RDAI tem 
validade de constructo pobre a moderada, com boas propriedades discriminativas 
mas considerável erro de medição. A RDAI e a RACS são medidas responsivas de 
dificuldade respiratória na bronquiolite, mas não abrangem todos os determinantes 
da gravidade da doença, o que limita o seu uso na prática clínica e na investigação.    
!
Embora o diagnóstico de bronquiolite seja habitualmente simples para os 
profissionais de saúde em pediatria, não existem critérios diagnósticos 
estandardizados. O rótulo ‘bronquiolite’ pode sobrepor-se aos diagnósticos de 
sibilância aguda e asma, o que limita a interpretação da evidência terapêutica. No 
Capítulo 4 apresentamos os resultados do estudo ABBA referentes às perspectivas 
de pediatras e MGFs sobre definição de bronquiolite. Utilizámos análise de 
componentes principais (PCA) para explorar as dimensões subjacentes à definição 
de bronquiolite. A maioria dos pediatras (76.5%) concordaram com uma definição 
baseada na presença de coriza, sibilância e/ou fervores/roncos, em comparação 
com 38.1% MGFs (p<0.001). Menos de 5% dos médicos concordou com uma 
definição habitualmente usada em ensaios clínicos (<12 meses, primeiro episódio 
de sibilância). Retivemos três dimensões através de PCA: uma baseada na presença 
de coriza e de fervores/crepitações, e ausência de início súbito; outra baseada no 
número de episódios e na idade; e outra na presença de sibilância. As dimensões 
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variaram consoante a especialidade médica e os anos de formação (p<0.01). Em 
conclusão, constatámos heterogeneidade nas definições de bronquiolite, 
frequentemente divergentes das utilizadas em ensaios clínicos, o que realça a 
necessidade de uma definição robusta e estandardizada. 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Acute viral bronchiolitis is the most common acute infection of the lower 
respiratory tract during the first year of life.1 It is a major cause of clinical morbidity 
and its financial burden is substantial. The diagnosis is clinical in infants and young 
children, based on a history of rhinorrhoea and low-grade fever that progress to 
cough and respiratory distress, with findings of tachypnoea, chest retractions and 
wheeze, crackles, or both, on examination.2,3 Although bronchiolitis is usually a 
straightforward diagnosis common to all pediatricians, some variability in its 
definition exists.4 
!
Respiratory syncytial virus (RSV) is responsible for the majority of cases, usually in 
seasonal epidemics, but other viral agents may also be involved as single or dual 
infections.5 Bronchiolitis is characterized by acute bronchiolar inflammation and 
submucosal edema, impaired mucociliary clearance, necrosis of small airway 
epithelial cells and increased mucus production.6 Disease severity is likely the 
result of a complex interplay between host, agent and environmental factors.6 
Further, basic, translational and clinical research studies are elucidating the links 
between bronchiolitis, preschool wheezing disorders and later asthma and long-
term respiratory morbidity.7 Treatment of bronchiolitis is an ever-controversial topic. 
There is substantial variation in its management throughout the world, and claims 
of efficacy of many interventions have been challenged by the growing evidence 
base from recent large randomized controlled trials.8-10  
!
In this introductory chapter we present an overview of relevant epidemiological, 
clinical and pathophysiological findings in bronchiolitis, preceded by an historical 
perspective of milestones in research in this field. These provide a background for 
the interpretation of current of evidence regarding treatment interventions, such as 
corticosteroids and bronchodilators. We then identify several shortcomings in 
current evidence in this field, and how recent methodological developments in 
clinical trial design and synthesis research may help address them. We end by 
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AN OVERVIEW OF BRONCHIOLITIS 
The sources cited in this chapter were selected by searching PubMed and the Cochrane database in 
mid-2014 using the term “bronchiolitis” and associated terms for each topic addressed. We hand 
selected what we deemed to be scientific and clinically relevant articles, with preference given to 
systematic reviews with explicit quality assessment criteria, high-quality randomized and 




The term ‘bronchiolitis’ is referenced in the medical literature from late 19th 
century onwards, although it may have been used previously in clinical practice.
11,12 ‘Capillary bronchitis’ or ‘capillary bronchiolitis’ were used to describe an 
inflammatory illness of the terminal bronchioles, based on clinicopathologic 
correlations done on postmortem studies.11,13 For years there was controversy as to 
whether bronchiolitis existed as a pathologic entity, distinct from conditions such 
as bronchopneumonia and tracheobronchitis. Some authors emphasized that there 
were no clear boundaries containing the bronchiolar inflammatory process from 
contiguous spaces, i.e. the tracheobronchial tree and the lobular structure.12 
Capillary bronchiolitis would therefore be either an extension of tracheobronchitis, 
or an early stage of bronchopneumonia, and might not have relevance per se. 
However, these early descriptions were mostly based on bronchiolar disease 
occurring in adults after epidemics of measles in U.S. Army camps during the first 
World War, or accompanying the influenza pandemic of 1918.14 This isolated acute 
condition was otherwise considered rare and was mostly restricted to the extremes 
of ages, particularly infants and the elderly.12 
!
By the early 20th century, authors in the field of pediatrics were reportedly aware of 
a clinical entity occurring frequently and almost exclusively in young children, 
characterized by severe respiratory distress and cyanosis.14 However, reports were 
sparse and based in disparate cases. The first comprehensive description is 
unanimously attributed to Hubble et al in a 1941 British Medical Journal paper 
which described an epidemic of bronchiolitis involving hospitalized children.15 
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That same year, Adams described an outbreak of nosocomial neonatal chest 
infections, with cytoplasmic inclusions identified in the lungs at autopsy.16 This was 
followed by numerous other consistent case series of children with similar clinical 
findings of obstructive dyspnoea, clinically distinct from classic pneumonia or 
bronchitis, with a putative role for bronchiolar obstruction.17,18 However, the 
discussions on the uniqueness of pathologic findings pervaded, and this “new” 
condition was initially considered a small portion of obstructive or interstitial 
pneumonias in traditional pediatric textbooks.19 Only by the end of 1960s would 
acute bronchiolitis be finally listed as a distinct clinical entity in reference’s such as 
Nelson’s or Holt’s Pediatrics.19 Earlier, however, Engel and Newns had elegantly 
demonstrated that inflammatory changes in infant bronchiolitis were dominated by 
bronchiolar findings, and were different from those previously described in adult 
studies.13 While the etymology of the word bronchiolitis suggested specific 
pathologic findings, the label soon started to be applied on the basis of clinical 
findings alone. 
!
Clarity on the etiology of the syndrome was lagging, however, which further limited 
its widespread recognition and study. The role of known bacterial and viral agents 
was disputed, as few were sporadically isolated and identified.15,18 A major 
breakthrough occurred between 1956 and 1957, when Chanock and colleagues 
isolated a novel virus from infants with severe lower respiratory illness.20,21 The 
virus had been first isolated from a chimpanzee and was originally called the 
“chimpanzee coryza virus”, but was renamed respiratory syncytial virus (RSV) 
because of its predilection for the respiratory system and its tendency to produce 
syncytia when inoculated into human cell lines.21,22 It was soon found to be 
responsible for a majority of cases of infants with the clinical complex labelled 
bronchiolitis seen in several outbreaks during the 1960s.23-26 These outbreaks 
enabled a consistent description of distinctive clinical features such as dyspnoea 
with expiratory wheezing, a disparity between seriousness of symptoms and 
temperature, and a relative paucity of radiographic findings, with a spectrum of 
severity ranging from mild disease to deadly cases.  
!
During the following years, relevant developments and failures in different fields 
provided insight into the pathogenesis, natural history and treatment response of 
bronchiolitis. The first therapeutic clinical trials started in the late 1960s, testing 
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various corticosteroids and adrenergic agonists based on a putative role for 
inflammation and bronchospasm, to mixed results.27,28 Development of a formalin-
inactivated vaccine against RSV was curtailed, as immunized children exposed to 
RSV in the community and seronegative for the virus before vaccination developed 
non-protective antibody responses and experienced an increase in the severity of 
lung disease.29 Further, links between bronchiolitis, other wheezing disorders and 
asthma were first suggested by Reynolds and Cook in 1963, who distinguished 
between bronchiolitis patients in whom airways obstruction was largely attributable 
to edema of the airways and secretions, and those with a predisposition to asthma.
30 But while our understanding of childhood acute and chronic wheezing disorders 
and asthma evolved with landmark respiratory birth cohorts such as the Tucson 
Children’s Respiratory Study in the 1980s, that of bronchiolitis as a distinct entity 
lagged.1 
!
The last decades showed a resurgence of interest in bronchiolitis research. The 
development of palivizumab, the first licensed monoclonal antibody for an 
infectious disease, was accompanied by many studies on populations at risk of 
severe RSV bronchiolitis.31 The role of RSV and other bronchiolitis-related viruses in 
recurrent wheezing and asthma has recently emerged.7 Much effort has gone into 
establishing whether infants who experience severe disease and sequelae do so 
because of features intrinsic to the agent’s virulence, as opposed to characteristics 
related to the host's own immunological response.6 The first genetic association and 
high-throughput genomic expression profile studies open new avenues in the 
identification of predictors of susceptibility and/or disease progression.32 Further, 
bronchiolitis is now the focus of promising drug and biologic development efforts, 
including targeted therapies and new vaccines.33-35  
!
But for clinicians and parents on the front line during every bronchiolitis season, 
these findings are yet to translate into major breakthroughs in infant care. For more 
than 50 years the mainstays of treatment have remained oxygen, fluids and, if 
necessary, respiratory support.30,36 Oximetry and non-invasive ventilation are two 
examples of significant improvements in management, but the burden of 
hospitalizations has been increasing in developed countries, while the impact of 
disease in developing countries is tremendous.37-41 While implementation of the 
first evidence-based guidelines can be traced to the 1990s,42,43 practice variation 
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remains considerable.8,44 Further, pivotal randomized clinical trials (RCTs) for many 
frequently used interventions are only recent.45,46 Many controversies on definition 
and management of bronchiolitis have lasted, partly because of heterogeneity and 
shortcomings in current studies in this field. 
!
!
EPIDEMIOLOGY AND BURDEN OF DISEASE 
Acute viral bronchiolitis encompasses a spectrum of severity, from mild disease 
cared for in the community, through cases that require acute care in the emergency 
department (ED), a proportion of which are hospitalized and may progress to severe 
disease requiring intensive care, and rarely lead to death. While it is known to be 
the most common acute infection of the lower respiratory tract during the first year 
of life, there are remarkably few population-based epidemiological studies that 
measure incidence and burden of illness across these different severities and 
settings.47 Further, a considerable proportion of children have postbronchiolitis 
symptoms, and the risk of recurrent wheezing and possibly asthma is increased.48,49 
Figure 1.1 aggregates results from selected studies that will be described in this 
section, in order to provide an overall perspective of the epidemiological impact of 
bronchiolitis.  
 53
Figure 1.1. Epidemiology of bronchiolitis across settings (based on references presented in the text)
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It should be noted that heterogeneity in epidemiological study design and methods 
contribute to considerable variability in some measures of burden of disease. The 
following methodological factors can affect estimates: choice of population (e.g. all 
newborns or selected children at risk such as preterm), operational case definition 
of bronchiolitis (e.g. age range, specific viral agent), disease severity and setting 
(e.g. clinic-based or hospital-based), method of case ascertainment (e.g. active 
prospective surveillance or passive use of administrative health records), and source 
of denominator of children at risk (e.g. census or population-based). Additionally, 
differences in how provision of acute care is structured likely impact these 




The Tucson Children’s Respiratory Study in the United States (US) was the one the 
first population-based studies conducted in a developed country that used 
prospective surveillance to assess the incidence of acute lower respiratory tract 
infections (LRTI) in infancy, including bronchiolitis.1,50 While many other respiratory 
birth cohorts have been conducted, their focus is mostly on recurrent wheezing and 
asthma, and bronchiolitis per se is rarely an a priori defined measured event or 
outcome.51,52 The Tucson cohort of 1149 infants showed a bronchiolitis incidence 
ratio of approximately 10% within the first year of life.1 This incidence is 
comparable with that observed in administrative data studies using International 
Classification of Diseases (ICD) coding, such as that from Koehoorn et al in 2008, 
showing 13.4% of singleton infants born in the Georgia Air Basin region in Canada 
had incident bronchiolitis requiring a clinical encounter in the first 12 months of 
life.47 The impact across different levels of care is reflected in another population-
based, retrospective, cohort study of about 100000 term, non–low birthweight, 
otherwise-healthy infants who enrolled in the Tennessee Medicaid Program, from 
1995 to 2003, and were followed for one year.53 Rates of health care visits for 
treatment of bronchiolitis during infancy were substantial, with about 20% infants 
having health care visits attributable to bronchiolitis during infancy, 13.3% having 
an outpatient visit, 6.2% an ED visit, and 5.5% being hospitalized (more than one 
episode could be included). 
!
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Data on incidence is also available from studies focusing on RSV LRTI, the main 
etiological agent of bronchiolitis. Many of these studies are hospital-based, focusing 
on episodes of severe RSV-associated LRTI necessitating hospital admission, and are 
likely to yield falsely low estimates of population incidence. Albeit RSV-based data 
encompasses other LRTI manifestations such as pneumonia and thus 
misclassification is possible, there is clinical overlap and known variability in 
labeling between both diagnoses.54,55 Community-based studies with active 
prospective surveillance are rare. The Houston Family Study, a small longitudinal 
study of RSV infection in children followed up from birth performed in the 1980s, 
was paramount in assessing the natural history of RSV infection and re-infection.56 
The incidence ratio of primary RSV LRTIs in the first year of life was 21.6%, 81% of 
which had a diagnosis of bronchiolitis. In a recent birth cohort of healthy 
newborns, 42 out of 298 (14%) developed RSV LRTI during their first year of life.57 
Studies in different settings confirm the impact of RSV-disease across the spectrum 
of severity. Hall et al performed a prospective, population-based surveillance of 
acute respiratory infections in three US counties, enrolling hospitalized children or 
children presenting as outpatients in EDs and pediatric offices.54 Among 5067 
children enrolled in the study, 919 (18%) had RSV infections. Overall, RSV was 
associated with 20% of hospitalizations, 18% of ED visits, and 15% of office visits 
for acute respiratory infections from November through April. 
!
Mortality 
Mortality due to bronchiolitis is very low in developed countries, with most 
estimates around 2 to 3 cases per 100000 live births in the US, United Kingdom 
(UK) and France.58-60 Estimates of RSV-related LRTI mortality are comparable.61 
Studies that examined temporal trends in bronchiolitis-associated outcomes have 
reported either a significant decline or no change in mortality between the 1980s 
and 2000s.58,62 The odds of in-hospital mortality from bronchiolitis declined 
significantly during the last decade in the US.60  
!
On the contrary, the impact of bronchiolitis and RSV-disease in developing 
countries is tremendous. It has been estimated that, globally, between 66000 to 
199000 children younger than five years die from RSV-associated LRTI, with 99% of 
these deaths occurring in developing countries.38 Additionally, case fatality ratios in 
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children younger than one year admitted to hospital for RSV-associated severe LRTI 
are much higher in developing countries.38 
!
Hospitalizations, intensive care and hospital-acquired infection 
Bronchiolitis is the leading cause of hospitalization in infants. A landmark US study 
by Shay and colleagues in 1999 found bronchiolitis to be associated with close to 
47% of all LRTI discharges and 16% of total discharges in children younger than 
one year.37 Most studies in developed countries have shown population-based 
hospitalizations rates up to 3% or higher within the first year of life, including data 
from the US,37,53,54,60,63 Canada,47,64 England,65 Sweden,66 the Netherlands,67 and 
France.59 Many studies have focused on the subset of RSV-bronchiolitis 
hospitalizations. In a recent systematic review and meta-analysis aimed at studying 
the global burden of RSV infection, the pooled incidence in developed and 
developing countries was 5.5 (4.2–7.2) and 5.6 (4.3–7.4) RSV-positive hospitalized 
cases per 1000 per year in children aged less than a year, respectively.38 These 
estimates were highly variable within countries or regions and between regions, 
which is likely due to the aforementioned methodological factors, as well as 
differences in sensitivity and specificity of diagnostic assays to identify RSV 
infection.  
!
Differing trends in bronchiolitis hospitalizations have been found in the last 
decades. Population studies from the US reported increases through the 1990s and 
early 2000s that were consistent over time and geographically.37,53 This increase 
was also seen in other countries.64,66,67 By contrast, a recent study in the US found a 
17% decrease in the incidence of bronchiolitis hospitalizations nationally between 
2000 and 2009, with recent figures at 18.1% of all hospitalizations for children 
aged less than one year and 19.2 per 1000 person-years.60 The reasons for these 
fluctuations in trends are unclear. Variations in hospitalization rates could be due to 
health-care system differences (e.g. organization, resource allocation, and provision 
of care), physician practices, or agent/host biological or environmental factors. 
Explanatory hypotheses for the initial upward trend included an increase in 
populations at risk such as preterms, and the generalized use of oximetry.37 
However, several studies did not find similar increases in other respiratory illnesses 
in which pulse oximetry is used routinely.37 The decrease in hospitalizations could 
likely be related to changes in child care practice or altered criteria for 
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hospitalizations.60 It should be noted that accompanying trends in hospitalization 
rates for pneumonia and asthma do not support the hypothesis that changes in 
bronchiolitis admissions are due to diagnostic coding variations.37,60  
!
A considerable proportion of hospitalized children with bronchiolitis require 
intensive care, with an important burden for pediatric intensive care units (PICUs) 
during seasonal outbreaks. In a large cohort of hospitalized children in the US, 17% 
were enrolled in the ICU, either directly from the ED or during the course of 
hospitalization.68 In a nationwide administrative data study in France, this 
proportion was about 13%.59 Between 2000 and 2009, the rate of children with 
bronchiolitis who required respiratory support (invasive or non-invasive) in the US 
increased significantly from 1.9% in 2000 to 2.3% in 2009.60 
!
As a major cause of hospital admissions, bronchiolitis and RSV LRTI leads to 
significant inpatient health care costs.69,70 Curiously, the recent apparent decrease 
in the incidence of hospitalization and in-hospital mortality in the US contrasts with 
an increase in national hospital charges.60  
!
There is a paucity of published data on the epidemiology of hospital-acquired 
bronchiolitis infection. RSV has been identified as a nosocomial hazard in pediatric 
wards, particularly in young children.71,72 Nosocomial RSV infection may occur 
during or outside community outbreaks, but reported incidence and transmission 
rates vary widely.73-76 Outbreaks of nosocomial transmission in pediatric and 
neonatal ICUs may cause considerable impact, and children with co-morbidities or 
who are technology dependent are at increased risk.77,78 Hospital-acquired RSV 
bronchiolitis may also increase risk of hospital readmission.79 Overall, the risk and 
cost of nosocomial RSV infection contributes to the overall burden of RSV.80 
!
Outpatient care 
While data on inpatients has been accumulating, the interest in the impact of 
bronchiolitis in community and outpatient settings is relatively recent. Yet results 
from aforementioned population-based studies highlight how hospitalizations are a 
tip of the iceberg of bronchiolitis burden of disease, with up to four times the 
number of outpatient visits.53 Mansbach et al have studied extensively the large 
impact of bronchiolitis as a motive for ED and office visits in the US throughout the 
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last decade, with reported rates around 35 ED visits per 1000 person-years, 
accounting for about 4% of all ED visits below two years of age, with higher rates 
(up to 60 per 1000) below six months.81-83 Large scale data is also available from 
Alberta, Canada, with standardized rates of about 40 ED visits per 1000 in 
2004/2005.84 Further, comparative data from Bourgeois et al based on three patient 
cohorts show how, in children, significantly more ED visits can be attributed to RSV 
as opposed to influenza.85 
!
The overall hospital admission rates vary between 20 to 25%.81,83,84,86 Admission 
rates from the ED are known to vary by organizational factors such as type of ED 
(general vs pediatric).86 It must be noted that most available data is from North 
American centers, and differences in acute care health services and patient 
management will likely lead to regional variation in these measures.  
!
Temporal trends for outpatient care have not necessarily followed those of 
hospitalizations. US ED visit rates for bronchiolitis were stable between 1992 and 
2000, and there were increasing trends in the early 2000s within a local population 
and patients with RSV only, and similar trends were found in Canada.53,54,81,84 A 
recent update looking at US data between 2006 and 2010 found a divergent 
temporal trend by age group, with an increase among children from 12 months to 
23 months, and a significant decline below that age.83 
!
Although relatively low at the individual level, the costs for ED expenses of 
bronchiolitis are considerable given the incidence of disease.87 This adds to the 




AGENT, HOST AND BRONCHIOLITIS SEVERITY: A COMPLEX 
INTERPLAY  
Agents 
RSV is the most common pathogen associated with bronchiolitis, but other relevant 
viruses include rhinovirus (RV), human metapneumovirus (hMPV), influenza A/B, 
parainfluenza (PIV), and adenovirus.56,89-95 Another recently discovered parvovirus, 
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human bocavirus (BoV), has also been linked to bronchiolitis.96-98 The clinical 
relevance of more recently identified viruses such as novel polyomaviruses and 
coronaviruses is uncertain.99-105 There is conflicting literature about the relevance of 
bacterial co-infection in children with bronchiolitis, which may be relevant in 
children requiring intensive care.106-110 
!
Respiratory viruses differ in structure and properties, but are known to be associated 
with a variety of acute upper and lower respiratory conditions, across age groups 
and co-morbidities. RSV is an enveloped Pneumovirus of the Paramyxoviridae 
family containing a negative-sense, single-stranded RNA genome.6 There are two 
major antigenic subgroups, A and B, which are defined by different envelope 
proteins and co-circulate each year. While usually associated with morbidity in 
infants and young children, RSV also carries substantial burden in elderly and high-
risk adults.111 hMPV is a RNA virus discovered in 2001 that belongs to the same 
family and genus of RSV.112 Human RVs, members of the family Picornaviridae, 
were first identified in culture in 1956, and currently, more than 100 serotypes have 
been described.112 Human RV serotypes were first classified into 2 phylogenetic 
groups, group A and group B, but recently, a novel group group C has been 
isolated.113,114 Although once thought to cause only common cold, it is now known 
that RVs are associated with LRTI, asthma exacerbations, exacerbations of chronic 
lung disease, sinusitis, and otitis media.114-116 Adenoviruses are double-stranded 
DNA viruses belonging to the family Adenoviridae. There are at least 51 known 
serotypes of adenovirus, which are categorized into six subgenera (A to F), 
associated with both respiratory and enteric infections.112 Influenza virus is a 
negative-sense single-stranded RNA virus belonging to the family 
Orthomyxoviridae, responsible for flu epidemics and pandemics, while PIV is a 
negative-sense single-stranded RNA virus belonging to the family Paramyxoviridae, 
with four serotypes responsible for a spectrum of respiratory tract infections, 
particularly croup.112 
Observational studies have examined the epidemiology of different viruses 
associated with bronchiolitis in different settings, but some methodological caveats 
must be considered when interpreting results. First, many studies do not focus 
specifically on bronchiolitis, but also include acute recurrent wheezing episodes 
and other LRTI manifestations. Age ranges and co-morbidities of included children 
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may also differ. Second, while most studies have been performed in hospitalized 
children, less evidence is available from children with less severe disease in 
outpatient care. Further, the diagnostic accuracy of viral detection methods is 
variable and has evolved through the last decades. The first descriptive studies of 
the viral etiology of bronchiolitis in the 1960 through the 1980s primarily used 
traditional diagnostic methods such as cell culture, antigen detection, and serologic 
testing. New molecular diagnostic technology, especially multiplex polymerase 
chain reaction, greatly improved the detection of known viruses, allowing the 
identification of apparently “new” viruses, and highlighting the existence of co-
infection.112 However, these improvements in viral detection do not prove that there 
is a pathological role for these viruses. There are numerous challenges in proving 
viruses as the etiologic causes of specific syndromes such as bronchiolitis.117,118 
These include, among others, the interpretation of asymptomatic viral shedding in 
children (e.g. frequent in RV or BoV), or the significance of detecting agents using 
different specimen collection techniques at different locations in the respiratory 
tract (e.g. nasopharyngeal aspirates vs bronchoalveolar lavage).119-121 Lastly, better 
analytical validity and diagnostic accuracy in detection viruses do not necessarily 
translate into clinical utility and improvements in patient management.122  
!
The epidemiology of bronchiolitis viral agents at different levels of severity and 
settings can be illustrated by three recent major studies performed at distinct levels 
of care, i.e. inpatient, ED, outpatient clinic. All studies used molecular viral 
detection methods and had a high proportion of viral isolation. The Multicenter 
Airway Research Collaboration of the US Emergency Medicine Network conducted 
a prospective, multicenter cohort study of hospitalized children younger than two 
years during the 2007-2010 winter seasons.5 Of 2207 participants, 1410 children 
(64%) had a single virus infection and 658 (30%) had two or more viruses; the 
remaining 139 children (6%) had no pathogen identified from an extended 
molecular testing panel. The most common agents were RSV (72%) and RV (26%); 
the incidence of each of the other viruses were 8% or less. Co-infections were 
found in 32% of children who tested positive for RSV, 23% of those who had 
negative test results for RSV, and mostly 70% of children with RV. These frequencies 
are comparable to older studies performed in Europe by Jartti and colleagues, and 
Calvo and colleagues, albeit these studies had slightly more cases of non-RSV non-
RV viruses isolated.95,123 Results in outpatients show similarities but also some 
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discrepancies. In a prospective, multicenter cohort study of 277 children aged less 
than two years presenting to US EDs with physician-diagnosed bronchiolitis, 
Mansbach et al examined the frequencies of RSV, RV, hMPV, and influenza A/B 
using nasopharyngeal aspirates collected during one bronchiolitis winter season.124 
At least a virus was detected in 84% of the samples, and multiple pathogens were 
identified in 9%. All cases considered, the two most common agents were RSV 
(64%) and RV (16%), and the most common co-infection was RSV with RV. Kusel et 
al performed a landmark community-based birth cohort study of 263 Australian 
children aged less than 12 months, at high risk for atopy.119 All acute respiratory 
infections, including bronchiolitis, were prospectively surveilled, and 
nasopharyngeal samples were collected for each episode for the detection of an 
extended panel of viruses. Of a total of 984 episodes, 33% were LRTIs, 29% of 
which were wheezy LRTIs, likely encompassing cases of bronchiolitis. Viruses were 
isolated in 69% episodes, 10% of which with dual co-infections. Attributable risk of 
wheezy LRTI was 32% for RV and 10% for RSV, followed by PIV (5%) and hMPV 
(4%). Overall, RSV and RV seem to be the two most common viruses associated 
with bronchiolitis and LRTI in early childhood. RSV is detected more frequently 
from children in the hospital or ED, and RV is detected more frequently from 
children in the outpatient clinic setting.  
!
Transmission and seasonality 
Bronchiolitis cases follow recognized seasonal and temporal patterns of infection 
across settings. Most seasonal variation is attributed to the dynamics of viral 
transmission, mostly RSV. Respiratory viruses display various transmission patterns 
among humans (direct/indirect contact, droplet spray, aerosol), and their 
transmissibility is influenced by the environment in which pathogen and host meet.
125 Transmission of RSV is usually by direct or close contact with RSV-contaminated 
secretions. The virus can survive for several hours on surfaces, and for 
approximately half an hour on hands, with common transmission among household 
and child care contacts.125 Respiratory viruses that cause bronchiolitis share a 
relatively short incubation period with median one to six days.126 
!
In geographic regions with temperate climates, epidemics of bronchiolitis and RSV 
peak during winter in both the Northern and Southern Hemispheres. While 
epidemiological data is scarce, in Portugal bronchiolitis and RSV outbreaks usually 
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begin in October, peak in January and end by March or April.127-129 In contrast, RSV 
activity is continuous throughout the year in warm equatorial areas, although peaks 
may occur during rainy seasons.130 Epidemics frequently start in coastal areas or 
areas surrounded by water and then move to inland areas in the subsequent 
months, e.g. the US southern states typically demonstrate an earlier season onset 
and longer duration than other North American regions.130,131 Knowledge of RSV 
seasonality can be used by clinicians and public health officials to determine when 
to consider RSV as a cause of bronchiolitis and when to provide RSV immune 
prophylaxis to high risk children. However, the extent of variation in the onset 
timing of RSV activity can vary between communities, even those in close 
proximity, during the same year or an year-to-year basis.131 While national RSV 
surveillance systems have been set up in some countries or geographical regions, 
tailoring the timing of immune prophylaxis precisely remains difficult.131,132 
!
The distribution and seasonality of bronchiolitis caused by other viruses has been 
described in recent years. RVs are distributed worldwide with no predictable 
pattern of infection based on serotype. In temperate climates, the incidence of RV-
bronchiolitis and other RV-related LRTI infections peaks mostly in fall, with another 
peak in spring, although RV infections occur year-round.93,123,133 These seasonal 
trends mimic the RV-triggered increase in asthma exacerbations each fall (often 
referred to as the “September asthma epidemic”).134 Peak RV incidence in the 
tropics occurs during the rainy season from June to October.114 Other viruses such 
as PIV and adenovirus circulate nearly year-round with seasonal peaks of illness.
94,135
!
Our knowledge of how viral epidemics are initiated and sustained is incomplete. 
Data from RSV suggests there is a complex interplay of climate factors such as 
latitude, temperature, humidity and UVB radiance, which may affect RSV stability 
in aerosols or alter host resistance.136 Demographic and sociological factors, such 
as overcrowding and population density, urban or rural location, also play a role in 
the intensity and duration of seasons.130 Mathematical models have been to 
developed to reflect, evaluate and possibly predict the transmission dynamics of 
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Pathogenesis 
Despite the global impact of bronchiolitis disease, our understanding of the 
immunopathogenesis of this condition remains incomplete. The manifestations are 
likely caused by a combination of viral cytotoxicity and the host immune response 
to infection. The extent to which any individual factor or its correlates (e.g. viral 
load, genetic predisposition, or dysregulated immune response) contribute to the 
severity of disease has been disputed, but current evidence suggests there is a 
complex interplay between agent and host factors (Figure 1.2). Most mechanistic 
studies on bronchiolitis have focused on RSV infection. While common biological 
pathways have been shown to be activated across multiple respiratory viruses, some 
aspects of agent virulence as well as the pattern and robustness of immune 
response to different viruses are distinctive (e.g. influenza, RSV and RV), which may 
affect the acute and long-term outcomes of bronchiolitis caused by different agents.
32,139-143
It should be noted that translational research studies in bronchiolitis are limited by 
ethical and practical reasons, particularly given the need for airway biological 
specimen collection. Many of the studies were performed in children that were 
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contribute to viral clearance and certainly play an important
role in protection against reinfection (21). They include secre-
tory immunoglobulin A (IgA) and transudated, serum-derived
IgG. Secretory IgA is particularly important in protecting the
upper respiratory tract, which is accessed only very inefficiently
by serum IgG (124, 137). The IgA response is short-lived fol-
lowing primary infection but can increase in duration following
reinfection (109). Serum IgG antibodies are somewhat more
efficient in accessing the lower respiratory tract and can pro-
vide substantial protection in that compartment. In RSV-naı̈ve
infants, the maternal serum antibody titer is positively corre-
lated with a reduced level of severe RSV disease. The clinical
experience with palivizumab also shows that serum antibodies
alone can provide substantial protection from severe disease.
However, protection from passive antibodies quickly wanes,
because they decay with a half-life of approximately 21 to 24
days. CD8! T lymphocytes are important for clearing virus-
infected cells as well as for contributing cytokines, notably
gamma IFN (IFN-"), that promote a protective Th1 response
(53, 142).
Protective immunity to RSV induced by natural infection is
generally described in the literature as weak and short-lived.
This is based mainly on the frequent incidence of reinfection of
humans in nature and under experimental conditions. How-
ever, as discussed later, viral immune evasion strategies also
may contribute to reinfection. Typical RSV-neutralizing serum
antibody titers in adults are quite high (mean reciprocal titer of
1,450 in a 50%-infected-well-reduction assay), and following
natural infection, they were increased fourfold or more in 64%
of young adult and 79% of frail elderly patients, suggestive of
good responses (41). While postinfection increases in antibody
titers wane in most individuals within a year, this decay might
not be unique to RSV (40), and the residual titers remain quite
high. Brisk serum antibody responses also have been noted in
children with primary and secondary infections (66), and even
young infants of 2 months of age can have substantial neutral-
izing serum antibody responses when the titer of immunosup-
pressive maternal antibody is low (R. A. Karron, personal
communication). Primary RSV infection of seronegative ex-
perimental animals, including the chimpanzee, results in ro-
bust protective immune responses, at least in the short term
(23). In addition, in clinical studies, experimental live RSV
vaccines do not seem to be obviously reduced in immunoge-
nicity compared to live human parainfluenza virus type 3
(HPIV3) and influenza A virus vaccines, although these studies
were not designed for virus-to-virus comparisons (R. A. Kar-
ron, personal communication). There are reports of effects on
cellular immunity. RSV-specific T-helper cell responses, as
measured by in vitro lymphoproliferation, appeared to be de-
ficient during reinfection in infancy (12). Increased apoptosis
of CD4! and CD8! lymphocytes resulting in lymphopenia also
has been described for RSV-infected infants compared to un-
infected controls, with the effect being greater with younger
age and more severe illness (130). Mitogen-induced prolifera-
tion of peripheral blood lymphocytes in vitro was inhibited by
contact with RSV-infected cell monolayers, an effect that did
not prevent the expression of T-cell activation markers but
impeded the cell cycle (135). This effect appeared to be medi-
ated by the viral F protein and was augmented by G. Studies of
mice suggested that the pulmonary CD8! CTL response to
RSV was less functional and shorter lived than that to influ-
enza virus (18). However, this difference between viruses has
not been confirmed and, as noted later, functional impairment
to the pulmonary CTL response might be a feature of the
FIG. 3. Estimated contributions of host and viral factors to RSV pathogenesis in the overall pediatric population, as discussed in the text.
Factors are placed in the vertical dimension approximately according to the extent to which they are determined by the host (top) or virus (bottom)
or a combination (in between). Placement in the horizontal dimension indicates the extent to which they are pathogenic (left) or protective (right).
The size of the symbol represents speculated aggregate impact.
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Figure 1.2. Viral and host factors in bronchiolitis pathogenesis (based on RSV model) (from: Collins, with 
p rmission)
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intubated and mechanically ventilated, from whom respiratory samples of the lower 
airways could be more easily obtained, and the immunopathogenesis of milder 
disease is largely inferred.144 Autopsy and biopsy findings are also scarce, although 
they provide important insight into the mechanisms of severe disease.141,145,146 
Further, findings from human studies are confounded by factors such as co-
morbidity, bacterial and viral co-infections, and concomitant treatments. Animal 
models of viral disease complete our understanding of the pathophysiology of 
human disease, and are also a critical step in preclinical testing of the effectiveness 
and safety of new pharmacological approaches and vaccine strategies.147 Current 
animal models of RSV infection include chimpanzees, sheep, cotton rats, and mice.
147 However, there are limits in the extrapolation of evidence from animal models. 
!
Respiratory viruses causing bronchiolitis have a direct cytopathic effect on 
respiratory epithelial cells. In the case of RSV, the virus replicates in nasopharyngeal 
epithelium and then spreads to the lower respiratory tract one to three days later, by 
both direct spread and aspiration of nasopharyngeal secretions.148,149 Evidence of 
RSV deposition in distant organs has also been shown in the myocardium, liver, and 
cerebrospinal fluid.150 Ciliated cells of the small bronchioles and type 1 
pneumocytes in the alveoli are major targets of infection in the lower airway, 
although dendritic cells, neutrophils and other cells are also infected.145,146,151-154 
The RSV virion consists of a nucleocapsid packaged in a lipid envelope derived 
from the host cell plasma membrane. The RSV envelope contains three viral 
transmembrane surface glycoproteins: the large attachment glycoprotein G, the 
fusion protein F, and the small hydrophobic SH protein.154 RSV has a tropism for 
superficial cells of respiratory epithelium, which it infects by attaching to the cell 
surface through protein G, while the F protein mediates fusion with the epithelial 
cell membrane along with adjacent cells.155 This (rarely) results in the formation of 
giant multi-nucleated cells – syncytia – for which the virus is named.154 The SH 
protein may play a role in both syncytial formation and blocking of cell apoptosis, 
or inflammasome activation.155,156 Virion assembly occurs at the plasma membrane 
of infected cells, and virions are released by budding. RV is also known to directly 
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It is known that influenza relies on rapid evolution and RVs on extensive diversity to 
escape immunity, thus influencing pathogenicity, and there is also evidence that 
RSV strain may contribute to differences in viral pathogenicity.143,157,160 However, 
even antigenically similar or identical RSVs can be be equally strongly pathogenic. 
Importantly, it has been suggested that RSV is more virulent than other respiratory 
viruses, as multiple studies have shown that higher RSV loads are predictors of 
increased disease severity.161-166 
!
The observations on the critical importance of the agent’s virulence challenge the 
long-standing immunopathology-based pathogenesis paradigm of an over-
exuberant immune cascade of inflammatory mediators and cellular infiltrates in 
bronchiolitis solely due to an exaggerated immune response.162,167 Recent findings 
suggest that the response to most respiratory viruses involves a complex interplay 
between dysregulated innate and adaptive immunity, as well as mucosal 
inflammation.142,168,169 The innate immune response has a critical role in the initial 
stages of infection, and innate immune mediators influence both early inflammatory 
responses and the subsequent development of an adaptive immune response.
168,170,171 Viral double-stranded respiratory virus RNA is recognized in epithelial 
cells and resident mucosal immune cells (e.g. dendritic cells and macrophages) 
through the recognition of pathogen-associated molecular patterns that activate 
various pattern recognition receptors, such as toll-like receptors and RNA-helicases, 
and the inflammasome.171 A range of pro-inflammatory cytokines, chemokines and 
growth factors are released that promote inflammation, direct recruitment and 
activation of immune cells, and initiate anti-viral responses including type I/III 
interferons.168,171-173 Dendritic cells and airway epithelial cells can link with 
adaptive immunity by activating antiviral effector and memory T-cells, or directly B-
cells.174 Neutrophils account for the majority of cells recruited into the airways of 
children with bronchiolitis, with lymphocytes representing up to 10%, mostly B 
cells.141,175  
!
While the innate immune system was originally thought to be at full strength at 
birth, recent evidence demonstrates its immaturity in the healthy neonate. Studies 
addressing the role of innate immunity on RSV disease severity have had somewhat 
inconsistent results, possibly due to differences in study design (e.g. settings, 
severity, outcomes) and measurements (e.g. stimulated vs unstimulated mediators, 
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location of specimen collection).172,176-187 However, evidence is accumulating that 
severe RSV bronchiolitis is associated with hypo-responsive innate immune 
function.32,140,146,153,176,178,179,187-189 For example, non-structural proteins of RSV, 
expressed in great abundance in the earliest phase of infection, are capable of 
inhibiting host type I interferon responses.190 The profile of innate immune 
dysfunction may differ quantitatively and qualitatively between viruses.32,188 For 
example, recent studies investigating RSV and hMPV suggest that they elicit unique 
cytokine profiles, and use different mechanisms to activate human dendritic cells.
183,191-193 This could contribute to differences in bronchiolitis pathogenesis 
depending on agent. Growing evidence has also demonstrated an important 
participation of several components of the pulmonary surfactant, particularly 
proteins SP-A and SP-D, in the mechanisms of lung innate immunity against RSV 
infection, and in the onset of the inflammatory response that follows infection.194 
Infants with RSV bronchiolitis are deficient in surfactant, both in content and 
function.194-197 
!
The dual role of the adaptive immune response in RSV bronchiolitis has also been 
subject of ongoing controversy, with debate on whether it protects against disease 
or instead causes symptoms by a vigorous inappropriate response.142 Cellular 
immunity plays a role in combating and recovering from RSV infection, with CD8 T-
lymphocytic stimulation and response implicated in viral clearance.169 Humoral 
immunity can also have a protective role, since RSV-infected infants with higher 
levels of maternal transplacentally transferred anti-RSV antibodies have been shown 
to have a lower risk of hospitalization and reduced severity of bronchiolitis.56,198,199 
Further, passive immunization with the humanized anti-RSV F protein monoclonal 
palivizumab is effective in reducing disease severity in high-risk infants.200 
Neutralizing serum antibodies are an important mediator of protection against 
lower respiratory tract disease, whereas local mucosal IgA responses may be 
important in mediating protection against infection in the upper respiratory tract.201 
However, it is now clear that an immature, weak adaptive immune response during 
infancy is a key factor in the pathogenesis of severe RSV infection, with a possible 
effect of RSV on T cell depletion and suppressed cell-mediated immune responses.
141,146,176,179,202,203 Studies in patients with severe RSV bronchiolitis show a profound 
decrease in local interferon II production, which is associated with disease severity. 
Further, RSV infection elicits an antibody response that fails to establish long-lasting 
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immunity and prevent periodic, albeit less severe, reinfections throughout life.
56,204,205 Antibody responses are of low magnitude and poor durability, most likely 
due to a combination of immunological immaturity and the suppressive effect of 
maternally transmitted transplacental antibody.199,206,207 Concurrently, there is 
evidence that T cells enhance disease. A balance between specific T cell subset 
function, such as Th17 cells and Tregs, may be involved in the regulation of 
protective immunity, immunopathology and mucosal inflammation during RSV 
infection.169 Despite extensive literature on the relative balance and possible skew 
between Th1 and Th2 cytokine signatures, it remains unclear what if any effect this 
has on RSV-induced disease severity.203  
!
The complex links between innate and adaptive immunity are revealed through the 
understanding of enhanced respiratory disease that affected children immunized 
with a formalin-inactivated vaccine against RSV in the 1960s. The vaccine was 
immunogenic, but it elicited a non-protective antibody response.29 The main 
clinical manifestations were bronchoconstriction and severe pneumonia, with non-
protective antibody complexed with virus deposited in affected tissue.208 Only 
recently studies were able to show that immunization with formalin-inactivated 
RSV elicited a low-avidity, RSV-specific antibody response, a robust RSV-specific 
CD4+ T cell response and no cytotoxic CD8+ T cell response, due to failure to 
engage and activate innate pattern recognition receptors.209,210 
!
In summary, the current picture of bronchiolitis pathogenesis involves a complex 
dysregulated immune response to viral infection. Immature and impaired innate 
and adaptive immune responses may interfere with the development of effective 
antiviral clearance, while misdirected cytokine responses and excess inflammation 
potentiate disease. Thus, severe RSV disease sequelae may be associated with an 
inappropriate immune environment, and heterogeneity in agent-specific virulence 
and host responses are only starting to be uncovered.  
!
The complexity of agent-host interactions is magnified by the polygenic nature of 
host genetic factors related to RSV severity. Studies using the candidate gene 
approach have identified specific loci that likely affect RSV disease severity, and 
genetic associations with single nucleotide polymorphisms in genes within 
plausible biological pathways have been reported (e.g. innate host defense genes, 
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cytokine or chemokine response genes, and altered Th1/Th2 immune responses).
211-213 This has allowed, for instance, to focus on relatively novel factors of disease 
pathogenesis for which epidemiological data is also emerging, such as the interplay 
between vitamin D, its receptors and downstream innate biomarkers like 
cathelicidin.211,214-217 However, methodological limitations of candidate gene 
approaches are well known, and larger-scale genome-wide association studies are 
yet to be conducted and replicated.218 Bronchiolitis research has lagged behind in 
using the emerging fields of “-omics” to improve our understanding of disease 
pathogenesis, in contrast to their exponential use in recurrent wheezing and asthma 
research.219-221 Only recently have the first high-throughput screening studies of 
host transcription profiles and gene suppression in animal models and humans 
begun to provide insights into the host response to, and regulation of, RSV 
infection.32,222,223 Other genomics, metabolomics and proteomics approaches may 
soon follow.224 A systems biology approach, which involves integrating information 
from all levels of structure and function of the system, will likely provide greater 
insight into the understanding of acute bronchiolitis and its links to recurrent 
wheezing and asthma.225 Further, biosignatures and integrated pathways may open 
new avenues for the discovery of biomarkers to identify phenotypes, to confirm 
diagnosis and establish prognosis, and to identify therapeutic and preventative 
targets. However, these expectations will have to match the many limits of validity 
of “-omics” research.226,227 
!
Pathophysiological mechanisms 
The pathological mechanisms of bronchiolitis lead to loss of cilial motility and 
impaired mucociliary clearance, submucosal edema with bronchiolar and 
peribronchiolar inflammation, increased mucus secretion, neutrophilic infiltration, 
necrosis and sloughing of respiratory epithelial cells of the small airways.6,141,145 The 
main physiological phenomena that ensues is small airways obstruction; critical 
narrowing of peripheral airways results in severe obstruction, with markedly 
increased respiratory system resistance (Figure 1.3).228-230 Whether there is 
associated bronchospasm is a matter of debate. The impact of airways obstruction is 
amplified by developmental changes in airway diameter and compliance, 
pulmonary parenchyma and chest wall properties in infants, which interact in a 
highly complex and dynamic manner.231-236  
!
 68
CHAPTER 1: GENERAL INTRODUCTION
CHAPTER 2
Obstruction is caused both by a ball-valve mechanism due to intraluminal plugging 
by mucus and cellular debris, and by dynamic small airways narrowing with 
disproportionate turbulence and decreased airflow during expiration.144 The small 
caliber and high wall compliance of the developing airways render the infant and 
child more vulnerable to the development of airway obstruction. Under normal 
breathing conditions the small caliber of the airways represents no mechanical 
disadvantage because there is good correspondence between airway cross-sectional 
area and gas flow. When obstruction develops, however, airway resistance 
increases as an exponential function of the reduction in airway diameter, according 
 69
Figure 1.3.  Pathophysiology of the classic form of bronchiolitis/RSV infection (adapted from: Javouhey, 
with permissions)
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to Poiseuille’s law.237 In young infants, peripheral airways may contribute as much 
as 50% of intrathoracic resistance.238 Further, airway compliance is likely greater in 
previously healthy infants than in adults, due to changes in the mechanical 
properties of the airway walls with increased collapsibility.239,240 
!
Small airways obstruction leads to air trapping and areas of atelectasis.144 Air 
trapping causes patchy hyperinflation, with breathing at a higher lung volume 
because of a raised functional residual capacity (FRC) despite reduced total lung 
capacity.228-230 Hyperinflation generates an extra elastic load from the chest wall 
and forces respiratory muscles to operate in unfavorable biomechanical conditions, 
with stiffer lungs and decreased lung compliance worsened by atelectasis.241 Risk of 
atelectasis is also increased because the pores of Kohn and other inter-alveolar 
pathways are not well developed in infants, so collateral ventilation is less effective.
235 Moreover, changes in surfactant lipid components and hydrophobic proteins 
impair the reduction of the surface tension at the alveoli and terminal bronchioles, 
resulting in decreased surface activity, atelectasis, and decreased lung compliance.
194 Infants must increase their work of breathing by using accessory respiratory 
muscles, which has been confirmed by various studies using different techniques to 
measure the respiratory muscle load in severe bronchiolitis.229,242,243 Nasal 
obstruction, which is commonly present in the context of bronchiolitis, adds to the 
work of breathing, since a large percentage of airway resistance in infants is nasal in 
origin.233 Further, infant head and neck anatomy is prone to upper airway 
obstruction.244 When total work of breathing against compliance and resistance is 
summated, an optimal respiratory frequency exists that minimizes the total work of 
breathing. In obstructive lung diseases with increased resistance such as 
bronchiolitis or asthma, despite tachypnea, the optimal frequency is theoretically 
relatively decreased leading to slower, deep breathing, as compared to the rapid, 
shallow breathing of restrictive lung diseases such as pulmonary edema, 
pneumonia, or acute respiratory distress syndrome (ARDS).245 However, in response 
to the higher inspiratory load, there is an increase in the inspiratory time/total 
respiratory time ratio and a shorter expiratory period due to airway obstruction.246 
This compounds dynamic hyperinflation and intrinsic positive end-expiratory 
pressure (PEEPi), which further decreases compliance and increases inspiratory 
work of breathing.242,243,246 
!
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All the aforementioned factors contribute to mismatching of ventilation and 
pulmonary perfusion giving rise to arterial hypoxemia. Other developmental 
changes in airway-parenchyma and lung-chest wall interactions also adversely 
affect the mechanics of breathing. Alveolar multiplication is largely a postnatal 
event, and infants have fewer alveoli and fewer alveolar attachments to airway 
walls than older children.235 A compliant chest wall offers little outward recoil to 
the respiratory system and thus the elastic characteristics of the respiratory system 
approximate those of the lung, which has an inward recoil only slightly less than 
that of adults.233,247-249 Since FRC is determined by the balance of lung and chest 
wall recoil forces, a high chest wall to lung compliance ratio leads to a low 
mechanically determined FRC relative to older children and adults.233 Bronchiolitis 
is a condition with elevated closing capacity (i.e. the volume of gas that remains in 
the lung when small alveoli and airways in dependent regions of the lung are 
collapsed or considered closed), which can easily rise above FRC, therefore some 
lung units are closed during breathing; these areas of collapse add to ventilation 
and perfusion inequality and intrapulmonary shunting.245 This is partially 
compensated by dynamic mechanisms that elevate the end-expiratory volume, such 
as modification of breathing patterns and rates.233,250 However, these dynamic 
compensatory mechanisms are highly depend on sleep state, which can adversely 
affect the mechanics of breathing in children, e.g. with worsening hypoxemia 
during sleep in bronchiolitis patients.245,251 All these deleterious developmental 
changes are intensified in preterm and younger infants, which are known 
prognostic factors for disease severity in bronchiolitis.234,252-254 
!
Respiratory failure and hypercapnia in bronchiolitis is usually the result of 
worsening lung compliance, airway resistance and respiratory muscle fatigue. 
Developmental factors also contribute to the latter. Chest wall muscle contractions 
are needed to stabilize the compliant infant rib cage, and increased diaphragmatic 
work of breathing leads to significant expenditure of calories and risk of fatigue.233 
Respiratory muscle fibbers are still developing, and the proportion of fatigue-
resistant fibbers is relatively low.255 Further, a significant portion energy is wasted 
through the distortion of the highly compliant rib cage during negative pressure 
generation from diaphragmatic contraction.235,256 
!
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Apnea is commonly found in bronchiolitis and RSV infection, but its mechanisms 
are not completely understood.257 Immaturity of central ventilatory centers is likely 
to be one of the explanations, which can explain the high prevalence of apnea in 
infants born prematurely and infants below two months of age.258 Younger and 
premature infants have been shown to be vulnerable to viral and inflammatory 
induced central autonomic dysfunction.259 Aforementioned changes in breathing 
mechanics may also contribute to apnea secondary to severe lung disease, which 
occurs as the consequence of continued high work of breathing and muscle fatigue. 
!
Some evidence suggests severe bronchiolitis and RSV-associated lower respiratory 
tract disease encompass distinct patterns of respiratory failure. Hammer and 
colleagues showed that the most frequent pattern is obstructive airway disease, 
which could be labelled as “classical” bronchiolitis, characterized by increased 
airway resistance, air trapping, reduced lung capacity, and low respiratory system 
compliance compared with normal values, with bilateral perihilar infiltrates and 
hyperinflation on chest radiography.230 A smaller proportion of children have a 
resistive profile, closer to pneumonitis and/or acute respiratory distress syndrome, 
with very low compliance and resistance, and bilateral alveolar consolidations on 
radiography. The latter pattern is more severe and evolves with large intrapulmonary 
shunt and a propensity to fluid retention or heart failure. Other authors have 
suggested that these patterns cannot be strictly dichotomized and form a 
continuum, with more severity at each end of the spectrum.260,261 
!
Risk factors and prognosis 
The majority of the children who develop bronchiolitis are healthy term infants 
without any known predisposing factors.65 Further, as previously described, most 
children have a mild course, only approximately 2% to 3% will be hospitalized, 
and less than 1% will be admitted to an ICU, intubated, or die. Observational 
studies have identified demographic, environmental, family history factors and 
comorbidities associated with incidence of bronchiolitis of different severity, some 
of which restricted to RSV bronchiolitis. These factors are summarized in Table 1.1. 
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There has been considerable research in risk of disease and prognosis of 
bronchiolitis, albeit studies are heterogeneous in objectives and study design, and 
share common methodological obstacles and limitations.262 Importantly, it is 
challenging to disentangle factors associated with bronchiolitis incidence in 
Table 1.1: Selected risk factors and prognostic factors of bronchiolitis
Factors Risk factors for bronchiolitis incidence Prognostic factors for bronchiolitis 
severity
Case definition Outcome
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Unknown Yes Not included Yes Variable Variable
CHD Unknown Yes Not included Likely yes Variable Yes
Down 
syndrome
Unknown Yes Not included Likely yes Yes Yes
*Based on references 272,273,275-277,282,283,288
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children without the condition (i.e. “risk factors”), from factors associated with 
disease severity in children who already have bronchiolitis (i.e. “prognostic 
factors”).262,263 While it is likely that some factors overlap, clarification on their 
distinct contribution to the incidence and severity of disease is scarce, as studies 
vary in their start points (populations) as well as their endpoints (clinical outcomes). 
Studies often focus on selected population subgroups, either likely to be at risk (e.g. 
pre-terms of a certain gestational age range) or recruited in specific settings (e.g. 
infants attending ED), with few population-based studies or studies in mild disease. 
Outcome definition and ascertainment also varies, often meshing measures of 
incidence and severity, e.g. restricting bronchiolitis cases to those with 
hospitalization, or encompassing different manifestations of LRTI. Moreover, most 
literature is focused on RSV bronchiolitis and LRTI, with the purpose of identifying 
children likely to benefit from preventive use of palivizumab. However, the 
direction and magnitude of association of several risk and prognostic factors may 
differ between viral agents. Finally, prognostic studies in bronchiolitis suffer from 
limitations in the design, analysis and reporting which are common in prognosis 
research, such as limited replication and small sample sizes, which limits the 
reliability and applicability of the published findings.264,265 
!
It is important to consider that risk and prognostic factors are not necessarily in the 
causal pathway to incidence and disease severity, as most are merely associated 
with the “true” causal factors.266 Estimating causal effects from observational studies 
has many challenges, particularly given confounding and selection biases, as well 
as effect modification between different factors; recent methodological 
developments in causal inference methods have been scarcely applied in the fields 
of bronchiolitis and wheezing disorders. Given the uncertainties regarding agent 
and host contributions to bronchiolitis pathogenesis, it is not surprising that results 
from epidemiological and prognosis studies have often informed further 
mechanistic studies. For example, epidemiological studies identified Down 
syndrome as a novel epidemiological risk factor for severe disease, with subsequent 
translational studies trying to identify specific underlying respiratory or immune 
susceptibilities.267,268 Conversely, structured approaches using biological rationale 
to inform possible potential prognostic factors are less frequent, albeit increasing. A 
recent study focused on a putative prognostic candidate biomarker, cathelicidin, 
based on the role of innate immunity and vitamin D pathways in bronchiolitis 
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pathogenesis.216 It should be noted that the fact that one or more prognostic factors 
are not in the causal pathway does not lessen their relevance in predicting disease 
and severity.  
!
Prognostic research includes also includes the development, validation, and impact 
of statistical models that predict risk of a future outcome, i.e. prognostic models.269 
Prognostic models use multiple prognostic factors in combination to estimate 
outcome risk for an individual, based on their specific set of prognostic factor 
values, and can form the basis of clinical prediction rules.270 Only recently has 
there been progress in the development of prognostic models and clinical 
prediction rules for bronchiolitis or severe bronchiolitis, mostly focused on the 
prediction of RSV disease with hospitalization in larger groups of late preterm 
infants or healthy term infants.57,271-277 These models often include host and 
environmental factors such as daycare attendance and/or presence of school-aged 
siblings, whose prognostic value is dependent on the geographical region and 
socio-cultural habits. Further, considerable heterogeneity in baseline risk of 
hospitalizations, which is a crucial outcome in these models, is likely due to 
country-dependent medical practices and hospitalization guidelines.  
!
Age, time of birth and gender are important risk and prognostic factors in 
bronchiolitis and RSV LRTI. In most studies, males have an increased risk of 
bronchiolitis with or without hospitalization as compared to females, and may also 
have increased mortality.37,47,60,81,278,279 When considering all cases regardless of 
setting or viral agent, population-based studies show bronchiolitis is more frequent 
within the first six months of life.1,47 Age distribution of incidence rates varies 
according to severity: hospitalizations are more frequent within the first two to three 
months and then decline, while outpatient visits are frequent during the first year.47 
In a recent population-based retrospective birth cohort in the UK, the median age 
of bronchiolitis admission was 120 days (interquartile range [IQR] 61 to 209); age 
of admission was slightly higher for children born preterm compared with infants 
born at term.65 Further, age is a relevant prognostic factor; in a multicenter 
prospective cohort study of hospitalized children with bronchiolitis, age younger 
than two months was a strong predictor of length of stay and need for mechanical 
respiratory support.5,68 Data on RSV disease shows similar findings. A narrative 
review of studies published before 2000 found that up to 28% hospitalized children 
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with RSV were aged below six weeks, and up 70% below six months, and more 
recent results are comparable.54,278,280 Further, the highest incidence of RSV 
bronchiolitis in the community is also observed at older ages, both in developed 
and developing countries. In the US, stable rates for outpatient visits are seen within 
the first year of life, while in a prospective cohort of healthy term children in the 
Netherlands with active community surveillance, the median age at the time of RSV 
LRTI was 6 months (IQR 4 to 8).54,57 Data from Kenya and Indonesia also found a 
substantial risk of outpatient severe bronchiolitis up to 18 months of age.204,281 The 
risk of hospitalization due to RSV infection is higher when the first few months of 
life coincide with the first half of the RSV season.57,282,283 Various causal factors 
have been suggested to explain the association of age and time of birth with severe 
disease, including exposure to viral agents, humoral and innate immunity 
deficiencies, and smaller airways.284 Male–female differences in lung function may 
also explain the influence of gender.285 Motives for a relatively low incidence of 
mild disease in healthy term infants are a matter of debate.278,284,286  
!
Day care attendance, crowding, and having young siblings, are potential risk factors 
for bronchiolitis, thru increased risk of close viral exposure and possibly a higher 
viral load.125,278 A recent systematic review explored the association of residential 
crowding and the risk of laboratory-confirmed RSV LRTI.287 The association with 
hospitalization was consistent across risk status, study design, and geographic 
location, but less so for outpatient RSV LRTI. Included studies used one or more 
measures of crowding, including presence, number and/or age of siblings and 
number of people living in household. Similar associations have been found in 
studies analyzing all cases of bronchiolitis.47,279 Day care attendance has shown 
somewhat mixed results. While it known that respiratory illness is increased in 
infants and young children attending day care and group care outside the home, 
not all studies have found a significant association with RSV infection with 
hospitalization.31,57,278,282,283,288,289 Differences can likely be attributable to distinct 
patterns of use of daycare (e.g. very low in a Spanish cohort, while high in 
Netherlands and Canada), but also confounding or effect modifier variables such as 
presence of school aged siblings or related socio-cultural parameters.  
!
Studies on the influence of tobacco smoke exposure on the risk of bronchiolitis and 
RSV LRTI have had somewhat conflicting results.278,290 Inconsistencies in some 
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results may relate to different measures used to quantify smoke exposure, as well as 
confounding or mediation by social deprivation.278,291 Tobacco smoke exposure is a 
known risk factor for many adverse health-related outcomes, and maternal smoking 
has been shown to reduce lung function in children, either through impairment in 
airway development or by changing lung elastic properties.292-295 Two recent 
systematic reviews found robust evidence across study designs, patient populations, 
countries and methods of analysis that both pre- and postnatal tobacco smoke 
exposure, increased risk of bronchiolitis and RSV LRTI, particularly with 
hospitalization.290,296 Results from these reviews and another study also suggested 
an independent association with disease severity among children hospitalized for 
RSV, and possibly increased risk of mortality from bronchiolitis.290,291 In a large 
retrospective cohort study, Carroll et al also found a significant dose-response 
relationship between the number of cigarettes smoked during pregnancy and 
clinically significant bronchiolitis.279 Evidence was less consistent of an association 
between tobacco exposure and outpatient mild RSV LRTI.290 
!
Breastfeeding has a well-documented beneficial effect against many infectious 
diseases, and previous systematic reviews of observational studies have 
documented a decrease in the risk of hospitalization due to LRTIs from both 
developed countries and developing countries.297-299 Different LRTIs are often 
aggregated in these studies, and data is less clear as to a specific protective effect of 
breastfeeding against bronchiolitis and RSV infection.278 Studies in cohorts of late 
preterm infants showed mixed results, but evidence seems to suggest reduced 
incidence and possibly severity of bronchiolitis and RSV infection.57,282,283,288,300,301 
Further, it is likely that breastfeeding interacts with other risk factors like weaning, 
crowding, daycare attendance, smoke exposure and socioeconomic status, and 
methodological limitations of most studies have been unable to address these 
interactions.299,302 Evidence is conflicting regarding the association of breastfeeding 
and wheezing illnesses and asthma, and reviews have often encompassed 
bronchiolitis as an outcome, which may be an additional source of bias.303-306 There 
are many biological reasons why breastfeeding would protect against bronchiolitis, 
including transfer of maternal antibodies, presence of antiviral and lung maturation 
mediators in milk, and its innate immune modulatory effects.278,307  
!
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Other sociodemographic factors have been associated with bronchiolitis incidence 
and severity, but results are somewhat conflicting. These include urban 
environments, low socioeconomic status, and low maternal age and education.
47,53,57,278 Certain clinical populations seem to be at higher risk of severe 
bronchiolitis with hospitalization, including native or aboriginal North American, 
American Samoan and Bedouin infants.47,308-313 Contradictory data exists regarding 
the risk of hospitalization, disease severity and outpatient visits for hispanic, black 
and white infants.53,81,278 Differences between ethnic groups are most likely 
attributable to associated socioeconomic determinants, health-seeking behaviors, or 
access to care, although they may also relate to genetic factors.313  
!
Traditional, well-established, high-risk populations with clinical comorbidities at 
increased risk for severe RSV bronchiolitis and LRTI, include preterm infants with or 
without underlying bronchopulmonary dysplasia (BPD)/chronic lung disease (CLD) 
of infancy, and children with hemodynamically significant congenital heart disease 
(CHD). Evidence from the pre-palivizumab era consensually identified prematurity 
and BPD/CLD as distinct independent and interacting risk and prognostic factors for 
severe RSV bronchiolitis and LRTI disease, despite heterogeneous study design and 
quality.31 Infants with hemodynamically significant CHD have also been shown to 
be at increased risk of severe RSV and all cause bronchiolitis, as well as to have 
increased severity of disease and mortality.31,65,314,315 As palivizumab use for these 
subgroups increased differentially in multiple countries and health systems, causal 
and prognostic associations with RSV disease are now harder to infer. Importantly, 
RVs are also emerging as important agents of bronchiolitis in very low birth weight 
infants, particularly in children with BPD/CLD.115 Recent studies continue to 
identify prematurity and/or BPD/CLD as risk factors for RSV-related but also all-
cause bronchiolitis hospitalizations, with likely impact on disease severity (i.e. 
length of stay, need of ventilatory support and mortality).5,31,54,65,68,289,314 Risk of 
bronchiolitis in both premature and BPD/CLD patients may extend longer during 
the first year than for term infants.65,77 Whether stratified levels of BPD/CLD severity 
modify the magnitude of risk of bronchiolitis is not clear.77,316 Most focus during the 
last decade has been on late preterm infants (33 to 35 weeks of gestational age) 
with no additional comorbidities, a subgroup particularly at high risk of RSV-
hospitalization.31,317,318 Some of the above mentioned individual and environmental 
risk factors have been included in prognostic models aiming to identify children in 
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this age range at higher risk of RSV infection with hospitalization; these models 
have been derived and externally validated in Europe and North America.
272,273,275-277,282,283,288 Low birth weight is also consistently independently associated 
with bronchiolitis visits and admissions even in term infants; it is also a prognostic 
factor for need for ventilatory support.47,68,319 Lung development and immune 
susceptibilities likely explain the role of prematurity and BPD/CLD, while 
intrauterine growth restriction may also have an independent role, alongside 
potential confounders (e.g. maternal smoking).233,236,254,294,320 Direct cardiac 
evolvement reported during RSV infections ranges from arrhythmias to global 
myocardial involvement with mechanical dysfunction, and anatomical cardiac 
lesions can worsen an already compromised respiratory status.321-323 
!
Recent studies have focused on the role of other chronic conditions, both 
congenital and acquired, as independent risk factors for bronchiolitis.324 A range of 
chronic neurological diseases, including neuromuscular diseases, cerebral palsy, 
and epilepsy,  have been shown to increase both the risk of hospitalization and the 
risk of a complicated course.65,314,324,325 In children with technology dependence 
and neuromuscular disorders, multiple pulmonary, immune and neurological 
factors contribute to increase their risk of clinical deterioration due to airway 
infections.326 Primary or acquired immune deficiency syndromes and other 
conditions with immune suppression, including solid organ or hematopoietic cell 
transplantation, have been associated with prolonged viral shedding and increased 
morbidity and mortality rates in bronchiolitis and RSV infection.31,324,327-330 In 
children with cancer, chemotherapy-induced lymphopenia is a prognostic factor for 
severe disease.331 It should be noted that all respiratory viruses may lead to severe 
respiratory disease and respiratory failure in immunocompromised children, and 
the clinical phenotype may be indistinguishable between bronchiolitis and 
pneumonia/pneumonitis.327 Down syndrome has emerged recently as a novel risk 
factor for disease incidence and severity.65,267,317,324,332,333 Both lung, airway and 
immune abnormalities may explain this increased susceptibility, which is 
independent from Down syndrome comorbidities such as prematurity and CHD.
268,334,335 A set of other chronic conditions, including cystic fibrosis, abnormalities 
of the airway and other types of CLD, chromosomal and genetic disorders, and 
congenital malformations, have been linked to a higher risk of hospitalization for 
RSV LRTI and possibly disease severity.65,324 More research is needed to clarify 
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whether these associations are due to specific susceptibilities, as opposed to 
confounding by admission threshold, misclassification of conditions, or other 
biases.324 Evidence also suggests that nosocomial/hospital-acquired RSV infection is 
an additional major risk factor for death in children with severe RSV infection, 
particularly those with chronic comorbidities.78,336,337 
!
While it remains unclear if the viral cause of bronchiolitis is a clinically relevant 
prognostic factor, recent studies seem to suggest an association with disease 
severity, particularly in the case of co-infections.5,338-340 The largest multicenter 
study of hospitalized bronchiolitis found an association of viral agent with length of 
stay, but not with need for ventilatory support.5,68 In particular, children infected 
with RV alone or in combination with non-RSV viruses had a significantly shorter 
length of stay, while for RSV/RV co-infections it was significantly longer. RSV is 
known to induce changes in airway epithelial cell adhesion molecules and to 
reduce interferon II response, both of which may enhance RV replication and 
explain the increased severity of illness of RSV/RV co-infections.5 However, other 
studies have found contradictory results on the prognostic value of co-infections 
using measures of disease severity such as hospitalization rate, length of hospital 
stay, symptoms, severity score, or duration of illness. Further, findings of a milder 
course for RV-alone bronchiolitis have been replicated by some, but not all related 
studies.91,123,133,341,342 Evidence is scarce about other co-infections, with some 
studies suggesting that combinations of RSV with hMPV or BoV may be deleterious; 
more research is needed to determine the clinical implications of the many other 
pathogen combinations.338-340,343 As previously mentioned, RSV viral load may 
affect disease severity.161,163-166 Data are conflicting regarding the influence of RSV 
serotypes, while RV groups are also being studied.114,163,344-347  
!
The association of bronchiolitis with family or child history of allergic disorders, 
asthma and atopic dermatitis, is complex and likely bidirectional.278,348,349 Results 
of studies of these variables as predictors of bronchiolitis incidence and severity 
have been conflicting, and will be further discussed in the section about 
bronchiolitis, recurrent wheezing and asthma, along with genetic predictors and 
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CLINICAL PRESENTATION, DIAGNOSIS AND NATURAL HISTORY 
Clinical findings 
Acute viral bronchiolitis is a clinically diagnosed condition based on a constellation 
of symptoms and signs.2,3,350 Diagnosis is usually straightforward during the 
epidemic months, but there is considerable variability in clinical findings and in 
their interpretation, both over time and between patients. Recent large multicenter 
cohorts have improved our understanding of how clinical findings on presentation 
can discriminate disease severity and predict clinical course, but considerable 
limitations remain in discriminating disease severity and predicting clinical course.
5,262,351,352 
!
Bronchiolitis is often preceded by a one- to three-day history of upper respiratory 
tract symptoms, such as nasal congestion and/or discharge and mild cough.2,3,350 In 
most instances, the patient’s history reveals exposure, either to an adult or older 
child with a common cold or other trivial respiratory tract infection, or to an infant 
with similar diagnosis at home or in the daycare setting. The onset of lower 
respiratory tract symptoms is usually relatively quick, often being recognizable from 
the caretaker’s description of the illness. The maximum severity of illness generally 
is attained within 24 to 48 hours of the first signs of lower respiratory tract illness.353 
The physical examination reflects the dynamic nature of the disease, and serial 
observations are required over time to fully assess the child’s status. Manifestations 
may range from mild signs of respiratory distress to respiratory failure. There are 
variable degrees of tachypnoea, tachycardia, and signs of increased work of 
breathing, including flaring of the alae nasae, grunting, supraclavicular, subcostal, 
and intercostal retractions, use of accessory muscles and abdominal breathing. In 
severe cases cyanosis may occur. Upper airway obstruction may also contribute to 
work of breathing.  
!
The predictive value of physical examination correlates of respiratory distress in 
bronchiolitis is not similar between different individual clinical findings nor 
consistent across studies, and has been rarely systematically studied.262,354,355 There 
are likely limits to the validity of static measurements in a highly dynamic 
condition, and different measures may reflect overlapping but distinct dimensions 
of respiratory distress related to airway and pulmonary involvement due to disease 
progression and severity. Further, the presence and magnitude of treatment response 
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(e.g. to some bronchodilators) and post-treatment values may also have distinct 
prognostic significance.356   
!
Some studies across outpatient and inpatient settings have found an association 
between absolute values of respiratory rate and/or presence of tachypnea and 
increased risk for severe disease, as assessed by hospitalization rates, length of stay 
and need for ventilatory support.352,357-362 However, others studies from similar 
settings and populations did not report such findings.5,68,356,363,364 It must be noted 
that there are many sources of within-patient variability when measuring respiratory 
rate in young children (e.g. fever, activity status, setting) and that the accuracy of 
measurement methods varies.365-373 Further, respiratory rate changes over the first 
year of life and between patient variability is considerable in this age range.369,374 
Evidence-based normative values for respiratory rate in healthy infants have only 
recently been obtained, and tachypnea thresholds are heterogeneous, being a 
possible cause of misclassification.372,374,375 The situation is similar for values of 
heart rate, which have been rarely associated with bronchiolitis disease severity.
356,360,361 Thus, the predictive value of such vital signs is probably best shown 
incorporating both their continuous nature and the effect of various confounders. 
!
Clinical findings of work of breathing have also been associated with disease 
severity in some studies.5,68,356,376 In a recent multicenter prospective cohort of 
hospitalized children, presence of retractions was associated with longer hospital 
stay, while only severe retractions were associated with need for ventilatory 
support.5,68 Interestingly, this study identified a novel subgroup of children with 
bronchiolitis that have a rapid respiratory decline, with an increased risk of 
ventilatory support if difficulty breathing had begun the day of hospital admission. 
!
On auscultation, the major findings include widespread adventitious sounds, with 
either or both wheezes and crackles.2,3,350 Wheezes are continuous sounds that 
represent ‘fluttering’ of the airway walls due to airflow limitation.377-379 Because the 
site of airway obstruction in bronchiolitis is variable, wheezes are polyphonic.379 In 
the presence of extensive small airway narrowing, the resultant high pleural 
pressure swings can cause compression (inward collapse) of larger airways during 
expiration, producing generalized expiratory wheezing.379 If airway obstruction is 
severe enough, wheezes may also occur during inspiration.380 The volume of the 
 82
CHAPTER 1: GENERAL INTRODUCTION
CHAPTER 2
wheeze is not an indication of the degree of airway obstruction: on the one hand, 
wheezing is often audible without the use of a stethoscope; conversely, severe 
obstruction may limit flow to such a degree that insufficient energy is dissipated to 
induce airway wall fluttering.380 Wheezes are traditionally high-pitched, but low-
pitched adventitious sounds, i.e. rhonchi, may also be present due to secretions 
within the large airways.350 Fine inspiratory crackles (i.e. rales, crepitations), which 
are discontinuous, interrupted explosive sounds, are also frequently heard on 
auscultation as units of alveoli pop open due to obstruction of distal airways with 
secretions.4,377,379 A prolonged expiratory phase of breathing can occur. Few studies 
have assessed the value of presence and quality respiratory sounds in predicting 
bronchiolitis severity, to mixed results.356,358 Moreover, a study on the validity and 
reliability of stethoscope examination in infants with acute respiratory disorders has 
shown that agreement between observers for the presence of crackles and wheezes 
was moderate and poor, respectively.381 Other thoracic findings include hyper-
resonance which may be detected on percussion, and chest may be full. Due to 
lung hyperinflation of the lungs secondary to air trapping, it is not uncommon to 
find a distended abdomen and palpable liver and spleen.350 
!
Bronchiolitis has a widely reported association with apnea, with most literature 
focused on RSV-related apnea. A recent systematic review found that the reported 
incidence of apnea in hospitalized patients with RSV ranged from a high of 23.8% 
to a low of 1.2%.257 This wide range likely reflects factors such as the use of 
different definitions and case ascertainment of apnea (e.g. variable duration of 
apneic period, method of apnea measurement) and different inclusion/exclusion 
criteria of study populations (e.g. regarding chronological and gestational ages, 
comorbidities such as neuromuscular disorders, and different levels of disease 
severity). Incidence of apnea incidence was higher in preterms and children with 
young chronologic age.257 A trend toward decreasing rates of apnea in more recent 
studies was also found; in studies that excluded children with serious underlying 
illnesses, the incidence of apnea was less than 5%, below the often-quoted risk of 
10% to 20%.150,257 In a recent large study of hospitalized patients with bronchiolitis 
caused by any viral agent, inpatient apnea occurred in 5% of patients. Independent 
predictors of apnea included: corrected ages up to eight weeks, birth weight less 
than 2.3 kilograms, and having a room air oxygen saturation before admission 
below 90%.382 There was also a U-shaped association between the respiratory rate 
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before admission and apnea, i.e. children with initial low or high respiratory rate 
had a higher risk of apnea. While apnea can occur early in the course of viral 
disease as its first manifestation (i.e. central apnea), in this cohort a considerable 
proportion of children had apnea after a few days of respiratory distress (i.e. apnea 
possibly related to failure of oxygenation and/or ventilation). In this study, the risk of 
apnea risk was similar across major viral pathogens, and non-RSV agents have also 
been associated with apnea.382-384  
!
Feeding problems are very common in bronchiolitis. Vomiting can occur, and 
dehydration is an important consideration in the clinical assessment of the infant, 
compounded by presence of fever and high work of breathing.350 Feeding or 
dehydration have been identified as predictors of hospital admission and length of 
hospital stay in some, but not all, studies.5,68,356,376 Irritability can occur; however, 
the infant is rarely systemically toxic in the absence of complications.3 Although 
reported numbers vary, a large proportion of infants have mild fever, but a 
temperature of ≥39.5 degrees centigrade is rare in uncomplicated bronchiolitis.3,350 
Few studies have identified fever as a predictor of disease severity.385,386 Other 
findings include a mild conjunctivitis and pharyngitis of varied severity.350  
!
Diagnostic tests and associated conditions  
Pulse oximetry was introduced into clinical practice in the early to mid-1980s, and 
has been rapidly adopted as a simple, noninvasive, and reasonably accurate 
estimation of arterial oxygen saturation for the clinical assessment of children with 
respiratory disorders.39 Oxygen saturation is a particularly relevant indicator of 
disease severity in conditions such as bronchiolitis where ventilation/perfusion 
mismatch and ensuing hypoxemia are key to disease progression. It has been 
proposed as the “fifth vital sign” in acute pediatric assessment, since clinical 
evaluation does not identify hypoxemia adequately.387,388 The use of pulse oximetry 
use has led to significant changes in physicians’ management of bronchiolitis, since 
decisions to initiate or discontinue oxygen therapy are mostly based on oxygen 
saturation values, and usually imply a decision to hospitalize or discharge at the 
ED, as well as the timing of discharge from hospitalized children. In turn, this can 
be a source of confounding when studying oxygen saturation as a prognostic factor 
of bronchiolitis severity, since hospital admission and length of stay are often used 
as outcomes of disease severity. Some studies have shown that lower oxygen 
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saturation values increase the likelihood of admission, and predict longer hospital 
stay, as well as need for ventilatory support.5,68,352,357-361,364,389,390 However, there is 
conflicting evidence on these associations, depending on time of measurement and 
intercurrent treatments.362,376,391,392 Importantly, thresholds of oxygen saturation that 
increase the risk of these outcomes vary widely in various studies (e.g. from <85% 
to <95%), and there is no consensus between management guidelines as to which 
thresholds are beneficial and safe to admit, treat, and discharge infants with acute 
bronchiolitis.36,393,394 Further, various studies have shown oxygen supplementation 
is the prime determinant of length of hospitalization, since feeding difficulties 
resolve sooner than hypoxemia (Figure 1.4).390,392 In particular, small differences in 
a range of values of oxygen saturation for which the predictive value and the 
benefit/harm of any intervention is not clear (e.g. 92 to 94%) are known to 
significantly influence the decision to admit/discharge at the ED, or to prolong 
hospitalization. This may be due to differences in physician's perceptions of benefit/
risk, local practices and methods of oxygen saturation monitoring (i.e. continuous 
vs. intermittent, with children awake vs. sleeping).390,395,396 A recent clinical trial 
that randomized patients to either true or altered oximetry, in which the true 
saturation measurements were increased by 3%, showed this minor elevation of 
modestly suboptimal saturations in bronchiolitis significantly decreased 
hospitalizations.397 Two ongoing randomized inpatient trials are addressing the 
issues of oxygen saturation thresholds for hospital discharge, as well as intermittent 
vs continuous monitoring strategies.398,399 We should note that normative pediatric 
oxygen saturation values have not yet been established, and there is variation in 
instruments used, probe positioning, measurement protocols, as well as well as 
with age, altitude, 24-hour cycle and sleep.39 Moreover, oxygen saturation does not 
necessarily provide reliable information regarding the oxygenation status of tissues, 
and does not reflect ventilation or acid-base status. In particular, children with 
discordance between clinical findings of respiratory distress out of proportion to the 
pulse oximetry findings must be evaluated carefully because respiratory failure may 
occur precipitously.350 While pulse oximetry has obviated the regular use of arterial 
blood gas sampling, it may still be useful in severe cases in which hypercarbia and 
low blood pH is a concern and respiratory support is considered.246 
!
The clinical utility of additional routine diagnostic testing is not well supported by 
evidence.400 There is significant variation in the use of supportive testing such as 
 85
CHAPTER 1: GENERAL INTRODUCTION
CHAPTER 2
chest radiography, blood counts, and specific testing to determine the viral agent of 
bronchiolitis in various settings.401-407 Use of these tests has been usually justified 
for the following reasons: ruling out other differential or concurrent diagnoses and 
complications (e.g. bacterial pneumonia), assessing disease severity (e.g. degree of 
pulmonary involvement), or stratifying treatment, predicting prognosis or cohorting 
inpatients (e.g. depending on viral agent). 
!
The issue of concurrent or complicated bacterial infection in bronchiolitis has been 
considerably studied. Acute otitis media (AOM) is very common, occurring in more 
than half of hospitalized patients with bronchiolitis.408-410 Bacterial pathogens can 
be isolated from middle-ear aspirates in a majority of patients with AOM, 
Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis 
being the most frequent isolates. Mixed bacterial and viral AOM seem to be very 
frequent, as RSV is also isolated from middle-ear aspirates in about half of cases, 
but no clinical features discriminate well between viral and bacterial AOM.408-410 
About a quarter of patients have or eventually develop otitis media with effusion.408 
AOM does not seem to influence the clinical course of bronchiolitis.409  
!
A systematic review of observational studies has shown that reported rates of 
serious bacterial infection were low in febrile infants younger than 90 days with 
bronchiolitis and/or RSV infection.110 No cases of meningitis were seen and very 
few cases of bacteremia were reported in the studies reviewed; urinary tract 
infection was the only infection reported with significant frequency, although the 
rates might be confounded due to asymptomatic bacteriuria. Saijo et al found 
elevated white blood cell counts and neutrophil counts were more likely in 
children with radiologically-defined pneumonia than in children with bronchiolitis.
411 This and other studies have suggested a possible role for inflammatory makers 
(e.g. C reactive protein and procalcitonin) in identifying or excluding bacterial co-
infection, defined by either positive culture or chest radiograph result.411-413 
However, data is contradictory on the diagnostic accuracy and clinical utility of 
these tests for the diagnosis of serious bacterial infection or pneumonia, or its 
predictive value for severe disease.109,414-418 Further, existing evidence does not 
differentiate between children with typical or atypical (e.g. high fever) findings in 
bronchiolitis.419-422 Thus routine use of these tests is currently not recommended by 
current practice guidelines.36,393,394 
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The radiographic appearance of the chest varies considerably in bronchiolitis. In 
many cases anteroposterior radiographs are normal, but they may reveal a spectrum 
of findings indicative of airway disease, most frequently hyperinflation (most 
prevalent), prominent bronchial markings and peribronchial thickening.42,423 
Multifocal patchy atelectasis may also occur, and on sequential imaging typically 
shows a shift in its distribution. A minority of infants with bronchiolitis have both 
airway and air space disease, while lobar consolidation is a rare occurrence. Some 
studies have reported predictors of chest ray abnormalities, e.g. presence of fever, 
hypoxemia, respiratory distress or inflammatory markers.411,424-426 However, these 
studies usually include older children with acute recurrent wheezing who may 
show differences from “typical” bronchiolitis, and radiological findings are defined 
heterogeneously.427 Importantly, whether the identification of such findings is 
clinically relevant ultimately depends on:  
1. the reliability of chest radiography in bronchiolitis;  
2. its diagnostic accuracy in identifying complicated disease such as bacterial 
pneumonia;  
3. its predictive value for severe disease; and  
4. its utility in changing clinical management.  
There is considerable variability in reported reliability of chest radiography in acute 
LRTI in children.428-433 Clinical interpretation of radiological findings is known to 
vary, and physicians may misinterpret atelectasis or airspace disease with infiltrates 
as possible bacterial infection. It is well known that children with suspected 
bronchiolitis or LRTI that undergo chest radiographs are more likely to receive 
antibiotics.417,423,434 However, as seen before, bacterial co-infection is uncommon 
and likely restricted to severe disease. Predictors of physicians performing a chest 
radiograph (e.g. young age, retractions, crackles) are somewhat distinct from those 
that are associated with abnormal findings, which suggests that a combination of 
factors prompts the diagnosis of pneumonia.426,434 Further, evidence is conflicting 
regarding an association of radiological findings with disease severity.42,400 It is thus 
not surprising that most studies do not suggest a clinically relevant change in 
management or prognosis of children undergoing chest radiographs.400,417,423,435,436 
Chest radiograph findings may have a role in severe disease, given the 
aforementioned continuum between bronchiolitis and pneumonia. Current 
guidelines do not support its routine use, and usually restrict it for inpatients who 
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do not improve, if the severity of disease requires further evaluation, or if atypical 
findings suggest another diagnosis.36,393,394 
!
The possible implications of specific viral agents in the epidemiology, pathogenesis, 
and short-term prognosis of bronchiolitis have been presented previously, while 
their importance in long-term complications will be discussed in the next section. 
We have also mentioned how different specimen collection techniques and viral 
identification methods are available. These may influence patient management 
depending on their diagnostic accuracy, prognostic value and speed with which 
results can be provided to the clinician.122 Suggested motives for viral testing have 
included: reducing unnecessary treatment with antibiotics; facilitating appropriate 
patient placement and cohorting of patients and staff; identifying viral agents for 
which effective antiviral therapy is available; collecting and reporting of health 
care–associated (nosocomial) infection rates; identifying emerging agents; defining 
and tracking of epidemiological trends; and assessing the effectiveness of preventive 
measures, including administration of palivizumab.437 However, the knowledge 
gained from point-of-care testing rarely alters therapeutic decisions or outcomes for 
the vast majority of children with clinically diagnosed bronchiolitis.5 No virus-
directed treatments are yet available except for influenza, and none of the currently 
used drugs have shown differential effects based on specific viral agent. There is still 
considerable uncertainty regarding the role of viral identification for the purpose of 
short- or long-term prognosis, thus its routine for the individual patient outside 
research and epidemiological monitoring studies needs to be clarified.  
!
The issue of virologic testing for cohorting of inpatients is more controversial. Many 
have recommended its use with the aim of reducing the risk of nosocomial cross-
infection of other patients.71,438-440 However, there are limitations to this approach, 
and current guidance is conflicting as to its routine use.36,393,394,441,442 Most hospital 
cohorting practices are based on point-of-care RSV testing. This is questioned by 
emerging evidence on the prevalence and possible prognostic value of co-infection 
detected by molecular methods.5 Further, evidence is conflicting as to a benefit of 
physical isolation and assignment of personnel to care only for these patients when 
compared to other strict contact isolation measures considering the risks and modes 
of transmission of the agents that are most likely to infect infants during the 
bronchiolitis season.71,72,314,443,444 Factors to consider may include resource 
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constraints, setting and patients at risk with underlying comorbidities. As new 
evidence accumulates, there could be marked changes in current understanding 
and consensus on the clinical utility of viral testing. 
!
Extra-pulmonary manifestations may occur in children with severe RSV infection, 
and possibly in cases of bronchiolitis by other viral agents. Life-threatening 
manifestations apart from central apneas include status epilepticus, ventricular 
tachycardias and fibrillation, heart block and pericardial tamponade.321,323,445 
Hyponatremia is also relatively commonly reported, and in severe cases can cause 
seizures.446 This may relate to the presence of inappropriate antidiuretic hormone 
secretion in the context of severe pulmonary disease, to the use of inappropriately 
hypotonic fluid therapy in hospitalized patients, or to direct central nervous system 
involvement by RSV.445,447,448 Renal function and electrolytes may be measured if 
this is suspected, or if the infant is clinically dehydrated. 
!
Course of disease 
For children with bronchiolitis admitted to hospital, the duration of hospitalization 
is influenced by aforementioned prognostic factors and local practices. In 
particular, oxygen supplementation (primarily) and feeding practices are key 
mediators in determining length of stay. Once infants are hospitalized and 
stabilized, subsequent deterioration to the point of requiring intensive care is less 
frequent but may occur. Most patients can be discharged from the hospital within 
two to three days after admission, although length of stay varies considerably in 
reported studies.10 A majority of children with bronchiolitis attending an ED are 
discharged home. Mansbach et al developed a comprehensive low-risk model for 
children with bronchiolitis, in which factors associated with discharge included: 
age equal or above two months, no history of intubation, a history of eczema, 
respiratory rates below age-specific calculated thresholds, no or mild retractions, 
initial oxygen saturation equal or above 94%, fewer salbutamol or adrenaline 
treatments in the first hour, and adequate oral intake.449  
!
Despite traditional clinical teaching usually describing bronchiolitis as a short-term, 
acute condition, evidence suggests that a small but important proportion of infants 
have a somewhat protracted clinical course.49,450-452 A follow-up observational 
study of hospitalized children found two thirds experienced difficulties with normal 
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routines (i.e. feeding, sleeping, contentedness, liveliness) on the day of discharge.451 
A substantial proportion of infants had respiratory symptoms by two weeks, 
including 31% of cough, 24% trouble breathing and 22% wheezing, with feeding 
problems being less common. Up to one fourth of children had one or more 
functioning limitations five or more days following discharge, and family routines 
remained disrupted accordingly. Delayed recovery was associated with parental 
work time loss and less favorable parental impressions of care in the hospital. 
Infants discharged from the ED with likely less severe disease also have a prolonged 
disease course. Using cough as a main outcome, Petruzella et al found a median 
duration of illness of 15 days in infants seen in the ED, and almost 25% of the 
infants continued to be symptomatic three weeks after the onset of illness (Figure 
1.4).452 In this cohort, children with a history of eczema trended toward a longer 
median duration of symptoms, while RSV status or secondhand smoke exposure did 
not affect disease duration. Approximately three-fourths of working caregivers 
reported missed days of work or day care. Such protracted recovery often leads to 
unscheduled medical visits to an ED or clinic in these infants. Norwood et al found 
one of six children had unscheduled visits within two weeks after ED discharge, 
and predictors included age under two months, male sex, and previous 
hospitalization.453 This proportion can reach close to 40% when considering a 
longer one month follow-up and all types of unscheduled medical visits.450,452 This 
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Figure 1.4. Course of disease in bronchiolitis: feeding support and oxygen supplementation for infants 
admitted to the acute medical wards (A), and duration of illness (based on cough) in infants 
evaluated in the emergency department (B; median duration of illness of shown in red) (adapted 
from: Unger, Petruzella, with permissions)
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recovery period is in line with biological evidence showing the respiratory 
epithelial cells usually recover within 2–4 days, but histologically the ciliated 




BEYOND BRONCHIOLITIS: RECURRENT WHEEZE, ASTHMA, AND 
LONG-TERM RESPIRATORY MORBIDITY 
The association between bronchiolitis, asthma and long-term respiratory morbidity 
has been the subject of enduring debates for decades.348,454-459 A first episode of 
bronchiolitis and wheezing may be a manifestation of recurrent wheezing 
phenotypes with heterogeneous biological, genetic, viral or environmental 
determinants, and distinct prognosis.50,460-465 A growing body of epidemiological 
evidence supports an association between bronchiolitis and increased incidence of 
subsequent recurrent wheeze and later asthma. The focus of controversy is whether 
viral bronchiolitis is a cause of wheeze, by affecting lung and airway structure and 
function or by inducing a long-term aberrant immune response to viruses or 
allergens (also called the serial hypothesis); or rather a first indication of long-term 
airway morbidity due to pre-existent host susceptibility factors such as alteration in 
airway function or structure or a susceptibility to develop immune responses that 
predispose to airway obstruction (parallel hypothesis).142,349,458 It is likely that both 
mechanisms interact and contribute to asthma inception, with complex and 
bidirectional causal links in which the nature of the response to the different viruses 
associated with asthma will depend on the genetic background of the individual, 
on concomitant environmental exposures, and on the timing of the infectious 
episode, in relation to the degree of maturation of both the immune system and the 
airways (Figure 1.5). 
!
Several systematic reviews of observational studies have focused on the association 
between RSV bronchiolitis and recurrent wheeze and asthma.48,466 In 2000, 
Kneyber et al pooled data from six studies with control groups and found up to 
45% of children reported recurrent wheezing until five years (defined as at least 
three episodes of wheezing verified by a physician, or the use of bronchodilators in 
the year preceding the follow-up study), as compared to only 6% in the control 
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group (odds ratio-OR 5.5, 95% confidence interval-CI 2.4 to 12.6).466 However, 
after this period, the difference was not significant (OR 2.4, 95% CI 0.7 to 8.4). A 
later review by Perez-Yarza and colleagues included a considerable number of 
original studies and follow-up reports published in the 2000s.48 The authors 
performed a qualitative assessment of methods and results but no meta-analysis. 
They concluded that there was an association between RSV infection and the 
emergence of different asthma phenotypes, with a gradient effect and progressive 
disappearance of this effect with increasing age. Two more recent reviews with 
meta-analysis provided quantitative results on the association between cases 
exclusively with RSV hospitalization, wheezing and asthma.467,468 In one review, 
the pooled overall OR was 3.84 (95% CI 3.23 to 4.58) with moderate heterogeneity 
between studies (I2 = 45%); using meta-regression, the association was found to 
decrease with age at follow-up, consistent with the findings of longitudinal studies. 
!
Methodological differences between included studies likely impact the magnitude, 
precision and risk of bias of these findings from observational studies. All reviews 
have highlighted methodological limitations and poor study quality that may 
compromise the validity of the results. Most cohort studies are not population-
based, and usually consist of a selection of “exposed” children with bronchiolitis 
compared to with an external comparison cohort of “unexposed” children (the 
label prospective case-control design is often used incorrectly). Challenges include 
how the cohort population and “exposure” are defined, i.e. what is the case 
definition of bronchiolitis (community surveillance, outpatient visits, or hospitalized 
cases), and how the control group is selected (i.e. what is the source population, is 
there matching or not). Further, outcome definition of recurrent wheezing and 
asthma varies (e.g. physician-diagnosed episodes, parent-reported symptoms), 
phenotypes may differ, as does timing of measurement, and other domains may be 
measured (e.g. lung function, inflammatory markers, allergic sensitization). The 
former factors may lead to confounding and selection biases, while the latter reflect 
how wheezing and asthma are heterogeneous and may encompass different 
phenotypes of disease.  
  
Large studies based on twin pairs mostly support the hypothesis that the association 
between RSV and asthma is essentially due to genetic background, and RSV disease 
is an indicator of the genetic predisposition to asthma.469-472 Arguments in favor of 
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pre-existent mechanisms of bronchiolitis and long-term wheeze include the 
presence of predisposing genetic, pulmonary, and immune susceptibilities.142 First, 
we have mentioned how candidate gene studies have found diverse genes 
associated with increased risk of RSV bronchiolitis, including those related to 
airway mucosal responses, innate and adaptive immune responses, chemotaxis and 
allergic responses. Importantly, genetic association studies including hospitalized 
children have found that genes associated with early and late wheezing (i.e. at three 
and six years, respectively) after RSV LRTI are distinct.473,474 This suggests that RSV 
LRTI hospitalization and subsequent early postbronchiolitis wheezing have different 
pathophysiological mechanisms from late wheezing or allergic asthma in later life.  
!
Second, pulmonary function abnormalities underlie the risk of bronchiolitis, 
recurrent wheeze and possibly asthma. There is now well established evidence that 
indices of airway size (e.g. obtained from either partial maximal flow–volume 
curves or other measures of airway resistance), are inversely associated with the risk 
of having wheezing LRTI including bronchiolitis during the first years of life.285 This 
may mediate the effect of smoking exposure in utero.294 Further, the degree of 
premorbid lung function changes is associated with the severity of bronchiolitis and 
LRTI. Prematurely born infants hospitalized with RSV or other viral LRTIs had higher 
resistance of the respiratory system at birth than those who were not admitted.475 
Similarly, a recent prospective cohort of unselected term infants found differences 
in neonatal respiratory system compliance and resistance between infants 
hospitalized RSV patients compared with non-hospitalized RSV-positive infants.476 
Further, these measures of neonatal lung function were also associated with post-
RSV wheeze, which was only marginally explained by any preexisting wheeze or 
the severity of the episode itself. Neonatal total lung resistance has also been shown 
to be associated with RV-induced wheeze.477 Congenital alterations in the 
regulation of airway tone may also predate bronchiolitis and wheezing. Data 
available on bronchial responsiveness are much scantier and less conclusive than 
that for earlier postnatal airway function tests without provocation. A recent large 
birth cohort of at-risk neonates born of mothers with a history of asthma found 
neonatal bronchial hyper-responsiveness to metacholine, but not airflow limitation, 
preceded acute severe bronchiolitis with hospitalization, irrespective of viral agent.
478 Previous exploratory studies showed similar results.479 Birth cohort studies have 
shown these changes in infant lung function at birth are associated with the risk of 
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wheezing illnesses through school age.479-488 The association with wheeze beyond 
school age and adolescence is less consistent.486,489-491 Further, both very premature 
and late born preterm infants have pulmonary structural abnormalities that place 
them at high risk for respiratory morbidity including bronchiolitis, and also airway 
obstruction, and increased bronchial responsiveness from infancy through 
adulthood.254,492-495 These observations are compatible with the hypothesis that 
diminished airway size and possibly airway tone shortly after birth are shared host 
factors for bronchiolitis and asthma.  
!
Third, immature innate and adaptive immune responses may play an important role 
in susceptibility to bronchiolitis. Studies have found that cytokine responses in cord 
blood predict the severity of later RSV infection, and cord blood transcripts of genes 
involved in innate and adaptive immune responses may also determine the severity 
of disease.186,496,497 Epidemiological data suggest that interferon type II responses 
during the first months of life strongly predict the subsequent development of 
wheezing illnesses, presumably due to viruses, during the first year of life.498 
Conversely, high concentrations of amniotic fluid IL-8 and tumor necrosis factor-α 
are associated with low risk of RSV bronchiolitis in healthy term infants, leading 
authors to hypothesize that direct exposure of fetal lungs to pro-inflammatory 
signals induces local protection against viral infection during infancy.286 Vitamin D 
deficiency identified in cord blood of healthy neonates has also been found to be 
associated with increased risk of RSV LRTI in the first year of life, likely through a 
complex interaction depending on genetic background, environmental exposure 
and influencing the developing neonatal immune system.215,217,307  
!
On the contrary, a body of evidence also supports the role of viral bronchiolitis in 
contributing to later pulmonary sequelae through its action during a critical period 
of lung development. A dose–response relationship between bronchiolitis severity 
(as defined by inpatient, ED, and outpatient clinic cases) and increased odds of 
early childhood asthma and asthma-specific morbidity was found using data from 
the Tennessee Medicaid database.499 This may be one possible explanation why 
some population-based studies including milder cases of bronchiolitis show weaker 
associations with wheezing and asthma than studies restricted to hospitalized cases.  
!
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Further evidence stems from the analysis of outcomes of children that were given 
palivizumab to prevent RSV bronchiolitis. Observational studies found that the use 
of palivizumab in premature infants with no CLD led to a significant reduction in 
wheezing episodes compared with control premature infants who did not receive 
prophylaxis.500,501 A recent randomized trial in otherwise healthy late preterm 
infants confirmed that treatment with palivizumab resulted in a significant 
reduction in wheezing days during the first year of life, even after the end of 
treatment.318 This provided the first human experimental proof of concept 
implicating RSV infection as an important mechanism of recurrent wheeze during 
the first year of life.  
!
Finally, experimental evidence on animal models has shown a direct effect of RSV 
on lung hyper-reactivity and chronic airway inflammation, including an increase in 
susceptibility to allergic sensitization.502 Clinical data from one of the oldest cohorts 
of children hospitalized for RSV bronchiolitis by Sigurs et al supports this 
association. Findings from this cohort have shown an increased risk of wheezing 
and asthma until adulthood compared with age-matched controls.503-508 Moreover, 
allergic rhino-conjunctivitis and sensitization to perennial allergens were also found 
to be increased (43% vs 17%; and 41% vs 14%, respectively). A persistent/ 
relapsing wheeze pattern throughout childhood and adolescence was associated 
with early allergic sensitization and predominated in the RSV cohort compared 
with controls. The pattern of airway obstruction was more pronounced in these 
subjects and tracked across ages. This strongly suggests an important interaction 
between RSV infection and early allergic sensitization. 
!
A middle ground between reconciling both hypotheses is the existence of a 
bidirectional link between predisposing factors, viral bronchiolitis and asthma, in a 
complex causal pathway that involves interaction between different factors and 
mediators.458 One example is the role of specific viral agent. There is now a 
consistent body of evidence highlighting bronchiolitis induced by RV (alone or in 
co-infection) as a stronger predictive factor for recurrent wheezing at preschool and 
school age when compared to RSV infection.116,119,157,510-513 Long-term follow-up of 
the first molecular based viral isolation studies suggests this differential effect of RV 
bronchiolitis on risk of asthma continues throughout adolescence and possibly into 
adulthood.514 RVs have the ability to invade lower airways and escape immunity, 
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they may promote exaggerated inflammatory responses towards further stimuli, 
such as allergens, and lead to enhanced airway responsiveness, possibly promoting 
the development of asthmatic features.116,157,513 Recurrent RV infections and 
associated inflammatory and remodeling processes during this time may thus 
interfere and disrupt normal processes of lung growth. In parallel, children 
hospitalized with RV bronchiolitis tend to be older, have more atopic risk factors or 
characteristics (i.e. eczema, allergic sensitization, and parental asthma), and are 
more likely to have wheezed previously.93,95,510,515 Thus the connection with 
subsequent asthma could be explained by an increased susceptibility to RV 
bronchiolitis among children with an atopic background, in whom the first episode 
of RV-related wheezing could be the first manifestation of atopic asthma. 
Conversely, evidence is conflicting as to whether a family history of atopy or 
asthma is a risk factor for RSV hospitalization. Further, RSV prophylaxis with 
palivizumab decreases by 80% the relative risk of preschool recurrent wheezing in 
non-atopic children, but does not have any effect in infants with an atopic family 
history.500 Many uncertainties remain, however, including whether this effect will 
endure regarding later wheezing and asthma diagnosis, how will it affect other 
domains of asthma (e.g. airway obstruction, bronchial hyper-reactivity, airway 
inflammation and allergic sensitization). The epidemiological and experimental 
evidence presented above reflects how asthma results from complex and 
differential interactions between genetic background, immune responses to 
allergens and respiratory tract viruses. 
!
Importantly, the discussion on the long-term effects of bronchiolitis per se can 
hardly be dissociated from other concurrent causal factors of recurrent wheezing 
and asthma, which are viewed today as complex labels encompassing different 
traits and phenotypes with likely differing causes, manifestations, treatment 
responses and natural histories at different ages.462,516,517 Gene-environment 
interactions are key to asthma inception, progression and exacerbation, and 
different factors may contribute as inducers, triggers and modulators.518 While viral 
bronchiolitis may be a first step in a “viral march” towards asthma, other 
determinants and exposures such as airway microbiome diversity, allergic 
sensitization and exposure, smoking, pollution, obesity, diet and social factors play 
a role, often interacting between each other and being modulated by genetic 
background, e.g. presence or absence of family atopy.7,487,519 The observation that 
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lung and immune function at birth may predispose to the subsequent development 
of asthma is not incompatible with the existence of acquired mechanisms for the 
deficits in lung function and increased bronchial responsiveness observed in 
asthma. Studies performed with biopsies in wheezing young children suggest that 
the early preschool years (up to two years) are a developmental window of 
opportunity for the establishment of deficits in lung function, airway inflammation 
and remodeling in asthma.520-523 Interactions between gene and environmental 
exposures are complex, as seen with the recently explored interactions between 
17q21 genotype variants, RV wheezing illness, and tobacco exposure in increasing 
early wheezing and later asthma.524-526 Thus, predicting future asthma remains 
elusive, as there are no simple, valid and universal discriminative and prognostic 
tools for children with bronchiolitis or recurrent wheezing.527 Attempts at 
preventative treatments to reduce post-bronchiolitis wheezing and asthma have also 
failed.528-530
!
Whether bronchiolitis is also, or rather, a first step or an indicator towards later 
Chronic Obstructive Pulmonary Disease (COPD) is now the focus of much 
research. There is a growing body of evidence to support the hypothesis that COPD 
has its origins in early life.236,487,531-534 Antenatal factors acting during critical or 
sensitive periods in early life may result in developmental adaptations that will 
produce permanent structural, physiological and epigenetic changes with lifetime 
consequences.535-537 These include for example tobacco smoke exposure, 
intrauterine growth, and other maternal and fetal factors, acting on diverse genetic 
background such as genes related to lung development or adrenergic receptors.538 
Further, cohort studies of infants recruited in the 1980s are now able to demonstrate 
tracking of lung function from early infancy into adolescence and early adulthood.
52,486,489,491 Thus, even small lung function deficits result in premature airflow 
obstruction with lung aging. Postnatal factors such as bronchiolitis and other 
respiratory infections, tobacco smoke exposure and pollution may magnify the 
accelerated decline in lung function.538 Since airway function is very likely 
established by school age, the pre-school years represent a critical time for lung 
injury and chronic airway obstruction. 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Figure 1.5. Antenatal and postnatal factors in the trajectories from bronchiolitis and recurrent wheezing 
to asthma and Chronic Obstructive Lung Disease (COPD) (RV: rhinovirus; RSV: respiratory syncytial 
virus; CLD: Chronic Lung Disease)
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THE DILEMMAS AND LIMITATIONS OF 
INTERVENTION RESEARCH IN BRONCHIOLITIS 
In the first section of the introduction, we have presented an overview of relevant 
epidemiological, clinical and pathophysiological findings in bronchiolitis, as well 
as its complex association with long-term respiratory morbidity. Here we focus on 
the main topics of this thesis: the uncertainties of current evidence on widely used 
treatment approaches, with emphasis on bronchodilators and corticosteroids, and 
how this evidence is limited by shortcomings in key areas of clinical trial design, 
namely disease definition and outcome selection and measurement. We will 
provide a rationale and backdrop for each question of the thesis partly based on 
findings present in the first section, and how new methodological developments in 
evidence synthesis, science of outcomes and measurement, and definition and 
clustering of disease may help to address them.  
!
!
GAPS IN EVIDENCE AND PRACTICE IN BRONCHIOLITIS 
TREATMENT 
Therapeutic management of bronchiolitis is an ever-controversial topic in 
pediatrics.27,539-541 Treatment options that are reportedly used and/or have been 
tested include a wide range of pharmacological and supportive interventions.10 The 
former include different drug groups, mostly corticosteroids, bronchodilators (β-2 
agonists, anticholinergic and adrenergic agents), antibiotics, and hypertonic saline. 
Other pharmacological therapies rarely used and/or tested include antiviral agents, 
DNase, montelukast, theophyllines and diuretics. Supportive treatments include 
feeding and fluids, steam inhalation, chest physiotherapy, and different types of 
respiratory/airways support, i.e. low or high-flow oxygen therapy (which may be 
heated and humidified), heliox, continuous positive airway pressure, and intubation 
with mechanical ventilation. The rationale for use of these treatments varies, but 
most target proven or hypothesized downstream pathological changes in 
bronchiolitis, i.e. submucosal edema, bronchiolar and peribronchiolar 
inflammation, increased mucus secretion, bronchospasm, as well as their 
physiological consequences, i.e. small airways obstruction, hypoxemia and 
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respiratory failure. Target populations for these interventions vary, e.g. in terms of 
timing and severity thresholds for use, as do the levels of care in which they can be 
implemented also vary. Some of the treatments have also been considered for 
postbronchiolitis symptoms and/or prevention of recurrent wheezing.528,542  
!
Importantly, most specific interventions have failed to show consistent and relevant 
treatment effects, with absence of clear evidence for any single treatment approach. 
Nearly 50 years ago Reynolds and Cook wrote that “oxygen therapy is vitally 
important in bronchiolitis and there is little convincing evidence that any other 
therapy is consistently or even occasionally useful”.30 During the 1970s, the 
concept of minimal handling was adopted from neonatal intensive care to the care 
of infants and small children with acute respiratory distress, emphasizing minimal  
disturbance and restriction to essential procedures.543 As of today, no routine 
treatment is yet recommended by most evidence-based clinical practice guidelines 
worldwide, and the mainstays of treatment remain oxygen, fluids, and if necessary, 
respiratory support.36,393,394 Bronchiolitis is now the focus of promising drug and 
biologic efforts in their initial stages of clinical development, with most focusing on 
viral agents as treatment targets (e.g. antiviral RSV drugs).35,544-546 
!
There is substantial variation in the use of different therapies for bronchiolitis 
around the world, as shown in results from practice surveys, retrospective audits 
and prospective studies. Use of specific pharmacological treatments has been 
shown to vary at a national, regional and local level. Data obtained from the 2001 
to 2009 National Hospital Ambulatory Medical Care Survey in the US showed 53% 
children below two years of age presenting at an ED with bronchiolitis received 
short-acting β-agonists, 33% received antibiotics, and 20% received systemic 
corticosteroids.547 A prospective cohort study in seven Canadian pediatric 
emergency departments found 73% of children were treated with bronchodilators, 
with a significant variation between hospitals in their rate of bronchodilator use 
(range 59 to 100%) and in the type of bronchodilator used (salbutamol vs 
adrenaline).8 Studies from European EDs also suggest frequent and variable use of 
pharmacotherapy, while some countries such as Australia and New Zealand seem 
to have lower use of any treatments.9,44,401,548-555 In inpatients, various North 
American and European studies have also shown considerable use and site-to-site 
variation for both pharmacological and supportive treatments.9,44,551,554-559 Our 
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nationwide practice survey in Portugal (the ABBA study, part of which is included in 
this thesis) highlighted differences in management between pediatricians and 
general practitioners (Figure 1.6), while North American studies have shown 
differences between general and pediatric EDs.86,404  
!
There are many possible motives underlying clinical practice variation on 
treatment.560 Table 1.2 present possible reasons for treatment variation in 
bronchiolitis. Prescribing is a complex task that requires interpretation of evidence 
in light of individual patient factors, within a context of personal, organizational 
and systemic factors.561 The World Health Organization’s (WHO) model of rational 
prescribing described a logical approach that includes making a diagnosis, 
estimating prognosis, establishing the goals of therapy, selecting the most 
appropriate treatment and monitoring the effects of the treatment.562 In 













































Figure 1.6. Treatment options chosen by pediatricians and general practitioners according to 
bronchiolitis severity (results from a nationwide electronic survey in Portugal) (from: Fernandes, 
personal communication)
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variation, i.e. that which is explained not by population differences or health 
determinants, but by the quality, appropriateness, and efficiency of health care.563 
With most evidence-based guidelines recommending against routine use of most 
treatments, there seems to be a gap between evidence and practice. Knowledge 
translation strategies aim to bridge that gap.564-566 Thus, many studies have 
evaluated the implementation of clinical practice guidelines and care pathways in 
reducing unwarranted treatment use.86,407,551,556,567-572 Despite partial success, 
however, persistent variation in treatment choices remains. Part of it may relate to 
barriers in evidence uptake by physicians and health systems. But it extends to the 
source, quality and interpretability of evidence itself, which are major problems in 
this field.  
!
!
Controversies on the efficacy and safety of older interventions (e.g. bronchodilators 
and corticosteroids) have persisted for years, while new or revisited treatments (e.g. 
hypertonic saline, heated humidified high-flow oxygen therapy) are usually 
championed by some but soon challenged by conflicting evidence. Many 
medications and devices used in bronchiolitis have not been adequately tested, 
which hampers rational prescribing and management. Some of the motives for this 
are common to other pediatric conditions and relate to the paucity and hurdles of 
pediatric drug research, with frequent off-label and unlicensed use of medicines.
573-575 Many drugs used in bronchiolitis were licensed before rigorous efficacy and 
safety approval plans were required by regulators, leading to wide disparities in the 
Table 1.2: Motives for practice variation in bronchiolitis treatment
Existing evidence Implementation of evidence
Gaps in current evidence (e.g. lack of 
comparative effectiveness data)
Diagnostic overlap (e.g. acute wheezing, 
pneumonia)
Heterogeneity in trial results Local protocols and experience (e.g. choice of 
bronchodilator)
Physician prescribing profile (i.e. urge to act vs 
“primum non nocere”)
Parental pressure
Both evidence generation and implementation
Heterogeneous disease definition
Importance given to a putative early asthma phenotype
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scrutiny with which evidence is assessed when compared to newer drugs.576 
Further, requirements on medical device research are relatively recent, so that 
respiratory support devices have often been implemented without much empirical 
evidence on their efficacy, safety and applicability in infants.577 Other reasons are 
more specific to the field of bronchiolitis. The overlap between bronchiolitis, 
wheezing disorders and asthma has repeatedly led to the inadequate extrapolation 
of drug treatment effects, such as with corticosteroids and bronchodilators, despite 
the uncertainties regarding bronchiolitis immunopathogenesis.578-580 Further, there 
is scarcity of pharmacokinetic and pharmacodynamic data for most inhaled 
therapies in young infants.581,582 Also, other factors may confound a putative 
specific treatment effect, such as the type of aerosol delivery device, the solution in 
which drugs are diluted, and any co-treatments. 
!
Conflicting results with limited validity may hamper one of the main objectives of 
practicing evidence-based medicine, i.e. actions informed by the best available 
evidence, what some have called ‘doing the right things’.583,584 Without clear 
evidence, different physicians will adopt different approaches, on the basis of their 
beliefs, training, incentives, and the local practice style. In that case, quality 
improvement efforts to bridge the evidence-practice gap and ensure that evidence 
is applied thoroughly, efficiently and reliably (what some have called ‘doing things 
right’) will have limited effect.584 Thus it is important to step back and evaluate the 
uncertainties of existing evidence itself, how they can be improved and how they 
relate to shortcomings of current research in this field. 
!
!
CONTROVERSIES AND MYTHS: CORTICOSTEROIDS AND 
BRONCHODILATORS IN BRONCHIOLITIS 
The case of the two most frequently used groups of treatments, bronchodilators and 
corticosteroids, highlights the uncertainties of research in bronchiolitis. The first 
randomized clinical trials in this field testing each of these drugs date from the late 
1960s.27,578,585,586 The drugs were meant to target inflammation and bronchospasm, 
in analogy of the clear benefits in children with acute asthma. However, findings 
were heterogeneous and conflicting right from the first studies, with distinct 
interpretations and recurrent controversies. As the growing body of evidence 
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created the need to synthesize findings from individual studies, the first systematic 
reviews and meta-analyses often fueled more discussion.587-590 Here we present a 
perspective of the clinical pharmacology of both groups of drugs, and we present a 
rationale for a new and integrated look at current evidence for individual and 
combined treatment in bronchiolitis. 
!
Bronchodilators: clinical pharmacology and rationale for use in bronchiolitis 
Bronchodilators are central in the treatment of airways disorders. Two major classes 
of bronchodilators have been used in bronchiolitis, adrenoceptor (AR) agonists and 
muscarinic receptor (M) antagonists.591 The most frequent fast- and short-acting 
agents used and tested in bronchiolitis are adrenaline/epinephrine (non-selective α- 
and β-AR agonist), salbutamol/albuterol (selective β2-AR agonist), and ipratropium 
bromide (non-selective M receptor antagonist). These agents are mostly 
administered by inhalation to allow delivery of the drug on the airway mucosa, 
optimizing their bronchodilator effect and reducing cardiopulmonary side effects. 
Aerosol generating devices used include mostly nebulizers and pressurized metered 
dose inhalers with holding chambers. 
!
Bronchodilators work mostly through their direct receptor-mediated relaxation 
effect on airway smooth muscle (ASM) cells, although other pharmacodynamic 
targets may be of relevance in bronchiolitis. Their effect on M receptors and ARs 
relies on the location of these receptors and subtypes expressed. Airway tone is 
regulated by both the parasympathetic and sympathetic nervous systems, although 
non-cholinergic and non-adrenergic autonomic neural controls of ASM exist.592 The 
parasympathetic system provides the dominant control of smooth muscle tone via 
efferent cholinergic autonomic nerves. Branches of the vagus nerve travel along the 
airways and synapse at peribronchial ganglia, from which short post-ganglionic 
parasympathetic cholinergic fibers innervate ASM, airway glands and 
microvasculature. Targets of non-selective M receptor antagonists include M3 
receptors, located predominantly in central airway ASM cells and submucosal 
glands, which are key mediators of smooth muscle contraction and mucus secretion 
.593-596 Other targets include M1 receptors which facilitate cholinergic transmission, 
and M2 receptors that provide feedback inhibition. The sympathetic nervous system 
provides direct innervation of airway vasculature but not ASM, although hormonal 
catecholamines play a role in regulating the airway tone. Autoradiographic 
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mapping and in situ hybridization studies show both β1- and β2-ARs are present 
throughout the lung.593,596,597 β2-AR agonists act directly on the ASM, with greater 
distribution of receptors in small rather than large airways. β2-ARs also reduce the 
cholinergic component of bronchoconstriction, and may mediate effects through 
other cell types, including bronchial epithelium, submucosal glands and type I 
pneumocytes (increased mucociliary clearance, possibly increased fluid clearance), 
type II pneumocytes (stimulation of surfactant secretion), pulmonary and bronchial 
vascular smooth muscle (vasodilation, possibly reduced permeability), many pro-
inflammatory and immune cells (anti-inflammatory effects).591,598 The consistency of 
these effects in vitro and in vivo and their translation into relevant beneficial 
clinical effects in various airways disorders are controversial (e.g. fluid clearance in 
acute lung injury, or anti-inflammatory effects).599 β1-ARs in the lung are confined 
to glands and alveoli and their role is less clear. α-ARs mediate vasoconstriction of 
pre-capillary arterioles in the airway vasculature, decreasing capillary hydrostatic 
pressure and leading to fluid resorption and improvement in airway edema. M 
receptors and α- and β-ARs have wide systemic tissue distribution, which mediate 
unwanted anticholinergic or adrenergic effects. While the complete nature of 
interactions between parasympathetic and sympathetic nervous systems is not fully 
understood, in theory combining β2-AR agonists and M receptor antagonists is 
pharmacologically reasonable and may maximize the bronchodilator response.591 
!
Adrenaline was isolated in 1901 and for years widely used for the treatment of 
acute asthma, pending later introduction of more selective β-AR agonists with less 
systemic adverse effects.591 Both drug names adrenaline and epinephrine have been 
used in different countries and by different conventions, with discussion as to which 
is appropriate.600 Adrenaline was first used parenterally, but multiple α- and β-AR 
systemic adverse effects led to preference for inhaled use in most airway disorders. 
The onset of bronchodilation using inhaled adrenaline is very quick (one minute), 
and the drug has a short half-life, with a duration of action less than two hours.591 
Serious adverse effects of inhaled adrenaline, including β1-AR mediated 
cardiotoxicity, are likely rare in healthy children.601 Given its short duration of 
action, symptoms may quickly return to baseline leading to what is sometimes 
referred to as the "rebound phenomenon”. Racemic epinephrine, which is a 1:1 
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mixture of the D- and L-isomers, was initially thought to produce fewer systemic 
side effects, although evidence is conflicting.602 
!
The modern era of selective β2-AR agonists began with the discovery of salbutamol 
(called albuterol in the US), first marketed in the late 1960s.600 Other less used 
short-acting β2-AR agonists (SABAs) in bronchiolitis include fenoterol and 
terbutaline. Salbutamol has a high β2:β1-AR selectivity ratio, and approximately 
equivalent bronchodilator potency than adrenaline. Maximum bronchodilation can 
be seen within 15 min of inhalation, but weak receptor biding and quick diffusion 
back into the microcirculation leads to a short duration of action (4 – 6 hours).600 
Adverse effects of SABAs include ventilation/perfusion mismatch, attributed to 
differential regional vasodilator and bronchodilator effects, restlessness, muscle 
tremor and hypokalemia at high doses.603 Despite its widespread use in most 
wheezing disorders and asthma, there is scarce pharmacokinetic data on use of 
salbutamol in preschool children, with heterogeneity in dosing criteria.604,605 A pure 
R-isomer of salbutamol, levalbuterol, was developed based on possible unwanted 
effects from the S-enantiomer in the lung. Animal model studies suggested that 
levalbuterol might have a better anti-inflammatory effect than racemic albuterol in 
RSV-infected airways, but evidence is controversial.606-608 Oral or parenteral 
administration has been seldom used and tested, despite increasing off target 
adverse effects without improving delivery of salbutamol to the lungs. 
!
Inhaled M acetycholine receptor antagonists have been used as treatments for 
respiratory diseases for centuries.591 Some plants are rich in anticholinergic 
alkaloids such as atropine, a tertiary ammonium compound with multiple systemic 
side effects due to its considerable systemic absorption and penetration of the 
blood-brain barrier. Ipratropium bromide is a quaternary ammonium 
anticholinergic introduced in 1974 that provides local anticholinergic effects to the 
lung while avoiding the systemic side effects of atropine as a result of its poor 
absorption. Ipratropium bromide starts to act within 15 to 30 minutes, but maximal 
bronchodilation may take up to 90 minutes. Its duration of action is approximately 
6 to 8 hours, but compared with SABAs, it has a slower onset of action, although 
probably a longer duration of action. Ipratropium bromide has a wide therapeutic 
margin, with scarce evidence of adverse anticholinergic effects i.e. hemodynamic 
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or ocular effects. Data available on the clinical pharmacology of this drug in infants 
is also limited.582  
!
The rationale for using bronchodilators in bronchiolitis is conditional on the 
assumption that bronchospasm is a relevant aspect of pathogenesis, but evidence is 
conflicting. On the one hand, some mechanisms of disease studies have shown that 
M2 receptors are dysfunctional in patients following lower respiratory tract 
infection, resulting in unopposed M1 and M3 receptor activity, producing excessive 
bronchoconstriction.609 Most evidence, however, comes from asthma studies. Also, 
neuro-immune pathways may be activated by RSV infection, leading to a change in 
the distribution and reactivity of sensory and motor nerves across the respiratory 
tract, causing non-specific airway hyper-reactivity during and after the infection.610 
On the other hand, evidence exists that RSV and RV epithelial infection induce a 
decrease of β2-AR function on ASM cells.611-614 Most evidence supports mucosal 
swelling and mucous plugging as key factors contributing to increased airway 
resistance observed in bronchiolitis, rather than constriction of bronchial smooth 
muscle.6 Adrenaline might have a theoretical advantage over SABAs, as α-AR 
stimulation could improve airway obstruction by inducing arteriolar 
vasoconstriction in the airway mucosa and thus reducing bronchial mucosal 
thickness. The stimulation of α-ARs might also avoid ventilation-perfusion mismatch 
induced by SABA. Interestingly, in an anecdotal report inhaled adrenaline was 
found to benefit an infant with RSV bronchiolitis who was also receiving β-
adrenergic receptor blockade with propranolol.615  
!
Proof of concept studies using lung function outcomes have had inconsistent 
results, showing that responses to bronchodilators in bronchiolitis range from 
marked improvement to deterioration of lung function.616-623 Many studies have 
provided evidence of airway reactivity to bronchoconstrictor or bronchodilator 
agents in healthy young infants.624-627 Discrepancies found in bronchiolitis studies 
may be due to various factors. First, there may be growth- or maturation-induced 
changes in the mechanical and functional properties of the respiratory system in 
infants influencing bronchodilator responsiveness, e.g. distribution and activity of 
β-ARs, anatomically small airways, increased smooth muscle tone, relatively thick 
airway walls, decreased chest wall recoil and increased chest wall compliance.233 It 
should be noted, however, that one study with lung function outcomes found 
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bronchodilator responsiveness in infants with bronchiolitis was not age-dependent.
628 Further, when existing, airway responses are not necessarily beneficial: 
bronchodilators may increase airway wall compliance and reduce the flow in 
collapsible immature airways, with paradoxical bronchoconstriction.629,630 Second, 
it would be tempting to think children with bronchiolitis at higher risk of asthma 
might have increased bronchodilator responsiveness. Interestingly, Sanchez et al 
found response to bronchodilator in infants with bronchiolitis could be predicted 
from wheeze characteristics.622 However, long-term follow-up results suggest that 
clinical responses to bronchodilators during acute bronchiolitis or initial episodes 
of wheezing in infancy are not associated with asthma risk factors, nor have they 
any association with later asthma at school age.631,632 Finally, β-AR-related genetic 
polymorphisms, e.g. ADRB2 genotype, might influence bronchodilator 
responsiveness.633 Importantly, results from these studies are limited by the current 
gaps in infant lung function regarding which techniques may be most useful for 
assessing changes in airway function, how to quantify the airway response or the 
potential clinical relevance of findings.634 
!
Corticosteroids: clinical pharmacology and rationale for use in bronchiolitis 
Corticosteroids (also named glucocorticoids) have been used to treat many pediatric 
respiratory conditions for over half a century, since the isolation and chemical 
synthesis of corticosterone and later cortisol, by 1950 Nobel Prize winners Kendall, 
Reichstein and Henchbeing.579,635 They are a cornerstone of treatment in acute 
asthma and croup, where efficacy is well established. These potent anti-
inflammatory drugs can be administered systemically or by inhalation, alone or 
combined with other treatments. Each corticosteroid can be described by its anti-
inflammatory potency and specific pharmacokinetic properties.636 There is 
considerable variation in dose, duration of treatment and type of regimen used in 
practice. Systemically administered corticosteroids include prednisone/
prednisolone, probably the most frequently used oral corticosteroids and often used 
as a reference standard, as well as dexamethasone. Typical use of systemic 
corticosteroids in acute respiratory conditions conditions is a one to five day high-
dose regimen. 
!
Corticosteroids diffuse through cell membranes and bind with high affinity to the 
cytoplasmic glucocorticoid receptor (GR) to form a complex which translocates to 
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the nucleus.637 This complex inhibits inflammation through both direct and indirect 
genomic, as well as non-genomic effects.579,637,638 The former include: binding to 
glucocorticoid-response elements (GRE) in the promoter region of steroid-sensitive 
genes, with trans-activation of anti-inflammatory proteins; interacting with negative 
GREs to suppress genes; and interacting with co-activator molecules of pro-
inflammatory transcription factors, such as nuclear factor-kB, to inhibit the 
inflammatory genes that are activated by these transcription factors. Most genes 
other than those that encode inflammatory proteins are not affected, but gene 
suppression may explain some adverse effects.638 Non-genomic effects include 
signaling through membrane-associated receptors and second messengers, post-
transcriptional effects and others. Inhibition of recruitment of inflammatory cells 
into the airway occurs through the suppression of chemotactic mediators and 
adhesion molecules, and by accelerating apoptosis. The end result of these 
molecular pathways is a direct inhibitory effects on many inflammatory cells, 
including eosinophils, T-lymphocytes, mast cells and dendritic cells. Conversely, 
corticosteroids inhibit neutrophil apoptosis. Epithelial cells may also be a major 
cellular target, and corticosteroids may reduce airway microvascular leakage, lead 
to acute airway mucosal vasoconstriction, and decrease mucus production. 638 Not 
all effects come into play with different doses and durations of treatment. 
Importantly, most data are from adult and animal studies, and there is a paucity of 
information on any developmental effects on these mechanisms. 
!
Prednisone is an inactive prodrug that undergoes oxidative metabolism in the liver 
to prednisolone, the active drug. Dexamethasone has a greater affinity for the GR 
than prednisolone, and its biologic half-life (i.e., the time required for the systemic 
effects to decrease by 50%) is longer than that of prednisolone, both factors 
accounting for its higher potency. Oral absorption of both drugs is rapid and nearly 
complete. Some of these formulations are available for delivery as aerosol, and 
inhaled budesonide is also used.  
!
Corticosteroids require a few hours before they produce a clinical response, and the 
wash out of effects are also prolonged. Pharmacological research has long focused 
on the adverse effects from long-term systemic use of these drugs, including growth 
inhibition, bone disease, infections, cardiovascular disease, adrenal failure and 
neurodevelopment effects.639 These effects are known to depend on drug (e.g. 
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specific corticosteroid, duration and dose) and patient factors (e.g. underlying 
disease, genetic factors). Neonates and younger children may be particularly 
vulnerable to long-term effects.640 There is uncertainty, however, regarding the 
safety of single or repeated short-duration systemic treatments in otherwise healthy 
children with conditions such as bronchiolitis.641 Palatability is an important 
consideration for oral corticosteroid products, as poor taste or non-liquid 
formulations are frequent, likely to reduce adherence and contribute to vomiting of 
medication.642 
!
Corticosteroids were originally considered for use in bronchiolitis given 
inflammation is key to pathogenesis. However, mechanistic studies have suggested 
that these drugs have limited anti-inflammatory effects in this condition. Various 
motives may contribute to this. First, neutrophilic inflammation is not responsive to 
corticosteroids, but plays a major role in bronchiolitis.175 Systemic administration of 
dexamethasone did not have a consistent effect on tracheal aspirate concentrations 
of pro-inflammatory cytokines in children with severe RSV disease.643 Other studies 
suggest RSV may have a deleterious effect on corticosteroid signaling and repress 
GR-mediated gene activation.644,645 Some authors have suggested that 
corticosteroid treatment response is virus-specific in wheezing children. A trial by 
Lehtinen and colleagues suggested that children with RV infection responded to 
prednisolone, as opposed to those with RSV.646 However, this study was a post hoc 
analysis and included children with recurrent wheezing; long-term follow-up seems 
to contradict the initial positive finding.509,513,646 Studies assessing the use of longer 
courses of corticosteroids started during the acute phase for the prevention of post-
bronchiolitic wheezing have also failed to show a long-term effect.528-530 Further, 
there is an ongoing debate regarding their efficacy in acute virus-induced wheezing 
in preschool children.647-649 
!
While the interactive effect of bronchodilators and corticosteroids has been widely 
known in asthma, both at a clinical and biological level, its use as a putative 
treatment option in bronchiolitis has only been explored recently. Combination 
therapy with inhaled corticosteroids and long-acting β2-ARs is key to the 
management of asthma and also COPD. Several synergistic effects at the molecular 
level have been described when combining therapies, which support clinically 
relevant effects for both conditions.650,651 On the one hand, the β2-AR gene 
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contains several GRE sequences in its promoter region, and their stimulation by 
corticosteroids results in an accelerated rate of transcription of the β2-AR gene, 
with unregulated expression of the receptor. The efficiency of coupling between the 
β2-ARs and downstream G-proteins may also be modulated by corticosteroids. On 
the other hand, experimental evidence indicates that long-acting β2-AR agonists 
can promote and accelerate translocation of the GR complexes from the cytosol to 
the nucleus. Whether these mechanisms are relevant for acute, short-term use of 
both bronchodilators and corticosteroids, by different modes of administration (i.e. 
inhaled vs. systemic) and with different specific agents (i.e. long- vs. short-acting 
bronchodilators, β2-ARs vs. other bronchodilators) is not known. 
!
Integrating evidence from multiple treatments using evidence synthesis 
The purpose of systematic reviews is to collate relevant evidence from individual 
studies to answer a specific research question.652 The formal synthesis and 
integration of research studies may be attributed to the advent of meta-analysis in 
the early 1970s within the areas of educational and psychological research.652 Over 
time numerous approaches to synthesizing research evidence have emerged. 
Systematic reviews use explicit, systematic methods in an effort to be as 
comprehensive as possible and to minimize bias in the results and conclusions. The 
Cochrane Collaboration has been instrumental in developing methods for 
systematic reviews related to interventions in healthcare.653 Previous systematic 
reviews, including Cochrane reviews, have examined the efficacy and safety of 
various bronchodilators and corticosteroids in bronchiolitis.587,589,654,655 However, 
there are four main motives to support a new synthesis effort:  
1. to include recent evidence from large clinical trials;  
2. to explore the use of combined therapy;  
3. to address shortcomings in previous reviews; and 
4. to use novel multiple treatment synthesis methods to integrate this evidence.  
!
The two largest randomized clinical trials in this field were recently published. The 
CanBEST trial included 800 children from Canada, and used a factorial design to 
examine adrenaline and dexamethasone, alone or combined, compared with 
placebo.46 Another trial completed concurrently in the United States compared 
dexamethasone with placebo in a sample of 600 children.45 Updating of systematic 
reviews is a major issue given the inevitable and rapid accumulation of new 
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research findings. Different systems have been proposed to identify which reviews 
may be out of date, including time-based periodic updating policies, or surveillance 
systems adjusted to the progress of research in each specific field.656 In this case, 
the review on corticosteroids was withdrawn from the Cochrane database in 2008 
due to lack of an update.655 Further these two large trials add substantially to the 
evidence and provide a strong signal for further synthesis work. 
!
The CanBEST trial raised new questions regarding combination therapy, by showing 
a 35% relative reduction on rates of admission to hospital with combined 
adrenaline and dexamethasone treatment compared with placebo. Combination 
therapy has not been examined previously at the level of systematic reviews nor 
placed in the context of other evidence. Examining potential additive (synergistic) 
or subtractive (antagonistic) effects between treatments such as bronchodilators and 
corticosteroids at a trial and systematic review level is challenging.657 At the trial 
level, the factorial trial design such as the one used by the CanBEST trial may 
answer these questions. However, this design requires special methodological 
considerations, particularly when interactions are not the focus of the study and are 
not anticipated, such was the case.658 Further, co-interventions that are not the main 
focus of study, such as use of bronchodilators (or, conversely, use of corticosteroids), 
are often used at the discretion of the attending physician in both arms parallel 
trials, which confounds analysis. While there is scarce guidance on how to 
investigate synergism/antagonism at a systematic review level, the fact that some 
studies use protocolized treatments provides an added opportunity to compare trial 
results at a subgroup level. 
!
Limitations of previous systematic reviews in this field include inconsistencies in 
definitions of disease, interventions studied, selected outcomes and methods used.
10 These differences were found both between reviews of different treatments, but 
also between reviews focusing on the same group of treatments. For example, two 
previous systematic reviews that assessed the use of corticosteroids in acute 
bronchiolitis focused on different populations and interventions: Garrison et al only 
included inpatient trials and was restricted to systemic corticosteroids, while King et 
al included children from all settings and all treatments; none excluded children 
with previous episodes of wheezing, nor used an age limit.587,589 Primary outcomes 
of each review also differed, even among reviews that focused on the same specific 
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population or setting. Finally, approaches to data analysis also varied, particularly 
in non-Cochrane systematic reviews. For example, some reviews either did not pool 
quantitative results or did so by analyzing modified composite outcomes.587,589 
None of the reviews used standardized updated instruments to assess risk of bias, 
such as the Cochrane ’Risk of bias’ assessment tool, or to grade the quality of 
evidence, such as the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) approach.659,660 Differences between methods have largely 
contributed to controversies in the interpretation of review findings. A 
comprehensive review with a broad scope that would include both bronchodilators 
and corticosteroids using a coherent standardized approach and current 
methodological guidance would allow to collate relevant evidence from individual 
studies to describe the relative benefits and harms of these interventions.  
!
A final motive to conduct a new systematic review in this field relates to emerging 
analytic methods in synthesis research, including network meta-analyses (NMAs).
661,662 These methods help to address some of the aforementioned challenges and 
limitations of previous analyses, while providing new information on comparative 
effectiveness of interventions. A limitation of previous individual systematic reviews 
is that they are narrow in scope, focusing on direct pairwise comparisons and 
excluding competing interventions. For example, no previous review compared 
evidence between different bronchodilators, or between bronchodilators and 
corticosteroids. When many competing treatments exist, meta-analyses lack formal 
comparisons across different interventions that are critical for informed decision 
making, e.g. to determine which is the “best” treatment to use in bronchiolitis. The 
Cochrane Collaboration introduced a new form of reviews, the “overviews of 
reviews”, which summarizes evidence for the relative effectiveness of several 
interventions for the same condition. The Cochrane Child Health Field has 
contributed to refining the methods of overviews and has been a leader in 
producing them.663 We contributed to one such overview focused on interventions 
for bronchiolitis, bringing together 11 individual previous Cochrane systematic 
reviews.10 However, authors of overviews are dependent on the decisions and 
methods used within the relevant systematic reviews. Further, overviews of reviews 
do not usually integrate this evidence coherently and quantitatively, making it 
difficult to judge which treatment should be used.662 In the bronchiolitis overview, 
readers might inappropriately make their own indirect comparisons between 
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treatments (e.g. comparing treatment effect estimate in admission rates from 
salbutamol or adrenaline vs. placebo), which could result in misleading 
conclusions. One solution is to conduct ‘comparative effectiveness reviews’ or 
‘comparing multiple interventions reviews’, which provide a coherent evidence 
base that reflects the network of comparisons that arises when collating studies 
involving different subsets of competing treatments.662 These reviews have an 
optional quantitative part, which is variably known as NMAs, multiple-treatments 
meta-analysis, or mixed-treatment comparison.664 The terms are often used 
interchangeably, and they refer to the same framework that combines direct and 
indirect information across a network of randomized trials to infer about the relative 
effectiveness of multiple interventions. The idea of indirect comparison, which 
underlines the methods, is a simple one: we can compare treatment A to treatment 
B via a common comparator C, by statistically combining the information from A 
versus C (AC) and B versus C (BC) studies (Figure 1.7).665 An NMA typically uses a 
Bayesian network model to compare all interventions simultaneously. While a 
network analysis in a frequentist framework is possible, at the present time there is 
much more methodology and support available for conducting these analyses in a 
Bayesian framework.664 NMAs are appealing because they can provide evidence 
about the relative effectiveness across a range of interventions, for instance they can 
provide a ranking of interventions which appears to be the most effective or can 
compare a given intervention with all other potential interventions. Incorporating 
both direct and indirect evidence can also provide stronger inferences about 
relative treatment effects, even when direct head-to-head comparisons are not 
available. The ability to compare treatments that have not been directly compared 
in any trial could allow a better evaluation of combination therapy. Nevertheless, 
several assumptions need to be met for the results of an NMA to be valid.666,667 In 
particular, conceptual and statistical heterogeneity (i.e. disagreement between 
estimates within the same comparison), and incoherence (i.e. differences between 
direct and indirect evidence in the network) should be assessed.  
!
In summary, we have presented motives that support the need for conducting a 
comprehensive comparative effectiveness review, with network meta-analysis, 
focusing on bronchodilators and corticosteroid use in bronchiolitis (Chapter 2). A 
further advantage of such effort was to have offer a panorama of current clinical 
trial research in this field. In particular, NMAs include the visualization of the 
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network geometry of comparisons performed in included trials, which allows one to 
understand how much evidence exists for each treatment, whether some types of 
comparisons have been avoided, and whether particular patterns exist in the 
choices of comparators. Further, such a comprehensive review would allow to 




OUTCOMES AND MEASUREMENT INSTRUMENTS IN 
BRONCHIOLITIS 
Selection of appropriate primary and secondary outcomes is essential for study 
design, as ultimately, any study is only as credible as its endpoints.668 To be useful, 
clinical trials that evaluate benefits and harms of interventions must measure 
outcomes of relevance to stakeholders.669 These include practitioners and patients 
or their proxies who make shared decisions about treatment options, regulatory 
authorities that assess and monitor approvals of drugs and devices, as well as health 
care funders and policy makers. Further, instruments used to measures these 
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Figure 1.7. Trial network with direct and indirect comparisons. Each trial network consists of three sets 
of independent trials: one set for direct comparison of A versus B and two sets for adjusted indirect 
comparison of A versus B with C as common comparator (From: Song, with permissions)
CHAPTER 1: GENERAL INTRODUCTION
CHAPTER 2
outcomes must be scientifically sound and have measurement properties that are fit 
for this evaluative purpose.670,671  
!
Inconsistent selection, measurement, and reporting of outcomes in clinical trials 
hampers the scientific, ethical and economic significance of RCTs.672 Three main 
problems may arise.673 First, outcomes may not consistently reflect endpoints that 
are meaningful for patients or other stakeholders. For example, one study found that 
outcomes in clinical trials of children with asthma tend to focus on how 
interventions affect short-term symptoms, measures of lung function, and acute 
exacerbations of illness, with longer-term outcomes, quality of life, and functional 
status being measured much less frequently. In clinical trials in neonatology, a 
reliance on short- term outcomes, rather than longer-term benefits and harms of 
interventions, has also been shown.674 Second, inconsistency in measurement 
domains and instruments is a barrier to compare, contrast, and combine trial 
findings, further affecting their interpretation. In the 1990s, the potential scale of the 
problem of multiple outcome measures was highlighted in a comprehensive review 
of 2000 trials in schizophrenia which were found to have used 640 different rating 
scales in their assessments of 600 interventions.675 A recent update of this data 
found on average, a new instrument to assess schizophrenia had been introduced 
for every fifth trial.676 Similar findings have been replicated in other fields. 
Cochrane reviews usually describe inconsistencies in the outcomes reported in 
eligible trials and regularly conclude for the need to standardize outcomes.672,673 In 
addition, there is great variability in the quality (for example, in reliability and 
validity) of outcome measurement instruments used and it is not always clear if the 
best instrument is being used for a given outcome. For example, fewer than 20% of 
906 different outcomes measured in breast reconstruction surgery trials were 
defined or measured with a validated tool.677 Third, if researchers have measured a 
particular outcome in a variety of ways, they might not report all of their findings 
from all of these measures. Outcome reporting bias can ensue, if the results of an 
analysis are used to choose which outcomes will be reported, e.g by selectively 
reporting only the most positive or statistically significant results.678-680 
!
In recent years there has been a call for the standardization of outcomes in clinical 
trials.672,681,682 Concurrently, the GRADE system has suggested that systematic 
reviewers and guideline panels identify critical outcomes that are important to 
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patients.683 Current limitations in outcome selection could be addressed with the 
development and application of agreed standardized sets of outcomes that have 
been termed ‘core outcome sets’.681,682 These should be measured and reported, as 
a minimum, in all relevant clinical trials for a specific condition. Adopting a core 
outcome set does not imply that a researchers are limited in their choice of primary 
or other outcome measures of interest, or that these should be restricted to only 
those outcomes. Rather, the expectation is that, as a minimum, core outcomes will 
always be collected and reported, which would allow an adequate assessment, 
comparison and synthesis of treatment effects of interventions between trials. Core 
outcome sets would foster research and consensus in identifying scientifically 
sound, clinically relevant and patient-important outcome measures for different 
conditions and interventions. Importantly, it would enhance the value of evidence 
synthesis by reducing the risk of outcome reporting bias and ensuring that all trials 
contribute usable information for end users. 
!
Some historically successful initiatives in standardizing outcomes can be used as 
examples. One of the earliest examples was an initiative by the WHO in the late 
1970s, that led to guidelines on the minimal requirements for data collection in 
cancer trials. The Outcome Measures in Rheumatology initiative (OMERACT) has 
pioneered the development of core outcome sets within rheumatology since 
1992.668,681,684 Other groups have been working on core outcome sets or related 
guidance in specific areas of health care, including the Initiative on Methods, 
Measurement, and Pain Assessment in Clinical Trials (IMMPACT) for chronic pain 
trials, Harmonizing Outcome Measures for Eczema (HOME), and TREAT-NMD 
Neuromuscular Network for neuromuscular disease. 685-687 A recent systematic 
review found a total of 198 studies on core outcome sets, most commonly in 
cancer, rheumatology, neurology, heart and circulation, and dentistry and oral 
health.688 Interestingly, few studies address the appropriate choice of outcomes for 
clinical research with children, and in most pediatric specialties no research has 
been undertaken.689 The COMET (Core Outcome Measures in Effectiveness Trials) 
Initiative, launched in January 2010, brings together researchers interested in the 
development, application and promotion of core outcome sets, derived using 
rigorous consensus methods, for effectiveness trials.673,682,690 
!
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Figure 1.8. Stepwise approach to the development of a Core Domain Set (A) and a Core 
Outcome Measurement Set (B), as proposed by the OMERACT group (adapted from: Boers, 
with permissions)
Areas. However, current trials do not quantify harm
(adverse effects) as carefully as benefit. Thus, OMERACT
endorses that adverse events continue to be labeled or
flagged to allow separate assessment of anticipated benefit
and potential harm.
4.3.2. Setting and contextual factors
Core set developers need to specify the setting of the
core set, and consider if any contextual factors need to be
documented in every trial. Setting (or scope) includes the
health condition, target population for the intervention, type
of intervention, and so on. Contextual factors can be
defined as those that are not the primary object of research
but that may influence the results or the interpretation of the
results. These include potential confounders and effect
modifiers (most of which should be eliminated by random-
ization), as well as factors that define the generalizability of
the study findings. One way of representing the interaction
between contextual factors and other measured aspects of
the impact of a health condition has been illustrated by
the so-called ‘‘impact triad’’ [28].
5. Developing a Core Outcome Measurement Set:
process suggestions
OMERACT suggests a stepwise approach to core set
development (Figs. 2 and 3). The first step is defining the
setting of the core set and deciding which (if any) contex-
tual factors need to be measured alongside the outcome
measures. Developers must also decide whether specific
adverse events need to be monitored as part of the core set.
The next step is determining what to measure (Fig. 2),
starting with a literature search to document all (sub)do-
mains and instruments used to date. At the same time,
Table 3. Comparison of OMERACT Framework to a model of Health-related Quality of Life [26] and the International Classification of Functioning,
Disability and Health (ICF) [25]
OMERACT framework core areas/concepts Health-Related quality of life model ICF
Death
Pathophysiological manifestations Biological and physiological variables Body function and structure
Life impact Symptom status Activity
Functional status
General health perceptions Participation
Overall quality of life
Contextual factors/scope Characteristics of the individual Contextual factors
Characteristics of the environment
Nonmedical factors
Health condition/scope Health condition
Abbreviations: OMERACT, Outcome Measures in Rheumatology; ICF, International Classification of Functioning, Disability and Health.
Fig. 2. Development of a Core Domain Set from the Core Areas of measurement. A Core Domain Set is defined as the minimum set of Domains and
Subdomains necessary to adequately cover all Core Areas, that is, fully measure all relevant concepts of a specific health condition within a spec-
ified setting.
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developers initiate stakeholder consultation to determine
what each stakeholder group deems essential to measure.
During this process, developers refer to the framework
and match the input to specific Domains and Subdomains
in each Core Area relevant to the chosen setting. To ensure
face and content validity, explicit input from all stake-
holders, including patients, is essential to identify relevant
(sub)domains and to expose gaps in what has been
measured to date [29]. The end result of this process is
a draft subjected to a consensus procedure with all stake-
holders, resulting in a Core Domain Set. Core Domains in
the Areas of Death, Life Impact, and Resource Use can be
equated with the ‘‘critical outcomes’’ of the Grading of
Recommendations Assessment, Development and Evalua-
tion (GRADE) system [30]. To do more justice to the
value of all the domains and instruments reviewed, these
can be viewed as occupying a series of concentric spheres:
the core domains in the middle, surrounded by domains of
decreasing importance [11].
The final step is deciding how to measure the selected
Core Domains (Fig. 3). The literature review provides a list
of available measurement instruments; where no instru-
ments are available in a (sub)domain, these need to be
developed. Each instrument is then studied to document
its applicability in the chosen setting (Table 1) [15]. Draw-
ing on key developments that have occurred after the
formulation of the first Filter such as the work by the COS-
MIN group [31,32], and the GRADE recommendations
[30], OMERACT is developing specific guidelines on the
procedures to document applicability of instruments.
When all Core Domains can be measured by at least one
applicable instrument, the end result is a draft that again is sub-
jected to a consensus procedurewith all stakeholders, resulting
in the Core Outcome Instrument Set. Where core contextual
factors and adverse events have been specified, instruments
tomeasure thesemust also pass theOMERACTFilter. Formu-
lation of a ‘‘preliminary’’ CoreOutcomeMeasurement Set can
be useful in situations where one or more Domains were
incompletely coveredbyapplicablemeasurement instruments.
6. Discussion
OMERACT has been active in the field of outcome mea-
surement in rheumatology since 1992. It has now upgraded
and clarified its working process for developing core
outcome sets in two ways. First, it has formulated a novel
conceptual framework of measurement of health conditions
in the setting of health interventions. The Core Areas do not
describe novel concepts, but their explicit juxtaposition in
the framework is novel; in this way they ensure content val-
idity across patient-important and intervention-specific in-
formation. In its overarching concept of ‘‘Impact,’’ the
framework confirms that assessment of patient-centered
outcomes in trials is essential to inform health care deci-
sions, as suggested by the PCORI [1]. Second, OMERACT
has made the process of subsequent outcome development
explicit by agreeing on the definitions of key concepts,
including that of a Core Domain Set that logically must
be developed before a Core Outcome Measurement Set.
Fig. 3. Development of a Core Outcome Measurement Set from a Core Domain Set. The Core Outcome Measurement Set is defined as: the min-
imum set of outcome measurement instruments that must be administ red in each intervention study of a certain health condition within a spec-
ified setting to adequately cover a corresponding Core Domain Set. As depicted, the development process allows core set developers to declare a
Preliminary Core Outcome Measurement Set when not all Domains are covered by at least one applicable measurement instrument.
7M. Boers et al. / Journal of Clinical Epidemiology - (2013) -
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Methods to support the development and implementation of core outcome sets are 
still evolving.682,691 Gargon and colleagues have shown how a range of methods 
have been used; it is uncertain which are most suitable, and there is limited 
empirical evidence regarding whether different methods lead to similar or different 
conclusions.688 Some core outcome sets have been developed through a literature 
review of outcomes used in trials, given to consideration by an expert panel of 
health care professionals; these then select relevant domains, often through ranking, 
and sometimes include suggestions for instruments to measure these domains.689,692 
Problems with this approach include failing to involve all stakeholders such as 
patients, not explicitly using a conceptual framework for choice of outcomes, and 
not basing instrument selection on systematic evidence of their measurement 
properties.691 Thus, these core sets may overlook important concepts and 
recommend inadequate measurement tools. Key issues in the development of a 
core outcome set include: clear definition of its scope, i.e. health condition, 
population and interventions; identifying existing knowledge comprehensively but 
efficiently; involving all relevant stakeholders using adequate and feasible 
consensus methods that allow for methodological rigor and inclusion of a diverse 
range of opinions; reviewing with feedback and updating; and implementing the 
core outcome set.682 Importantly, one must distinguish between potential domains 
(‘‘what to measure’’) and measurement instruments (‘‘how to measure’’); and the 
process to identify these and to reach consensus on which to include in a core set.
691 Table 1.3 presents definitions of key concepts in this field, albeit terminology 
varies for some of these concepts. 
!
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Table 1.3: Definitions of key concepts regarding outcomes and outcome measurement (adapted 
from Boers et al, Mokkink et al, and Williamson)
Concepts and definitions
(Sub)Domain Concept to be measured, a further specification of an aspect of health
Outcome Any identified result in a (Sub)Domain arising from exposure to a causal factor or a health intervention; 
generic word that has been used with different definitions; has often been used interchangeably with 
‘‘outcome measure’’ and ‘‘endpoint.’’
Core Domain/
Outcome Set
For studies of health interventions, the minimum set of Domains and Subdomains necessary to 
adequately measure all relevant concepts of a specific health condition within a specified setting. 
Describes what to measure. OMERACT uses the term “Core Domain Set”, while the COMET initiative 
uses the term ‘‘Core Outcome Set’’.
Measurement 
instrument
A tool to measure a quality or quantity of a variable, in this context a (Sub)Domain or a contextual 
factor. 
The tool can be a single question, a questionnaire, a score obtained through physical examination, a 




The minimum set of outcome measurement instruments that must be administered in each intervention 
study of a certain health condition within a specified setting to adequately cover a corresponding Core 
Domain Set. Describes how to measure.
Measurement 
Properties
Refers to the properties of a measurement instrument; the consensus-based COSMIN taxonomy and 
definitions are shown below. 
Reliability The degree to which the measurement is free from measurement error;  the extent to which scores for 
patients who have not changed are the same for repeated measurement under several conditions: using 
different sets of items (internal consistency), over time (test-retest) by different persons on the same 
occasion (interrater) or by the same persons (i.e., raters or responders) on different occasions (intrarater)
Internal 
consistency
The degree of the interrelatedness among the items
Reliability The proportion of the total variance in the measurements which is because of 
‘‘true’’a differences among patients
Measurement error The systematic and random error of a patient’s score that is not attributed to true 
changes in the construct to be measured
Validity The degree to which an instrument measures the construct(s) it purports to measure 
Content validity The degree to which the content of an instrument is an adequate reflection of the 
construct to be measured
Face validity The degree to which (the items of) an instrument 
indeed looks as though they are an adequate 
reflection of the construct to be measured
Construct validity The degree to which the scores of an instrument are consistent with hypotheses 
(for instance with regard to internal relationships, relationships to scores of other 
instruments, or differences between relevant groups) based on the assumption that 
the instrument validly measures the construct to be measured
Structural validity The degree to which the scores of an instrument 
are an adequate reflection of the dimensionality 
of the construct to be measured
Hypotheses testing Idem construct validity
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The issue of consistency and relevance of outcomes and measurement instruments 
is not new in bronchiolitis. Authors have commented how the use of different 
outcome variables, often focused on short-term and surrogate variables of 
respiratory distress, has limited the interpretation of trial results. 27,693 Further, it is 
known that many respiratory scales were developed ad hoc, and their measurement 
properties have not been studied adequately.694 Systematic reviews and guidelines 
have repeatedly indicated research in this field as a priority, and recommended the 
use of outcomes that are relevant to parents, clinicians, and health systems.695 
However, the extent of these gaps in outcome measurement is not known, and little 
original research has contributed to improve current measurement tools.  
!
What to measure: conceptual frameworks and outcome domains  
Outcomes may encompass a spectrum of different aspects of health or health 
dimensions or domains, each with distinct implications, e.g. biological, clinical, or 
patient-oriented perspectives. Because of the multidimensional aspects of health, 
researchers have used a variety of conceptual frameworks for considering the effects 
of illnesses and measurement of health across a range of outcome domains.696 A 
conceptual framework or model is a schematic representation of a theory that acts 
as a heuristic device to provide a better understanding of a phenomenon (e.g., 
health or health-related quality of life) by depicting interrelationships among 
concepts.671 These frameworks are useful for core outcome set development, by 
supporting and making explicit a comprehensive and coherent choice of areas/
domains of core set development. A recent scoping review found five such 
conceptual frameworks: the WHO tripartite definition of health (“a state of 
Cross-cultural validity The degree to which the performance of the items 
on a translated or culturally adapted instrument 
are an adequate reflection of the performance of 
the items of the original version of the instrument
Criterion validity The degree to which the scores of an instrument are an adequate reflection of a 
‘‘gold standard’’
Responsiveness The ability of an HR-PRO instrument to detect change over time in the construct to be measured
Interpretability The degree to which one can assign qualitative meaningdthat is, clinical or commonly understood 
connotationsdto an instrument’s quantitative scores or change in scores.
Table 1.3: Definitions of key concepts regarding outcomes and outcome measurement (adapted 
from Boers et al, Mokkink et al, and Williamson)
Concepts and definitions
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complete physical, mental and social well-being and not merely the absence of 
disease or infirmity”); the 5 Ds (discomfort, disability, drug toxicity, dollar cost, and 
death), the International Classification of Functioning, Disability and Health (ICF; 
based on functioning at the level of body or body part, the whole person, and the 
whole person in a social context); the Patient-Reported Outcomes Measurement 
Information System (PROMIS; based on physical health, mental health, and social 
health); and Porter’s Outcome Hierarchy (based on health status achieved or 
retained, process of recovery, sustainability of health).692 Health-related quality of 
life frameworks also exist, with the most frequently used being the Wilson and 
Cleary model, and its modification by Ferrans.697,698 Some of these frameworks or 
their adaptations have been used in previous core outcome set development 
studies, while other researchers have failed to use a conceptual model.692 However, 
differing conceptualizations limit the ability to have a coherent body of evidence to 
guide further core outcome set development.  
!
The OMERACT initiative has developed and updated a distinctive and 
comprehensive conceptual framework and a recommended process to develop 
core outcome measurement sets for rheumatology, which is likely to be useful as a 
template in other areas of health care.691 This framework comprises core areas that 
should encompass the complete content of what is measurable in a trial: three areas 
that describe the ‘‘Impact of Health Conditions,’’ specifically Death, Life Impact, 
and Resource Use; and a fourth area that describes “Pathophysiological 
Manifestations” (Figure 1.8). These areas may include various concepts of interest, 
i.e. domains or subdomains. A suggested stepwise approach to the development of 
a Core Domain set, i.e. “what to measure”, is shown in Figure 1.8. It implies 
deciding on the setting or scope, contextual factors and adverse events, followed by 
a literature search to document all domains used to date, while initiating 
stakeholder consultation to determine what is essential to measure. Work by the 
COMET group has shown that a variety of methods have been used to achieve 
consensus within and between stakeholder groups on core outcome sets, including 
semi-structured discussion, unstructured group discussion, the Delphi technique, 
expert panel meetings, surveys and Nominal Group technique.682 Researchers 
should consider the potential impact of group composition, questioning technique, 
the information participants receive, whether or not responses are anonymous, 
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interactions between group participants, the medium of the interaction, attrition 
bias, analyses, and the way in which consensus is reached. 
!
A review of previous trials or systematic reviews can provide evidence of need for a 
core outcome set in a certain area, and also identify a potential list of outcomes. 
Building partially on the comprehensive comparative effectiveness review planned 
for Chapter 2, as well as on a recent overview of reviews, Chapter 3 will address 
preliminary work in identifying primary and secondary outcomes selected and 
reported in current clinical trials of a range of interventions. Further, there is scarce 
evidence on which health domains are clinically relevant and patient-important in 
bronchiolitis. As one the most common acute diseases in childhood that 
encompasses a large spectrum of severity, it is likely that stakeholder perspectives 
vary by a number of factors. Bronchiolitis is at a crossroads of different levels of 
care (i.e. primary care, ED, inpatient, intensive care) and different physician 
specialties (general practitioners, general pediatricians, ED specialists, hospitalists, 
pediatric pulmonologists, intensivists). There is wide practice variation, and 
organizational differences and subjective clinical decision-making may influence 
main outcomes such as hospital admission rates and length of stay. Preexisting 
comorbidities, demographics, family history and disease severity might also affect 
parents’ and caretakers’ perspectives. Moreover, it is an acute and dynamic 
condition, but may recur and have long-term influences. These are challenges when 
integrating multiple perspectives in a core outcome set. A first step described in 
Chapter 4 includes a large scale survey of physicians in different settings that 
addresses (among other topics) the utilization of outcome measures. 
!
How to measure: measurement properties of measurement instruments 
Once a core outcome set or core domain set is defined, it is important to achieve 
consensus on how these outcome domains should be measured.682,691 When 
selecting health measurement instruments for use in clinical trials, a number of 
aspects need to be considered a priori, such as the constructs to be measured, the 
target population, and the goals of the intervention.671 It is imperative that these 
instruments cover the adequate concepts, and that their measurement properties 
(i.e. their validity, reliability, and responsiveness), are adequate and applicable for a 
purpose of evaluation, both in the population included in the trial and in the setting 
in which the trial is conducted. This issue is particularly relevant in pediatrics, as 
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instruments may be used based on the extrapolation of data from adults without 
proper validation and feasibility in children.699 Further, the metrics and type of 
analysis chosen are also relevant (Figure 1.9).700 
!
Measurement in medicine is hampered by a lack of evidence on which are the best 
instruments. Absence of consensus on taxonomy, terminology, and definitions has 
led to confusion about which measurement properties are relevant, which concepts 
they represent, and how they should be evaluated.701 Integration between different 
perspectives on measurement by scientific disciplines such as psychometrics and 
clinimetrics, has been the subject of debate.702,703 The Consensus-based Standards 
for the selection of health Measurement Instruments (COSMIN) initiative developed 
through consensus a taxonomy of measurement properties and their relationships 
relevant for evaluating health instruments, which is shown in Figure 1.10 and Table 
1.3.701 These include internal consistency, reliability, measurement error, content 
validity (including face validity), construct validity (subdivided into structural 
validity, hypotheses testing, and cross-cultural validity), criterion validity, and 
responsiveness. Design requirements and preferred statistical methods were also 
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description of a measure to be specific in order 
to sufficiently form the rows for the results table 
(with comparison groups as columns). In addi-
tion to time frame, a fully specified outcome 
measure includes information about the follow-
ing: domain (e.g., anxiety), specific measurement 
(e.g., Hamilton Anxiety Rating Scale), specific 
metric used to characterize each participant’s re-
sults (e.g., change from baseline at specified 
time), and method of aggregating data within 
each group (e.g., a categorical measure such as 
proportion of participants with a decrease great-
er than or equal to 50%) (Fig. 1).
We reviewed the first primary outcome mea-
sure, as initially registered, from 100 randomly 
selected non–phase 1 clinical trials in August 
2010. Entries were assessed for whether a spe-
cific time frame was provided and were catego-
rized according to level of specification (Fig. 1). 
We categorized 36% as level 1 (i.e., domain 
only), 25% as level 2, 26% as level 3, and 13% as 
level 4; of these, 72% included a specific time 
frame. When only a specific measurement or 
domain is registered, as occurred in 61% of the 
entries in our sample, post hoc choices of the 
specific metric or method of aggregation could 
mask the fact that multiple comparisons were 
conducted, potentially invalidating the reported 
statistical analyses and allowing for cherry-
picking of results. Some argue that the method 
of aggregation (level 4) is part of the statistical 
analysis plan and may properly be specified later 
— after data accrual but before unblinding. The 
archive feature of ClinicalTrials.gov enables 
those viewing such records to see the originally 
registered outcome measure and the full time-
line of changes (if relevant).
Reporting of Results in Analysis Population
The analysis population is another source of 
potential bias in results reporting. Substantial 
distortion of results can occur if all data are not 
accounted for or if missing data are not handled 
appropriately. The use of different analysis pop-
ulations for different outcomes may not be no-
ticed by many readers, but it can exert a strong 
effect on reported results. In a sample of 700 
records (representing 1749 study groups and 
5160 outcome measures), the mean number of 
different analysis populations per study group 
with at least one participant was 2.5 (median, 1; 
range, 1 to 25). The magnitude of the difference 
across groups and outcomes varied. To further 
explore the magnitude of these differences, we 
evaluated the percentage of participants who 
started the study and were analyzed for the first 
Anxiety Depression Schizophrenia
Beck Anxiety Inventory Fear QuestionnaireHamilton Anxiety Rating Scale
End value Time to eventChange from baseline
Mean Median Proportion of participantswith decrease ≥50%
Proportion of participants












Figure 1. An Example of the Four Levels of Specification in Reporting Outcome Measures.
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Figure 1.9. An Example of the Four Levels of Specification in Reporting Outcome Measures (Reproduced 
with permission from Zarin et al, Copyright Massachusetts Medical Society.)
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agreed upon. The results of the consensus were used to construct the COSMIN 
checklist, which can be used for systematic reviews of measurement properties to 
evaluate the methodological quality of the included studies on measurement 
properties, to assess to assess the quality of a measurement instrument when used 
in combination with criteria for good measurement properties, to design and report 
studies on measurement properties, and to identify the need for further research.
704,705 The original OMERACT Filter published in 1998 is another approach used to 
determine applicability of a measurement instrument in a setting.684 It summarizes 
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key instrument properties in three plain language words, namely Truth, 
Discrimination, and Feasibility, with feasibility of measurement as an important 
consideration. 
!
There is considerable debate and lack of guidance on the criteria for good 
measurement properties to support measurement instrument selection for clinical 
trials. This is illustrated when considering a key measurement property, 
responsiveness, and another important concept, interpretability. Instruments with an 
evaluative purpose that are meant to be used longitudinally to measure change over 
time should be responsive. However, many different definitions of responsiveness 
have been proposed, as well as a number of distinct methods to assess it.706 Further, 
while interpretability is not considered a measurement property, it is an important 
requirement for the suitability of an instrument in research and clinical practice.701 
Multiple methods have been proposed to support the interpretation of change 
scores or differences, both within or between groups of patients followed over time. 
In particular, a variety of statistical and anchor-based approaches are available to 
ascertain the Minimal Important Change (MIC), i.e. the smallest change in score 
that is perceived as important by patients, clinicians or relevant others.707-711 
However, no consensus exists on which methods are most appropriate, terminology 
varies (e.g. some authors prefer Minimal Important Difference - MID), and there is 
some debate as to how the MIC relates to measures of measurement error, e.g the 
Smallest Detectable Change.707,709,710,712,713 
!
Selecting measurement instruments to measure the core domains can start with a 
literature review that provides a list of available measurement instruments, followed 
by systematic reviews of their measurement properties evaluating the 
methodological quality of the studies and the quality of the instruments.682,691,705 
Instruments are then selected based on this assessment, but development of new 
instruments may be needed. Project 2 of this thesis will provide an overview of 
commonly used instruments in clinical trials of corticosteroids and bronchodilators 
in bronchiolitis. Previous reviews have identified the use of various scales to assess 
respiratory status in bronchiolitis, including the Respiratory Distress Assessment 
Instrument (RDAI) and the Respiratory Assessment Change Score (RACS). These 
instruments were first described by Lowell in a trial assessing the effect of 
adrenaline in wheezing infants.714 The RDAI is a scale of respiratory distress, 
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assessing retractions and wheezing, while the RACS is a change score based on 
change in both RDAI and respiratory rate (Table 3.3, Chapter 3). Despite their 
frequent use, systematic reviews of asthma or wheezing instruments have found 
limited evidence regarding the RDAI and RACS measurement properties and their 
suitability for use as evaluative instruments in clinical trials.694,715,716 A recent RDAI 
validation study reported poor construct validity, poor inter-rater reliability and mild 
responsiveness.717 The RDAI was used as an outcome measure in the largest clinical 
trial in this field. Chapter 4 of this thesis will use data from RCT to study the 
measurement properties of the RDAI and RACS, i.e. validity, reliability and 
responsiveness, using COSMIN’s taxonomy. 
!
!
DEFINING BRONCHIOLITIS: MOVING FROM WORDS AND LABELS 
TOWARDS PHENOTYPES 
While bronchiolitis is a relatively straightforward clinical diagnosis for most child 
health practitioners today, no standardized set of diagnostic criteria exist.2 The 
debate over the definition of disease has lasted for decades, and its origins can be 
traced back to the emergence of bronchiolitis as a distinct clinical entity.19,30 
Previously we’ve explained how consistent clinical descriptions of seasonal 
epidemics of infants with hallmark findings were decisive in the gradual recognition 
of the condition during the 1960s. The isolation of RSV and its prominent role as an 
etiologic agent concurred. However, heterogeneous features of bronchiolitis were 
identified early on and various authors repeatedly reflected on its implications.
19,30,718-724 Surprisingly, despite the frequency and importance of the condition, no 
significant progress was made in systematically addressing the lack of clarity on 
disease definition. Many motives may contribute to the latter, including: subjectivity 
and variability in the identification and interpretation of cardinal clinical findings; 
absence of accurate diagnostic tools; diagnostic overlap with conditions such as 
pneumonia and acute wheezing; different perspectives according to the spectrum of 
severity, levels of care, settings, specialties and context; perceived or real diagnostic 
and prognostic implications of having underlying risk factors for severity and 
asthma; and terminology and nosology issues. 
!
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While most existing bronchiolitis definitions highlight how bronchiolitis is a clinical 
diagnosis, there are important nuances in details of the constellation of 
demographics, history and physical examination findings. This is highlighted when 
comparing definitions proposed by landmark opinion papers, current clinical 
practice guidelines, and inclusion criteria from recent large clinical trials (Table 
1.4).  Variability is focused on key demographic and clinical items, including age, 
number of episodes and auscultatory findings. A 2004 systematic review by 
Viswanathan and colleagues reviewed the case definitions used in bronchiolitis 
clinical trials and found variability in included symptoms, with authors frequently 
using a broad  “physician-diagnosed" criteria without further details.695 Authors 
have highlighted how age limits vary in previous bronchiolitis observational studies.
95,725 When looking at the two largest clinical trials performed in this field, it is also 
interesting to note that large numbers of infants are screened but a large proportion 
of exclusions is due to definition-related factors such as having a history of 
wheezing.45,46 Further, some studies restrict bronchiolitis based on other factors 
such as specific viral agents (e.g. RSV), or use heterogeneous thresholds of severity 
(e.g. hospitalizations, ICU admission). The methods and rationale for these 
definitions is often not reported, and most authors agree that there is little evidence 
on which to establish recommendations for the definition of bronchiolitis. 
!
A rare attempt at using a structured approach to obtain a definition of disease was 
reported by a local clinical guideline development group in Nottingham, UK.726 A 
Delphi panel of 50 physicians and nurses (mostly pediatricians) reached 90% 
consensus on bronchiolitis as ‘a seasonal viral illness characterized by fever, nasal 
discharge and dry, wheezy cough’, with ‘fine inspiratory crackles and/or high 
pitched expiratory wheeze’. This definition could be considered in children below 
two years of age; no further details were given on any other demographic, clinical 
or biological parameters. Although a summary of evidence was given to the panel, 
this definition was clinically-oriented and it is not clear whether its implications for 
research were discussed. Unfortunately, no other such structured approaches are 
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known, and clinicians and researchers have repeatedly faced the dilemma of how 
to operationalize disease definition in the absence of clear guidance. The impact is 
considerable; in clinics, this has led to the use of the same diagnostic label in 
young children with important differences in their demographic, history and 
physical examination features.55 Variability between centers in diagnostic labeling 
of lower respiratory tract infections (e.g. as bronchiolitis, asthma or wheezing) has 
Table 1.4: Differences in bronchiolitis definitions in landmark opinion papers, recent clinical 
practice guidelines and large clinical trials
Document Bronchiolitis definition





















upper respiratory features; 













wheeze rhinorrhea, cough, 
dyspnea
NR
McConochie 1983 first <24M expiratory 
wheezing









































rhinitis, tachypnea, cough, 
use of accessory muscles, 
and/or nasal flaring
NR












wheezing feed poorly, mild upper 
respiratory tract infection, 
low-grade fever, 




Corneli 2007 first 2-12M wheezing NR NR
Plint 2009 first 1.5-12M wheezing signs of an upper 
respiratory tract infection
NR





upper respiratory features; 








*the SIGN guideline directly references the Nottingham guideline consensus definition
#this clinical trial uses part of Court’s clinical criteria
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been shown to influence treatment practices, and may explain an important part of 
persistent practice variation in management of bronchiolitis.55,556 It may also affect 
the accuracy of diagnostic coding (e.g. ICD codes), which is used to define 
bronchiolitis as an outcome in many prognostic studies. For all these motives, it is 
not surprising that many controversies regarding the interpretation of evidence on 
management and treatment options are often attributed to the details of disease 
definition.590,727,728 
!
In this regard, it is interesting to note how recent the history of bronchiolitis in 
formal medical coding and scientific terminology is. The term bronchiolitis only 
appeared in the 8th revision of the WHO-led ICD, published in 1965, included in 
code 466 “Acute bronchitis and bronchiolitis”.729 A separate diagnosis code (466.1) 
was included in the 9th revision (1975), with a later addition of a specific RSV code 
for the first ICD10 version in 1990, and the extended ICD9 - Clinical Modification 
by the US National Center for Health Statistics. Curiously, the uptake of specific 
codes for  different viral agents has lagged, e.g. metapneumovirus was only the 
second agent to be included in the ICD classification, in 2010. Similarly, the US 
National Library of Medicine Medical Subject Heading term for bronchiolitis was 
introduced as “viral bronchiolitis” in 1967, under the heading “bronchitis”, while 
“Respiratory Syncytial Viruses” was created in 1977 (information obtained from the 
National Library of Medicine database). In 1988 a subheading “bronchiolitis” was 
created, in order to accommodate both “bronchiolitis obliterans” and “viral 
bronchiolitis”. This latter subdivision highlights the confusing overlap with the 
group of complex histopathologic bronchiolar disorders for which no single 
classification scheme has been widely accepted.730  
!
Importantly, terminology and nosology issues have often been attributed to a 
worldwide geographical divide in clinical teaching and practice as to what exactly 
constitutes bronchiolitis.2,4,721,722 On the one hand, a North American definition is 
said to favor a first episode, with wheeze as a clinical finding, in up to one- or two-
year-olds. Conversely, hallmarks of bronchiolitis in the UK and Australia, include 
crackles/crepitations in younger infants, with or without wheeze. Other countries in 
Europe and worldwide would possibly follow one of these different perspectives. 
These different perspectives are partly reflected in opinion papers, medical textbook 
definitions and some management guidelines across countries. Overlapping labels 
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with conditions that may also be considered as distinct differential diagnoses is also 
problematic. The North American definition overlaps with labels such as ‘virus-
induced wheeze’ and ‘wheezy bronchitis’ in the UK; conversely, the UK definition 
could be labelled ‘pneumonia’ in the US.4,721,723 In both cases, children with 
predominant wheezing might be classified as having reactive airways disease or 
being early asthmatics. However, empirical evidence to support these differences in 
perspectives is scarce, and lack of agreement may also exist at a regional and 
individual level. 
!
Disease terminology is further complicated by differences in the nomenclature, 
identification and interpretation of respiratory sounds. Although there have been 
historical efforts to standardize the terminology of adventitious sounds, variation 
persists.377,378,731 Thus the terms ‘crackles’, ‘rales’ or ‘crepitations’ are used by 
different authors, but are not necessarily interchangeable; different qualities of a 
same sound, e.g. high- or low-pitched wheeze, may also be used. Further, reliability 
of stethoscope examination has been shown to be poor to moderate for adventitious 
sounds in young children with LRTIs such as bronchiolitis.381 In parallel, audible 
respiratory sounds in children are particularly prone to confusion by parents but 
also by health professionals, as they may be perceived and named differently.379 
Fernandes and other authors have showed this is a relevant issue with wheezing, 
which is a key symptom and sign driving both diagnostic and therapeutic decisions 
in bronchiolitis.731-733 This imprecision is a major problem, which may lead for 
example to misclassification of previous episodes of wheezing, one of the key 
parameters in defining bronchiolitis.  
!
Ultimately, the critical questions when dealing with definition of disease include:  
1. how consistent is it with different manifestations and at various levels of
severity;
2. how well does it reflect underlying pathogenesis; and finally
3. how does it impact aspects of epidemiology, diagnosis, prognosis, and
treatment.
Some evidence exists that variability in key clinical parameters of bronchiolitis 
definition may influence some of these aspects. For example, Elphick and 
colleagues categorized infants hospitalized with RSV infection as ‘acute 
bronchiolitis’ (based on findings of widespread crepitations) or ‘wheeze-associated 
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viral illness’ at admission, and at 3 years of age found a predictable increase in 
cough and wheeze with intercurrent viral infections but no increase in atopy and 
asthma in those admitted with acute bronchiolitis, as opposed to wheezers who had 
increased persistent symptoms, use of inhaled steroids and allergic sensitization.734 
This suggests that the acoustic characteristics of these two adventitious sounds and 
their pathological correlates might be markers of distinct host responses in 
bronchiolitis. Further, children hospitalized for wheezing at older ages, i.e. between 
12 and 24 months of age, as well as those with recurrent episodes, have a higher 
risk for having asthma.725 In turn, Jartti et al showed both age of the child and 
number of episodes are associated with viral etiology and atopic characteristics, 
both of which may also influence short- and long-term respiratory outcomes.95 
!
This inevitably leads to the close links and unclear boundaries between 
bronchiolitis and wheezing disorders. As previously mentioned, bronchiolitis may 
be the first or one of many episodes of wheezing with heterogeneous biological, 
genetic, viral or environmental determinants. Some authors suggest that when 
defining bronchiolitis we should consider prognostic factors for recurrent wheezing 
and asthma, since these likely reflect different underlying disease entities with 
distinct immunopathogenesis (e.g. underlying inflammation, previous lung 
function), and possibly treatment response (e.g. efficacy of corticosteroid or 
bronchodilator).95,457,725 For example, restricted definitions of bronchiolitis have 
been proposed focused on younger infants (e.g. below 6 or 12 months), first 
episodes, absence of allergic diseases, or isolation of specific viruses; this might 
allow studies to include more homogenous populations and less asthma-prone 
children with preexisting inflammation.95,725 However, it must be emphasized that 
our current ability to predict which trajectory a child with bronchiolitis will follow 
is limited.527,735 Further, what we call preschool recurrent wheezing disorders and 
asthma are also highly variable conditions in both their clinical presentation and 
time course.462 It is recognized that disease labels in inflammatory airway disease 
are imprecise, and the accuracy of disease classification matters less. 
!
To circumvent this obstacle, research on wheezing disorders has been progressively 
focusing on phenotype description as opposed to specific disease labels.736 The 
interpretation of the term ‘phenotype’ is variable, and can include sets of 
observable or measurable traits, pragmatic constructs with prognostic or therapeutic 
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relevance, or a more fundamental meaning related to separate disease entities 
(Table 1.5).462 Some distinguish phenotypes as ‘clinically observable characteristics’ 
of a disease without direct relationship to an underlying pathophysiology, from 
‘endotypes’, subtypes of a disease defined by an intrinsically ‘distinct pathogenetic 
mechanism’.737,738 Airway disease is composed of many domains or dimensions, 
e.g. environmental triggers, clinical features, physiology, pathology, immunology, 
cell biology, genetic background and response to treatment, and each of these 
dimensions contains measurable variables. Phenotype definitions have used either a 
single or a few of these disease dimensions (one-dimensional), or a wide range of 
them (multi-dimensional).462 “Hypothesis-free’’ approaches are being increasingly 
used in all fields of airway disorders, by applying multivariate methods such as 
cluster and factor analyses to observed features from large scale cohort clinical 
studies, in order to identify these phenotypes that might better reflect underlying 
biological pathways.462,739-741 Such methods allow phenotypes to be identified in a 
data-driven and might therefore minimize the subjectivity involved in selecting the 
features. However, clustering methods may distinguish groups regardless of whether 
they exist in the population as true entities or not. Validating such phenotypes 
requires evidence on their association with disease severity, prognosis and 
treatment response. Further, given the variability in concepts among clinicians and 
among researchers, plausible definitions and models of disease consisting of 
predefined disease entities are needed.462 Spycher and colleagues have obtained 
such models by using a panel of clinicians familiar with pediatric wheezing 
disorders and basing them on their clinical experience.742 Phenotype-based 
approaches to the definition and classification of bronchiolitis have been implicitly 
or explicitly suggested, but rarely explored. Everard has focused on auscultatory 
sounds (wheeze vs crackles) during bronchiolitis as a dimension that may suggest 
distinct entities.4,167,734 We can envision that phenotypes of bronchiolitis could be 
evaluated based on different dimensions and traits of disease, e.g. demographics, 
clinical symptoms, physiological variables, markers of inflammation. 
!
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In summary, there are many possible sources of heterogeneity in bronchiolitis 
definition with considerable impact in clinical practice and research, but scarce 
empirical evidence exploring them. Efforts to standardize definitions and 
subgrouping phenotypes of interest are needed; understanding physician 
perspectives would be a starting point before validating such classifications for 
epidemiology, disease severity, prognosis and treatment response purposes. In 
Chapter 4 of this thesis we will assess how pediatricians and general practitioners 
perceive the definition of bronchiolitis. 
Table 1.5: Different usages of the term ‘phenotype’ (based on Spycher et al, with permissions)
Usage Description Example of usage in airways 
disorders
Possible use in 
bronchiolitis
Any observable trait (partial 
phenotype)
Includes signs, symptoms, 
measurements and biological 
markers
Wheeze and cough 




Number of episodes 
Auscultatory findings 
Specific virus or co-
infection 
Clinically useful grouping Defines groups that differ 
with respect to features of 
interest: e.g. risk factors, 
response to treatment, 
prognosis; may not 
correspond to underlying 
entity
Difficult or severe asthma Based on one or more of 
the above dimensions/
traits, if validated
Hypothesized disease entity Defines a condition that is 
thought to represent a distinct 
disease entity








OBJECTIVES AND OUTLINE OF THE THESIS 
The general aims of this thesis are to provide a comprehensive and integrated 
perspective of current evidence on bronchiolitis interventions, and to address two 
key shortcomings in clinical trial design and interpretation in this field, i.e. disease 
definition and outcome selection and measurement.  
!
The following research questions regarding the management (1-3), outcome 
measurement (4-6), and definition (7,8) of acute bronchiolitis are addressed: 
1. What is the efficacy and safety of bronchodilators (β2 agonists, adrenaline, 
anticholinergics) as compared to placebo? 
2. What is the efficacy and safety of corticosteroids as compared to placebo? 
3. How do these therapies compare between them, and is there a positive or 
negative effect of combining them? 
4. Which outcome domains and measurement instruments have been used in 
previous clinical trials of bronchiolitis? 
5. Which outcomes are considered most important to physicians when 
measuring bronchiolitis?  
6. What are the measurement properties (i.e. validity, reliability and 
responsiveness) of two of the most commonly used instruments to assess 
bronchiolitis (RDAI and RACS scales)? 
7. How do physicians define bronchiolitis, do definitions differ between 
specialty (pediatricians vs general practitioners), and how well do they match 
the ones frequently used in clinical trials? 
8. Are there any meaningful dimensions underlying physician definitions of 
bronchiolitis? 
!
Our first objective was to conduct a comparative effectiveness systematic review 
with network meta-analysis on the efficacy and safety of bronchodilators and 
corticosteroids for the treatment of acute bronchiolitis (Chapter 2). In particular, we 
used a comprehensive approach to systematically evaluate and compare the 
evidence on use of β2 agonists, adrenaline, anticholinergics and corticosteroids, 
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alone or combined (with or without a fixed protocol), and we assessed the relative 
efficacy and safety of these interventions using network meta-analysis (Chapter 
2.1). Detailed analysis on corticosteroids is presented in a Cochrane review on 
corticosteroids, which was updated during the period of this thesis (Chapter 2.2). 
!
Based on the panorama of current evidence provided by this first project and a 
recent overview of reviews to which we contributed, our second objective was to 
identify and characterize outcome domains and measurement instruments reported 
in clinical trials (Chapter 3.1). We identified the RDAI and RACS as the two most 
frequently used instruments in included trials, for both of which there is limited 
evidence on their suitability as outcome measures. Chapter 3.2 reports the results 
of a study whose objective was to assess the measurement properties of the RDAI 
and the RACS. In particular, we evaluated and compared the validity, reliability and 
responsiveness of both scales using data from two large studies, one RCT and one 
prospective cohort.  
!
As a first step to the development of a core outcome set, we assessed the 
perspectives of physicians on important outcomes for bronchiolitis trials (Chapter 
4). We present results from a nationwide electronic survey with pediatricians and 
general practitioners to characterize and compare their views on important 
outcomes in bronchiolitis.  
!
Another objective of this survey was to evaluate the perspectives of physicians on 
the definition of bronchiolitis (also presented in Chapter 4). Further, we used 
exploratory factor analysis to examine whether any meaningful dimensions could 
be distinguished underlying these perspectives, in order to identify items and 
phenotypes that need to be addressed in a standardized definition of bronchiolitis. 
!
Finally, a general discussion of all findings in the present thesis is presented in 
Chapter 5. Here, implications for clinical practice and directions for future research 
in each of the three topics addressed (therapeutic management, outcome 
measurement, and definition) are given. 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To evaluate and compare the efficacy and safety of bronchodilators and steroids, 
alone or combined, for the acute management of bronchiolitis in children aged less 
than 2 years. 
!
Design  
Systematic review and meta-analysis. Data sources Medline, Embase, Central, 
Scopus, PubMed, LILACS, IranMedEx, conference proceedings, and trial registers. 
!
Inclusion criteria  
Randomized controlled trials of children aged 24 months or less with a first episode 
of bronchiolitis with wheezing comparing any bronchodilator or steroid, alone or 
combined, with placebo or another intervention (other bronchodilator, other 
steroid, standard care). 
!
Review methods  
Two reviewers assessed studies for inclusion and risk of bias and extracted data. 
Primary outcomes were selected by clinicians a priori based on clinical relevance: 
rate of admission for outpatients (day 1 and up to day 7) and length of stay for 
inpatients. Direct meta-analyses were carried out using random effects models. A 
mixed treatment comparison using a Bayesian network model was used to compare 
all interventions simultaneously. 
!
Results  
48 trials (4897 patients, 13 comparisons) were included. Risk of bias was low in 
17% (n=8), unclear in 52% (n=25), and high in 31% (n=15). Only adrenaline 
(epinephrine) reduced admissions on day 1 (compared with placebo: pooled risk 
ratio 0.67, 95% confidence interval 0.50 to 0.89; number needed to treat 15, 95% 
confidence interval 10 to 45 for a baseline risk of 20%; 920 patients). Unadjusted 
results from a single large trial with low risk of bias showed that combined 
dexamethasone and adrenaline reduced admissions on day 7 (risk ratio 0.65, 0.44 
to 0.95; number needed to treat 11, 7 to 76 for a baseline risk of 26%; 400 
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patients). A mixed treatment comparison supported adrenaline alone or combined 
with steroids as the preferred treatments for outpatients (probability of being the 
best treatment based on admissions at day 1 were 45% and 39%, respectively). The 
incidence of reported harms did not differ. None of the interventions examined 
showed clear efficacy for length of stay among inpatients. 
!
Conclusions  
Evidence shows the effectiveness and superiority of adrenaline for outcomes of 
most clinical relevance among outpatients with acute bronchiolitis, and evidence 
from a single precise trial for combined adrenaline and dexamethasone. !
INTRODUCTION 
Bronchiolitis is the most common disease of the lower respiratory tract during the 
first year of life.1 Respiratory syncytial virus is the underlying cause of most 
bronchiolitis and this infection is associated with substantial morbidity in young 
children.38,54 Ongoing research in bronchiolitis reflects both the burden of disease 
in developed and developing countries and a lack of clear evidence for its 
therapeutic management.2 Previous studies have shown substantial variation in the 
management of acute bronchiolitis throughout the world, including the use of 
different bronchodilators (β2 agonists, adrenaline (epinephrine), anticholinergics) 
and steroids.8,9,551,557  Some of this variation may be attributable to varying severity 
of disease or to different care settings and geographical location. 
!
Several systematic reviews have assessed various treatments, including β2 agonists 
and anticholinergics, adrenaline, corticosteroids, hypertonic saline, antibiotics, 
surfactant, ribavirin, and chest physiotherapy.10 These reviews have failed to provide 
convincing evidence to support any of these treatments in the acute management of 
bronchiolitis, and their routine use is not recommended by current clinical practice 
guidelines.393,394,743 Despite implementation of these guidelines, bronchodilators 
especially are still frequently used.744,745 
!
A 2003 report recommended rigorously designed, adequately sized randomized 
controlled trials on treatments that showed some potential for being efficacious, 
including nebulized bronchodilators (adrenaline, salbutamol, or ipratropium 
 141
CHAPTER 2: EVIDENCE ON CORTICOSTEROIDS AND BRONCHODILATORS FOR BRONCHIOLITIS
CHAPTER 2
bromide, alone or combined), oral or parenteral corticosteroids (preferentially 
dexamethasone), and inhaled corticosteroids (especially budesonide).695 Two large 
trials examining some of these interventions have recently been completed. The 
largest trial ever published in this area, concerning 800 children in Canada, used a 
factorial design to examine adrenaline and dexamethasone, alone or combined, 
compared with placebo.46 Another trial completed concurrently in the United 
States compared dexamethasone with placebo in a sample of 600 children.45 These 
two large trials add substantially to the evidence and provide a strong signal for 
further synthesis work.746 
!
These recent trials also raise new questions and potentially novel approaches to the 
acute management of bronchiolitis that warrant closer investigation. Specifically, 
one trial showed a 35% relative reduction on rates of admission to hospital with 
combined adrenaline and dexamethasone treatment compared with placebo.46 
Previously, a smaller trial was the first to show the effectiveness of oral 
dexamethasone in reducing hospital admissions in outpatients with acute 
bronchiolitis.747 The unique feature of this trial, among others that did not show 
effectiveness, was that high dose steroids were administered along with a 
bronchodilator (salbutamol) according to a defined protocol rather than at the 
discretion of the attending physician. Although the interactive effect of steroids and 
bronchodilators has emerged as a potential treatment option, it has not been 
examined at the level of systematic review and placed in the context of other 
evidence. 
!
Driven by recent evidence and current uncertainties in practice, we systematically 
evaluated and compared the efficacy and safety of bronchodilators (β2 agonists, 
adrenaline, anticholinergics) and steroids, alone or combined, for the acute 
management of bronchiolitis. We also determined the effectiveness of steroids with 
a fixed protocol for bronchodilator use compared with those in which the 
bronchodilator was given at the discretion of the attending physician, and 
bronchodilators given with and without steroids. By carrying out mixed treatment 
comparisons, we sought to improve on previous systematic reviews that focused 
primarily on pairwise, direct comparisons, often with the comparator being a 
placebo. Mixed treatment analysis is a relatively new development in the area of 
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evidence synthesis, with the advantage of combining data on different interventions 
for the same condition.661,748 
!
METHODS 
Through all stages of this work, we followed a protocol that was developed by the 
coauthors before the review began, in which all outcomes and analyses were 
specified a priori. 
!
Search strategy 
A medical research librarian searched Medline Ovid version (1950 to November 
week 2, 2009), Embase Ovid version (1980 to 2009 week 47), EBM Reviews —
Cochrane Central Register of Controlled Trials (4th quarter 2009), LILACS—Latin 
American and Caribbean Center on Health Sciences Information (25 November 
2009), PubMed (9 March 2009), Scopus (1823 to 25 November 2009), and 
IranMedEx (26 November 2009). We applied no restrictions on year or language. To 
identify unpublished studies and studies in progress, we searched conference 
proceedings for six relevant organizations and six clinical trials registers. Finally, we 
checked reference lists of relevant studies and previous reviews and contacted 
experts in the specialty. 
!
Study selection 
Studies were included if they were randomized controlled trials, involved inpatients 
or outpatients aged 24 months or less with bronchiolitis, and compared a 
bronchodilator (salbutamol or terbutaline, adrenaline, ipratropium bromide) or 
steroid (inhaled or systemic), or both combined, with another intervention (either 
placebo or another intervention including another bronchodilator or steroid). 
Bronchiolitis was defined as a physician diagnosed first episode of acute wheezing 
with respiratory distress and associated with clinical evidence of viral infection. We 
excluded studies in which any participants had a history of wheezing, respiratory 
distress, or a formal diagnosis of asthma. We chose to focus on first episodes of 
wheezing to deal with the possible overlap between bronchiolitis, recurrent 
wheezing, and asthma. We also excluded studies in the intensive care setting or 
with intubated or ventilated participants, and studies assessing longer courses of 
steroids started during the acute phase of bronchiolitis for the prevention of post-
bronchiolitic wheezing. The primary outcomes, selected by the clinician authors a 
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priori based on clinical relevance, were rate of admissions at day 1 and day 7 for 
outpatient studies and length of stay in hospital for inpatient studies. Secondary 
outcomes included change in clinical score, oxygen saturation, respiratory rate, and 
heart rate; readmissions (for inpatients); return visits to the emergency department 
or any healthcare provider; and harms or adverse events. 
!
Two reviewers independently screened the titles and abstracts to determine if an 
article met the inclusion criteria. The full text of studies classified as “relevant” or 
“unclear” were assessed independently by two reviewers using a standard form. 
Disagreements were resolved by consensus or adjudication by a third party. 
!
Risk of bias assessment 
Included studies were assessed using the Cochrane Collaboration risk of bias tool. 
749 The tool consists of six domains (sequence generation, allocation concealment, 
blinding, incomplete outcome data, selective outcome reporting, and “other 
sources of bias”). Blinding and incomplete outcome data were assessed separately 
for the following types of outcomes: administrative, clinical or respiratory scores 
and other clinical variables, and others (for example, adverse events). Two 
reviewers independently assessed risk of bias of included studies. One reviewer 
assessed reports written in Turkish. Discrepancies were resolved by consensus 
among three reviewers. 
!
Data extraction 
Data were extracted using a standardized form (available from authors) and entered 
into Microsoft Excel (Microsoft, Redmond, WA). One reviewer extracted data and a 
second reviewer checked these for accuracy and completeness. Extracted data 
included study characteristics, inclusion and exclusion criteria, characteristics of 
participants, interventions (including the use of a fixed protocol for co-
interventions), outcomes, and results. Reviewers resolved discrepancies by 
consensus or in consultation with a third party. All quantitative data were checked 
by the statistician during analysis. 
!
Grading the body of evidence 
Two reviewers independently graded the quality of the body of evidence for the 
comparisons deemed most clinically relevant. Assessments, based on a modified 
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GRADE approach, were completed for length of stay and admissions, change in 
clinical score, and adverse events.659,750 Domains examined were risk of bias, 
consistency, directness, and precision. Decision rules were developed a priori 
based on clinical and methodological relevance and are available on request. 
Discrepancies were resolved through discussion. The overall strength of evidence 
was graded as high, moderate, low, or insufficient. 
!
Statistical analysis 
We considered studies of inpatients and outpatients separately, except for harms 
related data. Weighted mean differences were used to pool continuous variables 
when the same measurement scale was used (for example, heart rate) and 
standardized mean differences when different scales were used (for example, 
clinical scores). For pairwise meta-analysis, we used risk ratios to pool dichotomous 
variables. Data were combined using the DerSimonian-Laird random effects models 
in Review Manager version 5.0 (Cochrane Collaboration, Copenhagen, Denmark).
751 Results are reported with 95% confidence intervals, and statistical significance 
was set at P<0.05. Statistical heterogeneity was quantified using the I2 statistic. A 
value greater than 50% was considered to be substantial heterogeneity.752,753 We 
calculated numbers needed to treat using the final risk ratios and the simple average 
baseline risk across all included trials—that is, the number of events divided by the 
number of participants across the placebo arms of relevant studies. We also 
computed numbers needed to treat using the minimum and maximum baseline risk 
for the trials included in the meta-analysis. In our main analysis, for studies where 
groups received combined interventions that followed a protocol, we considered 
the common intervention across groups to “cancel out.” For example, to obtain an 
overall main effect we considered a study comparing combined steroid and 
bronchodilator with bronchodilator alone in the comparison of steroid with 
placebo. Furthermore, two groups from factorial trials could contribute to the same 
analysis—for example, combined steroid and placebo compared with combined 
placebo and placebo, and combined steroid and bronchodilator compared with 
combined bronchodilator and placebo would both contribute to the comparison of 
steroid with placebo. The robustness of this assumption was tested by carrying out 
subgroup analyses comparing results in trials with co-interventions following a 
protocol versus trials with co-interventions at the discretion of the physician to 
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explore potential additive (synergistic) or subtractive (antagonistic) effects. A priori 
we planned to do sensitivity analyses based on risk of bias (low vs unclear or high). 
!
For the primary outcomes we carried out a mixed treatment analysis using a 
Bayesian network model to compare all interventions simultaneously and to use all 
available information on treatment effects in a single analysis.748,754,755 Mean 
differences or log odds ratios were modeled using non-informative prior 
distributions. A normal prior distribution with mean 0 and large variance (10 000) 
was used for each of the trial means or log odds ratios, whereas their between study 
variance had a uniform prior with range 0 to 2 (admissions) or 0 to 10 (length of 
stay). These priors were checked for influence with sensitivity analyses. We carried 
out Markov Chain Monte Carlo simulations using WinBugs software to obtain 
simultaneous estimates of all interventions compared with placebo as well as 
estimates of which interventions were the best.756 A burn-in sample of 20 000 
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iterations was followed by 200 000 iterations used to compute estimates. Results 
are reported with 95% credibility intervals. We considered all trial groups 
separately in the analysis. For example, a trial comparing steroid with placebo using 
a fixed protocol for bronchodilator use in both arms would contribute two arms to 
the mixed treatment analysis: combined steroid and bronchodilator and 
bronchodilator. Factorial trials contributed all four groups, and correlation between 
groups in such trials was factored into the computations. We checked the analyses 
for consistency using cross validation of all contrasts that had direct evidence.757 
!
RESULTS 
Figure 2.1 shows the flow of studies through the selection process. Forty eight 
studies totaling 4897 patients were included. Table 2.1 shows the comparisons 
made, the number of studies for each comparison by inpatient and outpatient 
population, the number of studies that provided data for our primary outcomes, the 
years of publication, and country of study. The drugs were administered in a variety 
of ways and varied across studies and interventions: corticosteroids –systemic (oral, 
intravenous, or intramuscular) or nebulized; adrenaline –nebulized; and 
bronchodilators –mostly nebulized. The risk of bias was low for eight studies (17%), 
unclear for 25 (52%), and high for 15 (31%). Twenty four studies only included 
infants aged less than 1 year. 
!
!
















Countries of study Risk of bias
Steroid vs placebo:
Inpatients 9 (772) 8 1996-2007 
(2000)
UK (2), Israel, Belgium, Mexico, Canada, 
Thailand, Brazil, USA
1 low, 4 
unclear, 4 
high
Outpatients 8 (1778) 8 1998-2009 
(2002/2004)
USA (2), Canada (2), Turkey (2), Israel, 
Paraguay
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Outpatients 5 (526) 4 1995-2009 
(2005)
Turkey (2), Iran, Canada, USA 2 low, 2 
unclear, 1 
high
Salbutamol* or terbutaline vs placebo:
Inpatients 9 (488) 6 1991-2009 
(1997)
Turkey (2), France, Saudi Arabia, Singapore, 
Canada, USA, Tunisia, Australia
1 low, 5 
unclear, 3 
high
Outpatients 11 (926) 6 1990-2008 
(1998)
Canada (3), Turkey (3), USA (2), Egypt, 
India, Iran




Inpatients 3 (194) 2 1995-2008 
(1997)
Saudi Arabia, Singapore, Turkey 3 unclear
Outpatients 1 (72) 1 1992 Canada 1 unclear
Adrenaline and dexamethasone vs other:
Inpatients 0 NA NA NA NA
Outpatients 2 (436) 2 2004, 2009 Turkey, Canada 1 low, 1 high
Ipratropium and salbutamol* vs placebo:
Inpatients 0 NA NA NA NA
Outpatients 1 (72) 1 1992 Canada 1 unclear
Steroid vs adrenaline:
Inpatients 0 NA NA NA NA
Outpatients 2 (444) 2 1995, 2009 Turkey, Canada 1 low, 1 high
Adrenaline vs salbutamol*:
Inpatients 6 (433) 4 1993-2007 
(2001/2002)
Canada (2), Jordan, Chile, Iran, India 1 low, 3 
unclear, 2 
high
Outpatients 8 (378) 6 1995-2007 
(2004)




Inpatients 0 NA NA NA NA
Outpatients 1 (45) 1 1995 Turkey 1 high
Salbutamol vs ipratropium:
Inpatients 4 (192) 3 1995-2008 
(2000)
Saudi Arabia, Singapore, Turkey (2) 3 unclear, 1 
high
Outpatients 0 NA NA NA NA
Steroid and salbutamol* vs other:
















Countries of study Risk of bias
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Inpatients 0 NA NA NA NA
Outpatients 2 (103) 2 1998, 2004 Turkey (2) 2 high
NA=Not applicable. 
*Salbutamol has been used throughout to also refer to albuterol.
















Countries of study Risk of bias
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Outpatients 
Figure 2.2 displays the effect estimates for the primary outcome of admission rates 
from the emergency department (day 1) for the different direct comparisons. The 
results were statistically significant for only one comparison, showing a reduction of 
33% for adrenaline compared with placebo (pooled risk ratio 0.67, 95% 
confidence interval 0.50 to 0.89). The strength of evidence for this finding was 
considered moderate owing to lack of precision. The number needed to treat based 
on the average baseline risk of admission from all studies (20%) was 15 (95% 
confidence interval 10 to 45). The number needed to treat ranged from 4 (95% 
confidence interval 3 to 12, baseline risk 75%) to 20 (13 to 59, baseline risk 15%). 
The results were sensitive to risk of bias: when studies with an unclear risk of bias 
were removed, the pooled estimate for the two studies (n=842) at low risk of bias 
was no longer statistically significant (pooled risk ratio 0.77, 0.56 to 1.07). 
Subgroup analyses showed non-statistically significant differences between studies 
combining adrenaline with steroids that followed a protocol (pooled risk ratio 0.74, 
0.45 to 1.23; one study, n=400) compared with those that did not follow a protocol 
(0.62, 0.40 to 0.94; four studies, n=520; ratio of risk ratios 1.19, 0.61 to 2.33). An 
effect of a similar magnitude was shown with combined adrenaline and 
dexamethasone compared with placebo (35%), but this did not reach significance 
(P=0.07) (pooled risk ratio 0.65, 0.4 to 1.05; one study, n=400). 
!
Figure 2.3 illustrates the comparisons and number of studies for each that were 
examined in the mixed treatment comparison for admissions at day 1. Cross 
validation showed that the results from the mixed treatment analysis were 
consistent with direct evidence not differing significantly from indirect evidence for 
any of the paired comparisons where direct evidence was available. The mixed 
treatment comparison identified adrenaline alone and combined adrenaline and 
dexamethasone as the interventions with the highest probability of being most 
effective, with about half the odds of being admitted from the emergency 
department compared with placebo (Figure 2.4). The odds ratios were 0.48 (95% 
credibility interval 0.18 to 1.01) for adrenaline alone and 0.52 (0.15 to 1.57) for 
combined adrenaline and dexamethasone. Although this provides evidence on the 
relative efficacy of the different interventions, none of the interventions compared 
with placebo was statistically significant in this analysis. 
!
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Admission rates were also examined up to seven days after the emergency 
department visit using direct comparisons (Figure 2.2). One large study with low 
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Figure 2.3. Comparisons (14 studies) contributing to mixed treatment analysis for 
admissions at day 1. Numerals within figure are studies at low risk of bias (four in 
total).
Figure 2.4. Results of mixed treatment analysis for admissions at day 1, showing probability 
ranking and probability of being best statistic.
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risk of bias showed a statistically significant result for combined adrenaline and 
dexamethasone, with a 35% reduction compared with placebo (pooled risk ratio 
0.65, 95% confidence interval 0.44 to 0.95); number needed to treat 11 (95% 
confidence interval 7 to 76). This result was based on a single large trial at low risk 
of bias; however, the study was factorial and the authors did not anticipate or 
hypothesize an effect for the combined adrenaline and dexamethasone group a 
priori.16 The strength of evidence for this finding, based on the modified GRADE 
system, is considered low, as evidence came from only one study with relatively 
few events. The overall results for steroids compared with placebo and for 
adrenaline compared with placebo were not statistically significant; however, 
subgroup analyses examining use of bronchodilators or steroids that followed a 
protocol showed some important effects (data not shown). Specifically, adrenaline 
along with steroids that followed a protocol compared with placebo and steroids 
showed a statistically significant reduction of 33% (pooled risk ratio 0.67, 95% 
confidence interval 0.45 to 0.98). Also, steroids with use of bronchodilators 
(adrenaline or salbutamol) that followed a protocol compared with placebo and 
bronchodilators showed a similar magnitude of effect (32%) but did not reach 
statistical significance (pooled risk ratio 0.68, 95% confidence interval 0.44 to 1.05; 
P=0.08). 
!
Mixed treatment comparison for admissions up to day 7 identified steroids with 
bronchodilators (adrenaline or salbutamol) as the interventions with the highest 
probability of being most effective, although the credibility intervals were wide and 
do not rule out the possibility of no effect (Figure 2.3 extra). 
!
Table 2.2 presents the results from pairwise meta-analysis for change in clinical 
score. Only nine of the 25 comparisons were statistically significant, and in six of 
these adrenaline or adrenaline and dexamethasone was the preferred treatment. 
Compared with placebo, significant benefits were observed for adrenaline at 60 
and 120 minutes, combined adrenaline and dexamethasone at 60 minutes, and 
salbutamol at 60 minutes. Adrenaline showed significant benefits compared with 
steroids at 60 minutes and salbutamol at 3-10 days. Combined adrenaline and 
dexamethasone was also superior to salbutamol at 3-10 days. The other two 
significant results were from one small study at unclear risk of bias showing benefits 
of salbutamol compared with steroids. The results for other clinical variables were 
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consistent with the findings of admission rates and clinical score or provided little 
additional information (data available from authors). The incidence of return visits 
did not differ for any of the five comparisons where data were available (steroid vs 
placebo, steroid vs adrenaline, adrenaline vs placebo, adrenaline vs salbutamol, 
combined adrenaline and dexamethasone vs placebo), although there was only one 
or two studies within each comparison for this outcome. 
!
Table 2.2: Results of direct comparisons for change in clinical score among outpatients
Comparison Time point No of studies (patients) Standardised mean difference 
(95% CI)
I2
Steroid vs placebo 1 hour 4 (1006) −0.04 (−0.16 to 0.09) 0
2 hour 3 (214) −0.17 (−0.55 to 0.21) 43
3-6 hours 4 (808) −0.14 (−0.50 to 0.21) 68
12-24 hours 1 (69) 0.13 (−0.51 to 0.76) 36
3-10 days 4 (224) −0.20 (−0.61 to 0.21) 55
Steroid vs adrenaline 1 hour 2 (442) 0.31 (0.12 to 0.50)* 0
2 hours 1 (45) 0.35 (−0.27 to 0.98) NA
3-6 hours 1 (45) 0.42 (−0.20 to 1.05) NA
Steroid vs salbutamol 1 hour 1 (45) 0.65 (0.01 to 1.28)† NA
2 hours 1 (45) 0.36 (−0.27 to 0.98) NA
3-6 hours 1 (45) 0.70 (0.06 to 1.34)† NA
Adrenaline vs placebo 1 hour 4 (900) −0.45 (−0.66 to −0.23)* 40
2 hours 1 (30) −0.83 (−1.58 to −0.08)* NA
Adrenaline vs salbutamol 1 hour 6 (248) −0.11 (−0.36 to 0.14) 0
2 hours 4 (207) −0.09 (−0.37 to 0.18) 0
12-24 hours 1 (69) −0.21 (−0.86 to 0.44) 41
3-10 days 1 (69) −0.50 (−0.98 to −0.02)* 0
Salbutamol vs placebo 1 hour 8 (565) −0.49 (−0.96 to −0.01)† 86
2 hours 2 (100) −0.04 (−1.07 to 0.99) 84
3-6 hours 1 (60) −0.79 (−2.53 to 0.95) 90




1 hour 1 (399) −0.34 (−0.54 to −0.14)‡ NA
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Inpatients 
Figure 2.5 displays the effect estimates for the primary outcome of length of stay for 




2 hours 1 (35) −0.17 (−0.87 to 0.52) NA
12-24 hours 1 (35) 0.00 (−0.70 to 0.70) NA
3-10 days 1 (35) −1.22 (−1.98 to −0.46)‡ NA
Steroid and salbutamol vs 
placebo
1 hour 1 (30) −0.34 (−1.75 to 1.07) NA
2 hours 1 (30) −0.67 (−2.04 to 0.70) NA
3-6 hours 1 (30) −1.08 (−2.43 to 0.27) NA
Steroid and salbutamol vs 
adrenaline
1 hour 1 (30) 0.36 (−0.36 to 1.08) NA
2 hours 2 (64) 0.25 (−0.26 to 0.77) 0
12-24 hours 1 (34) 0.30 (−0.43 to 1.02) NA
3-10 days 1 (34) −0.16 (−0.88 to 0.56) NA
NA=not applicable. 
*Results favour adrenaline.
†Results favour salbutamol. 
‡Results favour combined adrenaline and dexamethasone.
Table 2.2: Results of direct comparisons for change in clinical score among outpatients




Figure 2.5. Results from meta-analysis of direct comparisons for length of stay in inpatients. Only 
comparisons with quantitative results are shown.
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showing a shorter length of stay for adrenaline compared with salbutamol (mean 
difference −0.28 days, 95% confidence interval −0.46 to −0.09). The strength of 
evidence for this comparison is considered moderate. However, the practical 
implications of this result need to be considered alongside the finding that 
adrenaline showed no significant benefit compared with placebo. Furthermore, this 
finding was sensitive to risk of bias: only one study for this comparison was at low 
risk of bias and the result was not significant (mean difference −0.07 days, 95% 
confidence interval −1.01 to 0.88). The results showed high strength of evidence of 
no difference for steroid compared with placebo overall. Subgroup analyses 
showed a significant difference for steroids with use of bronchodilators that 
followed a protocol (mean difference −0.12 days, −0.23 to −0.00); however, the 
magnitude of effect is not considered clinically important. 
!
Mixed treatment comparison identified combined adrenaline and dexamethasone 
as the preferred treatment (Figures 2.6 and 2.7). This finding was driven by one 
small study at high risk of bias. The confidence interval was wide and did not rule 
out the potential for no effect. Moreover, the mixed treatment comparison shows 
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Appendix D. Comparisons contributing to mixed treatment analysis for admissions
up to day 7*
Salb=salbutamol; Epi=epinephrine; Ster=steroid; Pla=placebo
This figure illustrates all of the comparisons contributing to a mixed treatment analysis for admissions at
day 7 among outpatients.* Each treatment is shown by a node, and comparisons between treatments are
shown with links between the nodes; the width of the lines reflect the number of comparisons which is also
shown.
Overall 2/7 studies contributing to this mixed treatment analysis were at low risk of bias. Comparisons with
low risk of bias studies included (number at low risk/total studies): Epi vs. Pla (1/1); Ster vs. Pla (1/2); Epi
vs. Ster (1/1); Epi+Ster vs. Pla (1/1); Epi+Ster vs. Epi (1(2); Salb vs. Pla (1/2)
Results of mixed treatment analysis for admissions up to day 7
 
0.2 0.5 1.0 2.0 5.0
Odds ratio compared to Placebo
Steroid/Salbutamol: 0.53 (0.07, 4.57), PB=46.1%
Steroid/Epinephrine: 0.56 (0.12, 2.60), PB=37.1%
Epinephrine: 0.85 (0.18, 3.85), PB=8.2%
Steroid: 0.93 (0.29, 2.95), PB=4.0%
Placebo: 1.00 (95% CrI  not applicable), PB=1.7%
Salbutamol: 1.02 (0.20, 5.12), PB=2.9%
Numbers reported are odds ratios with 95% credibility intervals; PB=probability of being best (i.e., ranking
probability).
A B
Figure 2.3 (extra). Comparisons contributing to mixed treatment analysis for admissions up to day 7 
among outpatients - network geometry (A) and forrest plot with odds ratio compared with placebo 
and 95% credibility intervals, probability ranking and probability of being best statistic (B) [In Panel
A, each treatment is shown by a node, and comparisons between treatments are shown with links between the nodes; the 
width of the lines reflect the number of comparisons which is also shown. Salb=salbutamol; Epi=epinephrine; Ster=steroid; 
Pla=placebo]; in panel B, PB=probability of being best]
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that none of the interventions examined show clear efficacy in terms of length of 
stay among the inpatient population. 
!
In terms of change in clinical score (Table 2.3), few differed statistically significantly 
(5/23 comparisons). Significant benefits were observed for adrenaline compared 
with salbutamol at 60 and 120 minutes, steroids compared with placebo at 3-6 and 
6-12 hours, and salbutamol or terbutaline compared with placebo at 6-12 hours. 
The strength of evidence for these findings is limited by risk of bias, inconsistency 
(or unknown consistency owing to limited numbers of studies within individual 
comparisons), and lack of precision. The results for other clinical symptoms 
provided little additional or inconsistent information (data available from authors). 
Data for return visits and readmissions were available for four comparisons (steroid 
vs placebo, adrenaline vs placebo, adrenaline vs salbutamol, and salbutamol vs 
placebo). No significant differences were found although only one or two studies 
were available for each comparison. 
 156
Figure 2.6. Comparisons (19 studies) contributing to mixed treatment analysis for length of 
stay. Numerals within figure are studies at low risk of bias (two in total).
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Harms 
Sixteen studies provided data on short term adverse effects. No studies examined, 
or were necessarily designed to examine, long term adverse effects, such as 
cognitive injury. The types of adverse effects that were most commonly searched for 
(or reported on) included pallor, vomiting, tremors, hypertension, tachycardia, and 
infections. In general, the incidence of adverse effects was low and no important 
differences were observed between groups across the studies. 
!
Table 2.3: Results of direct comparisons for change in clinical score among inpatients by 
comparison
Comparison Time point No of studies (No of 
patients)
Standardised mean difference 
(95% CI)
I2
Steroid vs placebo 3-6 hours 1 (174) −1.03 (−1.87 to −0.19)* NA
6-12 hours 3 (269) −0.62 (−1.00 to −0.23)* 10
12-24 hours 3 (264) −0.28 (−0.66 to 0.09) 41
1-3 days 4 (271) −0.53 (−1.14 to 0.08) 70
Adrenaline vs placebo 1 hour 2 (232) −0.04 (−0.49 to 0.40) 46
Adrenaline vs salbutamol 1 hour 4 (248) −0.79 (−1.45 to −0.13)† 79
2 hours 1 (140) −0.52 (−0.86 to −0.18)† NA
Salbutamol or 
terbutaline vs placebo
1 hour 5 (223) −0.20 (−0.76 to 0.35) 76
2 hours 2 (68) −0.78 (−2.53 to 0.98) 91
3-6 hours 1 (89) −0.20 (−0.61 to 0.22) 0
6-12 hours 2 (136) −0.81 (−1.21 to −0.40)‡ 25
12-24 hours 2 (136) −0.21 (−0.62 to 0.20) 31
1-3 days 3 (195) −0.06 (−0.47 to 0.36) 53
Ipratropium vs placebo 1 hour 1 (89) −0.11 (−0.53 to 0.31) 0
3-6 hours 1 (89) 0.06 (−0.39 to 0.51) 13
6-12 hours 2 (134) −0.21 (−0.80 to 0.37) 65
12-24 hours 3 (193) −0.27 (−0.61 to 0.06) 27
1-3 days 3 (193) 0.05 (−0.38 to 0.49) 56
Salbutamol vs 
ipratropium
1 hour 1 (43) −0.22 (−0.82 to 0.38) NA
3-6 hours 1 (43) 0.20 (−0.40 to 0.80) NA
6-12 hours 3 (123) 0.16 (−0.40 to 0.72) 59
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Previous syntheses provide little conclusive evidence to support the choice of 
different treatment options in the acute management of bronchiolitis. By examining 
steroids and bronchodilators in a single systematic review and supplementing the 
standard meta-analysis with mixed treatment comparisons, this review pro- vides 
some important directions for clinical practice and future research. Adrenaline 
seems to be beneficial for short term outcomes among outpatients, including 
admission rates from the emergency department. Furthermore, adrenaline 
12-24 hours 4 (183) −0.24 (−0.54 to 0.06) 3
1-3 days 4 (183) −0.10 (−0.39 to 0.19) 0
NA=not applicable. 
*Results favour steroid.
†Results favour adrenaline. 
‡Results favour salbutamol or terbutaline.
Table 2.3: Results of direct comparisons for change in clinical score among inpatients by 
comparison
Comparison Time point No of studies (No of 
patients)




Figure 2.7. Results of mixed treatment analysis for length of stay, showing probability ranking and 
probability of being best statistic.
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combined with dexamethasone showed longer term effects, reducing admission 
rates up to seven days after the emergency department visit. The strength of 
evidence for this reduction in admission rates was considered low based on the 
GRADE system, largely because it came from a single trial; however, recent 
empirical evidence suggests that reliance on evidence from a single precise trial 
that has been carried out well is reasonable.758 The effectiveness of these 
interventions is supported by positive benefits in some of the secondary outcome 
measures, including short term changes in clinical score, with no observed 
concerns about short term safety. For inpatients, none of the interventions examined 
showed clear benefits for length of stay. Adrenaline showed some significant 
improvements for short term changes in clinical score, whereas steroids and 
salbutamol showed benefits com- pared with placebo over the longer follow-up 
periods (3-6 and 6-12 hours). 
!
Interpretation of findings 
The magnitude and timing of observed effects of adrenaline and steroids are 
supported through their known mechanisms of actions. Adrenaline has been shown 
to improve short term clinical variables, but its effect on admission rates was 
unclear, mostly due to underpowered studies.759 We did not confirm concerns that 
the early benefit shown might result in a later increase in admissions or return visits.
541 The longstanding claim that the α adrenergic vasoconstriction and edema 
reducing activity of adrenaline may confer advantage over β adrenergic only drugs 
was supported by direct and indirect comparisons suggesting some benefit over 
salbutamol.760 Findings also indicate that previous conflicting results on the use of 
steroids may be partially explained by interaction with bronchodilators. Our 
analysis clearly excludes a clinically relevant stand alone effect of steroids but 
shows additive effects when combining a long action steroid such as 
dexamethasone with use of bronchodilators that follow a protocol. It is recognized 
that the immune response plays a significant part in the pathogenesis of 
bronchiolitis, although the biological action of anti-inflammatory interventions may 
be limited.761,762 Clinical synergism between steroids and bronchodilators is a 
major topic in the long term treatment of asthma and chronic obstructive 
pulmonary disease.763 Findings from translational research show a two way 
molecular interaction between these drugs, including β2 agonist stimulated steroid 
mediated gene transcription, and a steroid induced increase in the transcription of 
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the β2 receptor gene.650 Whether these mechanisms are involved in the treatment 
of acute bronchiolitis, and the contribution of specific types and doses of 
bronchodilators and steroids, is unknown. 
!
Another outstanding problem is the difference in observed effects between inpatient 
and outpatient populations. Adrenaline shows benefits for outpatients but not for 
inpatients. This may be attributable to short term compared with long term response 
or characteristics of the patients (for example, responders vs non- responders) or 
illness (for example, timing and severity of infection). 
!
Safety concerns exist about the widespread use of adrenaline and steroids in young 
children with viral wheezing, particularly with repeated high doses.647,764 Our 
results do not suggest any serious or frequent short term expected or unexpected 
harms from any of the studied interventions in infants with bronchiolitis in the 
absence of comorbidities. However, our safety analysis is based on randomized 
trials, which often have limited power to detect important differences owing to the 
infrequent occurrence of events. Data from trials and observational studies in croup 
confirm a favorable short term safety profile.601 Long term problems raised by the 
use of steroids in prematurity include effects on adrenal function, cardio- vascular 
responses, somatic and lung growth, and neurodevelopment.765-769 Evidence is, 
however, scarce on the effects for short term use in otherwise healthy term infants, 
and none of these were studied in included trials. 
!
Limitations of existing evidence 
Our strength of evidence assessments provide clarity around the limitations of this 
body of evidence and direction for future research. Two key factors affected the 
strength of evidence: potential risk of bias in the included studies and sparsity of 
data for many of the outcomes and comparisons, which resulted in imprecise 
estimates and unknown consistency of estimates across studies. Risk of bias was 
high due to potential selective outcome reporting, incomplete outcome data, and 
lack of blinding. Reporting of sequence generation and allocation concealment was 
often unclear. Sparsity of data was a result of few studies making the same 
comparisons as well as variability in the choice of outcomes and timing of outcome 
assessments. The message around consistency and relevance of outcomes is not 
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new for this discipline.589,770 Further work to define clinically important efficacy 
and safety outcomes for bronchiolitis is ongoing. 
!
Implications for research 
Future research should focus on areas where there is some suggestion of benefit 
(significant or close to significant results in direct meta-analysis with a magnitude of 
effect that is clinically meaningful, or relative superiority in mixed treatment 
comparisons) but the strength of evidence is moderate or low—that is, future 
research may change our confidence in the estimate and may change the estimate. 
Based on this review, adrenaline and combined adrenaline and dexamethasone 
seem to be emerging as the preferred treatments for outpatients. This review found 
no clear advantage of steroids or bronchodilators among inpatients. This 
information should guide the choice of comparators, including their dose and 
combinations, for future large trials. 
!
Strengths and limitations of the review 
This review has followed current methodological standards for the synthesis of 
evidence. Moreover, we have incorporated new methods of analysis to 
simultaneously compare the different interventions and to provide greater clarity 
around their relative benefits. Limitations of mixed treatment comparisons have 
been cited, specifically assumptions of sufficient homogeneity to combine data and 
generalizability to individual patients.661 The influence of age, history of wheezing 
episodes, and wheezing phenotype has led to repeated controversies in this subject, 
and it is not yet clear how best to approach these problems at a trial and systematic 
review level.771,780 We focused on first time wheezing so results could be directly 
pertinent to infants with typical viral bronchiolitis. We searched extensively for 
relevant literature and included all studies regardless of language of publication. 
We are confident that this review represents the most comprehensive synthesis 




Uncertainty about the optimal management of bronchiolitis is underscored by 
evidence showing substantial variation in practice, even within homogenous 
clinical settings. Current clinical practice guidelines recommend only supportive 
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measures based on the absence of convincing evidence for any other approach. 
This systematic review shows a benefit of adrenaline for outcomes of most clinical 
relevance among outpatients. Moreover, adrenaline is shown to be safe and is 
relatively inexpensive. Some evidence exists for a beneficial synergistic effect of 
adrenaline and dexamethasone. Further research of this combined treatment is 
needed among outpatients. For inpatients, none of the interventions examined 
showed clear benefits for length of stay. Consensus on the most clinically important 
outcomes and consistency in their application will yield stronger evidence for this 
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CORTICOSTEROIDS FOR ACUTE VIRAL 
BRONCHIOLITIS IN INFANTS AND YOUNG 
CHILDREN 
Adapted from: 
•Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, Johnson
DW, Klassen TP, Hartling L. Glucocorticoids for acute viral bronchiolitis in infants
and young children. Cochrane Database of Systematic Reviews 2010, Issue 10.
Art. No.: CD004878. DOI: 10.1002/14651858.CD004878.pub3.
!
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DW, Klassen TP, Hartling L. Glucocorticoids for acute viral bronchiolitis in infants
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and young children. Journal of the American Medical Association. 2014;311:87-8.
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Previous systematic reviews have not shown clear benefit of glucocorticoids for 
acute viral bronchiolitis, but their use remains considerable. Recent large trials add 




To review the efficacy and safety of systemic and inhaled glucocorticoids in 
children with acute viral bronchiolitis. 
!
Search methods 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, 
Issue 12), MEDLINE (1950 to January week 2, 2013), EMBASE (1980 to January 
2013), LILACS (1982 to January 2013), Scopus® (1823 to January 2013) and IRAN 
MedEx (1998 to November 2009). 
!
Selection criteria 
Randomized controlled trials (RCTs) comparing short-term systemic or inhaled 
glucocorticoids versus placebo or another intervention in children under 24 months 
with acute bronchiolitis (first episode with wheezing). Our primary outcomes were: 
admissions by days 1 and 7 for outpatient studies; and length of stay (LOS) for 
inpatient studies. Secondary outcomes included clinical severity parameters, 
healthcare use, pulmonary function, symptoms, quality of life and harms. 
!
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Data collection and analysis 
Two authors independently extracted data on study and participant characteristics, 
interventions and outcomes. We assessed risk of bias and graded strength of 
evidence. We meta-analyzed inpatient and outpatient results separately using 
random-effects models. We pre-specified subgroup analyses, including the 
combined use of bronchodilators used in a protocol. 
!
Main results 
We included 17 trials (2596 participants); three had low overall risk of bias. 
Baseline severity, glucocorticoid schemes, comparators and outcomes were 
heterogeneous. Glucocorticoids did not significantly reduce outpatient admissions 
by days 1 and 7 when compared to placebo (pooled risk ratios (RRs) 0.92; 95% 
confidence interval (CI) 0.78 to 1.08 and 0.86; 95% CI 0.7 to 1.06, respectively). 
There was no benefit in LOS for inpatients (mean difference -0.18 days; 95% CI 
-0.39 to 0.04). Unadjusted results from a large factorial low risk of bias RCT found 
combined high-dose systemic dexamethasone and inhaled epinephrine reduced 
admissions by day 7 (baseline risk of admission 26%; RR 0.65; 95% CI 0.44 to 
0.95; number needed to treat 11; 95% CI 7 to 76), with no differences in short-term 




Current evidence does not support a clinically relevant effect of systemic or inhaled 
glucocorticoids on admissions or length of hospitalization. Combined 
dexamethasone and epinephrine may reduce outpatient admissions, but results are 
exploratory and safety data limited. Future research should further assess the 
efficacy, harms and applicability of combined therapy. 
!
BACKGROUND 
Description of the condition 
Acute viral bronchiolitis is the most common acute infection of the lower 
respiratory tract during the first year of life.1 It is diagnosed clinically in infants and 
young children, based on a history of rhinorrhoea and low-grade fever that progress 
to cough and respiratory distress, with findings of tachypnoea, chest retractions and 
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wheeze, crackles, or both, on examination.2,3 RSV is responsible for the majority of 
cases, usually in seasonal epidemics.2,772 Other viral agents, particularly rhinovirus, 
human metapneumovirus, bocavirus and adenovirus, may also be involved as 
single or dual infections.5,119,123,124 Although bronchiolitis is usually a 
straightforward diagnosis, some variability in its definition exists. This may be due to 
poor agreement on the identification of early childhood wheezing phenotypes and 
worldwide differences in disease semantics.4,214,460 
!
Bronchiolitis is a major cause of clinical morbidity and its financial health burden is 
substantial. Population-based studies in developed countries suggest an incidence 
ratio of approximately 10% within the first year of life, with hospital admissions up 
to 3%.1,37,47,81 While mortality is rare, hospitalizations have increased steadily in 
North America and Europe over the past 10 to 20 years, with rising inpatient health 
care costs.37,64,67,69,70,73 Additionally, a majority of cases with mild illness cared for 
in the community are responsible for a considerable number of outpatient visits, 
loss of parental work time and decreased quality of life.53,82,451 RSV infection, 
including bronchiolitis, is a major cause of childhood morbidity and mortality at a 
global level.38 
!
Bronchiolitis involves acute inflammation of the bronchiolar airways initiated by 
viral infection, regardless of the causative agent. Airway edema, necrosis and 
mucous plugging are the hallmark pathological features, and air flow obstruction 
ensues. Factors underlying disease severity are only partially understood, but 
clinical determinants include lower age, prematurity, chronic lung, heart or 
neurological disease, immunodeficiency and ethnicity.278,283,351,773 There is likely a 
complex interplay between host (i.e. genetic markers), agent (i.e. viral loads, 
specific agents and co-infections) and environmental factors (i.e. crowding, tobacco 
smoke exposure).5,6,91,212,287,290 Basic, translational and clinical research studies are 
elucidating the association between bronchiolitis, preschool wheezing disorders 
and later asthma.7,48,458,774 
!
Description of the intervention 
The current treatment for bronchiolitis is controversial. There is substantial variation 
in its management throughout the world, reflecting the absence of clear evidence 
for any single treatment approach.8,9,44,81,549,553 Many interventions failed to show 
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consistent and relevant effects.10 Recently, both nebulized epinephrine and 
hypertonic saline have emerged as options for improving relevant outcomes in 
outpatient and inpatient populations, respectively.775,776 However, no routine 
treatment is yet recommended by most evidence-based clinical practice guidelines 
worldwide.393,394, 743
!
The case of glucocorticoids highlights the uncertainties of research in this field. 
Trials assessing their use date back to the 1960s, with different potencies, modes of 
administration, dosages and regimens of these drugs having been recommended.
578,585 However, results from RCTs have been heterogeneous, leading to ongoing 
controversy regarding their use. Differences in participants, care settings and 
outcomes may account for these conflicting results, and have led to distinct 
interpretations.4,590,728,781,777 
!
How the intervention might work 
Glucocorticoid use in bronchiolitis was originally thought to have equivalent 
benefits to those in acute asthma. Similarities between clinical findings were 
expected to express equivalent biological and physiological mechanisms 
attributable to inflammation.578 However, evidence suggests there is heterogeneity 
in inflammatory pathways and mediators activated in different wheezing 
phenotypes which may underlie bronchiolitis (for example, neutrophil- versus 
eosinophil-mediated inflammation).778 Mechanistic studies have shown that 
glucocorticoids have limited anti-inflammatory effects in this condition and there is 
an ongoing debate regarding their efficacy in acute virus-induced wheezing in 
preschool children.643,647,648,649,779 Further, potential benefits need to be considered 
in light of possible short- and long-term adverse effects of glucocorticoid use. While 
the interactive effect of bronchodilators and glucocorticoids has been widely 
known in asthma, both at a clinical and biological level, its use as a putative 
treatment option in bronchiolitis has only been explored recently.46 
!
Why it is important to do this review 
While guideline implementation has changed prescription patterns, glucocorticoids 
are still widely used.551,552,780 The latest version of this review integrated critical 
results from the two largest multi-centre studies in this area and examined the use 
of combined therapy with bronchodilators or adrenaline.45,46 We continue to 
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update the current body of evidence in order to adequately assess the efficacy and 
safety of glucocorticoids in bronchiolitis. 
!
OBJECTIVES 
To review the efficacy and safety of systemic and inhaled glucocorticoids in 
children with acute viral bronchiolitis. 
!
METHODS 
Criteria for considering studies for this review  
Types of studies 
We included RCTs irrespective of risk of bias, sample size, publication status or 
language of publication. 
!
Types of participants 
Studies should include infants and young children ≤ 24 months of age with acute 
viral bronchiolitis. Bronchiolitis was defined clinically as a first episode of acute 
wheezing, respiratory distress and clinical evidence of a viral infection (cough, 
coryza, fever). Many bronchiolitis trial reports do not specify clinical findings 
required for participant inclusion; we included all studies if other diagnoses (for 
example, pneumonia) could be excluded.589 We did not restrict inclusion based on 
specific findings on examination (for example, crackles) or viral etiology. 
!
We excluded studies in which any participant had a history of wheezing or 
respiratory distress (one or more previous episodes), a formal diagnosis of asthma, 
or if reporting of these items was unclear. We focused on first time wheezing so 
results could be directly pertinent to infants with ’typical’ viral bronchiolitis, as 
opposed to children with acute recurrent wheezing. We did not exclude trials based 
on other reported participant characteristics, including gestational age and co-
morbidities. 
!
We included studies of both inpatients and outpatients (ambulatory care and/or 
emergency department), and excluded trials in the intensive care setting or with 
intubated and/or ventilated participants. 
!
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Types of interventions 
The interventions of interest were short-term systemic or inhaled glucocorticoids 
administered for the acute care of bronchiolitis. We considered all types of 
glucocorticoids, dosages, durations and routes of administration. Glucocorticoids 
could be administered alone or combined with co-interventions (for example, 
bronchodilators), used with or without a fixed protocol. We excluded trials 
assessing the use of longer courses of glucocorticoids started during the acute phase 
for the prevention of post-bronchiolitic wheezing. 
!
Comparators included either placebo or another intervention (for example, 
bronchodilators, other glucocorticoid). Inhaled isotonic saline is frequently used as 
a placebo control for inhaled drugs. We excluded studies comparing different doses 
or regimens of the same glucocorticoid. 
!
Types of outcome measures 
We selected primary outcomes based a priori on clinical relevance and patient 
importance; secondary outcomes assessed other relevant health domains (clinical 
severity, pulmonary function, healthcare use, patient/parent-reported symptoms and 
status, and harms). We included studies if they reported numeric data on at least 
one primary or secondary outcomes assessed within the first month after acute 
bronchiolitis. We considered different timings of outcome assessment, based on a 
priori relevance and available data. 
!
Primary outcomes 
1. Rate of admission by days one and seven for outpatient studies. 
2. Length of stay (LOS) for inpatient studies. 
Secondary outcomes 
1. Clinical severity scores. 
2. O2 saturation, respiratory rate and heart rate. 
3. Hospital re-admissions (for inpatient studies) and return healthcare visits (for 
all studies); LOS (for outpatient studies) 
4. Pulmonary function tests. 
5. Symptoms and quality of life. 
6. Short- and long-term adverse events. 
!
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We selected the following time points and intervals for clinical scores, O2 
saturation, respiratory and heart rate: 60 and 120 minutes, three to six hours, six to 
12 hours, 12 to 24 hours, 24 to 72 hours, and three to 10 days. The time points 
selected for re-admissions and return visits were days 1 to 10, and 11 to 30. We 
also considered data on all other reported outcomes. 
!
Search methods for identification of studies 
The previous version of this review used an inclusive search strategy as part of a 
comprehensive systematic review evaluating the effect of three types of 
interventions in bronchiolitis (glucocorticoids, epinephrine and other 
bronchodilators) (Chapter 2). 
!
Electronic searches 
Previously we searched the Cochrane Central Register of Controlled Trials 
(CENTRAL) (The Cochrane Library 2009, Issue 4), which contains the Cochrane 
Acute Respiratory Infections Group’s Specialised Register, MEDLINE (1950 to 
November Week 2, 2009), EMBASE (1980 to Week 47, 2009), LILACS (Latin 
American and Caribbean Center on Health Sciences Information) (1982 to 25 
November 2009), Scopus® (1823 to 25 November 2009) and IRAN MedEx (1998 
to 26 November 2009). We developed search strings by scanning search strategies 
of relevant systematic reviews and examining index terms of potentially relevant 
studies. We applied and modified a validated RCT filter according to each database 
(Glanville 2006). We applied no publication or language restrictions. 
!
For this 2013 update we searched the Cochrane Central Register of Controlled Trials 
( C E N T R A L ) 2 0 1 2 , I s s u e 1 2 , p a r t o f Th e C o c h r a n e L i b r a r y, 
www.thecochranelibrary.com (accessed 21 January 2013), which contains the 
Cochrane Acute Respiratory Infections Group’s Specialised Register, MEDLINE 
(October 2009 to January week 2, 2013), EMBASE (November 2009 to January 
2013), LILACS (Latin American and Caribbean Center on Health Sciences 
Information) (2009 to January 2013) and Scopus (2009 to January 2013). Search 
strategies were adapted from those presented in Appendix A1. 
!
Searching other resources 
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To identify unpublished studies and studies in progress we searched the following 
clinical trials registers on 1 August 2012: ClinicalTrials.gov and ICTRP Search Portal 
- World Health Organization. We searched the following conference proceedings: 
Pediatric Academic Societies (2003 to 2012), European Respiratory Society (2003 to 
2011), American Thoracic Society (2006 to 2012). We identified additional 
published, unpublished or ongoing studies by hand-searching reference lists and 
included or excluded studies of relevant reviews. In addition, we contacted topic 
specialists. 
!
Data collection and analysis  
Selection of studies 
Five review authors (AP, LB, LH, NH or RF) independently screened the titles, 
keywords and abstracts (when available) to determine if an article met the inclusion 
criteria. These review authors independently assessed the full text of all articles 
classified as ’include’ or unclear’ using a standardized form. We resolved 
disagreements by consensus or by an arbitrator (AP, TK, DJ, or RF). 
!
Data extraction and management 
We extracted data using a standardized form in paper or electronic format 
(available from authors). Seven review authors extracted data (LB, LH, AM, HM, RF, 
OT or JF) and three review authors (LB, AM or RF) independently checked for 
accuracy and completeness. We resolved discrepancies by consensus or in 
consultation with a third review author (TK, AP or DJ). A statistician (BV) checked 
all quantitative data during analysis. Extracted data included study characteristics, 
funding, inclusion/exclusion criteria, participant characteristics, interventions, 
outcomes and results. 
!
Assessment of risk of bias in included studies 
We used the Cochrane ’Risk of bias’ assessment tool, which includes seven 
domains: random sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessment, incomplete outcome 
data, selective reporting and other sources of bias.749 We assessed blinding and 
incomplete outcome data separately for the following groups of outcomes: 
healthcare use (rate of admission, LOS, hospital re-admissions and return 
healthcare visits); clinical parameters (clinical severity scores, O2 saturation, 
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respiratory rate and heart rate); pulmonary function; patient/parent-reported 
outcomes (symptoms and quality of life measures) and other outcomes such as 
adverse events. Where trial protocols or trial registers were unavailable, we 
assessed selective outcome reporting by comparing outcomes reported in the 
methods and results sections. We summarized risk of bias for each study across 
outcomes based on individual domain assessments (’high’ if one or more domains 
were high; ’low’ if all domains were low; ’unclear’ for all other studies). Three 
review authors (LB, LH or RF) independently assessed the risk of bias of the 
included studies; we resolved discrepancies by consensus. One review author (OT) 
assessed study reports written in Turkish. We pilot tested the risk of bias tool on a 
sample of five studies and used the results to adapt decision rules (available from 
authors). 
!
Grading the body of evidence 
We used the Evidence-Based Practice Centers GRADE approach, based on the 
standard GRADE system (GRADE 2009; Owens 2010), to assess domain-specific 
and overall strength of evidence on three relevant outcomes: length of stay or 
admission rate, clinical severity scores and adverse events. Two review authors (LH, 
RF) independently graded the body of evidence using adapted decision rules. 
!
We examined the following domains: risk of bias, consistency, directness and 
precision. Risk of bias was considered as low or medium, as we only included 
RCTs. There is limited evidence regarding clinically significant and patient-
important between- group differences in this field. We therefore defined a priori 
thresholds of clinical relevance based on expert opinion and GRADE guidance for 
the precision domain: risk ratio reduction > 20% for admissions, reduction in LOS 
> 0.5 days and clinical scale effect sizes based on GRADE guidance (GRADE 
2009). We graded overall strength of evidence ’high’, ’moderate’ or ’low’ based on 
the likelihood of further research changing our confidence in the estimate of effect 
(when evidence was unavailable or did not permit estimation of an effect, it was 
considered insufficient). All decisions were made explicitly and inter-rater 
agreement was calculated (data available from authors). We resolved discrepancies 
by consensus among two review authors (LH, RF). 
!
Measures of treatment effect 
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We pooled dichotomous variables using risk ratios (RRs). We derived the number 
needed to treat to benefit (NNTB) for significant results from primary outcomes. 
Since the only comparison with significant differences was based on a single trial, 
the NNTB is shown for that trial’s baseline risk. 
!
We analyzed measurement scale outcomes as continuous variables. For continuous 
variables measured on the same scale (for example, respiratory rate), we calculated 
mean differences (MD) for individual studies and mean differences for the pooled 
estimates. For those measured on different scales (for example, clinical scores), we 
calculated MDs for separate studies and standardized MD (SMD) for the pooled 
estimates. We used changes from baseline for all continuous variables. 
!
Unit of analysis issues 
Some of the studies included in this review were multi-arm or factorial studies in 
which more than two intervention groups were eligible to contribute several 
comparisons to a single meta-analysis. For example, a trial might compare 
glucocorticoid versus placebo in two arms, and glucocorticoid + bronchodilator 
versus placebo + bronchodilator in another two arms, with both contributing to the 
overall glucocorticoid versus placebo comparison. When the comparisons were 
independent, i.e. with no intervention group in common, we included data from 
these arms with no transformation and we shown them separately in each forest 
plot. If needed and feasible, we pooled the active groups to avoid double-counting 
of the comparator group when there was more than one active group: for example, 
two glucocorticoid groups versus placebo. We did not include any treatment groups 
twice in the same meta-analysis. 
!
Guidance regarding the analysis of factorial trials mandates caution when results 
suggest positive interaction/additive effects (’synergism’) between study treatments.
658,781 This was the case for a large trial included in this review. We therefore chose 
to include comparisons separately in meta-analysis (’within the table analysis’): for 
example, for the glucocorticoid versus placebo comparison, we included separately 
glucocorticoid + bronchodilator versus placebo + bronchodilator and 
glucocorticoid + placebo versus double placebo. We also performed sensitivity 
analysis pooling all arms (’at the margins analysis’). 
!
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Dealing with missing data 
We extracted information on incomplete outcome data and we classified trials that 
performed intention-to-treat (ITT) analysis as either ITT with all data, ITT with 
imputation of missing data, ITT with available case analysis, per protocol analysis 
or treatment-received analysis.749 We did not impute missing data for drop-outs. We 
estimated unreported means from figures or imputed from medians if possible. We 
computed standard deviations (SDs) from available data (i.e. standard errors, 
confidence intervals (CI) or P values) when missing. Failing this, we estimated them 
from ranges and inter-quartile ranges, or imputed them from a similar study. When 
standard deviations of change from baseline values were unavailable, we estimated 
correlation at 0.5.782,783 We occasionally encountered clinical score results 
presented as dichotomous data, for example, using a cut-off score or time-to-event 
analysis. When methods were feasible and assumptions judged reasonable, we 
used existing approaches to re-express odds ratios as standardized mean 
differences, thus allowing dichotomous and continuous data to be pooled together.
749 When data were unavailable for one of the predefined timings of outcome 
measurement, we used the time point closest or any time point in the range. If there 
was more than one time point, we chose the one with the largest magnitude of 
change. We did not contact trial authors of the individual studies to obtain 
additional data. 
!
Assessment of heterogeneity 
We quantified statistical heterogeneity using the I2 statistic. We used the following 
intervals for interpreting I2 statistic values: 0% to 30% low heterogeneity; 30% to 
50% moderate heterogeneity; 50% to 75% substantial heterogeneity; and 75% to 
100% considerable heterogeneity.749 
!
Assessment of reporting biases 
We assessed reporting biases for the main comparisons and primary outcomes by 




We meta-analyzed quantitative results within the different comparisons when 
studies were consistent on clinical grounds and had available outcome data; we 
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imposed no restrictions based on risk of bias. We performed separate meta-analyses 
for studies involving inpatients and outpatients. We combined results using random-
effects models regardless of heterogeneity, due to expected differences in 
interventions, outcomes and measurement instruments. We calculated fixed-effect 
models in a sensitivity analysis. We conducted meta-analyses of dichotomous 
outcomes using Mantel-Haenszel methods. We used inverse variance methods for 
continuous outcomes and measurement scales, and combined dichotomous and 
continuous data into a standardized mean difference whenever needed.749 All 
results are reported with 95% CI. We used Review Manager software for data 
management and analysis (RevMan 2012). 
!
Subgroup analysis and investigation of heterogeneity 
We planned to investigate heterogeneity by conducting subgroup analyses based on 
pre-specified study- and participant-level characteristics. The following subgroups 
were considered: 
1. Protocolized use of bronchodilators (studies with protocolized use versus no/
unclear protocolized use). 
2. RSV status (studies with all participants exclusively RSV- positive versus some 
RSV-negative/unspecified RSV status). 
3. Age of participants (studies with all participants exclusively less than 12 
months of age versus some participants older than 12 months/unspecified 
age). 
4. Atopy (studies with all participants exclusively atopic versus some 
participants not atopic/unspecified atopic status). 
5. Glucocorticoid: type of glucocorticoids; and daily and overall dose (high 
versus low). 
!
We explored potential positive or negative (i.e. ’synergistic’ or ’antagonistic’) 
interactions between glucocorticoids and bronchodilators by distinguishing trials 
where bronchodilator use was protocolized (i.e. comparing glucocorticoids + 
bronchodilator versus placebo + bronchodilator) from studies where use was either 
at the discretion of the physician or not allowed.657 The choice of RSV, age and 
atopy was based on clinical or biological evidence suggesting possible effect 
modification of glucocorticoid effects by these parameters. We studied drug type 
and dose to explore dist inct glucocorticoid pharmacokinetic and 
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pharmacodynamic properties; dosing was based on prednisolone equivalents. We 
planned to perform subgroup analyses only on the review’s primary outcomes. We 
also collected data from studies that analyzed these subgroups at a study level. We 
assessed subgroup differences comparing changes in effect estimate and CI overlap; 
statistical tests or meta-regression techniques were not used. 
!
Sensitivity analysis 
We decided a priori to perform sensitivity analyses on primary outcome results of 
trials with overall low risk of bias. We also checked for differences in the direction 
and magnitude of primary outcome results when using fixed-effect models, as well 
as using pooled data from all factorial trial arms (’at the margins analysis’). 
!
RESULTS 
Description of studies  
Results of the search 
The initial 2009 comprehensive search of all electronic databases identified 2249 
records, of which 344 were potentially relevant. Hand-searching had identified four 
more studies and overall 348 full-text articles had been assessed for eligibility. Of 
91 studies that used glucocorticoids, 17 trials fulfilled inclusion criteria. The 2013 
search identified 280 further records, of which 13 were assessed for eligibility using 
full text but all were excluded (flowchart in Figure 2.8). 
!
Included studies 
We included 17 trials with 2596 randomized participants. We considered different 
comparisons separately between glucocorticoids, alone or with fixed co-
interventions, and either placebo or active controls. Included trials contributed to 
one or more comparisons, depending on trial arms (Figure 2.8). 
!
Design, centers and sample sizes 
Fifteen trials were parallel-designed, 14 of which were double-armed (Bentur 2005; 
Berger 1998; Cade 2000; Corneli 2007; De Boeck 1997; Goebel 2000; Gomez 
2007; Klassen 1997; Mesquita 2009; Richter 1998; Roosevelt 1996; Schuh 2002; 
Teeratakulpisarn 2007; Zhang 2003) and one was six-armed (Barlas 1998).Two 
trials were factorial two-by-two (Kuyucu2004; Plint 2009). Eleven trials were single-
centred and five included multiple centres (range: 2 to 20) (Cade 2000; Corneli 
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2007; Goebel 2000; Plint 2009; Teeratakulpisarn 2007); one trial did not clearly 
report this item (Bentur 2005). All trials were conducted in a single country, either 
in North, Central or South America, Europe and the Middle East or Asia. 
!
Sample size calculations were reported in 12 trials (Bentur 2005; Berger 1998; 
Cade 2000; Corneli 2007; Klassen 1997; Mesquita 2009; Plint 2009; Richter 1998; 
Roosevelt 1996; Schuh 2002; Teeratakulpisarn2007; Zhang2003); the outcome used 
for sample size calculation was the reported primary outcome in all except one trial 
(Richter 1998). The overall median number of participants per trial was 72 (range 
32 to 800), with two large trials counting 600 and 800 (Corneli 2007; Plint 2009, 
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respectively), and all others fewer than 200. Funding was reported in nine studies, 
three of which had pharmaceutical industry support (Cade 2000; Richter 1998; 
Schuh 2002). 
!
Setting and participants 
Outpatients were included in eight trials, with 1824 randomized participants and a 
median of 85 participants per trial (range: 42 to 800) (Barlas 1998; Berger 1998; 
Corneli 2007; Goebel 2000; Kuyucu 2004; Mesquita 2009; Plint 2009; Schuh 
2002). Outpatient settings mostly included paediatric emergency departments. Nine 
trials included inpatients only, with 772 participants and a median of 61 
participants per trial (range: 32 to 179) (Bentur 2005; Cade 2000; De Boeck 1997; 
Gomez 2007; Klassen 1997; Richter 1998; Roosevelt 1996; Teeratakulpisarn 2007; 
Zhang 2003). Few details were reported regarding criteria for hospitalization and 
the type of admission unit in which patients received care, except for one inpatient 
trial report (Teeratakulpisarn 2007). In most trials bronchiolitis was defined by 
clinical findings; wheezing was always required. Three trials restricted inclu- sion to 
bronchodilator responders (Goebel 2000 - outpatients; Teeratakulpisarn 2007 and 
Zhang 2003 - inpatients). Seven trials only included participants under the age of 
12 months, all of which had a mean or median participant age below six months 
(Bentur 2005; Cade 2000; Corneli 2007; Plint 2009; Richter 1998; Roosevelt 1996; 
Zhang 2003). 
!
Bronchiolitis severity thresholds were used for inclusion in eight outpatient (Barlas 
1998; Berger 1998; Corneli 2007; Goebel 2000; Kuyucu 2004; Mesquita 2009; 
Plint 2009; Schuh 2002) and two inpatient trials (Gomez 2007; Klassen 1997). 
Severity was based on clinical scales or respiratory parameters, and thresholds 
varied. The Respiratory Distress Assessment Instrument (RDAI) baseline score 
thresholds varied between two and six (less than four usually considered mild 
bronchiolitis). 
!
Thirteen trials reported testing for RSV at least in a portion of participants, and three 
trials only included RSV-positive patients (Bentur 2005; Cade 2000; De Boeck 
1997). Prevalence of RSV in the remaining 10 trials varied from 33% to 89% (Barlas 
1998; Berger 1998; Corneli 2007; Goebel 2000; Klassen 1997; Mesquita 2009; 
Plint 2009; Richter 1998; Roosevelt 1996; Schuh 2002). Atopic status was reported 
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in nine trials (Barlas 1998; Berger 1998; Cade 2000; Plint 2009; Richter 1998; 
Roosevelt 1996; Schuh 2002; Teeratakulpisarn 2007; Zhang 2003), while one trial 
reported a family history of wheezing (Corneli 2007). Definitions for atopy and 
methods of assessment were rarely provided, and when reported were 
heterogeneous. No trials excluded participants with a history of atopy. 
!
Children with chronic cardiac, pulmonary or neurological conditions or 
immunodeficiency were frequently excluded. All or some premature infants were 
explicitly excluded in seven trials (Cade 2000; Corneli 2007; De Boeck 1997; 
Goebel 2000; Plint 2009; Schuh 2002; Teeratakulpisarn 2007). Other criteria for 
exclusion were length of illness and glucocorticoid-related parameters (previous 
use, history of adverse events, specific contraindications to their use). 
!
Subgroup analyses within studies were reported in five trials (Bentur 2005; Cade 
2000; Corneli 2007; Plint 2009; Teeratakulpisarn 2007), two of which being pre-
specified (Corneli 2007; Plint 2009). Subgroups were based on age, RSV status, 
family or personal history of atopy and eczema, duration and severity of illness, and 
exposure to smoke and/or dampness. 
!
Interventions 
There was heterogeneity regarding the choice of glucocorticoid, its dosage, route of 
administration and duration of treatment. Dexamethasone was the most frequently 
tested drug (11 trials). Nine trials used systemic dexamethasone, either oral (Corneli 
2007; Klassen 1997; Mesquita 2009; Plint 2009; Schuh 2002), intramuscular 
(Kuyucu 2004; Roosevelt 1996; Teeratakulpisarn 2007) or intravenous (De Boeck 
1997). Single-day doses were administered for one to five days. Initial dosing was 
higher (0.5 to 1 mg/kg), with later doses ranging from 0.15 to 0.6 mg/kg. The 
highest overall dose was seen in Plint 2009 and Schuh 2002 (1 mg/kg followed by 
0.6 mg/kg for five days), and the lowest in Mesquita 2009 (single-dose 0.5 mg/kg). 
Two trials used inhaled dexamethasone (0.2 mg to 0.25 mg every four to six hours), 
at least for one day, or until discharge for inpatients (Bentur 2005; Gomez 2007). 
Systemic prednisone or prednisolone were tested in four trials, three oral (Berger 
1998; Goebel 2000; Zhang 2003) and one intravenous (Barlas 1998). Duration 
varied between one and five days (1 to 2 mg/kg/day, once or twice daily). Three 
trials used inhaled budesonide (0.5 mg to 1 mg, once or twice daily) for one to six 
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weeks (Barlas 1998; Cade 2000; Richter 1998). Details on placebos were reported 
in nine trials. Inhaled placebos included mist (Barlas 1998) and 0.9% saline (Bentur 
2005; Richter 1998). Protocolized standard of care was used as a control arm in 
Zhang 2003. 
!
Eleven trials used protocolized bronchodilators in both glucocorticoid and placebo 
arms. The choice of bronchodilator, its dose and frequency varied substantially. 
Seven trials used salbutamol (Barlas 1998; Berger 1998; Goebel 2000; Gomez 
2007; Klassen 1997; Kuyucu 2004; Schuh 2002), four used epinephrine (Bentur 
2005; Kuyucu 2004; Mesquita 2009; Plint 2009) and one used salbutamol and 
ipratropium bromide (De Boeck 1997). Nebulized salbutamol was administered 
during emergency department stay (first two to four hours), or each four to six hours 
at home or during hospitalization (1.5 mg to 2.5 mg, or 0.15 mg/kg). Oral 
administration was also allowed in Goebel 2000. Nebulized epinephrine was 
administered every six hours to inpatients, or once or twice in the emergency 
department for outpatients (1 mg to 3 mg). All other trials used bronchodilators at 
the discretion of the attending physician, often with guidance on the choice of drug 
and dosage. Additional use of glucocorticoids was often restricted. Supportive 
measures, i.e. oxygen and intravenous or nasogastric fluids, were usually reported. 
!
Outcomes 
Pre-defined primary outcomes were specified in 12 trials (Cade 2000; Corneli 
2007; Goebel 2000; Klassen 1997; Kuyucu 2004; Mesquita 2009; Plint 2009; 
Richter 1998; Roosevelt 1996; Schuh 2002; Teeratakulpisarn 2007; Zhang 2003), 
three of which reported more than one primary outcome (Kuyucu 2004; Richter 
1998; Teeratakulpisarn 2007). Only the two largest trials used admission as a 
primary outcome (Corneli 2007; Plint 2009). Other primary outcomes included 
clinical scales (Goebel 2000; Klassen 1997; Kuyucu 2004; Mesquita 2009; Richter 
1998; Schuh 2002), clinical severity parameters or duration of disease (Kuyucu 
2004; Roosevelt 1996; Teeratakulpisarn 2007) and symptoms (Cade 2000; Zhang 
2003). Timings of primary outcome assessment were reported in 11 trials, six of 
which used multiple time points. Sample size calculations were either not reported 
or based on secondary outcomes in Goebel 2000, Kuyucu 2004 and Richter 1998. 
Reported outcomes included healthcare use domains and clinical severity 
parameters (all trials), pulmonary function (De Boeck 1997), patient/parent-reported 
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symptoms and status (seven trials: Berger 1998; Cade 2000; Plint 2009; Roosevelt 
1996; Schuh 2002; Teeratakulpisarn 2007; Zhang 2003) and other outcomes, 
including adverse events (10 trials: Bentur 2005; Cade 2000; Corneli 2007; Klassen 
1997; Kuyucu 2004; Plint 2009; Richter 1998; Roosevelt 1996; Teeratakulpisarn 
2007; Zhang 2003). Not all outcome and time point results were reported. 
!
Admission rates were assessed in all eight outpatient trials, both by day 1 (all trials) 
and day 7 (three trials; Corneli 2007; Plint 2009; Schuh 2002). Kuyucu 2004 and 
Goebel 2000 reported admissions by days 5 and 6, respectively, and were pooled 
with day 7 results. LOS was reported in eight of nine inpatient trials (except 
Roosevelt 1996) and three outpatient trials (Berger 1998; Corneli 2007; Goebel 
2000). Criteria for admission or discharge were rarely reported. Considerable 
variability was found in control group admission rates (from 0% to 44% by day 1, 
and 0% to 49% by day 7) and mean LOS (0.8 to 6.6 days) (Table 2.4). Hospital re-
admissions for inpatients and return healthcare visits up to one month were 
mentioned in six trials, with variable assessment methods (Berger 1998; Klassen 
1997; Plint 2009; Roosevelt 1996; Schuh 2002; Teeratakulpisarn 2007). 
!
Clinical severity scales were assessed in all except one trial (Zhang 2003), often 
using more than one scale (Corneli 2007; Plint 2009; Richter 1998; Schuh 2002). 
Measurement instruments were developed specifically for nine trials (Barlas 1998; 
Bentur 2005; Berger 1998; Cade 2000; De Boeck 1997; Goebel 2000; Richter 
1998; Roosevelt 1996; Teeratakulpisarn 2007), mostly based on previous scales by 
Schuh 1990, Tal 1983 and Westley 1978. The RDAI was used in eight trials (Corneli 
2007; Gomez 2007; Klassen 1997; Kuyucu 2004; Mesquita 2009; Plint 2009; 
Richter 1998; Schuh 2002). Corneli 2007 and Plint 2009 also used the Respiratory 
Assessment Change Score (RACS), based on RDAI and respiratory rate (both 
originally reported by Lowell 1987). All scales included items on wheezing and 
accessory muscle use; other respiratory items (for example, timing or location of 
wheezing) or disease domains (for example, general status, nutrition) were less 
frequently used. Oxygen saturation, respiratory and heart rates were reportedly 
measured in most trials. Heterogeneity in timings of repeated measurements was 
found; the two most frequently time points assessed were 60 minutes and three to 
six hours. Measurement of patient/parent-reported symptoms was inconsistent. Five 
trials reported symptoms data (Cade 2000; Plint 2009; Richter 1998; Roosevelt 
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1996; Teeratakulpisarn 2007). There were differences in the specific symptoms 
addressed (for example, respiratory, feeding), the measurement instrument used (i.e. 
questionnaires, diaries) and the time points of assessment. No trial reported the use 
of generic or disease-specific quality of life instruments. 
!
Other reported outcomes included temperature measurements (Corneli 2007; Plint 
2009; Roosevelt 1996), time to resolution or length of illness (Roosevelt 1996; 
Zhang 2003), and duration of oxygen therapy or fluids (Bentur 2005; Richter 1998; 
Roosevelt 1996; Teeratakulpisarn 2007; Zhang 2003). Data on the use of 
bronchodilator co-interventions were often reported as an outcome. 
Table 2.4: Placebo group risk of admission/length of stay*
Study Placebo group - participants Placebo group - primary outcomes
Outpatient studies Risk of admission day 1 (%) Risk of admission day 7 (%)
Barlas 1998 30 17% NR
Berger 1998 18 11% NR
Corneli 2007 295 41% 49%
Goebel 2000 24 8% 21%
Kuyucu 2004 11 0% 0%
Mesquita 2009 32 22% NR
Plint 2009 201 18% 26%
Schuh 2002 34 44% 47%
Inpatient studies Length of stay (mean ± SD days)
Bentur 2005 32 6.3 ± 8.8
Cade 2000 79 2 ± 2.2
De Boeck 1997 15 6.6 ± 1.2
Gomez 2007 25 0.8 ± 0.2
Klassen 1997 32 2 ± 0.7
Richter 1998 19 3 ± 1.6
Teeratakulpisarn 2007 85 2.8 ± 1.7
Zhang 2003 24 5 ± 3.3
*NR = not reported; SD = standard deviation
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Adverse events were mentioned in six trials (Corneli 2007; Goebel 2000; Klassen 
1997; Kuyucu 2004; Plint 2009; Teeratakulpisarn 2007). Five of these studies 
assessed specific gastrointestinal, endocrine or infectious complications. There was 
heterogeneity and incomplete reporting regarding which adverse events were pre-
specified, their definitions and measurement methods. All adverse effects were 
short-term and no study assessed long-term harms. 
!
Excluded studies 
Eighty-four out of 361 excluded papers involved glucocorticoids. Motives for 
exclusion from this subset mostly included inappropriate population (for example, 
trials including participants with a history of previous wheezing, or > 24 months 
old), type of publication and non-RCT study design. 
!
Risk of bias in included studies 
We assessed overall risk of bias as ’low’ in three trials, as ’high’ in seven and 
’unclear’ in seven. The glucocorticoid and epinephrine versus placebo comparison 
included one low risk of bias trial. All other comparisons included mostly high risk 
of bias trials (Figure 2.9). 
!
We found adequate sequence generation and allocation concealment in 10 and 11 
trials, respectively (Figure 2.10). We considered blinding adequate in 10 out of 17 
trials for the review primary outcomes and clinical severity parameters. Incomplete 
reporting explained most ’unclear’ assessments. Incomplete outcome data were 
adequately addressed in 12 out of 17 studies for the review primary outcomes, and 
11 out of 17 for clinical severity outcomes; it was unclear or inadequate when there 
was imbalanced attrition between groups, mostly in longer follow-up assessments. 
!
We considered nine out of 17 studies free from risk of selective outcome reporting. 
Assessment of this item was challenging given the large number of outcomes 
reported, the diversity of measurement time points, and the fact that trial protocols 
were not available. Using trial registry searches, we identified three trial registers 
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Regarding publication bias and small study effects, there was no asymmetry in 
funnel plots for the primary outcomes in the glucocorticoids versus placebo 
comparison by visual inspection or statistical testing (Egger test for admissions and 
length of stay, P = 0.98 and P = 0.77, respectively) (Figure 2.11; Figure 2.12). 
!
Other types of bias assessed as ’unclear’ included baseline imbalances, or active 
arm contamination with other related co-interventions (Kuyucu 2004 and Schuh 
2002, respectively). 
!
Effects of interventions 
Results are summarized by comparison, setting and type of outcome. GRADE 
assessments for the two main comparisons - glucocorticoid versus placebo and 
glucocorticoid and bronchodilator versus placebo are shown in Table 2.5 and Table 
2.6. All meta-analyses used  random-effects models; fixed-effect models did not 
modify the direction and magnitude of results unless mentioned. 
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glucocorticoids versus placebo (with or without protocolised bronchodilator, or with epinephrine or salbutamol] 
CHAPTER 2: EVIDENCE ON CORTICOSTEROIDS AND BRONCHODILATORS FOR BRONCHIOLITIS
CHAPTER 2
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Figure 2.11. Funnel plot of comparison: 1 Steroid 
versus placebo, outcome: 1.1 Admissions (days 1 
and 7) (outpatients) - review primary outcome.
Figure 2.12. Funnel plot of comparison: 1 Steroid 
versus placebo, outcome: 1.2 Length of stay 
(inpatients) - review primary outcome.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.



































































































S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glucocorticoid versus placebo for acute viral bronchiolitis in infants and young children
Patient or population: infants and young children with acute viral bronchiolitis
Settings: outpatients and inpatients
Intervention: glucocorticoid versus placebo
Outcomes Illustrative comparative risks* (95% CI) Steroid versus placebo No of participants
(studies)
Quality of the evidence
(GRADE)


















250 per 1000 215 per 1000
(175 to 265)
Length of stay (inpatients)
days
The mean length of stay
ranged across control groups
from
0.8 to 6.6 days
The mean length of stay in the
intervention groups was
0.18 lower




*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk



































































































Summary of findings for the glucocorticoid versus placebo comparison
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Glucocorticoid versus placebo 
Outpatients 
Primary outcomes 
All eight outpatient studies reported admissions by day 1, and five also reported 
admissions by day 7. Complete outcome data were available for 1762 participants 
by day 1 (out of 1824 randomized) and 1530 participants by day 7 (out of 1612 
randomized). 
!
The pooled RRs for admissions by days 1 and 7 were 0.92 (95% confidence interval 
(CI) 0.78 to 1.08) and 0.86 (95% CI 0.7 to 1.06), respectively, with no significant 
differences between groups (Analysis 1.1; Figure 2.13). Heterogeneity was low for 
day 1 results and moderate for day 7 (I2 statistic = 0% and 31%, respectively). There 
was no relevant change in the magnitude or direction of results when using pooled 
data from both Plint 2009 arms. Sensitivity analyses for both trials with low overall 
risk of bias showed comparable results (Analysis 1.22). Overall strength of evidence 
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Figure 2.13. Forest plot of comparison: 1 Steroid versus placebo, outcome: 1.1 Admissions (days 
1 and 7) (outpatients) - review primary outcome.
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Figure 2.10. Methodological quality summary: review authors' judgements about each 
methodological quality item for each included study. [For multi-arm studies (Barlas 1998, Kuyucu 2004 and
Plint 2009), we included one overall assessment for all trial comparisons, and two assessments for each separate comparison 
of glucocorticoids versus placebo (with or without protocolized bronchodilator, or with epinephrine or salbutamol)]
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for these findings was high for day 1 results and moderate for day 7, the latter due 
to some imprecision in the effect estimate (Table 2.5; Summary of findings for the 
main comparison). 
!
Subgroup analysis of studies using protocolized bronchodilator found lower pooled 
RRs for admissions by both days 1 and 7, but the CIs between subgroups 
overlapped (Analysis 1.15; Analysis 1.16). For admissions by day 7, the estimate for 
RR was 0.68 (95% CI 0.44 to 1.05) for protocolized bronchodilator trials (four trials, 
581 participants), and 0.95 (95% CI 0.82 to 1.11) for other trials (two trials, 949 
participants). Heterogeneity was low in both subgroups. 
!
The two largest outpatient studies only included participants under 12 months of 
age, while six smaller studies also included older patients (Analysis 1.17; Analysis 
1.18). For admissions by day 7, estimates were 0.92 (95% CI 0.80 to 1.06) and 0.67 
(95% CI 0.25 to 1.83), for < 12 months (two trials, 1346 participants) and trials 
including older participants (three trials, 184 participants), respectively. Trials 
including older participants had a lower effect estimate, but a large CI overlapped 
with the other subgroup and there was substantial heterogeneity (I2 statistic = 60%). 
!
No subgroup analysis according to respiratory syncytial virus (RSV) or atopic status 
was performed, since no outpatient trial restricted inclusion based on these 
parameters. Corneli 2007 and Plint 2009 reported pre-specified subgroup analyses 
based on atopic status, with no statistically significant differences. Plint 2009 also 
reported no differences according to RSV status, duration of illness and severity. We 
chose not to perform analyses based on glucocorticoid type or dose due to 
heterogeneity in glucocorticoid schemes. 
!
Secondary outcomes 
Clinical score data were available for time points/intervals between 60 minutes and 
3 to 10 days (Analysis 1.4; Figure 2.14). Different sets of studies with different scales 
contributed to each time point, with most data at 60 minutes (four trials, 1006 
participants); no trial assessed the period between 24 to 72 hours. There were no 
significant differences between groups at any time point. Strength of evidence for 
these findings was high at 60 minutes, with precise and consistent results (SMD 
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-0.04; 95% CI -0.16 to 0.09; I2 statistic = 0%). Evidence was weaker for later results 
due to imprecision and substantial heterogeneity. 
!
Six trials reported outcome data on oxygen saturation between 60 minutes and 24 
to 72 hours (Analysis 1.6). Data were most frequently reported at 60 minutes (three 
trials, 936 participants). At three to six hours, results favored placebo (MD -0.43; 
95% CI -0.84 to -0.02; units: %), while for all other time points there were no 
significant differences between groups. Respiratory and heart rate data were both 
reported in six outpatient trials, between 60 minutes and 3 to 10 days (Analysis 1.8; 
Analysis 1.10). The most frequently assessed time point for both outcomes was 60 
minutes; no trial assessed the period between 24 to 72 hours. There were no 
significant differences between groups for any of these outcomes. 
!
Regarding other health services outcomes, pooled data from three trials (255 
participants) reporting LOS of admitted patients did not show significant differences 
between groups (Analysis 1.3). Return to healthcare visits for bronchiolitis 
symptoms were only assessed in two trials (863 participants), both showing 
considerable event rate for a three to four-week follow-up period (26% to 53% in 
all groups; Table 2.7). Pooled results did not show significant differences between 
groups (RR 1.04; 95% CI 0.80 to 1.35) (Analysis 1.14). 
!
Plint 2009 reported data on parent-reported symptoms regarding time to return to 
normal feeding, sleeping, breathing and no coughing (Table 2.8). There were no 
statistically significant differences between glucocorticoid and placebo groups. No 





Eight inpatient trials reported data on LOS (633 participants), with no significant 
mean difference between glucocorticoid and placebo groups (MD -0.18 days; 95% 
CI -0.39 to 0.04; I2 statistic = 16%) (Analysis 1.2; Figure 2.15). On a sensitivity 
analysis using fixed-effect models and including all studies, the mean difference 
reached statistical significance favoring glucocorticoids, with a similar magnitude 
(MD -0.14 days; 95% CI -0.25 to -0.03). We graded the strength of evidence as high 
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given its precision, consistency and ’Risk of bias’ assessments for all included trials 
(Table 2.5; Summary of findings for the main comparison). 
Subgroup analyses showed a statistically significant reduction in LOS in trials with 
protocolized bronchodilator (-0.12 days; 95% CI -0.23 to -0.00; four trials, 206 
participants), although CIs overlapped between subgroups (Analysis 1.19).
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Figure 2.14. Forest plot of comparison: 1 Steroid versus placebo, outcome: 1.4 Clinical scale scores 
(outpatients) (change from baseline data).
CHAPTER 2
Only two trials reported outcomes of oxygen saturation and respiratory rate at time 
points between 6 to 12 hours and 24 to 72 hours, one of which also reported heart 
rate at 12 to 24 hours (Analysis 1.7; Analysis 1.9; Analysis 1.11). There were no 
significant differences between groups for any outcome or time point. Both hospital 
re-admissions and return healthcare visits were reported by three inpatient studies, 
with distinct durations of follow- up; no significant differences were found between 
groups (Table 2.7; Analysis 1.12; Analysis 1.13). 
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Clinical score data were only available for intervals between three to six hours and 
24 to 72 hours (Analysis 1.5; Figure 2.16). Glucocorticoids were favored at earlier 
time points (three to six hours, one trial, 174 participants: SMD -1.03 (95% CI -1.87 
to -0.19); and 6 to 12 hours, three trials, 269 participants: SMD -0.62 (95% CI -1.00 
to -0.23). There were no statistically significant differences at later time points. We 
assessed the overall strength of evidence for these findings as low or moderate, due 
to imprecision and low or unknown consistency, often with considerable 
heterogeneity. 
!
Heterogeneity was low in the protocolized group results (I2 statistic = 0%) and 
moderate in the other subgroup (I2 statistic = 38%). In subgroup analyses according 
to age and RSV status, CIs overlapped between subgroups for both parameters 
(Analysis 1.20 and Analysis 1.21). Heterogeneity was low in both < 12 months and 
RSV-only trial results, and moderate in the other subgroups. We did not perform 
subgroup analyses based on atopic status and glucocorticoid type and dose for the 
reasons mentioned previously. 
CHAPTER 2
!
Three inpatient trials reported data on parent-reported symptoms (Table 2.8). 
Different sets of symptoms were measured at distinct time points, and methods of 
measurement and analysis varied. In Teeratakulpisarn 2007 time to being symptom 
free was significantly shorter in the glucocorticoid group, while Cade 2000 used a 
different analysis and did not shown any statistically significant differences. There 
were no differences regarding respiratory symptoms and feeding in both Cade 2000 
and Roosevelt 1996. No inpatient trials assessed or reported quality of life 
outcomes. 
De Boeck 1997 reported results from pulmonary function tests on day three. No 
differences were found in minute ventilation, dynamic lung compliance, and 




Figure 2.16. Forest plot of comparison: 1 Glucocorticoid versus placebo, outcome: 1.6 Clinical scores 
(inpatients) (change from baseline data).
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Adverse events 
Six trials reported adverse events. Five assessed specific glucocorticoid-related 
harms including the two largest studies (Table 2.9). We considered all harms data 
together regardless of patient setting in order to adequately assess the safety profile 
of glucocorticoids. Data were available from 600 to 1579 participants for each 
safety outcome. We did not pool results given the heterogeneity in definitions, 
methods and timings of assessment. Individual trial analysis did not show 
significant differences between glucocorticoids and placebo regarding the 
occurrence of vomiting, gastrointestinal bleeding, hypertension, pneumonia or 
varicella.!
!























Inpatient Length of 
stay










3 175 Medium Consistent Direct Imprecise Moderate Glucocorticoid
Clinical 
score : 
12 to 24 
hours





24 to 72 
hours
4 113 Medium Inconsiste
nt









8 1762 Medium Consistent Direct Precise High No difference
Admissio
ns up to 
day 7




4 1006 Low Consistent Direct Precise High No difference
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2 808 Medium Inconsiste
nt










4 224 Medium Inconsiste
nt






5 1123 Low Consistent Direct Precise Moderate No difference
Table 2.5: GRADE assessments: glucocorticoid versus placebo






















GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO
Outpatient Admissio
ns day 1
1 400 Low Unknown Direct Imprecise Low Favours epi 
+ dex but 
NS
Admissio
ns up to 
day 7









1 400 Low Unknown Direct Imprecise Low No 
difference
*dex = dexamethasone; epi = epinephrine; NS = non-significant
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Glucocorticoid and bronchodilator (epinephrine or salbutamol) versus placebo  
Both outpatient trials assessing either of these comparisons used different severity 
thresholds for patient inclusion: Respiratory Distress Assessment Instrument (RDAI) 
score above four in Plint 2009 (moderate disease), and scores between 4 and 10 
using a trial-specific clinical scale in Barlas 1998 (mild to moderate disease). 
!
Primary outcomes 
The factorial trial Plint 2009 included a comparison of oral dexamethasone and 
nebulized epinephrine against double placebo (399 analyzed participants). This 
was the largest trial included in the review, with low overall risk of bias. The RRs for 
admissions by days 1 and 7 were 0.65 (95% CI 0.40 to 1.05) and 0.65 (95% CI 
0.44 to 0.95), respectively (Analysis 2.1). There was a statistically significant 
reduction in admissions by day 7, with a relative risk reduction estimate of 35%. 
Absolute risk reduction was 9% (95% CI 1 to 17), and the number needed to treat 
to benefit (NNTB) to reduce one admission by day 7 was 11 (95% CI 7 to 76); these 
results were obtained through unadjusted analysis. However, the factorial trial 
design requires special methodological considerations, since this was not the 
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Glucocorticoid and epinephrine versus placebo for acute viral bronchiolitis in infants and young children
Patient or population: infants and young children with acute viral bronchiolitis
Settings: outpatients
Intervention: glucocorticoid and epinephrine versus placebo
Outcomes Illustrative comparative risks* (95% CI) Steroid versus placebo No of participants
(studies)
Quality of the evidence
(GRADE)
Comments






















Low NNT: 11 (95% CI 7 to
76) (based on unadjusted
analysis results)
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: confidence interval
NNT: number needed to treat
RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.


































































































Summary of findings for the glucocorticoid and epinephrine versus placebo comparison
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study’s main comparison, and there was an unanticipated additive/synergistic effect 
between epinephrine and dexamethasone. Reported analyses adjusted for multiple 
comparisons were above the threshold for statistical significance (RR 0.65; 95% CI 
0.41 to 1.03). We graded the overall strength of evidence as low for these results 
given their imprecision and the fact that they were obtained from a single trial 
(Table 2.6; Summary of findings 2). 
!
Barlas 1998, a small high risk of bias trial, compared intravenous prednisolone and 
nebulized salbutamol versus placebo. Admissions by day 1 (30 participants) 
showed no statistically significant differences between groups (RR 0.67; 95% CI 
0.13 to 3.44) (Analysis 3.1). 
!
Secondary outcomes 
Clinical score results at 60 minutes favored glucocorticoid and epinephrine (SMD 
-0.34; 95% CI -0.54 to -0.14) (Analysis 2.2), while having an increased heart rate 
(MD 8.44; 95% CI 4.85 to 12.03) (Analysis 2.5). No differences were found 
between groups regarding oxygen saturation and respiratory rate (Analysis 2.3; 
Analysis 2.4). There were also no differences regarding return healthcare visits for 
bronchiolitis symptoms (RR 1.11; 95% CI 0.89 to 1.38) (Table 2.7; Analysis 2.6). 
Symptom results showed reduced time to normal feeding and quiet breathing in the 
glucocorticoid and epinephrine group (mean symptom duration ratios: 0.63; 95% 
CI 0.5 to 0.8 and 0.83; 95% CI 0.69 to 1.00) (Table 2.8). No differences were found 
in time to normal sleeping and time to no coughing. 
!
Results for clinical scores, oxygen saturation and heart rate at 60 minutes, 120 
minutes and three to six hours did not show any differences between groups in the 
single trial comparing glucocorticoid and salbutamol versus placebo (Analysis 3.2; 




These included glucocorticoid versus bronchodilator (epinephrine or salbutamol), 
glucocorticoid and bronchodilator (epinephrine or salbutamol) versus different 
bronchodilator (epinephrine or salbutamol), and direct comparisons between 
different types of glucocorticoid (prednisolone versus budesonide). All trials were 
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performed in the outpatient setting, and all except one were small-sized and had a 
high risk of bias. 
!
Primary outcomes 
The glucocorticoid versus epinephrine comparison included data from two trials 
(444 participants) for admissions by day 1, and one trial by day 7 (399 participants). 
Risk of bias was low for one trial and high for the other. There were no significant 
differences between groups at both time points (Analysis 4.1). Only one small high 
risk of bias trial included data on day 1 admissions for both glucocorticoid versus 
salbutamol (45 participants) and glucocorticoid and salbutamol versus epinephrine 
comparisons (30 participants), with no differences between arms (Analysis 5.1; 
Analysis 7.1). There were no admissions in another trial including the latter 
comparison, as well as glucocorticoid and epinephrine versus salbutamol (Analysis 
6.1; Analysis 7.1). Barlas 1998 multi-arm trial also performed an unblinded 
comparison between systemic prednisolone and inhaled budesonide, with no 
statistically significant differences in admissions by day 1 (Analysis 8.1). 
!
Secondary outcomes 
When compared to glucocorticoid at 60 minutes, epinephrine use was associated 
with lower clinical scores (SMD 0.31; 95% CI 0.12 to 0.50) and higher oxygen 
saturation (MD -0.99; 95% CI - 1.46 to -0.52; units: %) (two trials, 442 
participants), while heart rate was lower with glucocorticoids (MD -7.56 bpm; 95% 
CI - 11.34 to -3.79) and there were no differences in respiratory rate (Analysis 4.2; 
Analysis 4.3; Analysis 4.4; Analysis 4.5). There were no differences in the single trial 
assessing clinical scores and heart rate at later time points. 
!
Salbutamol was also favored when compared to glucocorticoids, in clinical scores 
at 60 minutes and three to six hours (SMD 0.65; 95% CI 0.01 to 1.28; and SMD 
0.70; 95% CI 0.06 to 1.34, respectively), but not at 120 minutes (Analysis 5.2). 
Heart rate at 120 minutes was lower in glucocorticoid group (MD -7.53 bpm; 95% 
CI -14.28 to -0.78) and there were no differences in oxygen saturation at any time 
point (Analysis 5.3; Analysis 5.4). 
!
At 3 to 10 days, clinical scores and respiratory rate results favored glucocorticoids 
and epinephrine as compared to salbutamol (SMD -1.22; 95% CI -1.98 to -0.46, 
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GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO: HOSPITAL RE-ADMISSIONS
Roosevelt 1996 Inpatients Days 1 to 
14
0 0 (No events in either group)
Klassen 1997 Inpatients Days 1 to 7 4/35 (11%) 1/32 (3%) P = 0.36
Teeratakulpisarn 2007 Inpatients Days 1 to 
30
3/89 (3%) 7/85 (8%)
Roosevelt 1996 Inpatients Days 1 to 
14
0 0 (No events in either group)
GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO: HOSPITAL RE-ADMISSIONS
Plint 2009 
(epinephrine - E; 




Days 1 to 
22
D + E 
95/199 (48%)
P + E 
93/198 
(47%)
Return to the health care 
provider for bronchiolitis 
symptoms; 
Difference between 
dexamethasone + placebo 
versus placebo + placebo, was 
significant in the unadjusted 
analysis  
(P = 0.04)
D + P 
106/199 
(53%)





Days 7 to 
28
9/35 (26%) 14/32 
(44%)
Medical visits for continuing 
symptoms;  
P = 0.069
Klassen 1997 Inpatients Days 1 to 7 29/35 (83%) 24/32 
(75%)
P = 0.77
Roosevelt 1996 Inpatients Days 1 to 
14
16/65 (25%) 5/53 (9%) P = 0.01; reported on visits 
made by the physician; 69% 
were for non-respiratory 
difficulties
Teeratakulpisarn 2007 Inpatients Days 1 to 
30
17/89 (19%) 26/85 
(31%)
Visit to emergency room or a 
private clinic because of 
respiratory symptoms
GLUCOCORTICOID versus EPINEPHRINE: RETURN HEALTHCARE VISITS
Plint 2009 
(dexamethasone + placebo 
versus epinephrine + placebo)
Outpatien
ts







GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO: RETURN HEALTHCARE VISITS
Plint 2009 
(dexamethasone + 




Days 1 to 
22
95/198 (48%) 86/201 
(43%)
-
*Berger 1998: no difference between groups, but did not report quantitative data. Data presented as n/N (%) 
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Inpatients Days 1 
to 30
Time from treatment 
to being symptom 
free - mean ± SD
7.0 ± 5.9 9.0 ± 6.4 P = 0.035
Cade 2000 Inpatients Days 1 
to 28
Time taken for half 
of infants to 
become 
asymptomatic for 
48 hours (95% CI) - 
time to event 
analysis
10 (10 to 13) 12 (10 to 
16)
HR 1.41  
(95% CI 0.98 to 
2.04), P = 0.07
Days with coughing 
or wheezing 
episodes - mean ± 
SD
17.0 ± 7.6 
days
17.1 ± 8.5 Mean difference: 
0.91 days  
(95% CI -2.72 to 
2.41), P = 0.91
Roosevelt 1996# Inpatients Day 10 
to 14
No current difficulty 
breathing - n/N (%)
45/45 (100) 37/42 (88) P = 0.07
Feeding and 
drinking well - n/N 
(%)
45/45 (100) 40/42 (95) P = 0.57
GLUCOCORTICOID versus PLACEBO, GLUCOCORTICOID versus EPINEPHRINE, GLUCOCORTICOID AND 
EPINEPHRINE versus PLACEBO
Plint 2009 
(epinephrine - E; 
dexamethasone - 





Time to return to 
normal feeding - 
median (IQR)
D + E: 0.6 (0.2 to 1.3) 
D + P: 0.8 (0.3 to 1.9) 
P + E: 0.5 (0.2 to 1.2) 
P + P: 0.9 (0.3 to 2.1)
Time to return to 
normal feeding - 
mean symptom 
duration ratio D + E 
versus P + P: 0.63 
(unadjusted 95% CI 
0.5 to 0.8)¶; 
Time to return to 
quiet breathing - 
mean symptom 
duration ratio D + E 
versus P + P: 0.83 
(unadjusted 95% CI 
0.69 to 1.00); 





Time to return to 
normal sleeping - 
median (IQR)
D + E: 0.7 (0.2 to 1.7) 
D + P: 0.8 (0.3 to 1.9) 
P + E: 0.8 (0.3 to 1.9) 
P + P: 0.8 (0.3 to 1.8)
Time to no 
coughing - median 
(IQR)
D + E: 12.6 (7.8 to 18.5) 
D + P: 13.8 (8.5 to 20.2) 
P + E: 13.2 (8.1 to 19.3) 
P + P: 13.3 (8.2 to 19.5)
Time to quiet 
breathing - median 
(IQR)
D + E: 3.1 (1.4 to 6.1) 
D + P: 3.7 (1.6 to 7.1) 
P + E: 3.6 (1.5 to 6.9) 
P + P: 3.7 (1.6 to 7.2)
*Units in days unless otherwise stated; no study assessed or reported data from generic or disease-specific quality of life 
instruments; Richter 1998 also reported number of symptom-free days for a 6-week follow-up period !
#Roosevelt 1996 primary outcome was time to resolution (defined as number of 12 h periods needed to achieve: O2 
saturation > 95% at room air, accessory muscle score = 0, wheeze = 0 or 1, and normal feeding); only association 
measures were reported: HR 1.3 (95% CI 0.9 to 1.3), P = 0.22 !
¶time to symptom relief was analysed by means of parametric survival models with Weibull distributions assumed; 95% CI 
adjusted for multiple analysis in a factorial trial. !
CI = confidence interval, HR = hazard ratio, IQR = interquartile range, SD = standard deviation 
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Table 2.9: Harms - adverse events














Vomiting 1466 Plint 
2009*  
D + E: 2/199 (1) 
D + P: 5/199 
(2.5)
P + E: 4/198 (2) 
P + P: 3/201 (1.5)
Observed in the emergency 




No events in either group (D + E, D + 




16/305 (5.2) 14/295 (4.7) Within 20 minutes after 
administration of the study 
medication
Bleeding 1576 Corneli 
2007




2/90 (2)  1/89 (1) Occult blood; also assessed 
diarrhoea separately. 
Methods/timings NR
Plint 2009 D + E: 17/199 
(8.5) 
D + P: 12/199 (6)
P + E: 14/198 (7) 
P+P: 16/201 (8)
Dark stools; reported by 
families during the 22-day 
telephone follow-up. No 




1397 Plint 2009 D + E: 0/199 (0) 
D + P: 1/199 
(0.5)
P + E: 1/198 (0.5) 
P + P: 0/201 (0)




No events in either group #
Infectious Pneumonia 851 Corneli 
2007





0/90 (0) 3/89 (3.4) Methods/timings NR
Klassen 
1997
1/35 (3) 1/37 (3) Methods/timings NR
Varicella 1397 Corneli 
2007
No events in either group #
Plint 2009 No events in either group Reported by families during 
the 22-day telephone 
follow-up
General Tremor 866 Kuyucu 
2004
No events in either group Methods/timings NR
Plint 2009 D + E: 4/199 (2) 
D + P: 5/199 
(2.5)
P + E: 4/198 (2) 
P + P: 2/201 (1)
Observed in the emergency 






No events in either group Methods/timings NR
Plint 2009 D + E: 23/199 
(11.5) 
D + P: 15/199 
(7.5)
P + E: 22/198 
(11.1) 
P + P: 16/201 (8)
Observed in the emergency 
department by research 
nurse
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and MD -13.70; 95% CI -20.56 to - 6.84, respectively) (Analysis 6.2; Analysis 6.3; 
Analysis 6.4). There were no other differences at earlier time points and regarding 
heart rate. Oxygen saturation at 60 and 120 minutes was higher in the epinephrine 
group when compared to glucocorticoid and salbutamol (MD -1.54; 95% CI -2.85 
to -0.23, and MD -1.27; 95% CI-2.41 to -0.13, respectively) (Analysis 7.2; Analysis 
7.3; Analysis 7.4; Analysis 7.5). No other statistically significant differences were 
found in clinical scores, oxygen saturation or respiratory or heart rate at other time 
points. 
!
When comparing systemic prednisolone and inhaled budesonide, oxygen 
saturation results favored budesonide at 60 minutes and 120 minutes (MD -1.46; 
95% CI -2.74 to -0.18, and MD -1.73; 95% CI -3.06 to -0.40, respectively), and 
heart rate was lower with prednisolone at three to six hours (Analysis 8.3; Analysis 
8.4). No differences were found in all other outcomes and time points (Analysis 
8.2). 
!
Plint 2009 reported safety assessments comparing glucocorticoid and epinephrine 
(Table 2.9). Pallor was observed in 7.5% of participants in the glucocorticoid group, 
compared to 11.1% in the epinephrine group. There were no significant differences 
in vomiting, bleeding, hypertension, varicella and tremor between glucocorticoids 




Summary of main results 
Results from this review do not suggest a clinically relevant stand-alone effect of 
systemic or inhaled glucocorticoids in either outpatient and inpatient settings 
(Summary of findings for the main comparison). There were no statistically 
significant differences in outpatient admissions by days 1 and 7, and pooled RR 
Additional reported adverse events: Goebel 2000 reported toxicity data: one patient was "jittery"; no evidence of further 
treatment complications. Plint 2009 also reported hyperkalaemia observed in infants admitted to hospital (only one case 
was noted in the dexamethasone group). 
*epinephrine - E; dexamethasone - D; salbutamol - S; placebo - P 
#Corneli 2007: Study clinicians and research assistants monitored the infants for adverse events during observation in the 
emergency department. Subsequent adverse events were determined at follow-up. A patient safety committee, made up of 
people not involved with patient enrolment, tracked all adverse events.
Table 2.9: Harms - adverse events
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estimates favoring glucocorticoids versus placebo were below commonly used 
thresholds for clinical relevance. Strength of evidence was moderate to high, 
indicating our confidence in these effect estimates. There were also no differences 
in secondary outcomes, particularly clinical scores, oxygen saturation and 
respiratory symptoms. For inpatient trials, precise and consistent results did not 
show differences in LOS as compared to placebo. The lower boundary of the 
pooled estimate confidence interval was about nine hours, likely excluding a 
clinically relevant benefit from glucocorticoids. While clinical score results were 
superior during the first day of treatment, no consistent differences were found at 
later time points or in any other secondary outcomes. Subgroup analyses according 
to age and RSV status did not suggest effect modification by these factors; 
heterogeneity did not allow adequate analysis of atopy and glucocorticoid type or 
dose. 
!
Exploratory evidence suggests that combined glucocorticoids and bronchodilators 
may have clinically relevant benefits. A large factorial trial with low risk of bias 
found that high-dose dexamethasone with epinephrine reduced admissions by day 
7 when compared to placebo, in outpatients with moderately severe bronchiolitis 
(Summary of findings 2). The unadjusted RR reduction estimate was 36%, and 11 
children with bronchiolitis had to be treated to reduce one admission given the 
study’s baseline risk. Clinical scores and symptoms results supported this benefit. 
However, these are the findings of a single study and should be interpreted 
cautiously. There were methodological issues with trial design and results may have 
arisen by chance. Further evidence regarding combined therapy is scarce and 
imprecise, and exploratory subgroup analysis was not conclusive as to an additive/
synergistic effect of glucocorticoids combined with bronchodilators. 
!
No relevant differences were found in short-term general and intervention-specific 
adverse effects for these comparisons. However, balancing harms and benefits of 
glucocorticoids alone or combined was hampered by the lack of long-term safety 
data. 
!
Overall completeness and applicability of evidence 
The heterogeneous definition of bronchiolitis is often a motive for controversy when 
interpreting trial and review results.588,590,784 There is no international consensus 
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due to variation in semantics and clinical findings (for example, in the UK, 
’crackles’ are often key to diagnosis, as opposed to ’wheeze’ in North America).4 A 
first episode of wheezing may be a manifestation of wheezing phenotypes with 
heterogeneous biological, genetic, viral or environmental determinants, and distinct 
prognosis.7,458,460 However, research is still ongoing to identify simple, valid and 
universal discriminative and prognostic tools to prospectively distinguish between 
them.460,785,786 We used a pragmatic definition and focused on first time wheezing 
so results could be directly pertinent to infants with ’typical’ viral bronchiolitis, as 
opposed to those with acute recurrent wheezing or asthma. 
!
We found variability in both bronchiolitis severity and glucocorticoids schemes, but 
this did not affect the consistency of results. Baseline disease in outpatients was 
often moderate, but the use of different clinical criteria and scales limited the 
comparison be- tween trials, particularly for inpatients. The wide range of control 
group admission rates and LOS can be partially explained by differing disease 
severity, but it also reflects variation in bronchiolitis management, for example, 
different admission/discharge criteria and standards of care.9,44,81,395,549,553,557 Our 
findings were consistent in trials performed worldwide, and results likely apply to 
settings with different resources and management strategies. 
!
Most studies were restricted to healthy infants, often excluding children with 
chronic conditions and prematurity. Lack of evidence for this subset of patients is 
problematic, since many are particularly at risk of adverse outcomes.193,283,351 
Epidemiological studies have highlighted the short- and long-term impact of RSV 
disease in prematurity, and underlying changes in respiratory pathophysiology may 
limit the external validity of our results in these populations.283 
!
Results from subgroup analyses did not identify any subset of participants with a 
different response to glucocorticoids. Older aged and atopic children are at higher 
risk of recurrent wheezing and asthma, and both factors have been traditionally 
proposed as markers of underlying glucocorticoid-responsive phenotypes in first-
time wheezers.590,787 We found no conclusive evidence of such effect with age. We 
were unable to study atopy, but subgroup analyses from individual studies did not 
identify any significant differences. Specific viruses may also modulate response, as 
RSV and rhinovirus infections are associated with recurrent wheezing and the latter 
 203
CHAPTER 2: EVIDENCE ON CORTICOSTEROIDS AND BRONCHODILATORS FOR BRONCHIOLITIS
CHAPTER 2
is a stronger predictor and possibly more responsive to glucocorticoids.512646,788,789 
We found no differences according to RSV status, while other viral etiologies were 
not reported. Accumulating evidence shows that glucocorticoids have reduced 
effectiveness in later acute recurrent wheezing.647,648 Further, each of these factors 
per se has limited prognostic accuracy in defining stable wheezing phenotypes.
460,776,790 Our results suggest that ’typical’ viral bronchiolitis is not glucocorticoid-
responsive. Potential methodological limitations include the use of aggregated data 
and heterogeneity in definition, ascertainment and reporting of subgroups. 
!
We found promising exploratory results from one large trial using combined 
dexamethasone with epinephrine for moderately ill outpatients. Although reliance 
on findings from single precise well-conducted trials is often reasonable, in this 
factorial trial the additive interaction between treatments was unanticipated, and 
this limits the interpretation of its results.658,758 Our observational and exploratory 
subgroup analyses of protocolized bronchodilators may indirectly support an 
additive effect, but findings were not conclusive for both outpatients and inpatients. 
The latter are often a separate population due to differences in severity, duration of 
symptoms or non-response to initial bronchodilators, and these may affect response 
to therapy. Replication is therefore needed to improve our confidence in the 
direction, precision and magnitude of the effect estimates for outpatients, and its 
applicability for inpatients. Whether results from combination therapy can be 
generalizable to different glucocorticoid or bronchodilator schemes is also not 
known. Systemic dexamethasone is favored in another common viral respiratory 
disorder, croup.791 Its long half-life and stronger potency may account for its effect, 
but underlying pathological changes are distinct between these two conditions. 
Plint 2009 used multiple high doses of dexamethasone. A previous dose-finding 
trial suggested similar results with a single high dose, although there was no 
placebo comparator; the lowest efficacious dose remains unknown.792 The choice 
of bronchodilator is also undecided. A recently updated Cochrane review on 
epinephrine in bronchiolitis showed a reduction in first day outpatient admissions, 
as well as other short-term severity outcomes.775,793 This might explain part of the 
early benefit of combined therapy seen in Plint 2009. Further research is needed to 
clarify whether combined epinephrine is superior to combined salbutamol, 
particularly given the variation in bronchodilator choice in practice. 
!
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Evidence from basic and translational research may support a synergistic effect of 
combined therapy, but it is not clear how this reconciles with the limited effect of 
glucocorticoids alone. Inflammation pathways and mediators involved in 
bronchiolitis seem to be distinct from those in glucocorticoid-sensitive asthma. 
Innate immunity, specific cytokine dysregulation patterns and neutrophilic 
inflammation may be relevant for some early wheezing phenotypes, which could 
explain the limited biological action of glucocorticoids alone.643,646,783,784
Paradoxically, clinical and biological synergism between glucocorticoids and 
bronchodilators has been a major topic in asthma treatment.763 Two-way molecular 
interactions exist, including β2-agonist-stimulated glucocorticoid-mediated gene 
transcription and glucocorticoid-induced increase in the transcription of the ß2-
receptor gene.650 Epinephrine’s α-adrenergic vasoconstricting and edema-reducing 
activity could confer an additional short-term benefit. Whether these mechanisms 
are involved in acute bronchiolitis therapy, and the role of specific types and doses 
of bronchodilators and glucocorticoids, is unknown. 
!
These positive results should be balanced against incomplete data on harms. Safety 
concerns are expected when considering the widespread use of epinephrine and 
glucocorticoids in young children with viral wheezing, particularly with repeated 
high glucocorticoid doses.647,764 Current data from RCTs and observational studies 
in croup suggest a favorable short-term safety profile from both dexamethasone and 
epinephrine.601,791 Considering all trials, our results do not suggest any serious or 
frequent short-term expected or unexpected harms from glucocorticoids in the 
absence of co-morbidities. However, the power to detect important differences was 
limited due to the infrequent occurrence of events, and adverse event detection was 
heterogeneous. Glucocorticoids also raises long-term safety issues. Their use in 
prematurity for neonatal respiratory distress has been associated with effects on 
adrenal function, cardiovascular responses, somatic and lung growth, and 
neurodevelopment.765-768 Evidence is scarce, however, regarding effects of short-
term use in otherwise healthy term infants, and none of these were studied in 
included trials. Further pharmacoepidemiologic data are needed to permit adequate 
short and long-term risk-benefit assessments. 
!
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Two key factors affected the strength of evidence: potential risk of bias in the 
included studies, and sparsity of data for many of the outcomes and comparisons, 
with imprecise estimates and unknown consistency across studies. 
!
A majority of trials had unclear risk of bias, usually due to in- complete or 
inadequate reporting, and many comparisons only included small trials at high risk 
of bias. Inadequate allocation concealment and blinding were likely to be relevant 
given the nature of interventions (for example, inhaled versus systemic 
administration) and outcome assessments (for example, physician-based admissions 
or discharge decisions). Incomplete outcome data were often found, with losses of 
follow-up in outpatient trials. However, for the main glucocorticoid versus placebo 
comparison, sensitivity analyses restricted to low risk of bias trials did not change 
the direction or magnitude of results for primary outcomes, highlighting their 
consistency. 
!
Sparsity of data was a result of a large number of comparisons as well as variability 
in the choice of outcomes and timing of assessments. Within trials, this also led to 
frequent uncertainties regarding selective outcome reporting. The message around 
consistency and relevance of outcomes is not new to this field.589,693,770 The 
absence of standardized, validated and patient-important outcome measures has 
been a serious threat to bronchiolitis trial validity. Our primary outcomes focused 
on hospital use, which has clear implications for patients, families and health 
services. However, there is no guidance supporting the choice of methodologically 
sound and patient-important outcomes. Lack of reporting of admission and 
discharge criteria is also problematic given the wide variation in bronchiolitis 
management. Additionally, the choice of clinical scales was inconsistent. RDAI was 
used in a considerable number of trials, but its clinimetric properties - for example, 
responsiveness and interpretability - are not well known, which limits the 
interpretation of findings. This was compounded by the absence of quality of life 
measures. Further work is needed to define a core set of clinically important 
efficacy and safety outcome measures and timing of assessments, for trials and 
systematic reviews in this field. 
!
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Some limitations have already been described, others should also be highlighted. 
We did not obtain further data from authors of included studies, which might have 
clarified ’Risk of bias’ assessments and further added to reported trial characteristics 
and secondary outcome results. There is scarce guidance on how to investigate 
synergism/antagonism at a systematic review level, therefore our approach should 
be considered exploratory, including our use of factorial trial results. However, we 
performed sensitivity analyses of different analysis methods and these did not show 
a change in the direction of results. Our choice of outcome time intervals may have 
been a source of heterogeneity, although it was limited by the sparsity of reported 
data. Limitations of subgroup analyses are well known and have been addressed. 
Grading of evidence was limited by the lack of guidance regarding clinically 
relevant differences in studied outcomes. !
Agreements and disagreements with other studies or reviews 
Two previous non-Cochrane systematic reviews assessed the use of glucocorticoids 
in acute bronchiolitis, one of which also performed meta-analysis.587,589 None of 
the reviews included data from the two recent large glucocorticoid outpatient trials. 
There was some discordance in inclusion criteria regarding population and 
interventions: Garrison 2000 only included inpatient trials and was restricted to 
systemic glucocorticoids, and no review excluded previous wheezing. The choice 
of primary outcomes and their definitions, timings and analysis also differed. While 
Garrison 2000 highlighted a statistically significant reduction in LOS for inpatients, 
this analysis used a modified outcome definition. When comparing similar analyses 
for this outcome, quantitative results were comparable between all reviews, 
including ours, and suggest no relevant benefit from glucocorticoids in inpatients. 
Outpatient descriptive and quantitative results from King 2004 also found no 
difference in admissions. No previous review assessed the hypothesis of synergism 
between glucocorticoids and bronchodilators at an analysis level, while subgroup 
analyses assessing possible dose-response and effect modifiers like age and RSV 
status showed similar negative results. !
AUTHORS’ CONCLUSIONS  
Implications for practice 
Current evidence does not support a clinically relevant effect of systemic or inhaled 
glucocorticoids on admissions or length of stay, when used alone in infants with 
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bronchiolitis defined as a first episode of wheezing. Clinical score results suggest 
some short-term benefit of glucocorticoids for inpatients, but no differences were 
found in other secondary outcomes. Absence of treatment effects was consistent 
throughout studies despite substantial heterogeneity regarding included 
populations, interventions and outcomes, and this finding is likely to be applicable 
in diverse settings. 
!
Exploratory results from a single large trial suggest combined high-dose systemic 
dexamethasone and epinephrine may reduce outpatient admissions in moderately 
severe bronchiolitis. These findings should be interpreted cautiously and may have 
arisen by chance. While no relevant differences were reported in short-term adverse 
events, long-term safety data were missing. Efficacy, harms and applicability of 
combined therapy need to be clarified further. 
!
Implications for research 
A large randomized controlled trial is needed to replicate and complement findings 
from combination therapy with glucocorticoid and bronchodilator for outpatients. 
Additional aims could include assessing the minimum efficacious glucocorticoid 
dose and the most adequate co-intervention. This strategy could also be tested in 
inpatient settings. Choice of comparators should take into account the wide 
variability in bronchodilator use, so that valid results may be more easily 
implemented. Further investigation of parent-reported outcomes is needed, as well 
as data to assess the long-term safety of this association. Future trials should use 
standardized sets of outcome measures in this field. 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OUTCOMES AND MEASUREMENT 
INSTRUMENTS IN BRONCHIOLITIS 
TRIALS  
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3.1 Exploratory Review Of Outcome Domains And 
Measurement Instruments In Trials Of Bronchiolitis 
3.2 Measurement Properties Of The RDAI and RDAI Scales In 
Bronchiolitis 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EXPLORATORY REVIEW OF OUTCOME DOMAINS 
AND MEASUREMENT INSTRUMENTS IN TRIALS OF 
BRONCHIOLITIS 
Presented at: 
Fernandes R. Bronchiolitis core outcome set. Third meeting of the COMET (Core 
Outcome Measures in Effectiveness Trials) Initiative, Liverpool, 20 June 2013. 
!
Background 
Selection of appropriate primary and secondary outcomes is essential for study 
design, as ultimately, any study is only as credible as its endpoints.668 To be useful, 
clinical trials that evaluate benefits and harms of interventions must select 
outcomes of relevance to stakeholders, and measure them using instruments with 
adequate measurement properties.669 
!
As discussed in Chapter 1, inconsistent selection, measurement, and reporting of 
outcomes in clinical trials raises three main problems.673,680,699 First, outcomes may 
not consistently reflect endpoints that are meaningful for all stakeholders, 
particularly parents and caregivers, or physicians in different settings. Second, 
inconsistency in measurement domains and instruments is a barrier to compare, 
contrast, and combine trial findings, which will inevitably affect their interpretation 
and future uptake. Third, if researchers have measured a particular outcome in a 
variety of ways, outcome reporting bias may ensue.  
!
These issues could be addressed with the development and application of agreed 
standardized sets of outcomes, i.e. ’core outcome sets’, that are important to 
relevant stakeholders, e.g. patients and health care practitioners.672,673,681 Methods 
to support the development and implementation of core outcome sets are still 
evolving.682,684,691 One must distinguish between potential domains (‘‘what to 
measure’’) and measurement instruments (‘‘how to measure’’); and the process to 
identify these and to reach consensus on which to include in a core set.691 Stepwise 
approaches for core outcome set development have been proposed, all of which 
suggest literature review as a starting point.  
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One of the key limitations identified by most systematic reviews of treatments in 
bronchiolitis has been the heterogeneity in the selection of outcomes and 
measurements instruments reported in clinical trials (Chapter 2).695 However, the 
extent of these gaps in outcome measurement is not known. A review of previous 
trials and/or systematic reviews can provide evidence on which outcome domains 
have been measured, which measurement instruments have been used and timings 
of measurement. Gaps and discrepancies identified help inform core outcome set 
development and consensus procedures with stakeholders.682,691  
!
Based on a recent overview of reviews of treatments for bronchiolitis, we designed 




Our primary objective was to identify outcome domains and measurement 
instruments reported in clinical trials of bronchiolitis included in previous Cochrane 
systematic reviews. 
!
Our secondary objectives included: 
- to stratify outcome domains by setting in which the trial was conducted; 
- to match measured outcome domains to existing conceptual frameworks, and 
identify gaps in measured domains; 
- to identify timings of measurement; 
- to identify outcomes used for sample size calculation (“primary” outcomes); 
- to identify primary outcomes of each systematic review. 
!
Methods 
Criteria for considering trials for inclusion 
We included RCTs examining pharmacologic or non-pharmacologic interventions 
for the treatment of bronchiolitis in children, provided they were included in one of 
the 11 Cochrane reviews of bronchiolitis treatments of a previously published 
overview of reviews on treatment of bronchiolitis.10 Inclusion criteria for these trials 
regarding population, interventions and outcomes, was dependent on the decisions 
and methods used within each systematic review. 
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Search methods for identification of trials  
We identified the references of all trials included in each of the 11 Cochrane 
reviews included in an overview of reviews on treatment of bronchiolitis. 
!
Data collection and analysis 
One reviewer (RF) extracted the following information using a standardized data 
collection form:  
- from each systematic review: type of intervention, number of trials, sample sizes, 
trial setting and primary outcomes 
- from each trial: setting in which the trial was conducted (outpatient, inpatient, 
intensive care), all reported outcomes, corresponding measurement instruments 
when applicable, timings of measurement, and outcomes on which sample size 
calculations were based. 
We analyzed outcomes, instruments and timings of measurement by setting. 
!
Further, we classified reported outcomes into domains and subdomains using two 
conceptual frameworks: one adapted from a scheme proposed by Sinha et al, and 
another adapted from a recently proposed conceptual frameworks of core areas, 
outcome domains and subdomains by the OMERACT group (Filter 2.0).691,794 The 
adapted frameworks with examples applied to bronchiolitis are shown in Table 3.1. 
!
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Table 3.1: Classification of outcomes, outcomes domains and subdomains according to 
conceptual frameworks
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Table 3.1: Classification of outcomes, outcomes domains and subdomains according to 
conceptual frameworks








Domain Subdomain Core Area Domain
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Results 
We included 90 unique studies from the 11 systematic reviews. Table 3.2 presents 
characteristics of each included systematic review, including setting, intervention 
and primary outcomes. Nine trials were conducted in the intensive care, 53 with 
inpatients, 19 in the ED and 9 in ambulatory settings; two trials were conducted 
both in the ED and outpatient clinics. 
!
Only three reviews selected all same primary outcomes (i.e. rate of admission and 
length of stay for inpatients); two of these reviews were conducted by the same 
group. Clinical severity and respiratory distress were the most frequently chosen 
outcome domain and subdomain (7/11 reviews), followed by healthcare resource 
use (5/11). 
!
Figure 3.1 presents the distribution of reported outcomes in included trials, by 
relevant domains/subdomains of bronchiolitis. The reported domains or 
subdomains were, by descending order of frequency: clinical severity  (i.e. 
respiratory distress and other dimensions of disease severity, clinician-reported) 
(97%), healthcare resource use (59%), adverse effects (28%), non-clinics markers of 
disease activity and organ function (e.g. lung function tests, radiological findings) 
(16%), caregiver-reported symptoms (14%),  mortality (8%), recurrent wheezing 
and asthma (6%); only two studies (1%) assessed quality of life outcomes.  
!
Only 38 trials (42%) explicitly reported which outcomes were used for sample size 
calculation. The domains of these outcomes were, by descending order of 
frequency: clinical severity (55%), healthcare resource use (29%), recurrent 
wheezing and asthma (8%), caregiver-reported symptoms (5%), and non-clinical 
markers of disease activity and organ function (3%) (Figure 3.1).  
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We found differences between measured outcome domains by setting (Figure 3.2): 
trials in outpatient settings measured more frequently caregiver-reported symptoms 
than in inpatient settings (none in intensive care unit and 19% in inpatient trials, vs. 
30% in ED and 44% in outpatient trials), with the inverse being true for other 
markers of disease activity such as lung function outcomes (44% in intensive care 
unit trials, vs. 5% in ED trials). 
!
Most reported instruments were used to measure dimensions of clinical severity. A 
majority were respiratory distress scales, while a few also encompassed other 
dimensions of disease severity (e.g. feeding, global status). These instruments were 
usually based on clinical assessment by a health care practitioner. Twenty-three 
such scales were reported, with more than one scale being seldom used. The most 
frequently used scales were: the Respiratory Distress Assessment Instrument and the 
Respiratory Assessment Change Score, two-related instruments, either in their 
original or adapted versions (22 trials); the scale by Wang et al, either in its original 
or adapted version (11 trials); and the scale by Tal et al (four trials). Twenty other 
scales were developed and reported in only one trial. Even when trials used the 
same instrument, there was variability in specific metrics (e.g. end value vs change 
from baseline) and methods of analysis and aggregation (e.g. for change from 
baseline, use of different cut-offs, or mean values).   
!
Most trials focused on measurement of short-term outcomes (Figure 3.3). Outcomes 
were measured most frequently during the first two hours after interventions (51% 
of trials), and from 6 to 24 hours, and from one to three days (both 39%). Only 30% 
of trials measured outcomes from three to 10 days, 14% from 10 to 30 days, 6% 
from one to six months, and 4% after six months. For trials in hospitalized patients, 
most but not all measured outcomes during the duration of admission (56% in 
intensive care unit and 73% in ward inpatient trials). We found some variability in 
timings of outcome measurement between settings.  Only trials conducted in the 
ED and trials with inpatients measured longer-term outcomes after 10 days.  
!
Discussion 
In this exploratory analysis of a sample of clinical trials in children with 
bronchiolitis, we found that reported outcome measurements were mostly restricted 
to short-term clinician-based clinical severity/respiratory distress and healthcare use 
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Figure 3.2. Spider chart of outcome domains reported in bronchiolitis trials by setting
CHAPTER 3: OUTCOMES & MEASUREMENT INSTRUMENTS IN BRONCHIOLITIS TRIALS
CHAPTER 2
domains, while few measured caregiver-reported symptoms and quality of life, or 
long-term outcomes. The same was found for outcomes used to power these trials. 
Further, more than 20 different measurement instruments were identified, with 
different timings of measurement, metrics and methods of analysis. Systematic 
reviews used to identify our sample of trials also showed variability in their 
predefined primary outcomes. The absence of standardized, validated and patient-
important outcome measures is a serious threat to the validity of bronchiolitis trial 
and systematic reviews. Further research should expand and confirm these 
preliminary results in order to support the development of a core set of patient-
important outcomes and consistent measurement instruments with adequate 
measurement properties. 
!
The focus on short-term outcomes related to clinical severity and respiratory distress 
is expected, given bronchiolitis is an acute respiratory condition. However, we 
found wide variability in specific outcome measurements and instruments used as 
well as their methods of analysis, leading to sparsity of data and limiting 
comparability of trial results based on these scales. Further, previous systematic 
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Figure 3.3. Matrix of timings of outcome measurement by setting
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reviews have found that there is limited evidence regarding the measurement 
properties of many respiratory scales, i.e. their validity, reliability and 
responsiveness.694 These instruments were often developed ad hoc, as shown by the 
20 unique scales developed for individual trials in our sample; few if any have been 
specifically validated in children with bronchiolitis by current methodological 
standards. Thus there is scarce knowledge on whether they are suitable for use as 
outcome measures in clinical trials. Further, few studies have assessed the 
magnitude in change scores that are perceived as important, i.e. minimum 
important changes. This limits the interpretability of trial and systematic review 
results, and also the use of these scores for sample size calculations. 
!
Health care resource use outcomes were measured by a considerable proportion of 
trials, often as primary outcomes. Most trials focused on measuring hospital 
admission rates and length of hospital stay. These are likely important measures for 
clinicians as well as health services, as bronchiolitis is a major cause of hospital 
admission, and inpatient health care costs are considerable. However, previous 
systematic reviews have found considerable variability in these outcomes, e.g. 
baseline risk of admission and length of stay, with few details on criteria for 
admission or discharge being reported. Many factors may influence hospital 
admission and discharge decisions beside individual factors related to clinical 
severity, including social issues, types of admission unit, health services constraints, 
local practices and protocols, and physician preferences. Given the wide practice 
variation in bronchiolitis, these factors may somewhat limit the use of outcomes 
such as hospital admission, length of stay and admission to intensive care as 
primary outcomes measures to infer a treatment effect. Further, other measures of 
resource use and economical impact, including ambulatory care and economical 
costs, were rarely measured.  
!
Our results also show very few bronchiolitis trials measure caregiver-reported 
outcomes, either as measures of clinical severity (i.e. longer-term symptoms), or 
measures of life impact, including functional status and quality of life. This scarcity 
of parent or proxy-reported measures is problematic. First, it reflects that the patient 
perspective is hardly incorporated into current outcome measures. Previous studies 
in other conditions have found that life impact measures are outcomes of great 
importance to patients. Further, research has shown that bronchiolitis has a 
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substantial and negative impact in health-related quality of life, including 
functioning limitations in children and delayed return to normal family routine. 
Second, observational studies have found that a substantial proportion of children 
have protracted recovery and disease can last a few weeks, including respiratory 
and non-respiratory symptoms. Patient-reported instruments are needed to capture 
these symptoms during the recovery period, as these are of relevance to children for 
patients with bronchiolitis in all settings.  
!
Most bronchiolitis trials focused on a very short time period of outcome 
measurement of a few days, and failed to assess long-term outcomes. Many trials of 
bronchiolitis are performed in acute settings, and interventions included in this 
sample of trials may not be expected to influence long-term outcomes. Further, 
limited trial resources are often a barrier to long-term follow-up in many pediatric 
trials. However, there is growing evidence linking bronchiolitis with recurrent 
wheezing and asthma, which are likely patient-important outcomes. Further, little 
insight can be gained from putative surrogate markers, since few trials assessed 
them, and there is no valid predictive marker for these later outcomes.  
!
The following limitations should be considered. First, the range of patient 
population and interventions of included trials was limited, we relied on the search 
and screening of the Cochrane reviews, and we restricted our sample to RCTs. 
Some of the included Cochrane reviews have been recently updated. Further, we 
did not have access to trial protocols and did not assess possible selective outcome 
reporting, nor did we seek follow-up publications on these trials, e.g. to report long-
term follow up. These factors may limit the external validity of our findings, i.e. 
other outcomes and relevant measurement instruments with longer timings of 
measurement may be reported in non-included bronchiolitis trials. 
!
Second, our approach to the classification of outcome domains according to 
existing frameworks is exploratory. On the one hand, there is overlap between 
measures of some domains and subdomains, e.g. global scales of disease severity 
that encompass both respiratory distress and global status and feeding as other 
dimensions/subdomains of disease severity; measures such as duration of 
mechanical ventilation and oxygen therapy which include concepts of respiratory 
distress and also health resource use. We chose to distinguish clinician-based 
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measures from caregiver-reported ones even though they may measure the same 
(sub)domain, to highlight the lack of patient-reported outcomes. Further, timing of 
measurement is an important factor for (sub)domain classification, e.g. parent-
reported symptoms may include shorter-term respiratory symptoms and longer-term 
recurrent wheezing. Also, criteria for classification of outcomes such as those 
pertaining to adverse effects is debatable, as some outcomes, e.g. clinical severity or 
hospital use, are possible adverse effects of many interventions. On the other hand, 
the conceptual frameworks themselves are emerging, and evidence is needed to 
support them.  
!
This preliminary assessment of outcomes and measurement instruments reported in 
bronchiolitis trials highlights gaps in current trial design that seriously affect trial 
validity and relevance. Trialists and systematic reviewers have assumed that their 
focus on primary outcomes such as respiratory scales and hospital admission are 
important for families, clinicians and health services. However, bronchiolitis is a 
condition at a crossroads of disease severity, pre-existing comorbidities, clinical 
specialties and health care settings, and it is likely that perspectives vary between 
different stakeholders. This is reflected, for example, in the heterogeneous choice of 
primary outcomes between systematic reviews. Thus guidance and consensus are 
needed to select outcome domains that are relevant to various stakeholders, 
particularly caregivers of children with bronchiolitis. Further, measurement 
instruments chosen to measure these outcome domains are discrepant, as are the 
methods used to analyze resulting scores. Work is needed to define a minimum 
core set of clinically important efficacy and safety outcome domains, instruments 
and timing of assessments, for trials and systematic reviews in this field. This will 
contribute to a rational choice of primary outcomes for the trial, balancing outcome 
importance, rigorous measurement and power and feasibility issues, while 
preserving the choice to assess other outcomes that are relevant to the intervention 
and the condition.
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The Respiratory Distress Assessment Instrument (RDAI) and Respiratory Assessment 
Change Score (RACS) are frequently used in bronchiolitis clinical trials, but 
evidence is limited on their measurement properties. We investigated their validity, 
reliability and responsiveness. 
!
Methods 
We included data from up to 1765 infants with bronchiolitis enrolled in two studies 
conducted in pediatric emergency departments (ED). We assessed RDAI construct 
validity by testing hypotheses of associations with physiologic measures (respiratory 
rate, SatO2) and with constructs related to hospitalization, using correlation 
coefficients and multivariable analysis. RDAI/RACS responsiveness was evaluated 
using anchors of change based on these constructs; measures of responsiveness 
included the area under the curve (AUC). RDAI test-retest agreement and inter-rater 




Baseline RDAI scores were weakly correlated with respiratory rate (r=0.38, 
p<0.001), and scores increased in lower SatO2 categories (p<0.001). Higher RDAI 
scores were associated with hospitalization (OR 1.36 [1.26-1.47]); scores differed 
between participants that were discharged, admitted or stayed in ED (p<0.001). Our 
hypotheses were met, but the magnitude of associations was below our predefined 
thresholds. RDAI test-retest LoA were -3.80 to 3.64 (20% of the range), while inter-
rater reliability was good (ICC=0.93). Formulated hypotheses for responsiveness 




RDAI has poor to moderate construct validity, with good discriminative properties 
but considerable test-retest measurement error. RDAI and RACS are responsive 
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measures of respiratory distress in bronchiolitis, but do not encompass all 
determinants of disease severity.  
!
BACKGROUND 
Acute viral bronchiolitis is the most common lower respiratory tract infection in 
infants and carries substantial clinical and financial burden.2,795 There is wide 
practice variation in its management, with heterogeneous evidence for many 
therapeutic approaches.8,10,81,405,775 Systematic reviews have highlighted various 
shortcomings in RCTs in this field (Chapter 2).589,654 One of the major issues is the 
heterogeneous choice of outcome measures. There has been inconsistency in 
selected measurement instruments, whose measurement properties have often not 
been adequately studied (Chapter 2).693 
Respiratory status is an important dimension and determinant of severity in 
bronchiolitis. The Respiratory Distress Assessment Instrument (RDAI) and 
Respiratory Assessment Change Score (RACS) are often used to measure this 
domain in bronchiolitis (Chapter 2). Lowell et al first described them in an RCT of 
epinephrine in wheezing infants.714 The RDAI includes items on retractions and 
wheezing, while the RACS is a change score based on RDAI and respiratory rate. 
Evidence is limited regarding RDAI and RACS measurement properties and their 
suitability for use as evaluative instruments in clinical trials.694,715,716 Previous RCTs 
have reported some data on which reliability and validity can be assessed, while 
the first formal validation study is recent.717  
!
The aim of this study was to assess and compare the measurement properties of 




We used data from two related studies conducted simultaneously in eight Canadian 
pediatric EDs during three bronchiolitis seasons (2004-2007): a 2x2 factorial RCT 
(Canadian Epinephrine/Steroid Trial, CanBEST; n=800); and a prospective cohort 
study (n=1554 infants, 584 of which also participated in CanBEST).46 Both studies 
included infants <12 months with acute bronchiolitis (first episode of wheezing) 
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and excluded those with previous asthma, wheezing or use of bronchodilators. 
Additional exclusion criteria in CanBEST were: prematurity with corrected age <6 
weeks, chronic cardiopulmonary disease or immunodeficiency, recent 
corticosteroid use or exposure to varicella, very mild or severe distress (pulse rate 
>200 beats/minute, respiratory rate >80  breaths/minute, or RDAI score <4 or >15) 
or lethargy.  
!
Participants in CanBEST were randomly assigned to receive oral dexamethasone or 
placebo, and nebulized epinephrine or placebo, both administered in the ED 
(Figure 3.4). During the first 90 minutes only supplemental oxygen or 
acetaminophen were allowed. Other participants in the cohort study were given 
standard treatment as decided by the attending physicians.  
!
In both studies written informed consent was obtained from the parents or 
guardians of the infants and both were approved by ethics committees at each site 
and by Health Canada.  
Instruments and outcome measures  
We assessed the RDAI as described by Lowell et al, and a modification of the RACS 
as reported by Schuh et al (Table 3.3).714,747 The following measurements were 
performed at baseline for both studies, and every 30 min until admission/discharge 
or 240 min for CanBEST: RDAI, respiratory rate, heart rate, oxygen saturation 
(SatO2), and activity status (Figure 3.4). Fever was also assessed at baseline. 
Research nurses performed all measurements after formal training and using written 
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Figure 3.4. Timing of intervention, measurements and clinical decisions in the CanBEST trial (Dex, 
dexamethasone; Epi, epinephrine; Pla, placebo; RR, respiratory rate)
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instructions. SatO2 was measured by using pulse oximeters available locally. In 
both studies, the attending physician independently determined whether to admit or 
discharge the infant; RDAI was not used clinically at any site. In CanBEST 
physicians and nurses were blinded to treatment interventions, and by protocol any 
decisions regarding admission, discharge or continued stay in the ED was only to 
be made after the study interventions (i.e. after 90 min).   
Table 3.3: The Respiratory Distress Assessment Instrument (RDAI) and the Respiratory 
Assessment Change Score (RACS)
RDAI: Respiratory Distress Assessment Instrument*
Variable Score Range
0 1 2 3 4
Wheezing (auscultation)
Expiration None End 1/2 3/4 All 0-4
Inspiration None Part All 0-3
Location None Segmental: 
≤2 of 4 
lung fields
Diffuse:  
≥3 of 4 
lung fields
0-2
Partial sum score 0-8
Retractions (visual assessment)
Supraclavicular None Mild Moderate Marked 0-3
Intercostal None Mild Moderate Marked 0-3
Subcostal None Mild Moderate Marked 0-3
Partial sum score None Mild Moderate Marked 0-9
Sum score (higher score indicates more severe disease) 0-17
Respiratory Assessment Change Score (RACS)
Variable Formula Range
Wheezing change score Final partial sum score-baseline partial sum score -8 - +8
Retractions change score Final partial sum score-baseline partial sum score -9 - +9
Respiratory rate “standardized 
change score
5% change: 0 units 
6-15% change: -1/+1 units 
16-25% change: -2/+2 units 
etc
-n - +n
Sum score (negative change scores indicate improvement) -17-n - +17+n
*the original RDAI as reported by Lowell et al also included respiratory rate, i.e. it did not differentiate between the RDAI 
and RACS, and only used RACS as an outcome measure 
#as modified by Schuh et al (2002); in the original RACS as reported by Lowell et al, final scores were substracted from 
baseline scores (i.e. positive change scores indicated improvement), and cut-offs to define respiratory rate change were 
defined at 10% intervals
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Statistical analysis 
We used COSMIN’s definitions of measurement domains and properties regarding 
validity, reliability and responsiveness.701 
!
1. Construct validity of RDAI  
There is no “gold standard” to assess bronchiolitis severity or respiratory distress. 
We assessed construct validity of the RDAI by formulating hypotheses about the 
direction and magnitude of the association of RDAI scores with both physiologic 
measures (respiratory rate, SatO2) and clinical decision-making constructs (decision 
to admit/discharge, and time to admission/ discharge).671 We studied both 
convergent and discriminative validity.  
!
We hypothesized that baseline RDAI scores and respiratory rate would have a 
strong positive correlation (Pearson’s r ≥0.7). We used multiple linear regression 
analysis to explore possible confounding of this association, by activity status and 
fever (data from both studies), and age and weight (data from CanBEST). We further 
hypothesized a negative association between RDAI and SatO2, which we expected 
to be weaker and non-linear (Spearman r ≤-0.5), and we compared RDAI scores 
between three categories of SatO2 (<92%, 92-95%, >95%) (data from both studies).  
!
We hypothesized that a higher RDAI score would increase the risk of admission 
(expected odds ratio for admission (OR) ≥1.5 for RDAI scores above the median). 
For this analysis, we used the last RDAI score assessed or registered before the time 
of admission/discharge (data from CanBEST). Multiple logistic regression analysis 
was used to evaluate whether that association was confounded by centre, treatment 
group, age and SatO2. Further, we expected participants that stayed in the ED 
longer to have intermediate scores as compared to those that were admitted or 
discharged sooner (data from CanBEST after the trial main interventions). 
!
2. Reliability of RDAI  
For RDAI test-retest reliability we considered that the group of CanBEST participants 
who had received both placebo interventions was stable between the 90- and 120- 
minute measurements. The same research nurse assessed the same child unblinded 
to the previous assessment. In a convenience sample of participants from each 
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study, two nurses performed baseline RDAI measurements independently in order 
to obtain inter-rater assessments. 
!
For both test-retest and inter-rater conditions, we distinguished measures of 
measurement error from reliability measures.796 To evaluate measurement error we 
calculated the standard error of measurement (SEM), the smallest detectable change 
(SDC), and we obtained a Bland-Altman plot and the 95% limits of agreement (LoA) 
(formulas in Appendix A3). The Bland and Altman Plot shows the mean differences 
between the test and retest scores (expressed in the unit of the scale) along the 
range of the scale. The LoA show the scores where 95% of these differences lay 
between. We assessed reliability by calculating the Intraclass Correlation 
Coefficient (ICC) in a two-way random effect model, including patient, time, and 
residual variance components (formulas in Appendix A3). 
!
3. Responsiveness of RDAI / RACS 
As with validity, we studied the responsiveness of the RDAI and RACS through 
testing hypotheses concerning the expected associations of change scores.671 There 
is no clear criterion for change in bronchiolitis and none of the studies included 
explicit assessments of change. We based our hypotheses on physiologic and 
clinical constructs of change using a-priori-defined criteria to identify groups of 
participants that improved, versus those who had kept stable or deteriorated, 
irrespective of interventions. Criteria were based on respiratory rate and SatO2, and 
we used combined group data from CanBEST (Table 3.4).  
!
We used different measures of responsiveness assessing statistical change or 
clinically important change, focusing on comparing the improved group with the 
stable/deteriorated group.706 These included: testing differences in RDAI change 
scores and/or RACS within and between groups, and calculating standardized/
Cohen’s effect size (ES) and the responsiveness ratio (formulas in Appendix A3). We 
hypothesized that patients who had improved would have larger change scores and 
effect sizes than patients who had not improved. We also used the area under the 
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!
For all analyses, we excluded participants with non-valid or missing data, with no 
imputation. Statistical significance was set at p<0.05 and we calculated 95% 
confidence intervals (95%CI) when applicable. We used SPSS version 19 (IBM SPSS 
Statistics, IBM Corporation, Armonk, NY).  
!
Results 
Figure 3.5 shows data sources and participants included in the analysis of each 
measurement property. The baseline characteristics of participants and selected 
outcomes from both studies are presented in Table 3.5. Participants in CanBEST 
were older than those in the cohort study, while baseline severity was greater in the 
latter. 
!
1. Construct validity of RDAI  
We found a weak positive correlation between RDAI score and respiratory rate at 
baseline with data from both studies - Pearson’s r=0.38 [95%CI 0.35–0.45] 
(p<0.001) (n=1765). Correlations for retractions and wheezing sub-scores were 
r=0.41 and r=0.17, respectively. Using simple linear regression the coefficient 
Table 3.4: Constructs of change and criteria used to assess responsiveness of RDAI and RACS
Anchor Population Timing of 
measurements
Criteria for change!



























Participants with tachypnea 
(baseline respiratory rate above 
50 breaths/minute [<6 months] 
or above 40 breaths/minute 
[6-12 months])























Participants with high baseline 
probability of admission 
(respiratory rate >60 breaths/
minute or SatO2 <90%)




Discharge 154 Admission 55
*Only for RDAI; not used to measure RACS responsiveness since respiratory rate is included in the RACS formula
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estimate was 1.55 [95%CI 1.38–1.73] increase in respiratory rate (breaths/minute) 
per increase in RDAI unit (p<0.001). The estimate was comparable when adjusting 
for fever and activity status (adjusted estimate 1.52). When restricting the analysis to 
CanBEST data, the correlation was weaker (Pearson’s r=0.22, unadjusted linear 
regression estimate 0.98, n=800). The association was not confounded by age, 
weight, fever or activity status (adjusted estimate 0.92).  
!
There was a weak negative correlation between baseline RDAI scores and SatO2 
levels - Spearman’s r=-0.24 (p<0.001) (n=1761). Correlations for retractions and 
wheezing were r=-0.25 and r=-0.14, respectively. RDAI scores increased in lower 
SatO2 categories (Figure 3.6). The median [interquartile range] RDAI scores were 
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Figure 3.5. Sources of data and number of participants included in the analysis of each 
measurement property (RR, respiratory rate)
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10 [8–12], 8 [6–10], and 7 [5–10] for SatO2 <92%, 92-95% and >95%, 
respectively (Kruskal Wallis test: p<0.001).  
!
We found an association between the decision to admit or discharge and the last 
RDAI score of CanBEST participants. The preceding RDAI score was higher in 
admitted patients than in those who were discharged (mean difference 2.28 [95%CI 
1.75–2.81] (t-test p<0.001) (n=798). A higher RDAI score was associated with 
Table 3.5: Baseline characteristics of participants and selected outcomes from the CanBEST trial 
and the cohort study





Age – months, median [IQ range] 5 [3-7] 4 [2-7]
Male gender – no. (%) 493 (62) 948 (61)
Caucasian – no. (%) 654 (82) 1243 (80)
History 
Personal history of atopy – no. (%) 89 (11) 157 (10)
Prematurity – no. (%) 83 (10) 202 (13)
Household smoking – no. (%) 305 (38) 575 (37)
Symptom length – days, median [IQ range] 4 [2-5] 4 [2-5]
Clinical characteristics
Respiratory rate – breaths/minute, median [IQ 
range] ; >60 breaths/minute – no. (%)
48 [42-58];  
196 (25)
48 [42-60];  
441 (28)
Oxygen saturation – % median [IQ range]; <90% – 
no. (%)
97 [95-98]; 24 (3) 97 [95-98]; 121 (8) 
Heart rate – beats/minute median [IQ range]; >180 
beats/minute – no. (%)
150 [139-160];  
33 (4)
152 [140-164];  
143 (9)
RDAI score – median [IQ range]; >12 – no. (%) 8 [6-10];  
76 (10)
8 [6-10];  
211 (14)
Patient outcomes
<90 minutes 103 (13) NA
90-120 minutes 261 (33) NA
120-240 minutes 248 (31) NA
>240 minutes 188 (23) NA
IQR=interquartile range; NA=not applicable 
*Data from the severity study include n=584 participants also included in CanBEST.
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higher risk of admission (OR 1.36 [95%CI 1.26–1.47] per increase in RDAI unit and 
2.54 [95%CI 1.65–3.92] when RDAI>8). Adjusted analyses for centre, treatment 
group, age and SatO2 found no relevant changes in these associations.  
!
In addition, we found that RDAI scores measured after CanBEST interventions 
differed between the groups of participants that were discharged (median 
[interquartile range] 5 [2–6]), hospitalized (8 [5–10]) or those that stayed in the ED 
(6 [4–8]) (n=695, Kruskal Wallis test: p<0.001) (Figure 3.7). Differences between 
discharged participants and the two latter groups were statistically significant 
(Bonferroni posthoc: p=0.01 and p<0.01, respectively). Patients with a higher RDAI 
score at 90 minutes had higher risk of ED stay >240 min (OR 1.33 [95%CI 1.24–
1.43] per increase in RDAI unit).  
!
Overall, while results were in accordance with our validity hypotheses, the 
magnitude of the associations was mostly below our predefined thresholds.  
2. Reliability of RDAI  
Test-retest assessments were available from 79 CanBEST participants. The mean 













Figure 3.6. Box plot displaying baseline RDAI 
scores by categories of SatO2 (The box spans the 
interquartile range (IQR), the solid horizontal line through the 
box is the median value, and the whiskers denote values 
within 1.5 IQRs lower than the first quartile and 1.5 IQRs 
higher than the third quartile)
Outcome at 90 min















Figure 3.7. Box plot displaying RDAI scores and 
clinical decisions at 90 minutes (The box spans the 
interquartile range (IQR), the solid horizontal line through the 
box is the median value, and the whiskers denote values 
within 1.5 IQRs lower than the first quartile and 1.5 IQRs 
higher than the third quartile)
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(p=0.72). The SEM was 1.34 and the SDC was 3.72 RDAI units. The test-retest 95% 
LoA were -3.8 to 3.64 RDAI units [95%CI -4.53 – -3.07, to 2.91 – 4.37]. This 
finding means that if a child is assessed twice, the second score could be between 
3.64 points lower and 3.8 points higher than the first score, just because of 
measurement error. The magnitudes of differences between repeated measurements 
remained the same over the whole range of mean values as shown in the Bland-
Altman plot (Figure 3.8).  The test-retest ICC was 0.80 [95%CI 0.70–0.87]. 
!
Inter-rater assessments were performed in 107 participants. There was no significant 
difference between two repeated assessments – mean difference -0.06 [95%CI 
-0.28–0.15] (p=0.54). The SEM was 0.78, and the inter-rater LoA were -2.1 to 2.22 
RDAI units [95%CI -2.46 – -1.74, to 1.86 – 2.58]. The ICC was 0.93 [95%CI 
0.9-0.94].  
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Figure 3.8. Bland and Altman plot of the difference between test-retest RDAI scores at t1 (90 
min) and t2 (120 min) plotted against the mean value of both scores. The central line corresponds 
to the average difference between two RDAI scores (which reflects systematic error), whereas the lower and upper 
dotted lines correspond to lower and upper 95% limits of agreement (which reflect random error), respectively)
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3. Responsiveness of RDAI and RACS 
Measures of responsiveness for RDAI and RACS based on the different constructs of 
change are presented in Table 3.6. By using both anchors, the mean RDAI scores 
decreased in both improved and stable groups (paired t-test p<0.001, for all within-
group comparisons), with larger mean changes in scores of the improved group 
(unpaired t-test p<0.001, for all between-group comparisons). These results were in 
accordance with our predefined hypotheses. Between-group differences in mean 
RDAI change scores ranged from -1.31 [95%CI -1.85 – -0.77] for the 25% 
respiratory rate reduction criterion to -2.03 [95%CI -2.9 – -1.16] for the probability 
of admission criterion. Standardized ES for the improved group ranged from 1.43 to 
1.71, while responsiveness ratios ranged from 1.54 to 1.61, and AUCs from 0.64 to 
0.7. The RACS was larger in the improved group (between-group difference -2.81 
(95%CI [-3.92 to -1.7]), with a responsiveness ratio of 1.96 and AUC of 0.72. 
!
!
Table 3.6: Measures of responsiveness for RDAI and RACS using different anchors of change
Responsiveness measure Anchor: respiratory rate 
25% reduction (n=796)
Anchor: respiratory rate 
tachypnea cut-off 
(n=305)
Anchor: probability of admission 
(n=209)
RDAI RDAI RDAI RACS
Within-group mean change 
(RDAI) or change score 
(RACS) ± SD 
Improved group -4.17 ± 2.86 -4.48 ± 3.07 -3.63 ± 2.96 -5.94 ± 3.76
Stable group -2.86 ± 2.71 -2.8 ± 2.78 -1.6 ± 2.36 -3.13 ± 3.03
Between-group difference in 
mean change (RDAI) or 











Improved group 1.54 1.71 1.43 NA
Stable group 1.22 1.15 0.67 NA
Responsiveness ratio 1.54 1.61 1.54 1.96
Area Under the Curve [95% 
CI]
0.64 [0.59-0.68] 0.65 [0.59-0.71] 0.7 [0.63-0.78] 0.72 [0.64-0.8]
Measurements were made at baseline and before admission or discharge. NA, not applicable
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Discussion 
This study of measurement properties of RDAI and RACS in acute bronchiolitis 
identifies strengths and limitations of their use as outcome measures. The RDAI was 
evaluated in three systematic reviews of measurement properties of asthma or 
wheezing severity scales in children.694,715,716 Limited data on its reliability and 
responsiveness were provided in the original description of the scale, and in later 
reports of RCTs.714,747,797 However, none of these were adequately designed 
measurement studies, and no formal assessment of validity was found. Destino et al 
recently reported the first validation study on RDAI in bronchiolitis, showing poor 
construct validity, inter-rater reliability and responsiveness.717 Findings on validity 
were fairly consistent with our results; differences in setting, raters and methods 
may explain why results on reliability and responsiveness were distinct.   
!
Our results show that the RDAI has poor to moderate construct validity. The RDAI 
was developed ad hoc with no elaboration on the underlying conceptual model, 
item selection, scoring or weighting. While in the original report only the RACS was 
used as an outcome measure, later trials used RDAI scores separately for single or 
repeated assessments.714 In our conceptual framework respiratory distress was 
putatively reflected by RDAI items (i.e. reflective model) and contributed to the 
multidimensional construct of bronchiolitis.671 We found poor convergent validity 
with respiratory rate, but RDAI scores discriminated well between clinically 
meaningful SatO2 subgroups. Measurement properties from other respiratory scales 
or their individual items, which often include respiratory rate or SatO2, are seldom 
available.694,715,716 When they are reported, there is substantial heterogeneity in 
correlations with SatO2, ranging from poor to moderate. Thus, our predefined cut-
offs may have been too strict. Most, but not all, studies are consistent with our 
findings of weaker correlations between SatO2 and auscultatory items when 
compared to work of breathing.694,715,716,798 
!
These results reflect the pathophysiology and clinical correlates of respiratory 
distress in bronchiolitis. It is known that, as disease progresses and severity 
increases, so do the disturbances in ventilation and ventilation-perfusion matching.
144,246 Many patients have effective compensatory mechanisms for these 
disturbances, while others do not. However, clinical signs of respiratory distress 
may not capture hypoxemia/hypercapnia balance equally. Furthermore, the 
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correlation between SatO2 (reflecting oxygenation), and respiratory rate (also 
dependent on respiratory drive and ventilation), varies across conditions.798 
Therefore, the RDAI likely does not represent all dimensions of respiratory distress 
in bronchiolitis, and a combination of parameters may be more relevant for the 
measurement of respiratory distress, as seen in formally developed scales.799,800 
However, most other scales were not developed specifically for bronchiolitis, and 
their measurement properties cannot be transferred between different respiratory 
conditions without further validation. 
!
We found that the RDAI had reasonable predictive validity based on its association 
with hospitalization and length of stay in the ED. Our findings are consistent with 
those of Corneli et al, who identified RDAI score, SatO2, and respiratory rate as 
predictors of hospitalization in bronchiolitis.352 On the contrary, Destino et al found 
that RDAI sum scores did not discriminate well between admitted and discharged 
patients, but the item on retractions did.717 Two large prognostic studies have also 
identified retractions as predictors of severe disease in ED and hospitalized patients.
68,351 Decisions regarding hospitalization and length of stay in the ED are 
multifactorial. Non-respiratory severity parameters (e.g. feeding), prognostic factors 
(e.g. age), social issues, clinical judgment, available resources and local practices 
influence decision-making.352 Further, there are limits to the validity of static 
measurements of respiratory distress in a highly dynamic condition. From an 
outcome measure perspective, RDAI does not encompass all determinants of 
bronchiolitis severity.  
!
Inter-rater reliability measured by the ICC was good, both at group and individual 
level, as was inter-rater measurement error. These findings means that RDAI scores 
can adequately discriminate participants assessed by different raters at the same 
time point in both clinical and research settings. Data from previous RCT reports 
also showed good inter-rater reliability, but Destino et al found a strikingly low ICC.
717 Differences may relate to training, familiarity with the instrument, raters and 
population heterogeneity. On the other hand, we found considerable test-retest 
measurement error at individual level, since a patient should change at least close 
to 4 points (about one-fifth of the scale) before a change is detectable beyond 
measurement error. Thus in clinical practice, changes in individual patients should 
be interpreted with caution. For the RACS, we must also consider measurement 
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error for respiratory rate.366,369 The SDC is paramount to interpretability parameters 
such as the minimal important change (MIC), since a large SDC relative to the MIC 
means that observed change may be caused by measurement error rather than 
change per se.709 At the individual level, taking repeated measurements and 
averaging the value would reduce the measurement error with a factor √k (k is the 
number of measurements). Although reassessment is a key component when 
evaluating children with respiratory distress, many repeated measurements might 
not be practical in clinical practice. At the group level, the SDC of a mean change 
is equal to SDC/√n, which reduces its impact.671 Since the ICC was high, the RDAI 
is reliable for use in studies. Overall, these results suggest that the RDAI has 
adequate discriminative properties, but test-retest measurement error should be 
minimized (e.g. through repeated measurements).  
!
The RDAI was responsive according to our predefined hypotheses based on two 
distinct constructs of change. Previous data on RDAI responsiveness is scarce.
694,715,716 Hardly any intervention can be considered clearly effective in 
bronchiolitis in the ED setting, and thus none is a reasonable gold-standard to 
assess change. Destino et al reported a mild correlation between the change in the 
RACS and the Children’s Hospital of Wisconsin Respiratory Score, but data on 
responsiveness of this latter scale is also missing.717 We anchored our constructs of 
change on physiological change, and change in clinical status likely to be relevant 
for decisions regarding patient disposition at the ED. Measures of responsiveness 
that took into account both improved and stable groups (responsiveness ratio and 
AUC) were comparable between anchors for the RDAI. The AUC value was close to 
the frequently used cut-off of acceptability (0.7) for both the RDAI and RACS, with 
the RACS being slightly more responsive. This data suggest the RDAI and RACS are 
moderately responsive, but any comparison with other respiratory scales is limited.  
!
Our study has limitations related to design constraints of both included studies. 
First, less heterogeneity of RDAI scores in the selected sample of CanBEST 
participants may explain why we found a weaker correlation with respiratory rate 
and lower test-retest ICC scores. Further validation is needed when considering 
children with very mild or severe disease, which were excluded in CanBEST. 
Second, our results are applicable to infants with a first episode of wheezing and no 
relevant co-morbidities, and should be interpreted with caution when defining 
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bronchiolitis differently in other populations.4 Third, concurrent factors that affect 
decisions of hospitalization were not collected, and the exact timing of this 
decision was not known. While, in ideal conditions, managing physicians would be 
blinded to RDAI/RACS scores, blinding to their individual items is not expected. 
Finally, defining stability and change can be problematic and time-dependent due 
to the dynamic nature of bronchiolitis. When assessing responsiveness using data 
collected at different time points (mostly between 90 and 240 minutes), we 
observed significant improvements in RDAI scores in groups that we considered a 
priori to be stable. This is likely a limitation of our anchors, and may also reflect the 
effect of supportive measures and the nebulized “placebo”. These limitations should 
be considered when calculating the MIC of the RDAI, which will be the focus of 
future work. 
!
In conclusion, we found the RDAI to be an incomplete measure of respiratory 
distress in bronchiolitis, with poor to moderate construct validity and adequate 
inter-rater reliability. The RDAI had considerable test-retest measurement error, and 
while both the RDAI and RACS were moderately responsive, methodological issues 
may limit the interpretation of this finding. Finally, the RDAI does not encompass all 
determinants of bronchiolitis severity.  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Two key limitations hamper intervention research in bronchiolitis: the absence of a 
clear definition of disease, and the heterogeneous choice of outcome measures in 
current clinical trials. We assessed how pediatricians and general practitioners 
(GPs) perceived definition and clinically important outcomes in bronchiolitis. 
!
Methods 
A nationwide online survey (ABBA study) was conducted through the Portuguese 
Society of Pediatrics and GPs’ mailing lists. We assessed agreement with statements 
on bronchiolitis definition, and participants were asked to score the relative 
importance of several outcomes. Principal component analysis (PCA) explored 
dimensions underlying disease definition. Outcomes were ranked by mean score 
and proportion given highest score. 
!
Results 
We included 514 pediatricians and 165 GPs (overall 59% were board-certified). 
Most pediatricians (76.5%) agreed with a definition based on coryza, wheezing 
and/or crackles/rales, compared to 38.1% GPs (p<0.001). Less than 5% physicians 
agreed with a definition commonly used in clinical trials (<12 months, first episode 
of wheeze). We retained three dimensions on PCA: one based on coryza, rales/
crepitations and no sudden onset; another on number of episodes and age; and a 
third on wheeze. Dimensions varied by physician specialization and training 
(p<0.01). Hospital admission and respiratory distress were top rated outcomes by 
both groups of physicians. 
!
Conclusion 
Physician definitions of bronchiolitis have considerable variability and often 
mismatch those of clinical trials. Rating of important outcomes was consistent. Our 
results highlight the need for a robust standardized definition of acute bronchiolitis 
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BACKGROUND 
Acute viral bronchiolitis is the most common lower respiratory tract infection in 
infants.2 It entails substantial clinical and financial burden across different levels of 
care. Treatment is controversial, and there is wide practice variation and 
inconclusive evidence for many therapeutic approaches.10,551 Systematic reviews in 
this field have highlighted two shortcomings in clinical trial design: the absence of a 
clear definition of disease, and the heterogeneous choice of outcome measures 
(Chapters 2 and 3.1). 
!
While bronchiolitis is a relatively straightforward clinical diagnosis for most child 
health practitioners, no standardized set of diagnostic criteria exists.2,4,19,719,720,721 A 
Delphi panel from a local guideline in the United Kingdom reported consensus on 
bronchiolitis as ‘a seasonal viral illness characterized by fever, nasal discharge and 
dry, wheezy cough’, with ‘fine inspiratory crackles and/or high pitched expiratory 
wheeze’.4 However, definitions may vary by auscultatory findings, age, number of 
episodes or other parameters.95,214,726 Furthermore, the label ‘bronchiolitis’ may 
overlap with acute wheezing and asthma, which hampers the interpretation of 
current evidence.465,764 Empirical data is lacking on physician’s perspectives of 
definitions and their determinants. 
!
The second issue relates to the inconsistency in reported outcome domains 
measured in bronchiolitis trials (Chapter 3.1).693 This limits the interpretability of 
trial findings and the opportunity for pooling results in meta-analysis. Initiatives 
such as OMERACT and COMET have supported the development and use of agreed 
standardized collection of outcomes, i.e. core outcome sets, to be used, as a 
minimum, in all trials for a specific clinical area.681,682 Core outcome sets should be 
meaningful for key stakeholders. However, there is scarce evidence on which 
outcomes in bronchiolitis are clinically relevant. 
!
The ABBA survey aimed to assess the perspectives of physicians, across the nation, 
on definition of bronchiolitis, and on clinical importance of different outcomes in 
this field. We engaged and compared perspectives from paediatricians and general 
practitioners (GPs), as both groups are key stakeholders involved in the 
management of bronchiolitis of varied severity at different levels of care, and have 
distinct background and training that may influence these perspectives. 
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METHODS 
Study design and subjects 
The ABBA study was a cross-sectional electronic survey targeting pediatricians and 
GPs working in Portugal, both board-certified physician specialists and 
postgraduate physicians in a residency training program. Pediatricians were current 
members of the Portuguese Society of Pediatrics (SPP), which has an open 
membership across levels of care. Electronic contact information was provided by 
the organization, after review and approval of the research protocol. Subjects with 
invalid e-mail addresses were excluded. We reached GPs who were registered in 
any of three national GP mailing lists with the support of the Portuguese Association 
of General Practitioners (APMGF). 
!
Questionnaire 
A multidisciplinary panel from the Pulmonology section of the SPP and the APMGF 
designed a questionnaire in Portuguese on various topics of bronchiolitis; definition 
and outcomes are the focus of this paper. The instrument was developed using a 
structured approach. Based on a literature review and the panel’s expertise, items 
were formulated for each construct and examined for face validity. Item selection 
and reduction was achieved through consensus. We obtained 18 items on 
definitions and outcomes, and we collected data on physicians’ training and 
workplace (questionnaire available in appendix A4). Response formats included 
multiple choice items, ordinal ratings (1 to 5) and 5-point Likert items (ranging from 
disagree completely to agree completely).  
!
First, we asked practitioners to express their level of agreement with six statements 
on key history and clinical findings in defining bronchiolitis. These included onset 
of symptoms, preceding coryza, auscultatory findings (crackles/rales and wheezing), 
upper age limit and maximum number of episodes. Regarding outcomes, 
participants were asked to score the importance given to a predefined list of 12 
outcomes in the interpretation and applicability of clinical trial results. We included 
outcomes that have been previously reported in bronchiolitis trials (e.g. hospital 
admission, clinical severity), and added outcomes recognized as relevant but often 
missing in this field (e.g. quality of life, parent-reported symptoms). The survey was 
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developed using the SurveyMonkey platform (www.surveymonkey.com), and the 
instrument was pilot tested for acceptability and feasibility.  
!
Implementation 
The survey ran from 5th April to 22nd May 2013. A modified Dillman technique 
was employed to optimize the response rate, including up to four reminder e-mails 
and a small incentive. Pediatricians were contacted through personalized e-mail 
invitations, with a unique link that prevented multiple entries. An e-mail invitation 
with an open link was sent to each GP mailing list. Consent was implied by survey 
completion, and data was anonymized for analysis. The Ethics Committee of Centro 
Hospitalar Lisboa Norte/Faculdade de Medicina de Lisboa approved this study 
(approval statement available in appendix A4). 
!
Preliminary data indicated approximately 1300 members of SPP from a universe of 
around 1750 pediatricians and 400 residents registered nationwide in 2011. About 
1400 GPs were registered in all three mailing lists. Previous electronic surveys 
performed within smaller pediatric organizations reached response rates up to 
60-75%. We anticipated 40-50% responses from pediatricians, but a lower rate 
from GPs due to the method recruitment. 
!
Statistical analysis 
Definitions of bronchiolitis 
We stratified results by pediatricians and GPs, and compared responses to Likert 
items using the t-test. We evaluated whether physician perspectives were in 
agreement with two existing definitions, one based on a consensus approach for a 
local guideline, the other based on inclusion criteria used in recent randomized 
trials (operational criteria shown in Table 4.1), using the χ2 test.45,46,726  
!
We used exploratory factor analysis to examine whether any meaningful 
dimensions could be distinguished underlying the perspectives on definitions of 
bronchiolitis.801 Principal component analysis (PCA) is based on item correlations; 
items that correlate highly with each other are clustered in one factor/component, 
and share variance explained by the underlying dimension. PCA aims to explain as 
much total variance with a minimal number of components. We performed PCA 
including data from all subjects on the six items on definition of bronchiolitis. We 
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determined the number of components to retain based on two criteria: magnitude 
of the eigenvalue >1 (main criteria) and examination of scree plot. Selected 
components were rotated to facilitate interpretation and to generate component 
loading scores, which measure the association between items and the underlying 
component. We used the varimax orthogonal rotation, since components did not 
show considerable correlation between each other (<0.2). Sampling adequacy was 
assessed through the Kaiser-Meyer-Olkin measure, and we used the Bartlett’s test of 
sphericity to test for homogeneity. Items with conventional loading >0.4 (absolute 
value) were interpreted for each component. Using the resulting components as 
dependent variables, we used multivariate analysis of variance (MANOVA) to 
examine associations with group of physician (pediatricians vs. GPs), training 
(resident vs. specialist) and location (Lisbon and south vs. other regions).  
!
!
Outcomes in bronchiolitis 
We analyzed the distribution of scores given to each outcome by pediatricians and 
GPs, and identified outcomes that were rated 4 or 5 by over 80% of participants. 
Further, we ranked outcomes within each subject (for equal scores, standard 
competition ranking, i.e. ‘1224’ was used). We then calculated for each outcome 
the proportion of participants giving it the highest score/ranking. Overall ranking of 
outcomes was based on this proportion, as well as on the highest mean scores.  
!
For all analyses, participants with incomplete responses were excluded for the 
corresponding parameter, with no imputation of missing data. p values < 0.05 were 
Table 4.1: Operational criteria used for preexistent definitions of bronchiolitis
Nottingham guideline-based definition* Clinical trial-based definition*
Agree or completely agree with ‘coryza preceding 
symptoms’  
AND  
agree or completely agree with ‘wheezing’ OR with 
‘crackles/rales’ on auscultation  
AND 
neutral or disagree or completely disagree with ‘sudden 
onset of symptoms’




‘<12 months of age’
*answers to other parameters were not restricted
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considered statistically significant. All analyses were performed using SPSS for Mac 
and Windows (SPSS Inc, version 21.0). 
!
RESULTS 
A flow diagram of participant recruitment is shown in Figure 4.1. We sent 1218 
invitations to potentially eligible SPP members, and included 514 (response rate 
44%). Of approximately 1400 GPs registered in mailing lists, 165 subjects 
participated (estimated 12% response rate). Complete responses were available 
from more than 90% pediatricians and more than 70% GPs. Table 4.2 summarizes 
the demographic characteristics of included participants. For both pediatricians and 
GPs the majority of responders were specialists (59.2%) and worked in Lisbon or 
north of Portugal (74.9%). Of pediatricians, 42.3% worked in all practice settings 
(ambulatory i.e. outpatient, emergency department and hospital), while most GPs 
provided pediatric ambulatory care (94.5%), and 29.7% also worked in pediatric 






Figure 4.1: Study flowchart of paediatricians and general practitioners




Definitions of bronchiolitis: descriptive statistics 
The perspectives of pediatricians (n=494) and GPs (n=147) on key history and 
clinical findings are shown in Figure 4.2 (number of episodes and age), and Figure 
4.3 and Table 4.3 (symptoms and signs). Most physicians on both groups agreed or 
agreed completely with presence of wheezing on auscultation (92.9% pediatricians 
and 95.2% GPs) (p=0.11). However, we found significant differences between 
groups on all other parameters (p<0.001 for all comparisons). Most pediatricians 
agreed or agreed completely with preceding coryza and presence of crackles/rales 
(92.5% and 89.5%, respectively), and disagreed or disagreed completely with 
sudden onset of symptoms (68%). Further, they most often restricted the diagnosis 
of bronchiolitis based on number of episodes (up to three episodes 47.3%, only first 
Table 4.2: Demographic characteristics of paediatricians and general practitioners
Demographic characteristics Paediatricians (n=514)* General Practitioners (n=165)*
Level of training - n (%)
Resident 215 (42) 62 (38)
Specialist 299 (58) 103 (62)
Time since graduation - median [P25-75] years
Resident 5 [4-6] 4 [3-5]
Specialist 14 [10-25] 9.5 [7-24.5]
Practice setting - n (%)#
Ambulatory care 319 (63) 156 (95)
Emergency department 432 (86) 49 (30)
Hospital care 362 (72) 1 (1)
Workplace - n (%)†
Lisbon region 206 (41) 65 (41)
North 175 (35) 50 (32)
Center 80 (16) 34 (21)
Other 42 (8) 10 (6)
*results were calculated based on the number of respondents to a particular question; data available from 
n=514 paediatricians and n=165 general practitioners unless specified 
#data available from n=503 paediatricians; practice settings were not mutually exclusive 
†data available from n=503 paediatricians and n=159 general practitioners 
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episode 32.4%), and upper age limit (up to 24 months 76.2%, up to 12 months 
13.8%). On the contrary, 52.4% GPs agreed or agreed completely with sudden 
onset of symptoms, with a lower proportion than pediatricians agreeing or agreeing 
completely with preceding coryza and presence of crackles/rales (70.1% and 
42.9%, respectively). Also, many GPs did not restrict bronchiolitis by number of 
episodes (56.3%) or age (16.7%). 
!
A definition of bronchiolitis close to the Nottingham guideline had the agreement 
of 76.5% pediatricians and 38.1% GPs (p<0.001). A commonly used clinical trial 
definition of bronchiolitis (limited to a first episode of wheezing below 12 months) 




Figure 4.2: Perspectives of pediatricians and general practitioners on number of episodes (panel A) 
and age (panel B) limits for the definition of bronchiolitis
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!
Definitions of bronchiolitis: factor analysis 
Principal component analysis was conducted with data from 644 participants: the 
correlation matrix between the six items is shown on Table 4.4, each component’s 
eigenvalues and percentages of variance explained are shown on Table 4.5, and a 
scree plot on Figure 4.4. Three components that explained 63.9% of the variability 
were retained. The rotated component matrix is shown in Table 4.6. The first 
component correlated with ‘coryza preceding symptoms’ and ‘crackles/rales on 
auscultation’, but was inversely correlated with ‘sudden onset of 
symptoms’ (Principal Component 1 - PC1, defined as ‘coryza and crackles/rales, no 
sudden onset’). The second component was determined by ‘number of episodes’ 
and ‘age of the child’ (PC2, ‘age and episodes’), which varied together, with a 
stronger correlation with the latter. The third component was mostly correlated with 
‘wheeze on auscultation’ (PC3, ‘wheeze’). 
Table 4.3: Perspectives of pediatricians and general practitioners on key history and clinical 
findings in bronchiolitis
Clinical findings Reported agreement with key findings p-value*
Disagree 
completely




PEDIATRICIANS (n=494)    
Sudden onset of 
symptoms
83(17) 253(51) 58(12) 91(18) 9(2) <0.001
Coryza preceding 
symptoms
4(1) 9(2) 24(5) 254(51) 203(41) <0.001
Wheezing on 
auscultation
0 7(1) 28(6) 331(67) 128(26) 0,11
Rales or crepitations 
on auscultation
3(1) 23(5) 26(5) 328(66) 114(23) <0.001
GENERAL PRACTITIONERS (n=147)    
Sudden onset of 
symptoms
14(9) 35(24) 21(14) 64(44) 13(9) <0.001
Coryza preceding 
symptoms
2(1) 17(12) 25(17) 67(46) 36(24) <0.001
Wheezing on 
auscultation
0 3(2) 4(3) 91(62) 49(33) 0,175
Rales or crepitations 
on auscultation
15(10) 42(29) 27(18) 56(38) 7(5) <0.001
*p-value based on t-test comparing group means of each Likert item
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Using MANOVA, we found significant associations of underlying components with 
physician group (p<0.001) and level of training (p=0.003), but not geographical 
workplace (p=0.811). In particular, pediatricians and residents assigned higher 
scores on PC1 (i.e. they placed more emphasis on this component), as compared to 
GPs and specialists, respectively (p<0.001). Compared to GPs, pediatricians scored 
lower on PC2 (p=0.011) and PC3 (p=0.002) (i.e. they placed less emphasis on these 
components).   















Age of the child
Sudden onset of 
symptoms
1,000 -,321 ,140 -,192 ,147 -,002
Coryza preceding 
symptoms
-,321 1,000 ,140 ,270 -,176 -,024
Wheezing on 
auscultation
,140 ,140 1,000 -,024 ,018 -,072
Rales or crepitations 
on auscultation
-,192 ,270 -,024 1,000 -,169 ,073
Number of episodes ,147 -,176 ,018 -,169 1,000 ,124
Age of the child -,002 -,024 -,072 ,073 ,124 1,000
Table 4.5: Principal component analysis: eigenvalues and percentages of variance explained
Principal 
component
Initial Eigenvalues Extraction Sums of Squared 
Loadings
Rotation Sums of Squared 
Loadings




Total % of 
Varianc
e




PC1 1,650 27,504 27,504 1,650 27,504 27,504 1,60
3
26,723 26,723
PC2 1,151 19,177 46,681 1,151 19,177 46,681 1,12
8
18,798 45,522
PC3 1,035 17,248 63,929 1,035 17,248 63,929 1,10
4
18,408 63,929
PC4 ,854 14,228 78,157
PC5 ,738 12,308 90,465
PC6 ,572 9,535 100,000
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Figure 4.3: Perspectives of pediatricians and general practitioners on key history and clinical 
findings in bronchiolitis
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Table 4.6: Perspectives on definition of bronchiolitis: principal component analysis with 




Sudden onset of symptoms -0,643 0,125 0,327
Coryza preceding symptoms 0,743 -0,112 0,298
Wheezing on auscultation 0,021 -0,027 0,938
Crackles/rales on auscultation 0,685 0,099 -0,010
Number of episodes -0,365 0,599 0,122
Age of the child 0,188 0,855 -0,118
Eigenvalue before rotation 1,65 1,151 1,035
Explained variance (%) 26,723 18,798 18,408
Eigenvalue after rotation 1603 1128 1104
*Factor loadings of absolute value ≥0.40 are shown in bold.
#Rotation Method: Varimax with Kaiser Normalization.
!
Figure 4.4: Principal component analysis - scree plot
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Outcomes in bronchiolitis 
Table 4.7 presents results on the relevance given by physicians to different 
outcomes. Mean scores for all outcomes were close to or above 4 in both groups, 
and all medians were 4 (interquartile range 3 to 5). Most outcomes were rated 4 or 
5 by over 80% of participants in both groups. Ranking outcomes by highest overall 
mean score and by more frequent highest score led to comparable results on the 
top outcomes, which were hospital admission and respiratory distress for both 
pediatricians and GPs. Outcomes which less than 80% pediatricians scored 4 or 5 
included feeding tolerance, treatment harms, return visits, quality of life and sleep; 
the latter three had the lowest mean scores of all outcomes. Scores for need for 
oxygen therapy, recurrent wheezing and asthma were more frequently less than 4 
or 5 by GPs when compared to pediatricians, both being among the lowest mean 
scores in the GP group.  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Table 4.7: Perspectives of paediatricians and general practitioners on relevance of outcomes in 
bronchiolitis
Outcome Mean score (SD) Scored 4/5 by >80% % given  outcome as 
highest score 
Rank (by mean 
score/by % 
highest core)
PEDIATRICIANS (n=466)    
Hospital admission 4.38 (0.7) yes 70 1/1
Length of hospital stay 4.29 (0.68) yes 60.9 4/4
Return visits 3.99 (0.82) no 44.2 10/9
Respiratory distress 4.37 (0.64) yes 67.8 2/2
Need for oxygen therapy 4.36 (0.62) yes 66.3 3/3
Feeding tolerance 4 (0.7) no 40.8 9/11
Duration of illness 4.11 (0.74) yes 50 6/8
Sleepa 3.83 (0.83) no 35.6 12/12
Treatment harms 4.11 (0.79) no 51.5 7/7
Quality of life 3.96 (0.81) no 43.1 11/10
Pulmonary function 4.2 (0.78) yes 59.2 5/5
Recurrent wheezing and 
asthma
4.1 (0.93) yes 55.8 8/6
GENERAL PRACTITIONERS (n=119)    
Hospital admission 4.42 (0.8) yes 74.8 2/2
Length of hospital stay 4.21 (0.85) yes 59.7 5/5
Return visits 4.11 (0.94) yes 53.8 9/10
Respiratory distress 4.5 (0.77) yes 81.5 1/1
Need for oxygen therapy 3.99 (0.97) no 50.4 12/11
Feeding tolerance 4 (0.87) yes 47.1 11/12
Duration of illness 4.2 (0.84) yes 58.8 6/8
Sleepa 4.18 (0.93) yes 60.5 8/4
Treatment harms 4.19 (0.93) yes 59.7 7/5
Quality of life 4.22 (0.89) yes 59.7 4/5
Pulmonary function 4.33 (0.94) yes 73.1 3/3
Recurrent wheezing and 
asthma
4.11 (0.97) no 58.8 10/8
aParent-reported measures
bRefers to long-term lung function prognosi
CHAPTER 2
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DISCUSSION 
To our knowledge, this study provides the first comprehensive assessment of 
bronchiolitis definitions from physicians. The debate over the definition of disease 
has lasted for decades, as the same diagnostic label is applied to children with 
important differences in their demographic, history and physical examination 
features.4,19,95,214,719,720,721 Distinct perspectives have often been attributed to a 
geographical divide between the North American definition favoring a first episode 
of wheeze in up to one- or two-year-olds, and the use of the term in the United 
Kingdom and Australia, with crackles/crepitations in younger infants as hallmarks, 
with or without wheeze.4,721 However, empirical evidence in this field is scarce. 
Our results suggest pediatricians have a broader view on auscultatory findings, 
including both wheezing and crackles/rales. This is in line with the Nottingham 
consensus, as well as with definitions mentioned in current practice guidelines.
393,394 We did find considerable disagreement between pediatricians on age for 
acute bronchiolitis and number of episodes, and none of the guidance documents 
adheres to strict limits on these parameters. Further, results from GPs clearly show a 
different perspective for most items, with only wheezing as a common feature. Thus 
we confirmed that physicians, at both individual and specialty-level, define 
bronchiolitis differently and we have identified heterogeneous clinical items that 
must be addressed in any future standardized definition of bronchiolitis.  
!
The heterogeneity in disease definition has considerable impact both for clinical 
practice and research in viral acute bronchiolitis. Variability between centers in 
diagnostic labeling of lower respiratory tract infections in young children has been 
shown to influence treatment practices, given the overlap with asthma and viral-
induced wheeze.55 We found a striking gap between physicians’ perspectives and 
the definition used in recent large clinical trials, mostly due to its 12-month limit 
and restriction to a first episode. This has important implications for the external 
validity and implementation of trial findings. A majority of clinicians uses a broader 
definition of bronchiolitis that includes older children with recurrent episodes, and 
may find it hard to extrapolate results from these trials. On the other hand, they may 
not necessarily consider evidence from trials in children with recurrent pre-school 
wheezing as applicable to bronchiolitis. Conversely, there are arguments in favor of 
a strict definition.725,802 Jartti et al showed both age and episodes are associated 
with factors such as viral etiology and atopic characteristics, which may influence 
short- and long-term outcomes.95 In clinical trials, randomization can balance these 
or other confounders that may affect treatment responses. However, both future 
trials and epidemiological, prognostic and even translational research in this field 
would benefit from a more robust case definition, with clear boundaries with other 
wheezing disorders. Since a balance is needed between study design and clinical 
practice, clarifying standardized definitions in current practice guidelines would 
help. Further, even if the clinical definition is kept broader, researchers could agree 
on major subgroups for stratification, based on current and upcoming markers for 
domains such as host susceptibility, agent virulence, immunopathogenesis and 
environmental predictors. !
Our exploratory factor analysis added to these findings by identifying three key 
dimensions of correlated clinical features that underlie individual perspectives, 
what we may call ‘physician-based phenotypes’ of bronchiolitis. The weight given 
to each component varied by physician specialty and training, but not by practice 
or geographical location, hinting at differences due to clinical teaching and 
experience, or severity of disease seen across settings. These ‘physician-based 
phenotypes’ should be put against patient data to clarify whether valid clinical 
phenotypes of bronchiolitis exist. Interestingly, two dimensions match previously 
proposed clinical phenotypes based on auscultatory findings: one characterized by 
crackles (close to the ‘coryza and crackles/rales, no sudden onset’ component), the 
other by wheeze alone.4 The acoustic characteristics and pathological correlates of 
adventitious sounds might be markers of distinct host responses in bronchiolitis, 
and results from one small study suggest they lead to different long-term respiratory 
outcomes.734 Further, Sanchez et al found response to bronchodilator in infants with 
bronchiolitis could be predicted from wheeze characteristics.622 However, 
validating such phenotypes requires more evidence on their association with 
disease severity, prognosis and possibly treatment response. Furthermore, while a 
separate ‘age and episodes’ component signals that physicians perceive these 
parameters independently, we’ve shown these and other putative phenotype-
defining traits interact and must be approached coherently for an inclusive 
definition.462   
!
Our study also addressed the critical issue of outcome selection, which has been 
often overlooked in bronchiolitis intervention research. Previous systematic reviews  
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of trials have repeatedly found variability in measured outcome domains and 
instruments used, noting the absence of guidance on clinically important outcomes 
(Chapters 2 and 3.1). Developing a core outcome set that is relevant to all 
stakeholders would be a major step forward in acute viral bronchiolitis research. 
We’ve made a first contribution by evaluating the physician perspective, and found 
hospital admission and respiratory distress as the highest ranked and rated 
outcomes. Interestingly, there was remarkable consistency between pediatricians 
and GPs for these top outcomes, but some differences were found in outcomes that 
scored below a commonly used threshold for consensus (i.e. 80%). Outcomes such 
as quality of life or sleep were more valued by GPs, which highlights the need to 
incorporate stakeholder perspectives across levels of care given the wide spectrum 
of severity of bronchiolitis. Overall, all listed outcomes were highly rated by either 
clinician group, and should be considered in a future core outcome set. Importantly, 
this study is just a preliminary step in a structured core outcome set development 
process.682,691 Our results may be used to support a formal consensus approach 
involving key stakeholders (other clinicians, researchers, parents, regulators), across 
settings and internationally. Both bronchiolitis definition and outcome selection 
could be addressed in such an initiative.  
!
Strengths and limitations of our study must be considered. First, we focused on a 
limited predefined set of clinical findings and outcomes, both of which may not 
encompass all relevant items. Our purpose was to generate representative data, and 
further in-depth analysis will require qualitative research techniques. Second, the 
demographics of participating pediatricians suggest they are likely representative 
nationwide and across settings, oversampled for residents. The sample of GPs was 
smaller and many worked in pediatric emergency; while primary care pediatrics is 
mainly provided by GPs, there could be a possible bias of our sample towards 
views closer to those of pediatricians. Moreover, answers in this survey may not 
accurately reflect individual practice when diagnosing bronchiolitis. Although we 
used standardized nomenclature of adventitious sounds, terminology varies and 
reliability of stethoscope examination is limited.381 Lastly, there may be limits to the 
extrapolation of our nationwide results to other countries. Stakeholder perspectives 
on relevance of outcomes are likely to vary by factors such as organizational care 
and societal values, and may not be generalizable worldwide. On the other hand, 
Portugal has not been connoted to any of the “geographical” bronchiolitis 
definitions, which may be a strength of our study.   
!
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In summary, this survey showed pediatricians’ and GPs’ definitions of bronchiolitis 
are heterogeneous and often mismatch those of clinical trials. Exploratory      
component analysis identified domains that underlie different definitions. Our 
results highlight the need for a robust standardized definition that accommodates 
relevant subgroups and possibly phenotypes, suiting both clinical practice and 
research design. Further, we identified outcomes of most relevance to physicians, 
contributing to the development of a core outcome for future clinical trials. 
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   CHAPTER 5
CHAPTER 2
In this thesis we have first provided a comprehensive and integrated systematic 
review with network meta-analysis on the comparative efficacy and safety of the 
two mostly frequently used groups of medications in bronchiolitis, i.e. 
corticosteroids and bronchodilators. Second, this body of evidence highlighted 
inconsistencies and limitations in outcome domains and measurement instruments 
reported in clinical trials with these interventions. We have further addressed the 
issue of outcome selection and measurement with a study on the measurement 
properties of the two most frequently used respiratory distress scales, RDAI and 
RACS. Finally, we have assessed physician perspectives on disease definition and 
important outcomes in bronchiolitis, as preliminary steps in obtaining a 
standardized definition and a core outcome set.  
!
Here we summarize sequentially the main findings on the three topics addressed in 
this thesis (evidence on the use of corticosteroids and bronchodilators, outcome 
selection and measurement, and disease definition), and we discuss their 
implications for clinical practice and research, including directions for future 
studies. 
!
Corticosteroids, bronchodilators and other interventions in bronchiolitis: next 
steps in evidence synthesis and trials !
Main findings 
Results from the comparative effectiveness review presented in Chapter 2 provide 
greater clarity for clinical decision-making regarding the relative benefits and harms 
of corticosteroids and bronchodilators in bronchiolitis. Adrenaline was beneficial 
for short term outcomes among outpatients, including hospital admission rates from 
the ED on day one, while exploratory evidence suggested a longer term synergistic 
effect of combining this treatment with dexamethasone, with reduction in 
admissions up to seven days. Clinical scores and symptoms results supported this 
benefit. However, these were the findings of a single study with methodological 
issues, and should be interpreted cautiously. Further, exploratory subgroup analysis 
was not conclusive as to an additive/synergistic effect of corticosteroids combined 
with bronchodilators. While no relevant differences were found in short-term 
general and intervention-specific adverse effects for these interventions, harms of 
combined therapy need to be clarified further, including long-term safety data. 
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Importantly, current evidence does not support a clinically relevant stand-alone 
effect of systemic or inhaled corticosteroids, β2-AR agonist or anticholinergics on 
most measured outcomes. Also, none of the tested interventions were found to be 
beneficial in hospitalized patients. This is possibly because admitted patients may 
have failed prior treatments, and, in the hospital, were provided optimal supportive 
measures. Overall, both direct and indirect comparisons supported these findings, 
and mixed treatment comparisons allowed us to rank interventions with the highest 
probability of being most effective.  
!
Implications for practice and research, future directions 
For the design and conduct of future systematic reviews 
One of the key strengths of this comparative effectiveness review is that uses 
consistent methods, including definition of disease and outcomes, set a priori at all 
levels of the review, including analytical methods, risk of bias and GRADE 
assessments.662 This allowed us to overcome the methodological heterogeneity 
found in previous systematic reviews. Controversies still may occur, as results from 
these studies were disputed based on our exclusion of recurrent wheezers.803 
Individual participant data meta-analysis would allow to explore any differential 
treatment effects based on these individual factors.804 Another strength was that 
network meta-analysis provided information on the relative effectiveness across a 
range of interventions, e.g. favoring adrenaline over other bronchodilators as a first 
choice for short term benefit.805 
!
This approach sets a standard for future reviews in this field. It could be used to 
evaluate and incorporate new evidence on these interventions as it is being 
published, while expanding and comparing it to other treatments that are being 
increasing tested, such as nebulized hypertonic saline. Evidence from other 
domains, e.g. economical evaluations, could also be added. Methodology for 
network meta-analysis has been evolving quickly since we concluded our project, 
as has the number of published reviews using this type of analysis.806 
Developments include methods to evaluate the quality of evidence and risk of bias, 
to conceptualize and assess the assumptions underlying indirect and mixed 
treatment comparisons, to visualize treatment networks and to explore additive 
effects.666,805,807-809 These methods will likely allow us to deal with the increasing 
complexity of evidence in bronchiolitis treatment, with many comparators, co-
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interventions with different doses and modes of administration (e.g. normal or 
hypertonic saline), and supportive treatments (e.g. low-flow oxygen or high-flow 
nasal cannula), all of which may interact with synergistic or antagonistic effects. On 
the downside, comparative effectiveness reviews are resource intensive and time-
consuming, thus less likely to be updated on a regular basis.662 Within the 
timeframe of this thesis, we were able to update our Cochrane review on 
corticosteroids, but not the comprehensive review. Further, complex reviews and 
network analysis are not overly familiar or well understood by clinicians, and 
readers may be skeptical of indirect comparisons.662 Many formats have been 
proposed to improve dissemination of evidence from systematic reviews to end 
users; results from our review contributed to a Continuous Medical Education 
activity (BMJ Learning module), an evidence synopsis (JAMA Clinical Evidence 
Synopsis), and a point of care online product (Cochrane Clinical Answer). While 
such comprehensive reviews may not always be feasible, homogenous inclusion 
criteria, outcomes and methods between individual systematic reviews would allow 
easier comparison between them. These reviews could be a starting point for 
identifying relevant primary studies and a source of study-level data for future 
network analysis, which could be conducted only when needed.810 
!
For the design and conduct of future clinical trials 
Our findings identify gaps in current evidence that may be addressed in future 
clinical trials. While adrenaline was favored for short-term benefit, results had some 
degree of imprecision and were sensitive to risk of bias, leaving room for further 
well-designed and adequately powered trials. The sample size for these trials could 
be calculated based on what is required for a conclusive and reliable meta-analysis, 
i.e. the required or optimal information size, using existing evidence from our 
review.811 Issues of adrenaline dosing and dilution solution should be considered in 
such trial. Further, while guidelines often suggest a treatment trial to document 
clinical response to bronchodilator, this strategy has not been systematically tested 
and could be considered at the RCT design level, both for outpatients and 
inpatients.394  
!
Combination therapy with corticosteroids and bronchodilators for outpatients is 
another obvious focus of interest for future trials, which may have different possible 
aims. First, replication is needed to confirm the robustness of our findings of benefit 
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from the association of adrenaline and high-dose dexamethasone. Second, while 
recent findings from a systematic review do not suggest any major short-term safety 
concern when using short-term courses of systemic corticosteroids in children with 
acute respiratory conditions, future trials should contemplate comprehensive short 
and long term safety data.641 Finally, studies should identify the minimum 
efficacious dose and type of corticosteroid, and whether other bronchodilators are 
also beneficial. 
!
One of the many challenges in designing and conducting clinical trials in 
bronchiolitis is the choice of comparators. The wide and persistent variability in use 
of bronchodilators makes it harder to achieve consensus when choosing acceptable 
comparators for multicenter protocols. This may also be an obstacle when obtaining 
funding or implementing results. Preference for active comparators is problematic, 
as most interventions have not been proven to be truly effective when compared to 
placebo. Conversely, placebo arms often consist of nebulized saline or similar 
solutions, and both the solution and the mode of administration per se can induce a 
beneficial or harmful “placebo” effect.812 For example, Skjerven et al recently 
showed that an “on-demand” strategy was superior over “fixed-schedule” use, 
regardless of the nebulized treatment, hinting at a harmful effect of nebulization in 
inpatients.813 Design of future trials must consider these findings, and our results 
identify candidate comparators for future trials, while future network analyses may 
use integrate indirect evidence for all comparisons. 
!
Evidence is emerging about promising treatments for bronchiolitis patients, either 
existing interventions such as hypertonic saline and high-flow oxygen, or new 
antiviral drugs or biologics.786,814 As these new treatments are being tested or used, 
it is important to highlight how long-lasting claims of efficacy of many decade-old 
and widely used interventions are challenged by a growing evidence base such as 
that from this review. Thus, it is paramount that these treatments are thoroughly 
assessed for their efficacy and safety in well-design, adequately powered trials, in 
order to support their possible role in the management of bronchiolitis. Further, as 
discussed below, it is important use standardized definitions and to consider 
subgroups of interest a priori, in order to explore any differential treatment effects, 
and in view of future data sharing and meta-analysis. 
!
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Towards a core outcome set of domains and measurement tools in bronchiolitis !
Main findings 
One of the key limitations of our comparative effectiveness review was the 
heterogeneity in the selection of outcomes and outcome measurements in included 
bronchiolitis trials. Chapter 3 shows how reported outcome measurements were 
mostly restricted to short-term clinician-based clinical severity/respiratory distress 
and healthcare use domains, while few measured caregiver-reported symptoms and 
quality of life, or long-term outcomes. The same was found for outcomes used to 
power these trials. Further, more than 20 different measurement instruments were 
identified, with different timings of measurement, metrics and methods of analysis. 
!
Results presented in Chapter 4 provide a first contribution to assess physician 
perspectives on relevant outcomes and outcome domains in bronchiolitis trials. 
Given the scarcity of quantitative and qualitative evidence in this field, the purpose 
of this project was to generate preliminary large scale representative data from 
physicians working in different settings and specialties relevant to bronchiolitis 
management. The top ranked and rated outcomes by both pediatricians and GPs 
were hospital admission and respiratory distress. Most outcomes that pediatricians 
scored above a commonly used threshold for consensus (i.e. 80%) were focused on 
core areas and domains of health resource use (hospital admission and length of 
stay), and pathophysiological manifestations, including clinical severity (respiratory 
distress and need for oxygen therapy), pulmonary function, and disease-related 
long-term manifestations (recurrent wheezing and asthma). Outcomes relating to 
life impact, such as quality of life or sleep were more valued by GPs. 
!
Physicians rated respiratory distress as a key outcome domain for bronchiolitis 
trials, and this domain was often measured in clinical trials of corticosteroids and 
bronchodilators using the RDAI and RACS. In Chapter 3.2, we provide data on the 
validity, reliability and responsiveness of these scales. We found that RDAI had 
limited validity according to our predefined physiological and decision-making 
constructs, as it did not meet all our hypothesis. Inter-rater and test-retest reliability 
were good, showing RDAI has adequate discriminative properties. There was 
considerable test-retest measurement error which is a limitation, particularly for its 
longitudinal use at an individual level in clinical practice. Both RDAI and RACS 
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were moderately responsive according to our hypotheses, with RACS being slightly 
more responsive. These results suggest that both scales may be suitable for use as 
evaluative trial outcome measures, with attention needed to measurement error. 
!
Implications for practice and research, future directions 
For the development of a core domain set for future trials in bronchiolitis  
The preliminary work on reviewing reported outcomes suggests there are gaps in 
measured outcome domains and discrepancies in measurement instruments in 
bronchiolitis trials. However, evidence from our sample of trials may not reflect all 
domains and instruments used to date in this field. For example, our sources of data 
did not include trials for all existing interventions and in all settings. Given the 
spectrum of disease severity in bronchiolitis, as well as the wide range of existing 
interventions, including both drug, device and supportive treatments, it is likely that 
reported measured outcome domains and instruments vary. Further, we focused on 
RCTs, but observational prognostic studies may add information on relevant 
outcome domains (e.g. harms, symptoms-related, quality of life). Importantly, they 
may report the use of other evaluative instruments of interest, and include other 
timings of measurement. Finally, we used a restrictive definition of bronchiolitis by 
excluding trials with participants with a history of wheezing; these trials may also 
contribute relevant information regarding outcomes. A next step would be to 
broaden the literature search and widen the inclusion criteria, in order to have a 
comprehensive on currently measured outcome domains and chosen instruments. 
Further, as new treatments for bronchiolitis are emerging recently, some of which at 
early phases of clinical development plans under regulatory supervision, it would 
be interesting to scope which outcomes domains and instruments are being 
selected for these ongoing and registered trials.  
!
Further in-depth analysis of physician and other health care practitioners and 
clinical researchers’ perspectives is needed through qualitative research techniques. 
This would allow for the inclusion of additional items, and to explore issues such as 
feasibility of outcome measurement (e.g. in the case of lung function testing) and 
timings of measurement. It is essential to consult other stakeholders groups, 
particularly parents and caregivers of children with bronchiolitis, to determine what 
they deem essential to measure. Results from a more comprehensive literature 
review and explicit input from all stakeholders would be incorporated in a 
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conceptual framework of outcome domains, and formal consensus techniques 
could be used to achieve consensus on important outcome domains. 
Methodological aspects to consider in this process include: the impact in parent 
and clinician perspectives of factors such as disease severity, settings, specialties, 
different types of interventions and individual patient characteristics (e.g. age, 
comorbidities, recurrent wheezing); and attention to both short- and long-term 
effects of bronchiolitis, despite uncertainty on the latter. Any further steps should 
take into account ongoing developments in the methodology for core outcome set 
development, including conceptual frameworks, quality assessment instruments, 
and effective methods for engaging, informing and obtaining consensus among key 
stakeholder groups in an iterative process that should be updated.682,688,689,692 Study 
protocols in which key decisions are documented regarding the choices made in the 
process of core outcome set development are emerging. Further, future 
implementation of core outcome sets should be considered upfront. For example, 
while the consistency of measurement of OMERACT’s core set of outcomes for 
rheumatoid arthritis has improved since the introduction, variation in the choice of 
measurement instrument remains.815 This should be considered with care in 
bronchiolitis, which involves stakeholders with different perspectives across settings 
and with wide practice variation. 
!
For the development of a core outcome set of adequate measurement instruments 
in bronchiolitis 
The aforementioned comprehensive literature review could identify existing 
instruments for each domain, and candidate instruments would then be evaluated 
by systematic reviews of studies assessing their measurement properties or other 
quality and applicability filters. An inclusive approach is needed to ensure that all 
domains are covered, and matching adequate instruments are found. Further, gaps 
in available instruments can be identified and lead to the development of new tools 
or adjustments in current ones. For some relevant domains, it is likely that 
instruments exist that may be not have been developed and tested specifically in 
bronchiolitis, but in related conditions (e.g. wheezing disorders) are still useful, e.g. 
regarding respiratory symptoms, quality of life. Thus it is important to have a 
broadened view on candidate instruments, based on expert content in each 
domain. It is also relevant to note that the COMET and COSMIN initiatives are 
working on guidelines to support outcome measurement instrument selection (Core 
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Outcome Measurement Instrument Selection project - COMIS), and OMERACT is 
reviewing its filter and guidance on the procedures to document applicability of 
instruments.691,816 Such developments should be included in a comprehensive effort 
to select measurement instruments for outcome domains in bronchiolitis.  
!
RDAI does not encompass all dimensions of the respiratory domain, nor of other 
domains of disease manifestations and severity of bronchiolitis. RDAI was initially 
proposed as a respiratory scale focusing on variables that reflected underlying 
wheezing pathophysiology and that were frequently used in clinical practice. 
However, the scale was developed ad hoc with no elaboration on the underlying 
conceptual model and construct to be measured, nor any rationale for item 
selection, scoring method or empirical weighting. Few respiratory distress and 
wheezing/asthma scales have been developed or validated in bronchiolitis.694 
Despite the overlap between conditions, it is likely that differences in clinical 
findings, pathophysiology and course of the disease influence the properties of 
measurement instruments. RDAI and RACS measurement properties should now be 
compared with those of other scales that have been tested in adequate 
measurement studies. This will highlight strengths and limitations of current 
instruments for outcome measurement of this domain. A consensus approach to 
instrument selection based on this body of evidence would allow to choose what is 
the most adequate and feasible instrument. It will also help identify whether new 
instruments focused on this domain or encompassing also other domains are 
needed. Few instruments in this field have been developed using a structured 
approach. A recent project is developing one such bronchiolitis severity scoring 
instrument for use by nurses and other healthcare professions.817 
!
For further study of RDAI and RACS 
Another open question regarding RDAI and RACS refers to the interpretability of 
change scores. Ascertaining the MIC of these scales would be useful when 
designing and interpreting studies, e.g. to define the proportion of responders.818 
Authors have also proposed that the MIC (or MID, depending on terminology) could 
be used to facilitate the interpretation of pooled results from clinical scores in meta-
analysis.819 However, methodology is still evolving as to which methods are most 
appropriate to obtain the MIC, or a range of MICs.671 The MIC depends on a 
number of factors, including choice of anchors, who assesses important change, 
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time interval during which change is being assessed, and whether improvement 
and/or deterioration are considered. Given the limitations of our data set, 
particularly the absence of a formal patient or physician anchor of change, these 
issues must be explored carefully before suggesting a “magical number” as an MIC. 
!
Back to basics: standardizing bronchiolitis definitions !
Main findings 
Chapter 4 addressed another key shortcoming in current intervention research, i.e. 
the absence of a consistent definition of bronchiolitis. Results form our nationwide 
survey found that there is variability at both individual and specialty-level in how 
physicians define bronchiolitis, and these definitions often mismatch those of 
clinical trials. We identified heterogeneous clinical items that must be addressed in 
any future standardized definition of bronchiolitis, particularly age, number of 
episodes and auscultatory findings. Further, exploratory factor analysis identified 
key dimensions of correlated clinical features that underlie individual perspectives, 
which we called ‘physician-based phenotypes’ of bronchiolitis: one based on 
‘coryza and crackles/rales, no sudden onset’, another on ‘age and episodes’, and a 
last one on ‘wheeze’. 
!
Implications for practice and research, future directions 
For the the development of a standardized definition of bronchiolitis  
Most research in bronchiolitis would benefit from a standardized, consistent 
definition of disease. This includes clinical trials, prognostic studies and 
translational studies that would use such definition as part of their inclusion criteria, 
but also epidemiological studies using bronchiolitis as an outcome measure. In 
turn, it would allow consistency and comparability in systematic reviews of these 
studies. One such definition would also have to strike a balance with the pragmatic 
implications for clinical practice, e.g. regarding disease labeling and management 
options. A key challenge is to obtain an operational definition that is consistent but 
allows for different traits and phenotypes; rigorous and validated e.g. regarding 




CHAPTER 5: DISCUSSION, CONCLUSIONS & FUTURE DIRECTIONS
CHAPTER 2
In this regard it is useful to reflect on two different perspectives on disease 
definition and classification of airway disorders proposed by Wardlaw and 
colleagues, that of ’lumpers’ versus that of ‘splitters’.736 The former are said to prefer 
to recognize commonality in disease processes, but risk denying the insight that 
accurate classification brings to understanding the disease. For example, the 
diagnostic term ‘asthma’ was originally coined to categorize a clinical presentation 
that appeared to comprise a more or less distinct disease process. As medical 
science progressed and our knowledge of measurable physiological, pathological 
and molecular abnormalities associated with disease processes became known, 
attempts to match these abnormalities to the original disease classification have 
been problematic. Thus in later years, the use of this term without any qualification 
or definition has begun to hinder rather than facilitate progress in research.820 On 
the contrary, there are those who emphasize complexity in disease definition, but 
can end up with endless and useless subgroups if classification is not grounded in 
pathogenesis. The phenotype and endotype approach we discussed in the 
introduction can carry that risk.   
!
A balance between both approaches could consist in deciding on an inclusive 
definition and agreeing on major subgroups for stratification. For example, using 
our results, most pediatricians agreed with the Nottingham guideline definition, in 
children up to 24 months of age and with up to three episodes. However, as 
mentioned in the Introduction, including  recurrent wheezers and older children is 
problematic, as these parameters may be proxy for asthma-prone children with 
distinct viral susceptibilities, preexisting inflammation and/or lung function. 
Conversely, a restricted definition might help obtain a more homogenous 
population, at the expense of being possibly less accepted in practice, and leaving 
some children in “limbo” of uncertain definition e.g. older children with a second 
or third episode.  In any case, subgroups could be defined based on different 
putative phenotypes related to physician perspectives (as we identified them), 
clinical and host susceptibility parameters (e.g. restricted to children below 6 
months, or to children with wheezing), agent virulence (e.g. RSV vs RV), 
environmental predictors (e.g. history of atopy), or any upcoming 
immunopathogenesis biomarkers. These subgroups could be validated based on 
underlying disease mechanisms, and their association with disease severity and 
prognosis. They could also be used for stratification to assess differential treatment 
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response in trials. In any case, a clear distinction should be made on the 
implications for research and for practice of any standardized definition and 
different subgroups. 
!
From the above, it ensues that a formal consensus procedure involving 
representative stakeholders is needed to obtain one such disease definition. Key 
stakeholders could include health care practitioners, researchers of different fields, 
and guideline developers. Care should be taken to account for the regional and 
international variation in bronchiolitis definition. Existing initiatives have focused 
on disease definition using consensus procedures, e.g. the ROME conference for 
functional gastrointestinal disorders.821 Both bronchiolitis definition and core 
outcome set development could be addressed in parallel and collaborative 
initiatives, given the similarity of consensus approaches and how both issues are 
related. 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Appendix B. Strength of evidence assessments using the GRADE system 










Inpatients      
Steroid vs. placebo 8 633 LOS high NS 
1 174 CS : 3-6 hours low Steroid 
3 269 CS : 6-12 hours moderate Steroid 
3 264 CS : 12-24 hours moderate NS 
4 271 CS : 24-72 hours low NS 
Epinephrine vs. 
placebo 
2 292 LOS moderate NS 
2 232 CS: 60 minutes moderate NS 
Epinephrine vs. 
salbutamol 
4 261 LOS moderate Epinephrine 
4 248 CS: 60 minutes low Epinephrine 
1 140 CS: 120 minutes low Epinephrine 
Salbutamol/terbutalin
e vs. placebo 
6 346 LOS high NS 
5 223 CS: 60 minutes low NS 
2 68 CS: 120 minutes low NS 
1 89 CS: 3-6 hours low Salbutamol 
2 136 CS : 6-12 hours moderate Salbutamol 
2 136 CS : 12-24 hours moderate NS 
3 195 CS : 24-72 hours moderate NS 
Outpatients      
Steroid vs. placebo 8 1762 Admissions D1 high NS 
5 1530 Admissions up to D7 moderate NS 
4 1006 CS: 60 minutes high NS 
3 214 CS: 120 minutes moderate NS 
2 808 CS: 3-6 hours moderate NS 
1 69 CS: 12-24 hours low NS 
4 224 CS: 3-10 days low NS 
Epinephrine vs. 
Placebo 
4 920 Admissions D1 moderate Epinephrine 
1 800 Admissions up to D7 low NS 
4 900 CS: 60 minutes high Epinephrine 
1 30 CS: 120 minutes low Epinephrine 
Epinephrine vs. 
salbutamol 
6 295 Admissions D1 moderate NS 
1 63 Admissions up to D7 low NS 
6 148 CS: 60 minutes moderate NS 
4 207 CS: 120 minutes moderate NS 
1 69 CS: 12-24 hours low NS 
1 69 CS: 3-10 days low Epinephrine 
Salbutamol vs. 
placebo 
4 196 Admissions D1 moderate NS 
2 259 Admissions D7 moderate NS 
8 565 CS: 60 minutes low Salbutamol 
2 100 CS: 120 minutes low NS 
1 60 CS : 3-6 hours low NS 
Epi+dex vs. placebo 1 400 Admissions D1 low NS 
1 400 Admissions D7 low Epi+dex 
1 399 Clinical score: 60 minutes moderate Epi+dex 
Epi+dex vs. 
salbutamol 
1 35 (no 
events) 
Admissions D1 insufficient n/a 
1 35 (no 
events) 
Admissions D7 insufficient n/a 
1 35 Clinical score: 120 
minutes 
low NS 
1 35 Clinical score: 12-24 
hours 
low NS 
1 35 Clinical score: 3-10 days low Epi+dex 
LOS=length of stay; CS=clinical score; NS=not significant 
* Strength of evidence assessments:23 
High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change 
our confidence in the estimate of effect. 
Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change our 
confidence in the estimate of effect and may change the estimate. 
Low: Low confidence that the evidence reflects the true effect. Further research is likely to change the 
confidence in the estimate of effect and is likely to change the estimate.  
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-Standard error of measurement (SEM): 
!"#!"#$$%$&' = !!! + !!"#$%&'(!           (o: observers)  
-Smallest detectable change (SDC): 
!"# = 1.96× 2×!"#!"#$$%$&'  
-95% limits of agreement (LoA): 
!"# = !"#$∆!"#$% ± 1.96×!"∆!"#$%       




    (o: observers, p: patients)    
2. Responsiveness
-standardized/Cohen’s effect size (ES) for both stable and improved groups: 
!" = !"#$(!"#!!!!"#!!)!"#$%!"#$%#!!"#$%
-responsiveness ratio (ReR) for the improved group: 
!"! = !"#$(!"#!!!!"#!!)!"#$%&'(!"(!"#!!!!"#!!)!"#$%&
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QUESTIONNAIRES (PEDIATRICIANS AND GPS), 
ETHICS COMMITTEE APPROVAL (CHAPTER 4) 
(only questions on definition and outcomes are shown; the questionnaire also 




Secção  de  Pneumologia  da  Sociedade  Portuguesa  de  Pediatria   
com o apoio da Associação Portuguesa de Medicina Geral e Familiar  
  
ABBA:  ABordagem  da  Bronquiolite  Aguda  




A  Secção  de  Pneumologia  da  Sociedade  Portuguesa  de  Pediatria  (SPP)  está  a  elaborar  uma  norma  de  orientação  clínica  sobre  Bronquiolite  
Aguda  (BA).  Com  este  inquérito  pretende-­se  saber  como  lidam  médicos  especialistas  e  internos  de  Pediatria  e  Medicina  Geral  e  Familiar  de  
forma  individual  com  a  BA.    
Sinta-­se  à-­vontade  para  recorrer  a  normas  que  habitualmente  consulta  para  a  sua  prática  clínica.    
  
Este   inquérito   é   efectuado   em   nome   da   Secção   de   Pneumologia   da   SPP,   com   a   aprovação   da   SPP   e   da   Associação   Portuguesa   de  
Medicina  Geral  e  Familiar.  A  confidencialidade  das  respostas  será  preservada.    
  
  
Para  avançar  ou  retroceder  no  preenchimento  do  questionário  clique  Seguinte  ou  Anterior  no  fim  da  página.  
  
Se  tiver  dúvidas  não  hesite  em  nos  contactar!    
  
Obrigado  pela  sua  participação!    
O  Grupo  de  Trabalho  da  Secção  de  Pneumologia  Pediátrica  da  Sociedade  Portuguesa  de  Pediatria  
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Questionnaire: GPs





Especialista  de  Medicina  Geral  e  Familiar
  







Indique qual o ano em que terminou o internato 
















Unidade  de  Saúde  Familiar  (USF)
  







Consultório  ou  clínica  privados
  

























































Distrito  de  Viana  do  Castelo
  













Consulta  de  Saúde  Infantil
  

Consulta  de  doença  aguda  a  nível  de  Centro  de  Saúde
  

Serviço  de  Urgência  Básica
  

Consulta  de  Pediatria  (geral  ou  subespecialidade)
  

Serviço  de  Urgência  Pediátrico
  

Unidade  de  Internamento  de  Curta  Duração  ou  Enfermaria  de  Pediatria
  










Quanto ao padrão clínico, indique se concorda/discorda com as definições que se 
seguem:
Quanto aos achados na auscultação pulmonar, indique se concorda/discorda com 
as definições que se seguem: 
  
Definição de Bronquiolite Aguda (BA)
*
discordo  totalmente discordo  
não  concordo  nem  
discordo
concordo   concordo  totalmente
A  BA  caracteriza-­se  por  
início  súbito  de  sibilância
    
A  BA  caracteriza-­se  por  
coriza  a  preceder  a  
sibilância
    
*
discordo  totalmente discordo  
não  concordo  nem  
discordo
concordo concordo  totalmente
Na  BA  auscultam-­se  
sibilos
    
Na  BA  auscultam-­se  
fervores/crepitações
    
  
Pedimos  que  responda  às  seguintes  perguntas  de  acordo  com  a  definição  de  Bronquiolite  Aguda  que  normalmente  
utiliza  na  sua  prática  clínica.    
Usa o termo de BA:
O diagnóstico de BA pode aplicar-­se em que idades?
  




Apenas  no  primeiro  episódio  de  sibilância
  

Até  3  episódios  de  sibilância
  





















Se fosse convidado a avaliar os resultados de um ensaio clínico de 
tratamento na BA, qual a importância que daria a cada um dos seguintes 
parâmetros (1 – nenhuma;; 5-­ importância máxima):
*






Redução  do  risco  de  internamento  hospitalar     
Diminuição  da  duração  de  internamento  hospitalar     
Melhoria  da  dificuldade  respiratória     
Diminuição  do  tempo  de  duração  da  doença     
Redução  da  necessidade  de  oxigenoterapia     
Melhoria  da  tolerância  alimentar     
Evitar  efeitos  adversos  da  terapêutica     
Diminuição  do  número  de  consultas  médicas  ou  idas  ao  SU  
necessárias  no  seguimento  da  doença
    
Melhoria  da  qualidade  de  vida  (avaliada  pelos  pais)     
Melhoria  da  qualidade  de  sono  da  criança  e  dos  pais  
(avaliada  pelos  pais)
    
Melhoria  da  função  respiratória     
Redução  do  risco  de  sibilância  recorrente  ou  asma  tardia     
  
  
Secção  de  Pneumologia  da  Sociedade  Portuguesa  de  Pediatria   
com o apoio da Associação Portuguesa de Medicina Geral e Familiar  
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A  Secção  de  Pneumologia  da  Sociedade  Portuguesa  de  Pediatria  (SPP)  está  a  elaborar  uma  norma  de  orientação  clínica  sobre  Bronquiolite  
Aguda  (BA).  Com  este  inquérito  pretende-­se  saber  como  lidam  médicos  especialistas  e  internos  de  Pediatria  e  Medicina  Geral  e  Familiar  de  
forma  individual  com  a  BA.    
Sinta-­se  à-­vontade  para  recorrer  a  normas  que  habitualmente  consulta  para  a  sua  prática  clínica.    
  
Este   inquérito   é   efectuado   em   nome   da   Secção   de   Pneumologia   da   SPP,   com   a   aprovação   da   SPP   e   da   Associação   Portuguesa   de  




Para  avançar  ou  retroceder  no  preenchimento  do  questionário  clique  Seguinte  ou  Anterior  no  fim  da  página.    
  
Se  tiver  dúvidas  não  hesite  em  nos  contactar!    
  
Obrigado  pela  sua  participação!    
  
O  Grupo  de  Trabalho  da  Secção  de  Pneumologia  Pediátrica  da  Sociedade  Portuguesa  de  Pediatria  
  







Como   forma   de   incentivo,   sortearemos   6   assinaturas   da   revista   "Evidence-­Based   Child   Health:   a   Cochrane   Review   Journal"   -­   basta  
preencher  o  questionário  completo  e  fica  habilitado  a  ganhar!  
com  o  apoio patrocinado  por
  
























Indique qual o ano em que terminou o internato 


















Hospital  público  de  referência/  central/  nível  3
  

Hospital  público  de  primeira  linha/  distrital/  nível  2
  






































































Distrito  de  Viana  do  Castelo
  














Consulta  de  Saúde  Infantil
  

Consulta  de  Pediatria  (especialidade  ou  subespecialidade)
  

Consulta  de  doença  aguda  a  nível  de  Centro  de  Saúde
  

Serviço  de  Urgência  Básica
  

Serviço  de  Urgência  Pediátrico
  

Unidade  de  Internamento  de  Curta  Duração  ou  Enfermaria  de  Pediatria
  





Quanto ao padrão clínico, indique se concorda/discorda com as definições que se 
seguem:
Quanto aos achados na auscultação pulmonar, indique se concorda/discorda com 
as definições que se seguem: 
  
Definição de Bronquiolite Aguda (BA)
*
discordo  totalmente discordo  
não  concordo  nem  
discordo
concordo   concordo  totalmente
A  BA  caracteriza-­se  por  
início  súbito  de  sibilância
    
A  BA  caracteriza-­se  por  
coriza  a  preceder  a  
sibilância
    
*
discordo  totalmente discordo  
não  concordo  nem  
discordo
concordo concordo  totalmente
Na  BA  auscultam-­se  
sibilos
    
Na  BA  auscultam-­se  
fervores/crepitações
    
  
Inicio  
Pedimos  que  responda  às  seguintes  perguntas  de  acordo  com  a  definição  de  Bronquiolite  Aguda  que  normalmente  
utiliza  na  sua  prática  clínica.    
Usa o termo de BA:
O diagnóstico de BA pode aplicar-­se em que idades?
  




Apenas  no  primeiro  episódio  de  sibilância
  

Até  3  episódios  de  sibilância
  



















Se fosse convidado a avaliar os resultados de um ensaio clínico de tratamento na 











Redução  do  risco  de  internamento  hospitalar     
Diminuição  da  duração  de  internamento  hospitalar     
Melhoria  da  dificuldade  respiratória     
Diminuição  do  tempo  de  duração  da  doença     
Redução  da  necessidade  de  oxigenoterapia     
Melhoria  da  tolerância  alimentar     
Evitar  efeitos  adversos  da  terapêutica     
Diminuição  do  número  de  consultas  médicas  ou  idas  ao  SU  
necessárias  no  seguimento  da  doença
    
Melhoria  da  qualidade  de  vida  (avaliada  pelos  pais)     
Melhoria  da  qualidade  de  sono  da  criança  e  dos  pais  (avaliada  pelos  
pais)
    
Melhoria  da  função  respiratória     
Redução  do  risco  de  sibilância  recorrente  ou  asma  tardia     
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